<SEC-DOCUMENT>0000914475-22-000058.txt : 20221101
<SEC-HEADER>0000914475-22-000058.hdr.sgml : 20221101
<ACCEPTANCE-DATETIME>20221101161037
ACCESSION NUMBER:		0000914475-22-000058
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221101
DATE AS OF CHANGE:		20221101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		221350326

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nbix-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:3520a338-fe51-42c9-b6ce-64a0958f0bdf,g:fc65d0f6-0ebc-4627-b8fe-1f4c71e82970,d:ff439a36db274cfaa026518ede3eda49--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:nbix="http://www.neurocrine.com/20220930" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl8yLTEtMS0xLTExNTQ5Ng_8ec60db0-87fe-41ee-a9d8-4e0ed90778da">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl8zLTEtMS0xLTExNTQ5Ng_181feacb-6beb-494b-b5e9-3a8ef17513b1">2022</ix:nonNumeric><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl80LTEtMS0xLTExNTQ5Ng_ac1be5a7-a751-40e9-aeed-491c4c7080ea">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl81LTEtMS0xLTExNTQ5Ng_849eaa6d-51c8-4a5e-895e-618e15bb7b70">0000914475</ix:nonNumeric><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl82LTEtMS0xLTExNTQ5Ng_3835d04f-77bd-4fb7-87d0-413e715a13f6">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjAtMC0xLTEtMTE1NDk2_1e393d84-1da2-402e-9cd4-e46f6dd5b945">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMTc2OQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjMyOQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjU3MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjg5NA_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTY0OTI2NzQ0NDE5NQ_53c700d8-36e0-4b90-b6dc-fbf8018a13aa">P13Y7M</ix:nonNumeric><ix:nonNumeric contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjY4MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81NS9mcmFnOjMzOWU2YzViYzNiYjRiYTU5NTAxMmZkNTk4YmVkMTQ4L3RhYmxlOmQzOWUxYzYwNGVmYjRhNThhNDAyNDMyOGYwYmY0NWUxL3RhYmxlcmFuZ2U6ZDM5ZTFjNjA0ZWZiNGE1OGE0MDI0MzI4ZjBiZjQ1ZTFfMi0xLTEtMS0xMTU0OTY_4fa9c01f-9861-4a2e-aaed-4b01f34a4a48">0.0131711</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if918665a526048bba62c5c916d1da24e_I20221028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7f42127857b54a13aa343398bb2d541d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i63a36f8809514653892aaae462d392cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibe44f84f3acc41678a991f68f4e0a4a0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9497c79ced4aeaa7f1db18e0399893_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic95f1ad2e17045e4abe097728c7590d4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19314b84529d46f99e5c461ac31afdc4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a0669f73bd42779f23c7b8c8b7807b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9814ecaf809a4416a7ffd9d41c7694f6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i401123ce4dd945a38b707d60c1882890_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb49c8d270504eda9057c294777b76eb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ed395fe9cc1449bb7d939fd514068ba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia07d586d340f45f99771c0d7a421770b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib88cff710aa64f0db32eff49fd8b81ef_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6f9adf4a4f46229cbde98aedf63b35_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44069ab866fd423cb33d0c69f2a3f908_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i324159b7704844d0ab9d10da3decc855_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6beacf8156fb48ea965024414adc5ab5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5825bdfeea8640ffa28b46a703daa81b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba66c4f94fa34d49b8f74b725073fd80_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaef5673cc82499992433df9a4170336_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ec663ae2974473c932ec901d2279e45_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14a6e7bfb09240da8df57c0b10f74e22_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f55b27df0414697becfc3c88fdb3675_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d7237003994ddb914ef3572076e2d3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1fb24b2c68e4e50a0786e67d741db84_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i031a6b6ce49a43efb4f5777c5cd53c63_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78153a6965184d7c88703cc188594611_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7f36f1d6364a3ba48295705c5a6577_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife1366392be644cdb1fdf15d68cc7c12_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96745670dede4bf7b3baf9f45f84ddbe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i858eddcb9f684bed940a6fbd8a8477ad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e66c6f25b84530a5fb28be5eae8546_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ae523d047d497ba5e50594b29cf3b2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516ff9b620b94979821df492ffccf0d2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9adb983cdb174ff39bb4b981e7ce9650_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd9ce6e56184b7999d247c1dc25eabe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d4f0a2cea8441e0b026692719475b64_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72d0b3550c5e44f5be3613d00e3a1b13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ee8e9be30b406da6b582097952f9d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b7d3cbd4ae44165b3954e2ed6ee365b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10242909a1074444b3e2545c393d3f32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9a3b29344c14dbe9ec425f46e47ae87_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c65102bd2e4adeb5ea816771ce177b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1ded1a54114c989385f9d44f2fea9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifde886332b6d4f1ab3402bed3a5fc8fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366ff930ea93441a960a632e36fee44b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38341b51bfd94d92bcf639e9e87abf56_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i567085fe5058473dabeb8fb3a2603864_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1223dc268f4291a7665d63b9b7a94b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic84e58872dfd4571bebfb56f5496b527_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74d31171db5404580903e96807daec4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fe17b0ffe694754b8dd32868036e3e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bac18c0efcf4ec5a02f7ce6edaaab4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e7fbc21c2904c9b893e0cbd3313df98_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide286c9ed2ab4936a7d1621b6a95fce8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie58820f78b294bfe91aa7c6ad11e3cd8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70caea784a864bd89ac94bdd2e53e6b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4d3b20629a004abe8438fa321eae8513_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5df8b3da765848b7b1e13148e4a5f0ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54ce1de757a4c65bf42b4362a4de196_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee8c3876d62e426f8ca317331158e084_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94db63ec77c8436ab4bc0f734a8773d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6afab7bf36d74de2bbf8ef61c544135a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f569faa178b45c18012ecef36524f9f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62cff9c5fde445f89dc7148fdddd5d1f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf4f4cb73b3749bbbf050c1a913538e0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i229c41a0bfa841e1a21acad7a1d13142_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7447780aa7a4acd84f15c1df4fd1ada_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i739f24694cca4f96aa40688cb5643a85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672c8742c0424d8e9899e8cf653e3879_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i436998f220e64b2d85633913fc679dd2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca44e6f568f4cce81a0f0b62a9e6ed8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1fc719c24174081baf340c8e1ed9345_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic054d101780b4681bad0f8685e5eb620_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i651b70e3e4884c87b5c8f6c691e732c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14108dce2bd342338c0eaada7d66ed9f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c2d75942864117893c1167135a171c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb6ee5ada95b4566aa1c9a8b49eccd5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc36a091f0fb425ca083c03b1d5b9108_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22270e6ff4f141aea1c8f066676c3e93_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9baa790a842c4e00b5d7aea97ed51955_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i704ab482b22e45fa8b591f730cc65111_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0635b37952e44f7286d405737fc817b2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4243abfeabbc4f8fb0fcb634ef8fc677_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac2a51b5f62848819ec910c25d7f2308_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2fb655446647d285e1b13940b27b9a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6fe2cc66814ab7bb20abd508f23227_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c2e568d37774c2babc5f26a9b4a305b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf793309e7a403c9867c00418ded9b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966fced94cdb4f9b9b690c806b6192f2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8edd28eddf194035b1e8ecf4e46d867d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if991653053864b2a904fed8d29ebc17e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if53c84fbe1cd4494b369d17f941323c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76a54806004342ca99ad41187b5f18ff_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33f86e14bc93493b8cdc4da223c47077_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>nbix:security</xbrli:measure></xbrli:unit><xbrli:context id="i4839e374f144412a9f7b6a7f7818e610_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b0b098d67fd4b36b7ad36c659fff363_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6de012629174382b73ae25ee390d53d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dd7f53c0917469fb5aa137f42fa9641_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id71a72a0204343a2ba932bbdf699fd15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a60cfe6cb248f28f728ecc7b0d9dac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3554cf0de1b74187a218d6f9def209e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i595e5cac95e64a078c1b2e3ba8fcad00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d72cc605f044c39df6e8ac34e59455_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i092271effac144f483e64869aea849d1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca50849466f4f388fa755ae299a561f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1638a41bfc4a4188eb4b991772a3c5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i180afdb708d547789b9d9c373554692d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieca3d6e4dcde4876b83e7398f46fed0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i222b84b6200c4687ae6fad5eb6c114eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02faf276f4724aa4ad454f7424494fa8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd7fbc215c547fe9905956a7d3b2d0b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i427d6d88fbf5403a90f978999cec31c1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f1de29717fb412b8d0f3ede241f8bb3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0287a3f58248fd9c60960a29b9c6d7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2455f9d7a9344e94b5e44642abae8dec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7b9e17b5b754d4086db11dcfe954416_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c322608454a431fb44e4870cfcf20e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e7878b6282f4161a51f2ecb11e6ee6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icad8bd51420d47599a0bbb9a64c2debc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c20de1be0b54d57a763e3ccf1e3ffd2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4870a12f1c34345966751447c52154e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0223e03f957402ba98f263591110328_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1df5c5dc8a46219d57553226f03b5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebc376687d434b2f95f43d1c9e9eca69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6810cd7a4b24c838b72ecadd02e9522_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d07e5ef45644257bbcfa85ae04c08a9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36692663da7d47208855243ce31dfad4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80aeccc4b4694ebd8b20044eeae2adc2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dedc56fd35f4871bf88c063a6ff6849_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd7fa1d696ab44f8be8a258fb5120a82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4207c67f0d44accbd49d0bd44c9afb5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8bf998110245f8b80ff377a8f82542_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08641e1abc544caad6433c0c27d62c6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f76ef824ec4b4c9f74fdf2aca12a07_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1f93fe5331c425f98f7d5e731495d7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7146d8e9d0640aa93ae219f21de2a1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc1594a5b6774dc8b404800132ae9d9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bf809ef29d94cf38cf7aaf31b95dbc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ca0198fc8364c69827b4bcd85bfda5c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c36d96155624c52aa5e2d8d06ca58f6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f5e98291034c5ebdd1aaa8e86213e7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic534f177a08b41618f86a8447e6aa13b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22d1bdea9d1346bc84bff185b75f4d8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16add8cd888840ba965b71e41d99d856_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3482a00ad8dd4f2e803c923b8f328ea5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292aeff53ad84fc0ba0c70a3a9c01173_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd2750ce3bd433caa60ae155d4dae98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie49ac4b8f7504f74ae784614035b01ea_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i252ec6df430b4181b19dba818761eefa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b89d380f2a64113845905298e656b37_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie39d31443ce649c9b07f69bd9027d2fc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32c048dc598a4c8d8d72fe8f04ccf8a4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66dcf8a5e7154e9fadd29e9e4be560b2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i215cbb49fff34b958a3ad2dc5ab67b77_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbf97cbe7b5a4eeca45e05f5d6e775d3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e35fa4d9f3455b80e4ddf1bb260920_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i293bb336d80d473eb69da7cf494b8713_D20220208-20220208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-08</xbrli:startDate><xbrli:endDate>2022-02-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016360b58b9248388c5ea2f0970527a4_I20220208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewaloption"><xbrli:measure>nbix:renewalOption</xbrli:measure></xbrli:unit><xbrli:context id="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1203e4c8b5dc4172916025c8100cbdf2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d2b40e50ad4aa48f0578112016e986_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f1503bf3ac46d1b34a4f8bb6f92140_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8302f1e6814a9987ec49ca9af465a2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5bcc60ead14ba1ac643d19e4770911_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66f160f54d404d8bb80d4edd382393c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="i5d6487fd362c4e36a923415c3752b4f7_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b91f81d53147c9b20bab4e275695ef_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03ac1eae74a42adac16fd393cd612f3_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i075bf5beb06a450d897f5554a7c9f675_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia976ce0a469f43dd8529daa7ded8f407_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ffc106e9c034ce0a4ec85dfbc149c80_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97c06ced3466414480ad4f43ed22809c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10df804649bf4f5881d03f512c323aad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b33cfb43b446bb98d589fcf33582cd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67742768ef2045548179b11e33a332c8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6cd5647e0764102ae7a3f85ef3b6d57_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7a804747bab486687e11ad36d58a3ce_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcaf85e03f214f0fa6d79c0c4f6af669_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a294335166245f6a43fd1a87aa252a7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia51e5bcf01714c6fa740643677798f18_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8ceebe0bfe84be1b0d7f9f9ae5831b9_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nbix:DiurnalGroupPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="iff439a36db274cfaa026518ede3eda49_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk2_ca21bdca-583d-4c99-a035-6e69da2d401b">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk3_e9e2c741-dec1-4c67-8480-177d688d6636">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yMjE_91e786b8-bdb4-4414-915d-b24403e09a9d">September&#160;30, 2022</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg3_c043fb4e-b74a-4dfa-a305-09ef38bcb6c9">&#9744;</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDgy_f9d34fc1-9b43-4754-8ad8-0bd6aa7a89fd">0-22705</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><img src="nbix-20220930_g1.jpg" alt="nbix-20220930_g1.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:420px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk4_f678eafe-2c79-423b-8a23-0bba07d16658">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk5_c03afa65-353d-414a-b5a4-b3f706d6b429">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(State or other jurisdiction of</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">incorporation or organization)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNTAw_7553d6cc-7748-44e5-af92-1170ac5a08d5">12780 El Camino Real</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDgz_e886a431-42c0-44ba-95fb-7af8c673ea6f">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg4_8c45ce85-e093-4c7c-b5c4-3c945ac377be">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive office)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg5_baf7fa77-8428-4e2e-a45d-0ffeb45cddd9">33-0525145</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(IRS Employer</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Identification No.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDkw_1bb25b93-3ce9-402d-96cc-5e6bf004adc1">92130</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDkx_7c19b2b6-0e34-430c-ac36-73f15af54646"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(858</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">)</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg0_5c83621e-1c07-43cb-bd2d-33e5ad349973">617-7600</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGFibGU6ZWUyYWQyNzYyYTQ5NDBkZmE0ZGRhMTJlZDc3MmY1M2YvdGFibGVyYW5nZTplZTJhZDI3NjJhNDk0MGRmYTRkZGExMmVkNzcyZjUzZl8xLTAtMS0xLTExNTQ5Ng_6392a969-b39b-455a-899f-73d4d24f7c51">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGFibGU6ZWUyYWQyNzYyYTQ5NDBkZmE0ZGRhMTJlZDc3MmY1M2YvdGFibGVyYW5nZTplZTJhZDI3NjJhNDk0MGRmYTRkZGExMmVkNzcyZjUzZl8xLTItMS0xLTExNTQ5Ng_5d9dab63-1415-4215-834c-88a09c3fb0a8">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGFibGU6ZWUyYWQyNzYyYTQ5NDBkZmE0ZGRhMTJlZDc3MmY1M2YvdGFibGVyYW5nZTplZTJhZDI3NjJhNDk0MGRmYTRkZGExMmVkNzcyZjUzZl8xLTQtMS0xLTExNTQ5Ng_1e1621b1-9af9-414f-b9e0-6c5ac0be11a1">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days:&#160;&#160;<ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDkz_5e051790-d1f8-4de6-b369-ef9d09ab2a0c">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg1_82f706f7-3ad1-4d57-9a8c-53653d6e9b19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk0_b22649a8-710b-4118-9b1e-09c7ce774fd5">Large accelerated filer</ix:nonNumeric> &#9746;  Accelerated&#160;filer &#9744;  Non-accelerated&#160;filer &#9744;  Smaller&#160;reporting&#160;company <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg2_5d577bed-7caa-4a83-a0a8-d8daf2f41765">&#9744;</ix:nonNumeric>  Emerging&#160;growth&#160;company <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk1_13fcf187-3c51-4d59-84a9-b7761b2ae5e5">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDky_7417608a-d8da-4ed1-89bb-35f8d7994b8c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was <ix:nonFraction unitRef="shares" contextRef="if918665a526048bba62c5c916d1da24e_I20221028" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDY5_25b3ce56-6a81-458e-9503-5eb0ece2322c">96,134,388</ix:nonFraction> as of October&#160;28, 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_10">Part I. Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_19">Condensed Consolidated Statements of Income and Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_22">Condensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_25">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_28">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_61">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_61">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_64">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_64">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_67">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_67">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_70">Part II. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_70">26</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_73">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_73">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_76">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_76">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_79">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_79">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iff439a36db274cfaa026518ede3eda49_82">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iff439a36db274cfaa026518ede3eda49_82">53</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div id="iff439a36db274cfaa026518ede3eda49_13"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="iff439a36db274cfaa026518ede3eda49_16"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMy0xLTEtMS0xMTU0OTY_c8b6adbe-3363-401e-8264-c12161500fe2">212.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMy0zLTEtMS0xMTU0OTY_2997440a-bb9d-4dda-ba61-e0fe9db023e8">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNC0xLTEtMS0xMTU0OTY_b6a5c7ea-9cde-4ea8-aa0c-c1a393701313">587.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNC0zLTEtMS0xMTU0OTY_0a21d8fc-b82f-459a-aa92-e7cd059b1277">370.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNS0xLTEtMS0xMTU0OTY_dc8a575c-25cb-4519-a8dc-7bafabc79282">301.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNS0zLTEtMS0xMTU0OTY_d143d0a1-0136-44ba-ae58-d0a85ae2f8b4">185.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNi0xLTEtMS0xMTU0OTY_2acf3527-8f6a-45da-843d-245483464d71">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNi0zLTEtMS0xMTU0OTY_de5683a0-b4c9-4f89-a5a7-2b927ec47616">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNy0xLTEtMS0xMTU0OTY_f726eadf-411b-4bfa-a9db-9d993da9b17f">67.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNy0zLTEtMS0xMTU0OTY_b8852866-ada0-4f85-8704-0ec5672e2247">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfOC0xLTEtMS0xMTU0OTY_c485c2bd-ce74-4492-a52a-b6c959c3102e">1,205.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfOC0zLTEtMS0xMTU0OTY_ca39c333-81e4-4ff5-b414-03e21270bd3f">972.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfOS0xLTEtMS0xMTU0OTY_3974f56f-f0f4-4f7e-be78-d7ba97ebb662">319.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfOS0zLTEtMS0xMTU0OTY_c1e6bf69-6ff1-4ce0-a792-9dbc8b303957">315.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTAtMS0xLTEtMTE1NDk2_41ebe3e1-97fb-4ca4-a3f4-38d90b618794">362.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTAtMy0xLTEtMTE1NDk2_e177eed6-f2b2-4172-be30-5e76414616a7">560.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTEtMS0xLTEtMTE1NDk2_1403e698-f837-402e-afeb-9a95563ce0c6">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTEtMy0xLTEtMTE1NDk2_10446065-604e-42ff-b718-5cd4af6d1fe8">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTItMS0xLTEtMTE1NDk2_90e88d90-99ef-4b92-acf8-8e8226d9da1f">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTItMy0xLTEtMTE1NDk2_8467f0b7-4dac-4297-897b-fe720ceba2d8">63.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTMtMS0xLTEtMTE1NDk2_b205b02c-6222-4670-a43b-0a1df9726ba4">60.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTMtMy0xLTEtMTE1NDk2_7c384ecd-ac96-41a2-9d6c-8eba2a0d8c08">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTQtMS0xLTEtMTE1NDk2_7c205957-24a4-40c3-9886-ae199b842e2c">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTQtMy0xLTEtMTE1NDk2_bfbbac6e-3482-4ca9-b96d-0df2fa682ac6">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTUtMS0xLTEtMTE1NDk2_af59cbe0-e930-4dea-8dbd-a4f0bbdc86a3">2,143.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTUtMy0xLTEtMTE1NDk2_2d1a7446-b333-4937-89b7-63f73ff024d3">2,072.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTktMS0xLTEtMTE1NDk2_b8f27331-796f-466d-aabc-d16a579a10bc">297.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTktMy0xLTEtMTE1NDk2_92b27d74-3f1e-44cb-85f6-c5ab3707449b">225.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjAtMS0xLTEtMTE1NDk2_a6fcdd7a-2384-45ee-8f63-00ee55ebe659">169.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjAtMy0xLTEtMTE1NDk2_695e13a9-6853-41c7-88dd-78c3f578d27a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjEtMS0xLTEtMTE1NDk2_59299c0b-108c-4676-bc7f-b6e8820267f2">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjEtMy0xLTEtMTE1NDk2_7fdedcda-8672-46d1-b1af-b86e5a1ec1ab">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjItMS0xLTEtMTE1NDk2_fee87665-af10-43ae-a7ce-5bd429752505">485.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjItMy0xLTEtMTE1NDk2_48b3cb71-2734-460f-8002-daf264125afa">245.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjMtMS0xLTEtMTE1NDk2_8ffca999-e8ee-4dde-8f50-e03a1dd8b789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjMtMy0xLTEtMTE1NDk2_3195a3fb-d9a0-4856-af85-8c4410be56e6">335.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjQtMS0xLTEtMTE1NDk2_97a10809-530d-4248-a842-a45bfe3d801b">96.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjQtMy0xLTEtMTE1NDk2_79bbec1f-7c77-4a33-8738-d206c53dcf8a">105.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjUtMS0xLTEtMTE1NDk2_023f5c24-75b2-4901-b599-e2301a2f6c95">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjUtMy0xLTEtMTE1NDk2_6bed4028-197e-44f1-80e7-a6431a2f2787">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjYtMS0xLTEtMTE1NDk2_24b66448-0535-476d-869b-479a22597511">598.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjYtMy0xLTEtMTE1NDk2_cccfa236-8265-4e29-bdc8-e742b4d7809c">698.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfMjE_3dfeb356-d101-46cf-81ca-b0c1fcd35025"><ix:nonFraction unitRef="usdPerShare" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfMjE_d8a0dcbd-6fcd-407d-978a-fde372253bd4">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfMzU_2187fa67-02f8-4142-89a9-3b2ae1dfa0bf"><ix:nonFraction unitRef="shares" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfMzU_9595a44d-6bb8-4353-8478-900703c78af3">5.0</ix:nonFraction></ix:nonFraction> million shares authorized; <ix:nonFraction unitRef="shares" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfNTc_4c6e34ab-49bc-47c9-bf8b-59d0a41dbf16"><ix:nonFraction unitRef="shares" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfNTc_5497a515-2009-4189-b650-a7bfeaef19ac"><ix:nonFraction unitRef="shares" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfNTc_dce86cb3-04f1-4aad-a590-d7b7440f1e71"><ix:nonFraction unitRef="shares" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfNTc_e25c1c2e-d334-4ad5-ab2f-aeb8e753fb4c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMS0xLTEtMTE1NDk2_28b6119e-7177-45a0-84e4-e01f6e8a0aae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMy0xLTEtMTE1NDk2_23e97a46-2de7-4ebe-96aa-109147469501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfMTg_48760c82-34fb-4093-978d-7dd2b75e15fe"><ix:nonFraction unitRef="usdPerShare" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfMTg_9fe717fc-1665-4f71-b6ea-b2434da6eb09">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfMzI_09ea582f-8a7d-49ad-a508-e794306cbce8"><ix:nonFraction unitRef="shares" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfMzI_a025a65b-02e6-463f-b164-b5161f0ef196">220.0</ix:nonFraction></ix:nonFraction> million shares authorized; <ix:nonFraction unitRef="shares" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfODQ_57ed3050-6ce8-4d8c-a27c-1a8e6dad5a1f"><ix:nonFraction unitRef="shares" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfODQ_f82c8773-9541-4704-88b5-795bd5fdf4d1">96.1</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfOTc_978b0d99-94aa-45fd-9a01-9d99d4dc0891"><ix:nonFraction unitRef="shares" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfOTc_b0f4a36a-19c1-403e-8366-42fc9a5c4886">94.9</ix:nonFraction></ix:nonFraction> million shares issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMS0xLTEtMTE1NDk2_442ac603-7ea8-4783-9916-4ed7f09832fe">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMy0xLTEtMTE1NDk2_1ddd3c53-400d-4615-9cb6-9b77dc4a8cf4">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzEtMS0xLTEtMTE1NDk2_cfbb4437-3665-478a-8aac-fcd9ea6e2d7d">2,054.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzEtMy0xLTEtMTE1NDk2_6dd54054-a0f3-4980-86eb-802f89e3aba5">2,011.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzItMS0xLTEtMTE1NDk2_d3355d80-c7dd-4b2e-a93e-aba4aa432677">14.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzItMy0xLTEtMTE1NDk2_dd742540-65d5-484d-83c9-af6cde88f16b">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzMtMS0xLTEtMTE1NDk2_9614e04d-7050-4855-9591-d091747046e9">495.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzMtMy0xLTEtMTE1NDk2_0228c96c-2031-418e-b71c-82c0524bc8d9">635.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzQtMS0xLTEtMTE1NDk2_eaded246-79c4-4333-958e-914d280a3e73">1,544.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzQtMy0xLTEtMTE1NDk2_dac379a7-e52d-492f-ab65-3a2f0eadd377">1,374.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzUtMS0xLTEtMTE1NDk2_febd102f-ff21-4bf2-80eb-068b46b636ea">2,143.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzUtMy0xLTEtMTE1NDk2_fad62869-019f-4072-9a56-53e244cf7463">2,072.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND COMPREHENSIVE INCOME</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44f84f3acc41678a991f68f4e0a4a0_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMy0xLTEtMS0xMTU0OTY_f4e0a268-4a66-4347-93de-25ebbf5364a4">379.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9497c79ced4aeaa7f1db18e0399893_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMy0zLTEtMS0xMTU0OTY_d19f659c-b473-436c-af4e-46d6185fa645">288.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic95f1ad2e17045e4abe097728c7590d4_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMy01LTEtMS0xMTU0OTY_702b0ecc-9841-47b9-bafb-38210d56803a">1,036.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19314b84529d46f99e5c461ac31afdc4_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMy03LTEtMS0xMTU0OTY_67c2c7d9-2fd2-4d44-a980-fe1925cb3ede">786.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a0669f73bd42779f23c7b8c8b7807b_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNC0xLTEtMS0xMTU0OTY_4278fb1c-571b-436d-905e-c19a620c0f06">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9814ecaf809a4416a7ffd9d41c7694f6_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNC0zLTEtMS0xMTU0OTY_88106d89-58e6-4598-8035-932cfa85acc7">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i401123ce4dd945a38b707d60c1882890_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNC01LTEtMS0xMTU0OTY_513420ae-a2d8-4f67-a096-127b1e842cb0">40.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb49c8d270504eda9057c294777b76eb_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNC03LTEtMS0xMTU0OTY_d8953838-3afd-464e-82b5-a16387e5c3d7">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNS0xLTEtMS0xMTU0OTY_0562b7ab-23ce-4b71-9b83-8d3726503db0">387.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNS0zLTEtMS0xMTU0OTY_da2a495b-0be1-448b-a44d-c2b65f6ad24c">296.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNS01LTEtMS0xMTU0OTY_04587b01-ce62-4615-a4b3-2f33b955600e">1,076.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNS03LTEtMS0xMTU0OTY_9b860406-79b5-4c8a-a8cb-4ae203caf1f4">821.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNy0xLTEtMS0xMTU0OTY_30521e5e-ca80-4f62-adab-4434fe1cef64">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNy0zLTEtMS0xMTU0OTY_7381b8c2-026b-42e7-b83c-d20464459499">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNy01LTEtMS0xMTU0OTY_03c4ee2f-8cac-4660-9a51-bc0b7d45bc84">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNy03LTEtMS0xMTU0OTY_12059404-a3b0-46aa-9234-542cae82a51a">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOC0xLTEtMS0xMTU0OTY_fd842791-6571-4332-a9cf-13b815115bf0">107.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOC0zLTEtMS0xMTU0OTY_ff9ca6e5-7a43-4683-b27e-f34979c79074">92.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOC01LTEtMS0xMTU0OTY_677447cc-0bfa-4dce-a2b5-da81567c44b6">345.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOC03LTEtMS0xMTU0OTY_31226472-5538-4640-bf9d-aa4ffbb4015d">240.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOS0xLTEtMS0xMTU0OTY_454a3ee4-fecb-403f-a45f-d55f30dac13e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOS0zLTEtMS0xMTU0OTY_d16ce717-e171-4378-b053-e5898dc04c11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOS01LTEtMS0xMTU0OTY_5e58c864-20cc-4251-9fb8-8088b9b3222a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOS03LTEtMS0xMTU0OTY_3a40b12c-bb1a-41f0-814e-dcd0c6146f8e">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTAtMS0xLTEtMTE1NDk2_22a2ce11-7577-408d-8e52-afaaa65a9386">186.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTAtMy0xLTEtMTE1NDk2_b3e638f7-c6ec-47c3-b64a-cec366e002c6">154.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTAtNS0xLTEtMTE1NDk2_f597090e-b2dd-4655-a8e4-3174afb6170a">569.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTAtNy0xLTEtMTE1NDk2_1194b80d-79bc-491e-9c2e-b51ec9fdd983">426.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTEtMS0xLTEtMTE1NDk2_f39bc802-4478-48a2-acf7-7523b1234d7b">300.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTEtMy0xLTEtMTE1NDk2_800c3684-09da-4b64-bdb8-35d8c8caadff">251.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTEtNS0xLTEtMTE1NDk2_56f2b1ff-8bb3-4bcc-8a48-759fb5bdab7d">931.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTEtNy0xLTEtMTE1NDk2_2e8960d7-7193-4ba4-aa64-0b6468fb3cfd">682.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTItMS0xLTEtMTE1NDk2_933bd2da-4a7b-496a-bf5e-038b8c284be6">87.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTItMy0xLTEtMTE1NDk2_2ecb2837-105e-4194-9b95-a8e405d4d415">44.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTItNS0xLTEtMTE1NDk2_384d74ba-9e45-4be8-a6c5-bdd594676f70">145.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTItNy0xLTEtMTE1NDk2_0d762584-2a87-4ea0-aee4-2168740b5e72">138.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTQtMS0xLTEtMTE1NDk2_5172cc68-c032-45c0-b396-05f3d6065712">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTQtMy0xLTEtMTE1NDk2_7cdcb526-52f5-4955-93bc-4d5e570b2cff">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTQtNS0xLTEtMTE1NDk2_84a17b6c-c1e1-4e25-81b5-c3784a5d98c2">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTQtNy0xLTEtMTE1NDk2_001b748c-c2d3-4ae1-ae64-0ce5ba0eedb0">19.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTUtMS0xLTEtMTE1NDk2_79a5704f-8ea3-4f4a-a2df-65b29e48551f">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTUtMy0xLTEtMTE1NDk2_83be080f-5ad6-4e5c-a406-72420d925b77">8.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTUtNS0xLTEtMTE1NDk2_fe0820a4-4d9f-4f77-8cae-50797d502ea6">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTUtNy0xLTEtMTE1NDk2_2dfcb9e1-2ebf-4de7-9ec7-f147d916029e">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTYtMS0xLTEtMTE1NDk2_8f2ce059-011e-4cfc-85ea-2571f14dd781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTYtMy0xLTEtMTE1NDk2_695616c7-9c33-490f-8f0a-d923542fc33a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTYtNS0xLTEtMTE1NDk2_4fd765ce-5cda-4e6e-9d48-8576a7517045">70.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTYtNy0xLTEtMTE1NDk2_f3f8f4fc-55e2-4c6b-a416-83acfd4fb352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTctMS0xLTEtMTE1NDk2_15e4d388-e50c-43f8-8de1-b5837c2d3536">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTctMy0xLTEtMTE1NDk2_ead5c851-5e04-40a1-baf4-34beaa0d4995">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTctNS0xLTEtMTE1NDk2_7af0dfdf-26e9-4eb4-8cc0-90b9857d9692">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTctNy0xLTEtMTE1NDk2_f39052cc-bf4d-49be-8776-75f2aad310c1">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTgtMS0xLTEtMTE1NDk2_876278ef-a962-4d34-aa5a-7eb8d7129e62">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTgtMy0xLTEtMTE1NDk2_d8528b9d-9fb7-4fbb-b608-c0a6680b55a7">14.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTgtNS0xLTEtMTE1NDk2_5b33d3be-ab45-481d-aee1-3d505d8afe96">49.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTgtNy0xLTEtMTE1NDk2_831dc846-08ff-40ca-9d8f-19ec239d8d19">23.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTktMS0xLTEtMTE1NDk2_09f5dcca-4a33-4b47-b369-70cd7edcfed6">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTktMy0xLTEtMTE1NDk2_103e9f48-37d7-4de2-9adf-bbd186c73eb3">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTktNS0xLTEtMTE1NDk2_deebfaee-455c-43fd-8a63-414c3acb47af">96.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTktNy0xLTEtMTE1NDk2_60655422-c92d-4a25-ac46-14621c712a2e">115.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjAtMS0xLTEtMTE1NDk2_808cc7cd-be91-4213-a1cc-05849cd21a4f">29.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjAtMy0xLTEtMTE1NDk2_fde93efa-c1f3-42ee-83ba-60e43e4a4ba9">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjAtNS0xLTEtMTE1NDk2_2fe37e83-0a30-4009-9d88-9e626c182d1b">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjAtNy0xLTEtMTE1NDk2_00e618c2-0626-41ae-a4ca-26b125744f6f">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjEtMS0xLTEtMTE1NDk2_d165bd12-0af6-4bd3-bf84-e36b589ccd9b">68.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjEtMy0xLTEtMTE1NDk2_bc5b4feb-6033-4dd0-84cb-56f7b9205d07">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjEtNS0xLTEtMTE1NDk2_5005142b-ac6d-4c39-965e-9a18d4976e1f">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjEtNy0xLTEtMTE1NDk2_343ed79c-6daf-4d35-95f7-8d3746fdbc03">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjItMS0xLTEtMTE1NDk2_9df9aa12-d91a-4fb3-aba5-b010b9a77b19">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjItMy0xLTEtMTE1NDk2_32154ca1-f4ab-45ec-befb-d51938b0a4d8">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjItNS0xLTEtMTE1NDk2_a98720fd-f7cc-4d32-a0c7-1bc7a7190454">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjItNy0xLTEtMTE1NDk2_f4dad365-2d6c-4916-ba79-5eb5adec3734">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjMtMS0xLTEtMTE1NDk2_ca56db13-40e8-40b4-8827-0bede05fb854">66.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjMtMy0xLTEtMTE1NDk2_7493a26e-8e38-47ec-b0ff-c5ba8d8780cc">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjMtNS0xLTEtMTE1NDk2_fdcc6c53-8928-4b63-bb7f-3cbd15d70191">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjMtNy0xLTEtMTE1NDk2_dd185b8c-b97a-459b-bbab-d2989f3fefe5">95.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjUtMS0xLTEtMTE1NDk2_7ff4463e-2408-4053-bd59-8394a73a5fb9">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjUtMy0xLTEtMTE1NDk2_5b7563d2-c365-4b2c-a853-8d19e6b0589f">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjUtNS0xLTEtMTE1NDk2_771d20eb-c450-48af-8121-6df08025e468">0.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjUtNy0xLTEtMTE1NDk2_81cc0c2e-3cfd-4a03-afe6-b2ccac956b24">1.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjYtMS0xLTEtMTE1NDk2_c596af9f-c370-4809-8d76-c7613c3700c8">0.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjYtMy0xLTEtMTE1NDk2_d91598bb-1d39-42c0-b5bf-3bd8749e3b3d">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjYtNS0xLTEtMTE1NDk2_96085df6-6d00-48af-ac3a-c29b72de220d">0.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjYtNy0xLTEtMTE1NDk2_9ffa606a-e1e7-45aa-81ef-6f575b092053">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjgtMS0xLTEtMTE1NDk2_f0cedefb-764d-4219-ad88-7b768e7f0ff4">95.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjgtMy0xLTEtMTE1NDk2_df66b321-6202-45b0-9ede-60601a897ccf">94.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjgtNS0xLTEtMTE1NDk2_ff0bdab6-77e4-4e62-a237-08994ea9fb9c">95.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjgtNy0xLTEtMTE1NDk2_bb1b6241-8870-469d-bfc0-3019bf4de0e9">94.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjktMS0xLTEtMTE1NDk2_b2c439d2-b493-4d63-adfc-52f5831e0bda">99.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjktMy0xLTEtMTE1NDk2_b603c4e7-4ebf-4662-b3c7-24b9653d01ee">97.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjktNS0xLTEtMTE1NDk2_ff5db5dc-2c2e-402f-bfaf-0c447e83930f">98.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjktNy0xLTEtMTE1NDk2_547ab153-89ad-4e9b-bcec-b3e18a6fe1d7">97.9</ix:nonFraction></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.469%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ed395fe9cc1449bb7d939fd514068ba_I20220630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy0xLTEtMS0xMTU0OTY_0317bbec-ee71-417f-b945-58e8106dfbb2">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ed395fe9cc1449bb7d939fd514068ba_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy0zLTEtMS0xMTU0OTY_da6251b5-f553-4a3d-a852-926d09299dbe">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07d586d340f45f99771c0d7a421770b_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy01LTEtMS0xMTU0OTY_4000fc33-9f8d-4837-96cf-7ec906d23e75">1,999.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib88cff710aa64f0db32eff49fd8b81ef_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy03LTEtMS0xMTU0OTY_340a2f7c-d6ec-4e61-bece-3afa77d5be42">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c6f9adf4a4f46229cbde98aedf63b35_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy05LTEtMS0xMTU0OTY_0ff4a175-b3ff-4453-852e-219262ca4ab0">564.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44069ab866fd423cb33d0c69f2a3f908_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy0xMS0xLTEtMTE1NDk2_b0c2b9b2-ee32-4a68-b901-ed4278f14e0e">1,423.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i324159b7704844d0ab9d10da3decc855_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNC05LTEtMS0xMTU0OTY_0eb0cd7e-9a8f-4819-9261-38c16daf4173">68.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNC0xMS0xLTEtMTE1NDk2_a12d8120-73cb-40ec-bf63-39794b67f822">68.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6beacf8156fb48ea965024414adc5ab5_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNS03LTEtMS0xMTU0OTY_9d143a23-eb88-4bc3-a621-77e58cab393e">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNS0xMS0xLTEtMTE1NDk2_3966ac36-2d4f-427c-bc30-e5bd9f987c42">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5825bdfeea8640ffa28b46a703daa81b_D20220701-20220930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNi01LTEtMS0xMTU0OTY_8dcabc5f-4e0b-4167-8c02-55c22ccc5106">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNi0xMS0xLTEtMTE1NDk2_d85ef80e-8e03-42db-ae60-4d6bd234854e">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba66c4f94fa34d49b8f74b725073fd80_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNy0xLTEtMS0xMTU0OTY_943ea159-cf33-4dfa-b695-6943ad72f40d">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5825bdfeea8640ffa28b46a703daa81b_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNy01LTEtMS0xMTU0OTY_653b430d-7e5a-48d8-af58-fbd1189fff82">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNy0xMS0xLTEtMTE1NDk2_a4614402-9a6f-4cae-adb7-a630e487c534">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaaef5673cc82499992433df9a4170336_I20220930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC0xLTEtMS0xMTU0OTY_55a4a076-f446-4a27-b417-b640fd2a40bf">96.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaef5673cc82499992433df9a4170336_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC0zLTEtMS0xMTU0OTY_e887345f-2ced-4773-845d-990a73cc1d27">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec663ae2974473c932ec901d2279e45_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC01LTEtMS0xMTU0OTY_753566a3-f04d-4775-8ca3-efe4dc1fdb51">2,054.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14a6e7bfb09240da8df57c0b10f74e22_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC03LTEtMS0xMTU0OTY_c37d4124-2675-42af-991f-a94dc249c44d">14.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f55b27df0414697becfc3c88fdb3675_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC05LTEtMS0xMTU0OTY_f45461dd-944a-4613-8923-39da261365a8">495.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC0xMS0xLTEtMTE1NDk2_b660c7fe-80c4-473e-9042-2ec840e4ce94">1,544.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0d7237003994ddb914ef3572076e2d3_I20210630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtMS0xLTEtMTE1NDk2_f619a80b-5ee4-4ecb-b21b-e510e6eb77e4">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d7237003994ddb914ef3572076e2d3_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtMy0xLTEtMTE1NDk2_2495c4db-f0b5-43f4-95ec-c0739728731d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1fb24b2c68e4e50a0786e67d741db84_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtNS0xLTEtMTE1NDk2_0502752a-7f01-416e-ba4a-df7da44d5167">1,929.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031a6b6ce49a43efb4f5777c5cd53c63_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtNy0xLTEtMTE1NDk2_2ab0e412-1191-41b6-af5a-55357dc9696e">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78153a6965184d7c88703cc188594611_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtOS0xLTEtMTE1NDk2_9f16b92e-4064-478d-b2bf-6b0327769fb5">651.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7f36f1d6364a3ba48295705c5a6577_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtMTEtMS0xLTExNTQ5Ng_f71a8cf0-e43c-4819-806b-a85e34f9cfab">1,279.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1366392be644cdb1fdf15d68cc7c12_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTEtOS0xLTEtMTE1NDk2_31fd1479-8557-4583-af3e-2aeba1800fb1">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTEtMTEtMS0xLTExNTQ5Ng_90e5d7d5-aed5-4746-a186-f28c367ef68a">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96745670dede4bf7b3baf9f45f84ddbe_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTItNy0xLTEtMTE1NDk2_5078c081-a1de-49fb-b868-4df5f270a935">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTItMTEtMS0xLTExNTQ5Ng_4300d0bb-e518-4961-966a-33d7cdaa8536">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i858eddcb9f684bed940a6fbd8a8477ad_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTMtNS0xLTEtMTE1NDk2_b764f469-3644-498a-b71d-7d5f36cb2808">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTMtMTEtMS0xLTExNTQ5Ng_f04a3768-904c-4bb0-9b7d-2ac3bfd3b65e">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9e66c6f25b84530a5fb28be5eae8546_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTQtMS0xLTEtMTE1NDk2_f7cc4b37-92e2-4383-9073-ad8cda4365d5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i858eddcb9f684bed940a6fbd8a8477ad_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTQtNS0xLTEtMTE1NDk2_f21c6305-a62d-42f4-bd5c-3c66aa714683">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTQtMTEtMS0xLTExNTQ5Ng_c4d551b3-d459-4471-b8ae-e1aec20305f2">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5ae523d047d497ba5e50594b29cf3b2_I20210930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtMS0xLTEtMTE1NDk2_2eefda1f-8641-4448-abe2-bd319d5072a6">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ae523d047d497ba5e50594b29cf3b2_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtMy0xLTEtMTE1NDk2_da1b59e2-5a6c-4126-95ab-5a6d3c6557d6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516ff9b620b94979821df492ffccf0d2_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtNS0xLTEtMTE1NDk2_1b014b59-e0b3-41bf-9747-9f38fd9438de">1,974.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adb983cdb174ff39bb4b981e7ce9650_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtNy0xLTEtMTE1NDk2_754c25a2-46c6-48a9-b59c-3e24bc27b109">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedd9ce6e56184b7999d247c1dc25eabe_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtOS0xLTEtMTE1NDk2_787a1fbf-41bb-42f5-afc1-cd4a2e77bcc2">628.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtMTEtMS0xLTExNTQ5Ng_aafd9c3d-cdac-4542-871a-935b965c16d6">1,346.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72d0b3550c5e44f5be3613d00e3a1b13_I20211231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctMS0xLTEtMTE1NDk2_b92abf76-9309-4488-9791-69e4defa4ab7">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d0b3550c5e44f5be3613d00e3a1b13_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctMy0xLTEtMTE1NDk2_1e9560e1-3bdb-47d9-b468-5bb3f8a546b9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ee8e9be30b406da6b582097952f9d4_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctNS0xLTEtMTE1NDk2_3ed78212-f588-484d-871a-b2491214f68c">2,011.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b7d3cbd4ae44165b3954e2ed6ee365b_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctNy0xLTEtMTE1NDk2_cf690b87-f6cf-4a1b-8193-8a28fc3f36c6">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10242909a1074444b3e2545c393d3f32_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctOS0xLTEtMTE1NDk2_8cd5ab37-e8cf-4c47-9018-9220af3e7176">635.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctMTEtMS0xLTExNTQ5Ng_0caf46d5-efda-43ec-89da-3ee0d6936bcf">1,374.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a3b29344c14dbe9ec425f46e47ae87_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTgtOS0xLTEtMTE1NDk2_b8526c83-6c98-46a2-a0a7-2f18dae272fc">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTgtMTEtMS0xLTExNTQ5Ng_ea022516-225d-4d6d-87f5-a09570a87bb3">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23c65102bd2e4adeb5ea816771ce177b_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTktNy0xLTEtMTE1NDk2_0f9a7885-63a0-48cd-93ea-cd882bff9d9b">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTktMTEtMS0xLTExNTQ5Ng_33f85228-8047-4e6f-8cef-9e972121938e">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjAtMC0xLTEtMTE1NDk2_1e393d84-1da2-402e-9cd4-e46f6dd5b945">Cumulative-effect adjustment due to adoption of ASU 2020-06</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c1ded1a54114c989385f9d44f2fea9e_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjAtNS0xLTEtMTE1NDk2_3223897c-6a05-4bff-8931-7cc63606cd8e">106.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde886332b6d4f1ab3402bed3a5fc8fc_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjAtOS0xLTEtMTE1NDk2_603d4105-1a4e-4d32-9688-7948b2b55da6">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i366ff930ea93441a960a632e36fee44b_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjAtMTEtMS0xLTExNTQ5Ng_d0f2b6f2-e722-412e-a170-256ab87c5965">32.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38341b51bfd94d92bcf639e9e87abf56_D20220101-20220930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjEtNS0xLTEtMTE1NDk2_18d6520a-2e21-4586-87b2-05a715f86a75">129.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjEtMTEtMS0xLTExNTQ5Ng_7b3b13cf-8c02-42c0-a21d-6389235b67d8">129.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i567085fe5058473dabeb8fb3a2603864_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjItMS0xLTEtMTE1NDk2_9ace3d95-772c-4f06-a1ed-424a5ddfcceb">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38341b51bfd94d92bcf639e9e87abf56_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjItNS0xLTEtMTE1NDk2_6ba0b635-e0f6-4054-aff1-3e973452c330">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjItMTEtMS0xLTExNTQ5Ng_98f180f4-026e-479a-bd4f-6289cf531d08">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaaef5673cc82499992433df9a4170336_I20220930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtMS0xLTEtMTE1NDk2_11112210-d9d8-4576-9793-d7ce4b0070aa">96.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaef5673cc82499992433df9a4170336_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtMy0xLTEtMTE1NDk2_d7d59f16-85ed-4857-a668-31d6d68d2e8d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec663ae2974473c932ec901d2279e45_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtNS0xLTEtMTE1NDk2_078c1165-e86a-42c6-bec5-bb1257a3ac92">2,054.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14a6e7bfb09240da8df57c0b10f74e22_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtNy0xLTEtMTE1NDk2_d3abecdf-d001-4e39-8fca-d90acae3482a">14.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f55b27df0414697becfc3c88fdb3675_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtOS0xLTEtMTE1NDk2_13fa274e-454d-442b-a1ba-61ecd1a52f68">495.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtMTEtMS0xLTExNTQ5Ng_3c9f8b60-8a24-4685-9379-914a45b1901f">1,544.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc1223dc268f4291a7665d63b9b7a94b_I20201231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtMS0xLTEtMTE1NDk2_7c624106-d413-4b47-9f95-aabf1226ca5c">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1223dc268f4291a7665d63b9b7a94b_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtMy0xLTEtMTE1NDk2_371b7315-3997-430e-8692-105dcb99249a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84e58872dfd4571bebfb56f5496b527_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtNS0xLTEtMTE1NDk2_cbf60a6d-66ed-4827-b57e-109bd7224bfc">1,849.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74d31171db5404580903e96807daec4_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtNy0xLTEtMTE1NDk2_0170b05d-c8da-4563-9833-722bfbb37e7a">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe17b0ffe694754b8dd32868036e3e1_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtOS0xLTEtMTE1NDk2_fd5db390-91dd-4234-8e3a-14826fadfa9c">725.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bac18c0efcf4ec5a02f7ce6edaaab4e_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtMTEtMS0xLTExNTQ5Ng_88ca0f80-68f2-45da-a759-202274aadd8f">1,126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7fbc21c2904c9b893e0cbd3313df98_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjYtOS0xLTEtMTE1NDk2_47c35b01-74d9-4a72-a3c6-247dac7b04a9">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjYtMTEtMS0xLTExNTQ5Ng_111b3d25-ecb5-4ba4-923b-d3a944e43ba1">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide286c9ed2ab4936a7d1621b6a95fce8_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjctNy0xLTEtMTE1NDk2_42f7ed2e-894a-4ac4-8e30-0804c0e159c6">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjctMTEtMS0xLTExNTQ5Ng_165c9b38-f30b-4dee-a409-4c7d20315b9a">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58820f78b294bfe91aa7c6ad11e3cd8_D20210101-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjgtNS0xLTEtMTE1NDk2_828cbc3f-fe6e-4a5c-b690-b1d536c9d281">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjgtMTEtMS0xLTExNTQ5Ng_8dbceab1-7d81-494f-b0a0-12f70a916420">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70caea784a864bd89ac94bdd2e53e6b8_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjktMS0xLTEtMTE1NDk2_5ded6f7c-a747-4192-a1ef-e16b64ce23d0">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58820f78b294bfe91aa7c6ad11e3cd8_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjktNS0xLTEtMTE1NDk2_e30cb695-d590-4968-ae83-87d52251115b">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjktMTEtMS0xLTExNTQ5Ng_ffbbdd63-4305-4e57-9702-b8f88154deae">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5ae523d047d497ba5e50594b29cf3b2_I20210930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtMS0xLTEtMTE1NDk2_f18ee2d4-5dc7-482c-8327-1f2a98932b78">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ae523d047d497ba5e50594b29cf3b2_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtMy0xLTEtMTE1NDk2_3e39b9a6-7f7a-447e-a2dd-b0f596e3d4f1">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516ff9b620b94979821df492ffccf0d2_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtNS0xLTEtMTE1NDk2_8086e5fd-118e-452d-ab3d-d41a6380e4df">1,974.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adb983cdb174ff39bb4b981e7ce9650_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtNy0xLTEtMTE1NDk2_ae4e7356-d22f-4c40-a764-61e50924a6ce">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedd9ce6e56184b7999d247c1dc25eabe_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtOS0xLTEtMTE1NDk2_5decca5f-aa0c-4f1b-9fa6-818c5aec4d53">628.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtMTEtMS0xLTExNTQ5Ng_c8d691ea-edf9-4978-aa78-b4a6d1a11e97">1,346.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMy0xLTEtMS0xMTU0OTY_1c1e8760-6156-4c21-b340-8afed23f19fe">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMy0zLTEtMS0xMTU0OTY_02d82184-8904-40fb-a9e2-255c2658689b">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNS0xLTEtMS0xMTU0OTY_c8084eeb-0a69-4f77-a46a-465b6e80adfd">129.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNS0zLTEtMS0xMTU0OTY_eb1427a9-68d5-43d6-8dc8-39bcc37a0aec">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNi0xLTEtMS0xMTU0OTY_9f62d3a9-e784-400f-b899-d1e3fd4c697b">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNi0zLTEtMS0xMTU0OTY_e03dc57d-2449-4136-ac28-f4f26774f6b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNy0xLTEtMS0xMTU0OTY_bc5ed9cd-9d18-44b2-a175-29ab6370131a">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNy0zLTEtMS0xMTU0OTY_f3b74cd8-3095-4e85-87fd-d23a7209c46f">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfOC0xLTEtMS0xMTU0OTY_434fae77-6904-4a04-9115-b1f58b85e719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfOC0zLTEtMS0xMTU0OTY_603bae7f-d9d3-401e-85ca-b7804ae8fe62">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfOS0xLTEtMS0xMTU0OTY_d9b51c55-36ad-46b1-b298-cba3dc1f6857">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfOS0zLTEtMS0xMTU0OTY_bfd22372-2a2d-4afc-971a-dd849769f1f6">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity security investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTAtMS0xLTEtMTE1NDk2_12b72872-414b-4427-8723-5a4dc2ee4747">23.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTAtMy0xLTEtMTE1NDk2_24f8ae84-f49b-4d70-946b-1a8156c13ff9">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTEtMS0xLTEtMTE1NDk2_54dbd905-7484-4f84-bebb-cddc0c9cf820">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTEtMy0xLTEtMTE1NDk2_2e021f41-baa7-4c73-b66a-c6185f613857">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTItMS0xLTEtMTE1NDk2_b510fe00-78cc-4e97-88b7-377a116de4c5">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTItMy0xLTEtMTE1NDk2_1b3e07df-8548-4e21-b2e9-28d1bc3f9c9a">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTQtMS0xLTEtMTE1NDk2_2deb35de-d34b-414e-ba32-56e7be097646">115.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTQtMy0xLTEtMTE1NDk2_c5b00af0-7258-4898-a71a-512b4b2516cd">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTUtMS0xLTEtMTE1NDk2_24a4b6f4-fa17-4308-a142-4979ba7d9c8e">6.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTUtMy0xLTEtMTE1NDk2_becfd72f-3acf-4b49-a7d1-95d751cb6554">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTYtMS0xLTEtMTE1NDk2_c2523147-30d9-4163-98a8-de35122727d1">77.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTYtMy0xLTEtMTE1NDk2_a2098cf7-eba1-4287-8d08-1bc792104c82">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTctMS0xLTEtMTE1NDk2_1b06df28-9114-4769-93a2-c183aa2a2e84">20.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTctMy0xLTEtMTE1NDk2_66eb57ff-8d98-42cc-9632-8db75ef11b5e">21.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTgtMS0xLTEtMTE1NDk2_ba871aeb-c10f-4d1b-b331-c091bc177ff2">196.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTgtMy0xLTEtMTE1NDk2_80be3042-a84b-415b-8d1c-85aa527e20b5">252.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjEtMS0xLTEtMTE1NDk2_b27bec77-036d-44aa-87bf-f352d7762cc9">387.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjEtMy0xLTEtMTE1NDk2_1c3ba597-2e0e-4ca7-8d48-081053a96733">658.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjItMS0xLTEtMTE1NDk2_78772e24-97e2-4b42-83cf-3474b7efb9f9">348.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjItMy0xLTEtMTE1NDk2_ea97b75b-63d4-4cbe-a884-8662aa8df9e4">523.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjMtMS0xLTEtMTE1NDk2_97a9b58b-861d-46b5-ac6c-a91743140be6">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjMtMy0xLTEtMTE1NDk2_a4ca32e6-674f-475a-95fd-0c204e27a5d6">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjQtMS0xLTEtMTE1NDk2_f9f7406e-6942-42df-9b06-e4ec466c2617">14.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjQtMy0xLTEtMTE1NDk2_bf8bfe41-3ff0-4ae3-93d8-5ce4681f5ec8">14.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjUtMS0xLTEtMTE1NDk2_dabae256-81e4-4bd0-b67a-d5c4d63f9514">61.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjUtMy0xLTEtMTE1NDk2_eb21e8f3-2bc3-48d4-8889-d3c4ff149151">153.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjgtMS0xLTEtMTE1NDk2_9085e880-f4e1-455a-a4ca-7ee725168a67">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjgtMy0xLTEtMTE1NDk2_ce1df91f-0437-4f81-a677-2d2276994e9e">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjktMS0xLTEtMTE1NDk2_9f8a4ace-5420-44d5-b76d-dd5b108c8ba2">279.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjktMy0xLTEtMTE1NDk2_8f99fee3-5f4c-451c-8938-5e3c04799692">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzAtMS0xLTEtMTE1NDk2_e7fbbc77-d6a3-4630-9b8e-3d0c3d449167">258.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzAtMy0xLTEtMTE1NDk2_2aa398fd-3835-410a-9f4e-f2be220cefcb">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzEtMS0xLTEtMTE1NDk2_25ce5e0f-18d6-4ba5-aa61-18e90f511ef6">124.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzEtMy0xLTEtMTE1NDk2_d8425f94-9102-4a24-82f8-efaf828a38b8">124.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzItMS0xLTEtMTE1NDk2_7b69bd07-7514-4268-a145-b4439fd751ea">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bac18c0efcf4ec5a02f7ce6edaaab4e_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzItMy0xLTEtMTE1NDk2_16bd4e0f-f52e-459a-b165-0bbb4d2f16ac">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzMtMS0xLTEtMTE1NDk2_f7815c9c-e0b6-4a43-b058-c52d5176f12b">220.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzMtMy0xLTEtMTE1NDk2_996c595c-c04e-4336-a8ff-daf8a182c0b1">314.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash capital expenditures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzYtMS0xLTEtMTE1NDk2_a1db4d0e-bcc1-4223-b778-13d4d6b96dc1">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzYtMy0xLTEtMTE1NDk2_102e5766-496a-4ed2-a8ef-7777ce5caa8e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets acquired through operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzctMS0xLTEtMTE1NDk2_487e67bd-cf1b-4642-90d9-2d8aed5af79c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzctMy0xLTEtMTE1NDk2_b611385f-8a60-4259-8560-1e5b3c38e26b">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzgtMS0xLTEtMTE1NDk2_fd71ed82-3be7-4a3b-a714-e126a7853db8">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzgtMy0xLTEtMTE1NDk2_334394f2-8d16-4539-8e74-a21f1e1b0f15">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzktMS0xLTEtMTE1NDk2_bacfb1a7-80d6-4b9a-b3f7-0514ab223e0b">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzktMy0xLTEtMTE1NDk2_e369bc07-93d1-44c2-940a-5e023b219765">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="iff439a36db274cfaa026518ede3eda49_31"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzMzNQ_62f9a57f-ec40-4534-a2a7-156a53051d56" continuedAt="ib480aec8609e41a08e084f6dc954ff3b" escape="true">Organization and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ib480aec8609e41a08e084f6dc954ff3b"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzMzNw_f95d1718-7729-464c-b772-b4bd29218011" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzMzOA_308a7a41-84d0-49e5-908f-5786b34760a8" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMTc2OQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjMyOQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjU3MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the <ix:nonFraction unitRef="number" contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjgyNQ_f1039814-97ea-4016-af7e-82d16e67cdd1">2.25</ix:nonFraction>% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjg5NA_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $<ix:nonFraction unitRef="usd" contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzIwOA_3fadbf96-fab2-4a82-9eb0-63ce21e29837">42.2</ix:nonFraction> million, reduced deferred tax liabilities by $<ix:nonFraction unitRef="usd" contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzI0OA_cf096fb4-0369-4106-b684-b56c27e6f653">9.9</ix:nonFraction> million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzI5MA_c3d58a77-1cb2-4f4c-ba05-6c06fe4c9975">106.8</ix:nonFraction> million and reduced the accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzMzMg_5f4baac4-e767-43f4-9684-8d5a56c1dbfa">74.5</ix:nonFraction> million.</span></div></ix:nonNumeric></ix:continuation><div id="iff439a36db274cfaa026518ede3eda49_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjE1MDU_20d66ece-2443-4a73-b370-3079ca72ba94" continuedAt="i392997dd33b044a79a0a3e293c839509" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i392997dd33b044a79a0a3e293c839509" continuedAt="i102619b8a77f4990ae639474bec74194"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heptares Therapeutics Limited, or Heptares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which compounds we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase II clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing and commercialization costs of any collaboration product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Heptares $<ix:nonFraction unitRef="usd" contextRef="i5df8b3da765848b7b1e13148e4a5f0ac_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTMxMQ_a718ce03-7fe2-4a1d-bedc-67fb1431c0d0">100.0</ix:nonFraction> million upfront, which, including certain transaction-related costs, was expensed as in-process research and development, or IPR&amp;D, in 2021. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i102619b8a77f4990ae639474bec74194" continuedAt="ifc962f5097c3450ea20729284ee90f58"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the United States Food and Drug Administration's, or FDA's, acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $<ix:nonFraction unitRef="usd" contextRef="ic54ce1de757a4c65bf42b4362a4de196_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfNTQ5NzU1ODM4ODU3_c2ccea06-5e25-4131-a9de-55a8581c73fc">30.0</ix:nonFraction> million, which was expensed as research and development, or R&amp;D, in the second quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="iee8c3876d62e426f8ca317331158e084_I20220930" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA0MQ_f08bae6f-f777-419d-9d0a-34713e79b7d3">2.6</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#8217; written notice to Heptares during the research collaboration term and upon 90 days&#8217; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early to mid-stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the 4 non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development and commercialization costs of any royalty-bearing product. With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase II clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical trial for such compound.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $<ix:nonFraction unitRef="usd" contextRef="i94db63ec77c8436ab4bc0f734a8773d3_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfNTQ5NQ_600b112f-2d90-4be5-91ed-c66172155082">120.0</ix:nonFraction> million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i6afab7bf36d74de2bbf8ef61c544135a_I20220930" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfNTgxMQ_c69931f1-ac8f-470d-b1b1-e7312d6e3fb9">1.9</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in July 2022, a milestone of $<ix:nonFraction unitRef="usd" contextRef="i1f569faa178b45c18012ecef36524f9f_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfNTQ5NzU1ODQ0Njg1_66151077-556c-4a41-86fe-48c5212d87dc">5.0</ix:nonFraction> million was expensed as R&amp;D in the third quarter of 2022, which we expect to pay to Takeda in the fourth quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifc962f5097c3450ea20729284ee90f58" continuedAt="i893c4c331b5448ce8c828c75aa900554"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or in one or more (but not all) of the United States, Japan, the European Union and the United Kingdom, or, collectively, the major markets, upon six months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#8217; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Idorsia $<ix:nonFraction unitRef="usd" contextRef="i62cff9c5fde445f89dc7148fdddd5d1f_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfOTIwMw_3fb226b1-a2eb-4fd4-9299-d85fa7bc890c">45.0</ix:nonFraction> million upfront, which was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="ibf4f4cb73b3749bbbf050c1a913538e0_I20220930" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfOTQ3NA_abd2e36c-0adb-457c-9e24-83360761ea36">1.7</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Xenon $<ix:nonFraction unitRef="usd" contextRef="i229c41a0bfa841e1a21acad7a1d13142_I20191231" decimals="-5" name="nbix:UpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA1MzQ_abaaf02e-ec1b-4389-a771-56d3b3269eec">50.0</ix:nonFraction> million upfront, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="ic7447780aa7a4acd84f15c1df4fd1ada_D20190101-20191231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA1ODQ_6e309a4d-4a96-456f-a2a6-707ec96ec46e">1.4</ix:nonFraction> million shares of Xenon common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="i229c41a0bfa841e1a21acad7a1d13142_I20191231" decimals="3" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA2MjA_44537838-efad-4142-857e-40903261ebca">14.196</ix:nonFraction> per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i229c41a0bfa841e1a21acad7a1d13142_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA4MDc_2e7ba1d2-f128-4e9b-b495-1ee673f06a69">14.1</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="i739f24694cca4f96aa40688cb5643a85_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA5NDY_c17d1f70-ba79-4641-939c-ed58da411bd4">36.2</ix:nonFraction> million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the European Union&#8217;s approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021, we paid Xenon a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="i672c8742c0424d8e9899e8cf653e3879_I20211231" decimals="-5" name="nbix:MilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTEyNjI_1638fd7e-cb32-45aa-b6ad-d8e5bd10a93f">10.0</ix:nonFraction> million, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="i436998f220e64b2d85633913fc679dd2_D20210101-20211231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTEzMDQ_d6ee462e-2a59-4822-827c-02379124ec79">0.3</ix:nonFraction> million shares of Xenon common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="i672c8742c0424d8e9899e8cf653e3879_I20211231" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTEzNDA_8b1de6c1-8f03-44fe-b371-0b466609fe82">19.9755</ix:nonFraction> per share). The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i672c8742c0424d8e9899e8cf653e3879_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE0MDk_ab654c71-918a-4e24-8137-aa283e0482ce">4.6</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="ieca44e6f568f4cce81a0f0b62a9e6ed8_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE1NDg_f6d74feb-8160-4d28-9700-24faf954fedf">5.4</ix:nonFraction> million of the milestone payment was expensed as R&amp;D in 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in January 2022, we paid Xenon a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="ie1fc719c24174081baf340c8e1ed9345_I20220331" decimals="-5" name="nbix:MilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE3NDA_b1d83f44-89b1-48e9-a3fd-2d0c2e1f5787">15.0</ix:nonFraction> million, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="ic054d101780b4681bad0f8685e5eb620_D20220101-20220331" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE3ODI_9b6e0e9a-0abc-424e-89ad-c1ec6990d79e">0.3</ix:nonFraction> million shares of Xenon common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="ie1fc719c24174081baf340c8e1ed9345_I20220331" decimals="3" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE4MTg_b7a3a213-7257-44a0-a03e-066eff35c363">31.855</ix:nonFraction> per share). The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="ie1fc719c24174081baf340c8e1ed9345_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE4ODc_37689116-54eb-47d8-9314-39fab9a0c057">7.7</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date. The remaining $<ix:nonFraction unitRef="usd" contextRef="i651b70e3e4884c87b5c8f6c691e732c9_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE5Njc_a75fdc01-3be3-41a2-8d7b-d6c330525cdf">7.3</ix:nonFraction> million of the milestone payment was expensed as R&amp;D in the first quarter of 2022.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i893c4c331b5448ce8c828c75aa900554" continuedAt="i7f2e726e362e438896fc3180eda85822"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i14108dce2bd342338c0eaada7d66ed9f_I20220930" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTIxNDc_96642a96-c350-432d-be07-b964863dc91e">1.7</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the United States and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#8217; written notice to Xenon, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Voyager, pursuant to which we acquired certain rights to develop and commercialize the NBIb-1817 for Parkinson&#8217;s disease program, Friedreich&#8217;s ataxia program and two undisclosed programs. We are responsible for all development costs of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program, which became effective August 2, 2021. The termination did not apply to any program other than the NBIb-1817 for Parkinson&#8217;s disease program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="id5c2d75942864117893c1167135a171c_I20191231" decimals="-5" name="nbix:UpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQzMzE_69e62237-c636-46a6-9961-ca847751a6e6">165.0</ix:nonFraction> million upfront, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="icb6ee5ada95b4566aa1c9a8b49eccd5d_D20190101-20191231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQzODE_e213be40-4d1c-4e03-930c-df5254133490">4.2</ix:nonFraction> million shares of Voyager common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="id5c2d75942864117893c1167135a171c_I20191231" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQ0MTk_b65db9e3-ca22-49c8-bd51-0ff4e01735b0">11.9625</ix:nonFraction> per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="id5c2d75942864117893c1167135a171c_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQ2MDY_780a383a-2c40-4c95-9a18-20c15e2116ef">54.7</ix:nonFraction> million after considering Voyager&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="ifc36a091f0fb425ca083c03b1d5b9108_D20190101-20190331" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQ3NDc_f43091ea-65f2-4d71-a645-7c54ed5b63b5">113.1</ix:nonFraction> million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019. In addition, we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="i22270e6ff4f141aea1c8f066676c3e93_D20190401-20190630" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQ4ODM_4a416ca6-e294-4198-9017-55a904ce8b35">5.0</ix:nonFraction> million upfront, which was expensed as IPR&amp;D in 2019, to acquire the rights outside the United States to the Friedreich&#8217;s ataxia program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i9baa790a842c4e00b5d7aea97ed51955_I20220930" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTUxMjA_1413ce7e-7abf-4bdd-8c5f-2a086973e48f">1.3</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement. We may terminate the agreement upon 180 days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired the United States and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(opicapone) from BIAL in 2017, and launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We are responsible for all commercialization costs of ONGENTYS in the United States and Canada and rely on BIAL for the commercial supply of ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, BIAL may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i704ab482b22e45fa8b591f730cc65111_I20220930" decimals="-5" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTY0Mjk_63004f0b-3caa-4bf9-877c-49eef1d1c976">75.0</ix:nonFraction> million upon the achievement of certain event-based milestones. In addition, with respect to ONGENTYS, in the event we fail to meet certain minimum sales requirements for a particular year in comparison to our annual sales forecast for such year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year. Further, upon our written request to BIAL 12 months prior to the estimated expiration of the term of a licensed product, we will negotiate the continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is no longer supplying such licensed product, BIAL would be entitled to receive a low double-digit royalty on our future quarterly net sales of such licensed product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until a generic product with respect to such licensed product is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7f2e726e362e438896fc3180eda85822"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement upon nine months&#8217; written notice to BIAL. BIAL may terminate the agreement in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#8217;s insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In December 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we agreed to supply MTPC with valbenazine drug product for commercial use in Japan and other select Asian markets. MTPC is responsible for all development, manufacturing and commercialization costs of valbenazine in such markets.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, MTPC launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan for the treatment of tardive dyskinesia. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i0635b37952e44f7286d405737fc817b2_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTg4OTU_6b79f97c-b997-4814-985d-c9ec0b7bfdde">20.0</ix:nonFraction> million in the second quarter of 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#8217;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in the second quarter of 2022. In addition, we receive royalties at tiered percentage rates on MTPC net sales of DYSVAL.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i4243abfeabbc4f8fb0fcb634ef8fc677_I20220930" decimals="-5" name="nbix:PotentialMilestonePaymentReceipts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTk4NTY_e40002d2-1847-46d0-906e-e5547d83b734">30.0</ix:nonFraction> million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of <ix:nonNumeric contextRef="iac2a51b5f62848819ec910c25d7f2308_D20220101-20220930" name="nbix:PatentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjAwMzc_f6d4e0ca-862f-4254-bdf1-e74612cf5dc6">10</ix:nonNumeric> years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the United States for the treatment of moderate to severe pain associated with endometriosis. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="i2d2fb655446647d285e1b13940b27b9a_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA5MDk_d387630d-7f2e-4c1e-bb21-93a950ecd93b">6.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iae6fe2cc66814ab7bb20abd508f23227_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA5MTY_796e0b72-6b70-4b8e-9fc9-9239c08bbb67">15.5</ix:nonFraction>&#160;million, respectively, for the three and nine months ended September&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i7c2e568d37774c2babc5f26a9b4a305b_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA5NjU_b5229f6a-ca08-4134-be45-5ff2a3d7eb4e">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5cf793309e7a403c9867c00418ded9b8_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA5NzI_58817195-245f-4075-bd40-5730a067c262">16.3</ix:nonFraction> million, respectively, for the three and nine months ended September&#160;30, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i966fced94cdb4f9b9b690c806b6192f2_I20220930" decimals="-5" name="nbix:PotentialMilestonePaymentReceipts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjExMzc_8b557a26-768e-4767-a93b-d3da9c5cad5e">366.0</ix:nonFraction> million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of <ix:nonNumeric contextRef="i8edd28eddf194035b1e8ecf4e46d867d_D20220101-20220930" name="nbix:PatentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjEzMTc_9a0a4aaf-ad37-492f-a223-8c2cf5eb098e">10</ix:nonNumeric> years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTc5Mw_ade95ea4-1f06-4fc5-b1af-8f837e53c494" continuedAt="i30b44d36600c4c989cb113cc3b6e48c8" escape="true">Debt Securities</ix:nonNumeric></span></div><ix:continuation id="i30b44d36600c4c989cb113cc3b6e48c8"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTc5NA_6932090e-6132-4cfb-a4bf-f5becfa2ebe1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0zLTEtMS0xMTU0OTY_7dab9c0b-8d56-4959-8b36-8680b40552fb">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi01LTEtMS0xMTU0OTY_bae4c493-8f01-4d7f-a87a-21702d29a2d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi03LTEtMS0xMTU0OTY_29e516ec-cae3-48fb-b82c-78c3821022f5">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi05LTEtMS0xMTU0OTY_02ab5b9b-f08a-4d20-a830-133f7921b86c">97.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53c84fbe1cd4494b369d17f941323c3_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0xMS0xLTEtMTE1NDk2_9ce8e4cf-edc4-4c55-865a-00d89209112c">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53c84fbe1cd4494b369d17f941323c3_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0xMy0xLTEtMTE1NDk2_cfc314c6-5014-4bc1-841c-7bd6fc05385b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53c84fbe1cd4494b369d17f941323c3_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0xNS0xLTEtMTE1NDk2_ffe7fe15-ba84-4c11-8044-a2915facd779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53c84fbe1cd4494b369d17f941323c3_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0xNy0xLTEtMTE1NDk2_9feae00f-92f9-491a-a76a-47f483337c99">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0zLTEtMS0xMTU0OTY_87d858af-afee-42fd-9df5-a48bc42ab385">260.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy01LTEtMS0xMTU0OTY_d428b901-21d9-4106-8462-d9ce0a8e9688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy03LTEtMS0xMTU0OTY_2d4bcf74-ae67-473c-b9ee-f8f504f6f857">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy05LTEtMS0xMTU0OTY_e5433f29-8a32-4fbd-9bad-4de6912d00db">257.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0xMS0xLTEtMTE1NDk2_1cf4dfd3-3af0-4757-ae96-ef81fc2483b3">128.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0xMy0xLTEtMTE1NDk2_fe9f794d-5080-4e20-9a79-b0893fde91bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0xNS0xLTEtMTE1NDk2_79c541a0-0106-4437-9afd-379b2edf2dbb">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0xNy0xLTEtMTE1NDk2_b5f7fe5e-7136-40f8-8f93-3590afc1a086">128.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0zLTEtMS0xMTU0OTY_473f22d5-2ac6-499f-9f47-908d22f21d20">237.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC01LTEtMS0xMTU0OTY_6c5c4d33-8b10-42d8-8fbc-930be3afaff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC03LTEtMS0xMTU0OTY_d6a88a9a-22c5-427e-8978-7899ae493017">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC05LTEtMS0xMTU0OTY_4aa9758e-a6ed-40bc-85c5-946e66d65000">232.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0xMS0xLTEtMTE1NDk2_2eb624ba-cb49-4c16-9e3d-9e77de2b1093">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0xMy0xLTEtMTE1NDk2_8de0aba1-85a3-4b05-ba41-69eb5f7f3ef3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0xNS0xLTEtMTE1NDk2_608a270d-0f5d-4224-9311-ffa6a6b92a1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0xNy0xLTEtMTE1NDk2_9d0d803c-08b6-44b4-8395-7862f84ac84f">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0zLTEtMS0xMTU0OTY_03fb1589-5729-494f-80d8-40d0e1afe333">595.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS01LTEtMS0xMTU0OTY_4614bcdc-bb31-44c2-b467-97f6aeab1b14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS03LTEtMS0xMTU0OTY_59276614-4255-4955-9dbf-a795b5952089">8.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS05LTEtMS0xMTU0OTY_68f73d94-f38a-4afd-b8d4-070418e2a33b">587.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0xMS0xLTEtMTE1NDk2_f0bc1683-6f2e-47bb-9208-ca9917bb07db">370.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0xMy0xLTEtMTE1NDk2_246c677c-67de-4bfe-b16b-f43a82d4926f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0xNS0xLTEtMTE1NDk2_1eec525a-1405-47ea-862d-2b1474c2f2f6">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0xNy0xLTEtMTE1NDk2_e9972dad-6e4e-44a0-8406-b4316cfb2d39">370.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0zLTEtMS0xMTU0OTY_52005b43-f4ea-491d-b607-1bb44488d1f8">270.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy01LTEtMS0xMTU0OTY_99d60e45-d74e-4b1d-998e-47714a234506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy03LTEtMS0xMTU0OTY_d9360b8f-7826-436d-acda-bacb20d5da22">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy05LTEtMS0xMTU0OTY_80158ac2-ffbd-48b1-81fe-c047e81b570b">264.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0xMS0xLTEtMTE1NDk2_58fbf18e-5197-49c1-a52b-e0a4439a051d">358.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0xMy0xLTEtMTE1NDk2_4411ca76-ed3f-428b-bf95-e3d331dd346a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0xNS0xLTEtMTE1NDk2_4c57e54d-20ed-4362-bd3d-176a0fb9b98a">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0xNy0xLTEtMTE1NDk2_abe59a87-1b94-4387-94ba-46ba983b9caf">357.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0zLTEtMS0xMTU0OTY_44483ab0-5ebb-442f-ba76-f603d011a82f">102.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC01LTEtMS0xMTU0OTY_623aad95-f01b-418c-943d-2b5c87b7dfac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC03LTEtMS0xMTU0OTY_033d0f67-5eb3-4704-836b-c5e640e79cef">4.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC05LTEtMS0xMTU0OTY_d6fc9b08-fb07-4d10-b37b-d107264b017d">98.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0xMS0xLTEtMTE1NDk2_64e5c6d2-11a9-43b5-b9c6-7629837e1e4d">204.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0xMy0xLTEtMTE1NDk2_40a5df63-88e7-4bfd-90a5-78b96728050f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0xNS0xLTEtMTE1NDk2_db5310df-2c16-4c55-ba25-3319a1d0a37f">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0xNy0xLTEtMTE1NDk2_2ae01b1b-f9ea-4177-81f4-340326b573c3">203.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0zLTEtMS0xMTU0OTY_3409b7ad-5edd-4045-b372-1a289887797d">373.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS01LTEtMS0xMTU0OTY_64e04e23-9143-4d09-b120-4ab0c6ce4398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS03LTEtMS0xMTU0OTY_9776778a-8fad-4845-9a7f-19f1b7e54528">10.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS05LTEtMS0xMTU0OTY_b052f942-05c9-4ab1-9346-56f406eb6ea0">362.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0xMS0xLTEtMTE1NDk2_2d07447b-c28e-4936-8e60-7235c74f0fe7">563.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0xMy0xLTEtMTE1NDk2_ebb6f63e-d9d8-4a54-b94e-5fb10e455cb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0xNS0xLTEtMTE1NDk2_202c102e-4a7c-40e7-9994-b8d1a85cbb94">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0xNy0xLTEtMTE1NDk2_c902b8e8-6486-4adc-a92b-5d43e720d412">560.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, our security portfolio consisted of <ix:nonFraction unitRef="security" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="INF" name="nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMzIw_2d324ab9-e65f-4170-badd-bd501d9794c8">193</ix:nonFraction> debt securities available-for-sale, including <ix:nonFraction unitRef="security" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMzY5_975b9ae3-4df8-40e3-b96c-c09ee54765b5">183</ix:nonFraction> such securities that were in an unrealized loss position but of high credit quality. Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of September&#160;30, 2022 or December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTc5NQ_2143d720-b852-4f03-bad3-287df5e8e7ee" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of September&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi0xLTEtMS0xMTU0OTY_e977366f-e17c-4161-b502-8d13d33c1ae8">52.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi0zLTEtMS0xMTU0OTY_9166a5a1-aa2a-4dec-8f3d-33e6c712c9d7">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi01LTEtMS0xMTU0OTY_e6274b13-5f28-46e8-bf5e-781ba40e4897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi03LTEtMS0xMTU0OTY_f9c969c6-e344-4328-bf87-278e1eec417a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi05LTEtMS0xMTU0OTY_1ec33bc1-a567-4997-96f2-fa0b02042881">52.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if991653053864b2a904fed8d29ebc17e_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi0xMS0xLTEtMTE1NDk2_f170bd8b-9c3e-4f9c-a6fb-0b2fdc9fdc53">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy0xLTEtMS0xMTU0OTY_0b535cba-6c29-464b-9bcf-f107d8c7b1d0">251.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy0zLTEtMS0xMTU0OTY_a3239ef2-2d2e-4b5c-919a-52fcf4ec8a21">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy01LTEtMS0xMTU0OTY_403dbb65-0b91-441a-a881-df38d583505b">263.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy03LTEtMS0xMTU0OTY_1a845006-2bc7-4155-90da-1560bceec24c">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy05LTEtMS0xMTU0OTY_53fa3d54-7504-471f-b058-7b37d448d469">514.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy0xMS0xLTEtMTE1NDk2_5b075ffb-e5eb-4e78-ad8e-8358c91bb159">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC0xLTEtMS0xMTU0OTY_d19679cc-cf6f-40ce-a1e7-47211a24709f">235.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC0zLTEtMS0xMTU0OTY_563eed60-37a3-443f-af6f-614820827782">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC01LTEtMS0xMTU0OTY_a716f66e-125f-45b8-8d08-7c2fea47bdf7">92.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC03LTEtMS0xMTU0OTY_88fbb261-ff6b-4c80-9eb3-95bec250e672">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC05LTEtMS0xMTU0OTY_4b57fcd7-51b8-48b1-90fc-678688e9a30c">327.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC0xMS0xLTEtMTE1NDk2_b98f53fb-d85f-4603-800d-50acfc4eeb4f">9.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi0xLTEtMS0xMTU0OTY_d84aa91d-c816-4ed5-a3eb-24d701d4eeca">428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi0zLTEtMS0xMTU0OTY_20091dad-d21d-4b46-818e-e9e24daf6129">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi01LTEtMS0xMTU0OTY_534a0ca9-caf5-49aa-8436-4cf88ab38382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi03LTEtMS0xMTU0OTY_c0f37a01-1a9f-4820-a9df-1e0281f76828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi05LTEtMS0xMTU0OTY_e4f8a26f-d4f4-4922-9500-6bbc0cc35c14">428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi0xMS0xLTEtMTE1NDk2_04f93284-aa52-4fef-a5dc-e1ccfc87a6dd">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy0xLTEtMS0xMTU0OTY_d6944973-01af-4b64-9f08-fcf3db87dffd">230.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy0zLTEtMS0xMTU0OTY_94c89936-22e6-449c-be54-3c72f2d4d1d2">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy01LTEtMS0xMTU0OTY_bf9694d5-ff4b-4cf6-a368-3412e445ab23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy03LTEtMS0xMTU0OTY_33831746-8adc-47b0-b1ef-e6f0d62801b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy05LTEtMS0xMTU0OTY_26d0ee54-374f-468f-ab4b-bcd7942bfb11">230.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy0xMS0xLTEtMTE1NDk2_73622ca9-af86-4c45-8ccf-ed29d0c741af">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTI2MA_18c9a994-b34b-4d53-98d2-1715e2f3fc7d">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTI2Nw_c18b8a74-631e-47e4-b69c-8862aedc0de2">2.2</ix:nonFraction> million, respectively, as of September&#160;30, 2022 and December&#160;31, 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. <ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTcwOA_13a96779-be18-49b4-96ee-373ce8af070c"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTcwOA_72b21827-9b98-406d-bc8d-9e69257fc617">No</ix:nonFraction></ix:nonFraction> accrued interest receivables were written off during the nine months ended September&#160;30, 2022 or 2021.</span></div></ix:continuation><div id="iff439a36db274cfaa026518ede3eda49_40"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RleHRyZWdpb246MzhlZmY1NGYxNTJiNDlmMmEzOTgyMjJiZjFlOGNkNzNfMTQ0Mg_8eebf1b3-1447-4a30-82de-af23b40d7022" continuedAt="i772e6c9f95954b818727cbe0469f499e" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i772e6c9f95954b818727cbe0469f499e" continuedAt="i7a6a6916431041e4a4036b154ec167bf"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RleHRyZWdpb246MzhlZmY1NGYxNTJiNDlmMmEzOTgyMjJiZjFlOGNkNzNfMTQ0Mw_07bb592a-6717-467c-9960-91676dda0612" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7a6a6916431041e4a4036b154ec167bf"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RleHRyZWdpb246MzhlZmY1NGYxNTJiNDlmMmEzOTgyMjJiZjFlOGNkNzNfMTQ0NA_7b346606-2a60-43ff-a2f5-69547c3f0a1a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of investments, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4839e374f144412a9f7b6a7f7818e610_I20220930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0xLTEtMS0xMTU0OTY_cb5f0c26-b7d4-46ad-89cb-d4c69c8d8342">212.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0b098d67fd4b36b7ad36c659fff363_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0zLTEtMS0xMTU0OTY_f0e8fe0d-4b9a-4568-8974-a4fef9c0dfb1">212.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6de012629174382b73ae25ee390d53d_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC01LTEtMS0xMTU0OTY_e8ca826d-1406-4ba7-9933-a8a6b86422ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd7f53c0917469fb5aa137f42fa9641_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC03LTEtMS0xMTU0OTY_f4fdd5a0-369f-4678-8c67-104328726d54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id71a72a0204343a2ba932bbdf699fd15_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC05LTEtMS0xMTU0OTY_ba288bf1-3465-48d4-bc34-1a4cf0ecd27c">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a60cfe6cb248f28f728ecc7b0d9dac_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0xMS0xLTEtMTE1NDk2_32a7b167-c278-4cbc-adef-875bad55196c">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3554cf0de1b74187a218d6f9def209e1_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0xMy0xLTEtMTE1NDk2_9a423eea-2d5d-4f7e-8a6f-5b9dc3c77988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595e5cac95e64a078c1b2e3ba8fcad00_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0xNS0xLTEtMTE1NDk2_1291d758-41ec-445b-bc6b-c7e07b870389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1d72cc605f044c39df6e8ac34e59455_I20220930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0xLTEtMS0xMTU0OTY_a336e972-a9d9-47a0-9ea6-21102ccf25f1">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092271effac144f483e64869aea849d1_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0zLTEtMS0xMTU0OTY_93255296-6fd9-4e8b-a194-875f256eb20f">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca50849466f4f388fa755ae299a561f_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi01LTEtMS0xMTU0OTY_f8678d42-acce-46c7-8be0-f41fd687c309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1638a41bfc4a4188eb4b991772a3c5_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi03LTEtMS0xMTU0OTY_18321ea9-c177-41fc-9d8b-b145b3b7e62c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i180afdb708d547789b9d9c373554692d_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi05LTEtMS0xMTU0OTY_2600323b-e461-4df9-b90f-61ba4c07ac28">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca3d6e4dcde4876b83e7398f46fed0e_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0xMS0xLTEtMTE1NDk2_3e6bc78f-da67-4bce-90df-79c194147c22">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i222b84b6200c4687ae6fad5eb6c114eb_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0xMy0xLTEtMTE1NDk2_cf51c173-1aff-40da-bd67-c5558ca31201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02faf276f4724aa4ad454f7424494fa8_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0xNS0xLTEtMTE1NDk2_e231869c-d5ca-49d1-95a0-da98808d0a1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd7fbc215c547fe9905956a7d3b2d0b_I20220930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0xLTEtMS0xMTU0OTY_f79ec0a1-ebb5-4158-ad2d-f5ccfa85c37b">97.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i427d6d88fbf5403a90f978999cec31c1_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0zLTEtMS0xMTU0OTY_f4ef8f4b-cddb-4fe6-834a-940fd7c8a14a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1de29717fb412b8d0f3ede241f8bb3_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC01LTEtMS0xMTU0OTY_7cad3680-7900-44fb-aeb2-8156d308b935">97.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0287a3f58248fd9c60960a29b9c6d7_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC03LTEtMS0xMTU0OTY_ff6d2ac2-7b3c-4683-aeeb-290ece3d834c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2455f9d7a9344e94b5e44642abae8dec_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC05LTEtMS0xMTU0OTY_549ba19c-bca5-426a-9473-2ffe33d82814">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b9e17b5b754d4086db11dcfe954416_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0xMS0xLTEtMTE1NDk2_2cfdfa61-5db3-4042-902b-24fdd0bd4e88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c322608454a431fb44e4870cfcf20e0_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0xMy0xLTEtMTE1NDk2_c378e402-4feb-4e56-bbe7-3ee6317a4e90">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7878b6282f4161a51f2ecb11e6ee6a_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0xNS0xLTEtMTE1NDk2_6b9ad549-1ba3-4be9-a9b4-d009dbd20120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0xLTEtMS0xMTU0OTY_b791975d-b672-420c-8f65-6c825fc59036">521.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icad8bd51420d47599a0bbb9a64c2debc_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0zLTEtMS0xMTU0OTY_fc6147d4-5432-491f-80b7-abb58f118037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c20de1be0b54d57a763e3ccf1e3ffd2_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS01LTEtMS0xMTU0OTY_c469b009-41d0-42f4-96ff-cbe6fb345d0e">521.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4870a12f1c34345966751447c52154e_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS03LTEtMS0xMTU0OTY_1c5bdfaa-00a7-4964-9ada-710c75370cc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS05LTEtMS0xMTU0OTY_ebcadee1-94c3-4777-a6bc-898ab0e2f6eb">485.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0223e03f957402ba98f263591110328_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0xMS0xLTEtMTE1NDk2_bb2c8b1c-1ea7-4cf6-b2fe-6974b6288119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1df5c5dc8a46219d57553226f03b5a_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0xMy0xLTEtMTE1NDk2_3003c12d-bd62-43e2-9ec6-e6f43fa8cb29">485.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc376687d434b2f95f43d1c9e9eca69_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0xNS0xLTEtMTE1NDk2_4e119bdd-94fe-4fd0-a04d-c56ae0db2c6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMS0xLTEtMTE1NDk2_529036ed-d97a-4f69-8b8b-8997d6769a6f">330.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6810cd7a4b24c838b72ecadd02e9522_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMy0xLTEtMTE1NDk2_11c60723-e2a6-48ac-ae7d-8a8e81ec1759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d07e5ef45644257bbcfa85ae04c08a9_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtNS0xLTEtMTE1NDk2_3b953b94-3636-43b3-ae2e-d18f24f476ac">330.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36692663da7d47208855243ce31dfad4_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtNy0xLTEtMTE1NDk2_82988261-9ad2-4bf2-b972-d4b15d04d610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtOS0xLTEtMTE1NDk2_3442d97a-908b-4261-b146-5ecc670b5a4a">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80aeccc4b4694ebd8b20044eeae2adc2_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMTEtMS0xLTExNTQ5Ng_46bfe878-54ba-420b-9231-bf8c1cdfa197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dedc56fd35f4871bf88c063a6ff6849_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMTMtMS0xLTExNTQ5Ng_962b4e66-9813-4798-a219-8b5cfc47a794">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7fa1d696ab44f8be8a258fb5120a82_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMTUtMS0xLTExNTQ5Ng_533529c9-e405-46e2-a932-2598b33d1a86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4207c67f0d44accbd49d0bd44c9afb5_I20220930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMS0xLTEtMTE1NDk2_af9e532c-6cb7-4227-b3d0-2c8ada46b062">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8bf998110245f8b80ff377a8f82542_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMy0xLTEtMTE1NDk2_558d0053-fa09-47b8-94ec-7a88d4a03b3b">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08641e1abc544caad6433c0c27d62c6_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItNS0xLTEtMTE1NDk2_a3e0db6d-b6a1-4d8e-b8a6-d216fda2676e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f76ef824ec4b4c9f74fdf2aca12a07_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItNy0xLTEtMTE1NDk2_b529c133-58d5-4fb1-99c7-c0a7726035a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f93fe5331c425f98f7d5e731495d7f_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItOS0xLTEtMTE1NDk2_2de3516c-3bcb-42ec-b9c1-1d9682229c0a">63.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7146d8e9d0640aa93ae219f21de2a1c_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMTEtMS0xLTExNTQ5Ng_f55bc9dd-e011-46aa-bcea-ce51bb1aa55d">52.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1594a5b6774dc8b404800132ae9d9f_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMTMtMS0xLTExNTQ5Ng_bf7f94c6-6c14-4862-a9d2-f4632613c9e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf809ef29d94cf38cf7aaf31b95dbc9_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMTUtMS0xLTExNTQ5Ng_08d5fe62-857d-4470-af3f-6cecd53616c1">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMS0xLTEtMTE1NDk2_25dccb5a-b780-40b5-b715-3aaa6b4a612e">1,264.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca0198fc8364c69827b4bcd85bfda5c_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMy0xLTEtMTE1NDk2_79e6d13d-92ba-44e3-8495-2f8daa5ecdbf">314.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c36d96155624c52aa5e2d8d06ca58f6_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtNS0xLTEtMTE1NDk2_d37a6923-0941-45e2-bedb-883af725415c">949.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f5e98291034c5ebdd1aaa8e86213e7_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtNy0xLTEtMTE1NDk2_e833a971-b5a1-4011-8f6d-1385ce3e6a0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtOS0xLTEtMTE1NDk2_250fb384-3e0f-42c6-a31b-92df63754489">1,338.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic534f177a08b41618f86a8447e6aa13b_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMTEtMS0xLTExNTQ5Ng_c6e48aa2-72dc-4e87-bb33-a74c31d511e9">396.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22d1bdea9d1346bc84bff185b75f4d8a_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMTMtMS0xLTExNTQ5Ng_a89301a9-1c5c-41c1-9e0f-ceac6aeef91e">931.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16add8cd888840ba965b71e41d99d856_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMTUtMS0xLTExNTQ5Ng_1638d710-e989-40c8-b8b3-20b78fcec4b6">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RleHRyZWdpb246MzhlZmY1NGYxNTJiNDlmMmEzOTgyMjJiZjFlOGNkNzNfMTQ0NQ_bca77f9d-d9d5-4c68-8ae0-1a94e536f6ae" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3482a00ad8dd4f2e803c923b8f328ea5_I20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMi0xLTEtMS0xMTU0OTY_7dd7a58f-ee98-4965-91fb-b112eed81668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292aeff53ad84fc0ba0c70a3a9c01173_I20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMi0zLTEtMS0xMTU0OTY_cb2951e6-92ba-443c-aa70-41088f670e15">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf809ef29d94cf38cf7aaf31b95dbc9_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMi01LTEtMS0xMTU0OTY_e246f295-a87d-45fc-ab60-5311bd184558">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd2750ce3bd433caa60ae155d4dae98_I20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMi03LTEtMS0xMTU0OTY_a0d28a12-eb47-493e-8aa6-7ff1568bb3dc">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49ac4b8f7504f74ae784614035b01ea_D20220701-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMy0xLTEtMS0xMTU0OTY_6925d69d-fb99-47f0-960f-c1738a6d9133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252ec6df430b4181b19dba818761eefa_D20210701-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMy0zLTEtMS0xMTU0OTY_0881b0e6-c4d7-4b56-b536-1e331e6060db">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b89d380f2a64113845905298e656b37_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMy01LTEtMS0xMTU0OTY_83f23ffe-973b-406e-ba5a-ad785120e980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39d31443ce649c9b07f69bd9027d2fc_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMy03LTEtMS0xMTU0OTY_da524543-48bf-4d69-8c46-11f9e3cf8683">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) included in earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c048dc598a4c8d8d72fe8f04ccf8a4_D20220701-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNC0xLTEtMS0xMTU0OTY_ac63dd22-584f-421b-bb73-4a88495629db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66dcf8a5e7154e9fadd29e9e4be560b2_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNC0zLTEtMS0xMTU0OTY_49a37e97-0c97-41ed-b235-a89c764d01b5">8.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i215cbb49fff34b958a3ad2dc5ab67b77_D20220101-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNC01LTEtMS0xMTU0OTY_7833498b-f731-4ed8-855b-7b4f6abc646e">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbf97cbe7b5a4eeca45e05f5d6e775d3_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNC03LTEtMS0xMTU0OTY_decbaa24-c7c9-456b-ba2a-466625f5c62b">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c048dc598a4c8d8d72fe8f04ccf8a4_D20220701-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNS0xLTEtMS0xMTU0OTY_70101c6e-0378-498d-b751-61ddef4b5ff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66dcf8a5e7154e9fadd29e9e4be560b2_D20210701-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNS0zLTEtMS0xMTU0OTY_47d6a0f3-2e53-4fdb-bd8d-b6000d9b3507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i215cbb49fff34b958a3ad2dc5ab67b77_D20220101-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNS01LTEtMS0xMTU0OTY_7f1c6c41-6c51-4042-83c2-2ed1cd68df0c">31.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf97cbe7b5a4eeca45e05f5d6e775d3_D20210101-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNS03LTEtMS0xMTU0OTY_ee02eec1-53de-4d26-8b58-02ef2560c17a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f76ef824ec4b4c9f74fdf2aca12a07_I20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNi0xLTEtMS0xMTU0OTY_36c2c17a-3166-47af-8cf5-5052756ceb5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e35fa4d9f3455b80e4ddf1bb260920_I20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNi0zLTEtMS0xMTU0OTY_fbff2102-a8c0-47e8-88a6-17ac60e893a5">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f76ef824ec4b4c9f74fdf2aca12a07_I20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNi01LTEtMS0xMTU0OTY_7952e29e-1c35-49f9-9d66-7035124e5ecb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e35fa4d9f3455b80e4ddf1bb260920_I20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNi03LTEtMS0xMTU0OTY_b488d04d-2ef4-4006-a386-fd8ed3152949">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.</span></div></ix:nonNumeric></ix:continuation><div id="iff439a36db274cfaa026518ede3eda49_43"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RleHRyZWdpb246NmM2ZDNhODNlYzI3NGM4NGJjOTk5NDQ4YmJjOWFiMWZfNjE_71af5f0d-97fd-4bf9-8ad5-e041420d9c15" continuedAt="i8bf7a5af65a74625b70529142cf590cd" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i8bf7a5af65a74625b70529142cf590cd"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RleHRyZWdpb246NmM2ZDNhODNlYzI3NGM4NGJjOTk5NDQ4YmJjOWFiMWZfNjI_d0e47ac7-a080-4802-8e96-664602c1f9d8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMS0xLTEtMS0xMTU0OTY_dfbd8100-d59d-418b-9034-7623c5dac2a8">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMS0zLTEtMS0xMTU0OTY_5e6b678e-cde9-4db4-b823-d51279e28de9">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMi0xLTEtMS0xMTU0OTY_6c0b1aa3-42f2-45c8-9565-f8669897066d">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMi0zLTEtMS0xMTU0OTY_d88d6ea7-9b0b-4404-8792-78bbaee18078">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMy0xLTEtMS0xMTU0OTY_cbc35e78-37dd-4b32-930f-916737b66a49">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMy0zLTEtMS0xMTU0OTY_8b234c9d-3c27-40b5-b109-45fb79554f4e">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfNC0xLTEtMS0xMTU0OTY_76d5e915-ce11-4c0f-86f6-827cd48b8278">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a36f8809514653892aaae462d392cf_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfNC0zLTEtMS0xMTU0OTY_e2d468ee-a26e-44e6-b441-331b509f0c2b">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iff439a36db274cfaa026518ede3eda49_46"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="nbix:RestrictedCashTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RleHRyZWdpb246ZWY1ZGNmYWJlNGNiNDBiYTlkZTg3NDk0NWVlODA1MThfMjE3_8b91401a-2437-4e02-b513-0b9a60625e65" continuedAt="i9ad5c5501a6f467a8d84427bc60997bd" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="i9ad5c5501a6f467a8d84427bc60997bd"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RleHRyZWdpb246ZWY1ZGNmYWJlNGNiNDBiYTlkZTg3NDk0NWVlODA1MThfMjE4_f89a0682-7fed-4ca1-9a49-64569d8da984" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMS0xLTEtMS0xMTU0OTY_b6c81e59-5367-46fa-8938-f2e1341ef784">212.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMS0zLTEtMS0xMTU0OTY_9949752e-04f3-4ea6-9cc8-16934f89ecbb">311.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMi0xLTEtMS0xMTU0OTY_c4318502-144d-4b27-be8d-f3e86ab0587a">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMi0zLTEtMS0xMTU0OTY_0733febf-5d2d-489b-b3b6-33202a5cfe12">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMy0xLTEtMS0xMTU0OTY_ecd90947-ebe6-4e2f-8b9c-0036a7869d72">220.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMy0zLTEtMS0xMTU0OTY_28344a86-3f59-4ddc-af24-6a628527358b">314.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUyMQ_12737661-a932-455b-938b-47b7280a8854" continuedAt="i012ea9be30bb4212a098cdf32c19bbcc" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i012ea9be30bb4212a098cdf32c19bbcc"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a <ix:nonNumeric contextRef="i293bb336d80d473eb69da7cf494b8713_D20220208-20220208" name="nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUxMw_87d6db83-3ef5-4b40-84ea-07186292b9d5">six-year</ix:nonNumeric> option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters. This lease has not commenced for accounting purposes. Under the terms of the lease, on a building-by-building basis, base rent will be subject to a <ix:nonNumeric contextRef="i293bb336d80d473eb69da7cf494b8713_D20220208-20220208" name="nbix:RentAbatementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUxNA_cd09db41-08fd-4a00-a625-6612f5315fae">10-month</ix:nonNumeric> rent abatement period following the respective lease commencement date, which dates will be determined in the future based upon achievement of substantial completion of construction with respect to each such building in the condition suitable for the installation of our furniture, fixtures, and equipment, and on which date we will record a lease liability, corresponding right-of-use asset, and begin lease expense recognition with respect to each such building. After the rent abatement period, monthly base rent will be $<ix:nonFraction unitRef="usd" contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208" decimals="0" name="nbix:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTY4MA_f62e04d5-ad94-4041-98f0-0ca8f504d0d3">6</ix:nonFraction> per square foot, subject to annual escalations of <ix:nonFraction unitRef="number" contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208" decimals="INF" name="nbix:AnnualRentEscalationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTczMw_bda942e5-1d07-49ed-b693-272a4aa30bae">3</ix:nonFraction>% during the initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTY0OTI2NzQ0NDE5NQ_53c700d8-36e0-4b90-b6dc-fbf8018a13aa">13.6-year</span> lease term, which term we have the option to renew for <ix:nonFraction unitRef="renewaloption" contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208" decimals="INF" name="nbix:NumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUxNw_9f9bfd8b-9ac6-4db7-a3af-cb2578ee5646">two</ix:nonFraction> additional terms of <ix:nonNumeric contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTg0MQ_504f7af5-f9b6-49b5-9916-a0982e3b786a">five years</ix:nonNumeric> each.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our operating leases, in lieu of a cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjAzMQ_7488bcca-5578-4638-a5d5-55c406a33727">7.8</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUxOA_d35e25db-4669-4408-b58d-f1aabd4d407e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information for operating leases that have commenced.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfMi0xLTEtMS0xMTU0OTY_0d57b3da-df05-4df5-b685-63bfb2feab56">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfMi0zLTEtMS0xMTU0OTY_5fe33ccd-28b1-471a-a132-da02050835a1">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfMy0xLTEtMS0xMTU0OTY_754914f7-fb8c-467d-9968-c438ca97e798">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfMy0zLTEtMS0xMTU0OTY_c1bcb0ac-5df9-41eb-9934-23fee462babe">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfNi0xLTEtMS0xMTU0OTY_7e9ffde3-670e-421d-8a2c-3c820baada4e">8.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfNi0zLTEtMS0xMTU0OTY_cac40119-d5e0-4594-afb1-57c9234523f5">9.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfNy0xLTEtMS0xMTU0OTY_16548bf5-d526-473c-814f-392c10257cbe">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfNy0zLTEtMS0xMTU0OTY_e81c4e22-cd4a-40c5-b13d-f0929de0c20a">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUyMw_c7c496a3-5af8-49a3-9eb2-74ced93874c0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate non-cancelable future minimum lease payments under operating leases as of September&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 (3 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMS0xLTEtMS0xMTU0OTY_ffb3cc40-f876-4725-ae86-b59441f17b18">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMi0xLTEtMS0xMTU0OTY_218eaca2-3484-45df-ba88-e64fe4a83d0e">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMy0xLTEtMS0xMTU0OTY_2ce60205-d86e-4c9a-a599-8912ad7dd8c4">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfNC0xLTEtMS0xMTU0OTY_e0e26c3b-b98a-43d9-9f6c-bc85b3cbea8b">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfNS0xLTEtMS0xMTU0OTY_7953f148-d796-446c-a665-da841bfaea40">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfNi0xLTEtMS0xMTU0OTY_4cfa9607-add0-4937-9982-27ee189826e9">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfNy0xLTEtMS0xMTU0OTY_203d2735-cd1e-427d-af36-9116ac5d2688">141.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfOC0xLTEtMS0xMTU0OTY_ce9f7795-4a82-42de-92c0-26bd96a52590">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfOS0xLTEtMS0xMTU0OTY_ce7060fc-5e4d-4ffa-8427-cb7346362878">113.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities included in other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMTAtMS0xLTEtMTE1NDk2_d898a7f1-5dc9-45ec-b081-cac3a1c6a894">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMTEtMS0xLTEtMTE1NDk2_6a0f5201-9bd0-441b-b720-7da804628f09">96.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjM0NQ_4bb3b5d8-058f-44ea-86ed-bd4e46eb3139">17.2</ix:nonFraction> million for 2024, $<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjM1OA_5f03a482-42d3-42c1-baed-ef0a571cf0ba">33.3</ix:nonFraction> million for 2025, $<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjM3MQ_73b81380-74e0-445c-b399-9b4969b2ecbb">41.9</ix:nonFraction> million for 2026, and $<ix:nonFraction unitRef="usd" contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjM4OA_7cf84875-67b4-472c-9060-6795961eb325">479.7</ix:nonFraction> million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwMw_8102aff9-5a08-4715-934c-812e51e956bf" continuedAt="ia761975fae80499a8df5830fdd03f3d9" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><ix:continuation id="ia761975fae80499a8df5830fdd03f3d9" continuedAt="i9dd13e3cb4af47d0a4e1432ef883e62c"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwNQ_ef8f04f5-41e3-4904-9590-625dd3555ec1">517.5</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTEy_f1039814-97ea-4016-af7e-82d16e67cdd1">2.25</ix:nonFraction>% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance in effect at the time of issuance, we were required to separately account for the liability and equity components of the 2024 Notes. The initial carrying value of the liability component of $<ix:nonFraction unitRef="usd" contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502" decimals="-5" name="nbix:CarryingAmountOfLiabilityComponentUponIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTAy_05c132a7-8b9c-4fc6-921c-e5ee96192abc">368.3</ix:nonFraction> million was calculated using a <ix:nonFraction unitRef="number" contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTI4_d419db2e-ffb8-4d3d-af28-24e1760f7799">7.50</ix:nonFraction>% assumed borrowing rate, which reflected the market interest rate for a similar non-convertible instrument at the date of issuance. The equity component of $<ix:nonFraction unitRef="usd" contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjg2_f4d90fe0-7912-4edd-b4dc-dd8e8df05861">149.2</ix:nonFraction> million, which was treated as a discount on the liability component and amortized over the <ix:nonNumeric contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwNg_62e356d3-16f9-413a-b2d0-69ea430b501a">seven-year</ix:nonNumeric> term of the 2024 Notes using the effective interest rate method, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and recorded as an increase to additional paid-in capital on the issuance date. In addition, we allocated transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTA2Mw_048b9a22-7240-4174-9ab0-47c0cb3d1071">14.7</ix:nonFraction> million related to the issuance of the 2024 Notes to the liability and equity components based on their relative values on the issuance date. Transaction costs attributable to the liability component were being amortized over the <ix:nonNumeric contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwNw_1ab501c3-438f-405b-bf1f-c5ae86a6e19f">seven-year</ix:nonNumeric> term of the 2024 Notes using the effective interest rate method, while transaction costs attributable to the equity component were recorded as a reduction to additional paid-in capital on the issuance date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="i1203e4c8b5dc4172916025c8100cbdf2_I20201231" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTYyMw_d5031a6b-4ca9-4527-a11e-dd42a1729c43">136.2</ix:nonFraction> million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTcwMA_9335aed7-d0cc-475d-af8d-c37fd0b790fd">186.9</ix:nonFraction> million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $<ix:nonFraction unitRef="usd" contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231" decimals="-5" name="nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTgxNQ_85003fd5-1f47-4065-b8d5-6c896a4df574">130.7</ix:nonFraction> million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of <ix:nonFraction unitRef="number" contextRef="i77d2b40e50ad4aa48f0578112016e986_I20201231" decimals="4" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjA5OA_e9c70af4-7b4b-4ff5-a1ed-1429f1a52e66">3.37</ix:nonFraction>%, which was the market rate for similar notes that have no conversion rights. The difference of $<ix:nonFraction unitRef="usd" contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjE5Ng_9d533d65-1a5a-4712-b625-888e1736d877">56.3</ix:nonFraction> million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recorded as a reduction to additional paid-in capital. The carrying amount of the liability of $<ix:nonFraction unitRef="usd" contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231" decimals="-5" name="nbix:CarryingAmountOfLiabilityComponentAtSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjQ5Ng_eb6b7b4f-70fc-45cd-95d0-447b5ac97d10">112.4</ix:nonFraction> million at settlement was recognized as a reduction to the 2024 Notes and resulted in an $<ix:nonFraction unitRef="usd" contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjU3Mg_097364e0-7e52-447d-949e-2fe857c4ad15">18.4</ix:nonFraction> million loss on extinguishment, which we recognized in the fourth quarter of 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjY4MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $<ix:nonFraction unitRef="usd" contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjk4OA_3fadbf96-fab2-4a82-9eb0-63ce21e29837">42.2</ix:nonFraction> million, reduced deferred tax liabilities by $<ix:nonFraction unitRef="usd" contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzAyOA_cf096fb4-0369-4106-b684-b56c27e6f653">9.9</ix:nonFraction> million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzA3MA_c3d58a77-1cb2-4f4c-ba05-6c06fe4c9975">106.8</ix:nonFraction> million, and reduced the accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzExMw_5f4baac4-e767-43f4-9684-8d5a56c1dbfa">74.5</ix:nonFraction> million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="ia4f1503bf3ac46d1b34a4f8bb6f92140_I20220630" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzI2MQ_c70a5d9c-7681-469e-9c65-4dad1e872684">210.8</ix:nonFraction> million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="ifa8302f1e6814a9987ec49ca9af465a2_D20220401-20220630" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzM0Ng_c943e8fd-4717-4134-b8ae-62e32a61a37b">279.0</ix:nonFraction> million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment, which resulted in the recognition of a $<ix:nonFraction unitRef="usd" contextRef="ifa8302f1e6814a9987ec49ca9af465a2_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzQ4MQ_b8055ecf-d8cf-4446-8843-99e898968530">70.0</ix:nonFraction> million loss on extinguishment in the second quarter of 2022.</span></div><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwOA_2a43db28-e856-420b-b272-ce55bba37383" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of September&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi0xLTEtMS0xMTU0OTY_de93fb2d-bd68-4e0b-be2c-eeff71377af4">170.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi0zLTEtMS0xMTU0OTY_0887833b-d041-4156-b008-480e92212d1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi01LTEtMS0xMTU0OTY_7d24b9bf-8183-44ff-a698-cb04b3e95797">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi03LTEtMS0xMTU0OTY_1b5daa40-b446-4045-ba8a-d1149dd601d5">169.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930" decimals="-5" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi05LTEtMS0xMTU0OTY_086836e8-c49e-4844-9b0d-09969b74916e">238.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi0xLTEtMS0xMTU0OTY_129df4b4-e022-41f7-9aa7-ae19ee61f9b9">381.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi0zLTEtMS0xMTU0OTY_46508e92-a0d4-48f6-b7b5-770654887507">43.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi01LTEtMS0xMTU0OTY_72e8fc48-9e8f-46d2-baa6-caf7786e86dd">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi03LTEtMS0xMTU0OTY_84d1c285-1e6d-4fab-81d4-3d916ec27d7b">335.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi05LTEtMS0xMTU0OTY_715ae0a8-c637-49d5-bc8a-98ed9ae7d866">464.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMi0xLTEtMS0xMTU0OTY_6c788a80-8438-49a5-b7f0-658e632e4176">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMi0zLTEtMS0xMTU0OTY_1c777305-4a4b-45d0-a2ae-522ee2bbf026">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMi01LTEtMS0xMTU0OTY_df1418d2-0e56-4646-b10c-ca933c773681">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMi03LTEtMS0xMTU0OTY_be89cbf4-4f6e-415a-9b75-6d5f979aaab2">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMy0xLTEtMS0xMTU0OTY_c032c65c-47c1-4f64-a397-0de7ab9203ee">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMy0zLTEtMS0xMTU0OTY_ffc53860-722f-4e9b-9e9b-702566a06aad">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMy01LTEtMS0xMTU0OTY_bbee3bb9-46a4-4fad-91fb-2864be65e2d2">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMy03LTEtMS0xMTU0OTY_75b375b9-bb58-4b8e-b9d5-bb3c60254ef4">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfNC0xLTEtMS0xMTU0OTY_e171ddd5-939e-498f-9c52-4f94e7b813b7">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfNC0zLTEtMS0xMTU0OTY_8e04450f-234f-4a50-9bb3-72a9df18248a">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfNC01LTEtMS0xMTU0OTY_415d1e2c-4f28-4cde-9bc8-391ec6e43dc9">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfNC03LTEtMS0xMTU0OTY_c27028c7-e478-42ff-9305-a9c934eea6be">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9dd13e3cb4af47d0a4e1432ef883e62c"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2024 Notes in cash upon conversion and to settle any conversion premium, calculated based on the per share volume-weighted average price for each of the <ix:nonFraction unitRef="d" contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNDU4MA_71a207e0-6b22-4f0b-9752-e61f72ccbc99">30</ix:nonFraction> consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $<ix:nonFraction unitRef="usd" contextRef="i5d6487fd362c4e36a923415c3752b4f7_I20170502" decimals="INF" name="nbix:PrincipalAmountOnConversionRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNDg3NA_ad79e3a5-cf3d-47bb-b457-e6ebdb22a5b2">1,000</ix:nonFraction> principal amount and equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNDk1Nw_6e7c5540-6ddf-4e25-9d32-beb18298bc2a">75.92</ix:nonFraction> per share, reflecting a conversion premium of approximately <ix:nonFraction unitRef="number" contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502" decimals="3" name="nbix:DebtInstrumentConvertibleConversionPremium" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTAyMA_1a4342af-18d1-4633-8abb-d2eae8020329">42.5</ix:nonFraction>% above the closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTA1MA_7242e294-674f-4c29-a036-c9007a4c519e">53.28</ix:nonFraction> per share of our common stock on April&#160;26, 2017.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTIyOA_b65e7df1-9cbb-404a-b4e0-85be383f5c23">130</ix:nonFraction>% of the conversion price then in effect (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ib8b91f81d53147c9b20bab4e275695ef_D20220101-20220930" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTI4MA_9fe7e6d9-d5c5-4e90-b038-af7fc6ca5dd4">98.70</ix:nonFraction> as of September&#160;30, 2022) for at least <ix:nonFraction unitRef="d" contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTMwNg_f16a96d8-4d75-4365-a502-dd4175d000ff">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="d" contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTM2Mg_71a207e0-6b22-4f0b-9752-e61f72ccbc99">30</ix:nonFraction> consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;<ix:nonFraction unitRef="d" contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTgwNg_f16a96d8-4d75-4365-a502-dd4175d000ff">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during a period of&#160;<ix:nonFraction unitRef="d" contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTg3MA_71a207e0-6b22-4f0b-9752-e61f72ccbc99">30</ix:nonFraction>&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;<ix:nonFraction unitRef="number" contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTk5MQ_b65e7df1-9cbb-404a-b4e0-85be383f5c23">130</ix:nonFraction>%&#160;of the conversion price (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ib8b91f81d53147c9b20bab4e275695ef_D20220101-20220930" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjAyOA_9fe7e6d9-d5c5-4e90-b038-af7fc6ca5dd4">98.70</ix:nonFraction> as of September&#160;30, 2022) on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;<ix:nonFraction unitRef="d" contextRef="ic03ac1eae74a42adac16fd393cd612f3_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjA4NA_7b8e6d1f-7b02-4e38-9655-3a5bd0312451">five</ix:nonFraction> business-day period immediately after any&#160;<ix:nonFraction unitRef="d" contextRef="ic03ac1eae74a42adac16fd393cd612f3_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjEyOQ_7b8e6d1f-7b02-4e38-9655-3a5bd0312451">five</ix:nonFraction>&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$<ix:nonFraction unitRef="usd" contextRef="i5d6487fd362c4e36a923415c3752b4f7_I20170502" decimals="INF" name="nbix:PrincipalAmountOnConversionRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjI0Mg_ad79e3a5-cf3d-47bb-b457-e6ebdb22a5b2">1,000</ix:nonFraction>&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;<ix:nonFraction unitRef="number" contextRef="ic03ac1eae74a42adac16fd393cd612f3_D20170502-20170502" decimals="INF" name="nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjMzMw_b6c6eb49-b4d9-4488-8e07-8fc1b7d1ae92">98</ix:nonFraction>% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the conditional conversion feature described under (i) above was triggered as of September 30, 2022, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on October 3, 2022, and ending at the close of business on December 30, 2022. Accordingly, the 2024 Notes have been classified as a current liability as of September 30, 2022. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes in cash and any excess conversion value, calculated based on the per share volume-weighted average price for each of the <ix:nonFraction unitRef="d" contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTQ5NzU1ODI1OTY4_71a207e0-6b22-4f0b-9752-e61f72ccbc99">30</ix:nonFraction> consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNzA1NA_21ae2697-8db1-406e-9f4b-ae21716ac2c5">100</ix:nonFraction>% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, <ix:nonFraction unitRef="number" contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODAwMA_21ae2697-8db1-406e-9f4b-ae21716ac2c5">100</ix:nonFraction>% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RleHRyZWdpb246ZDY0ZWU3YTZkYWFlNDFjOGE5OGZhMWQxN2U2MzEyYTRfODc_28054010-cf6a-4c80-99ce-0a3ba3a13ac8" continuedAt="i55cea231b2094c28bc1eb6aa324d79e1" escape="true">Earnings per Share</ix:nonNumeric></span></div><ix:continuation id="i55cea231b2094c28bc1eb6aa324d79e1"><ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RleHRyZWdpb246ZDY0ZWU3YTZkYWFlNDFjOGE5OGZhMWQxN2U2MzEyYTRfODg_96fcc8e4-38f1-4f5f-b2db-a0cf36e97d64" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi0xLTEtMS0xMTU0OTY_3ebc5759-ee58-4fc9-bdda-d493086fc4f4"><ix:nonFraction unitRef="usd" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi0xLTEtMS0xMTU0OTY_4c09bcfe-b01f-41cf-a3cb-f82236210625">68.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi0zLTEtMS0xMTU0OTY_41450c54-7e9d-4fb5-bf04-9c55077f0137"><ix:nonFraction unitRef="usd" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi0zLTEtMS0xMTU0OTY_e13a42d1-494b-4a1e-b731-283032badaa9">22.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi01LTEtMS0xMTU0OTY_7bb0bd91-3b0b-43f2-8177-6ac5a653d1e7"><ix:nonFraction unitRef="usd" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi01LTEtMS0xMTU0OTY_dfd9483c-c195-461b-be53-5e89bc51d664">65.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi03LTEtMS0xMTU0OTY_c2d92018-f677-4bce-baeb-8a9af6c6e4f1"><ix:nonFraction unitRef="usd" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi03LTEtMS0xMTU0OTY_d18b3d3c-0b1a-40bd-9056-220697e7276d">96.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNC0xLTEtMS0xMTU0OTY_b041e636-0195-404c-b708-5f9942b6c4c5">95.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNC0zLTEtMS0xMTU0OTY_f67856ff-da54-4467-8e03-2c970cb28bbd">94.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNC01LTEtMS0xMTU0OTY_2efb94e3-ed3a-4f23-8bd8-bb660a5da969">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNC03LTEtMS0xMTU0OTY_3de27984-7796-46a1-a02f-63ada51da9b2">94.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i075bf5beb06a450d897f5554a7c9f675_D20220701-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNi0xLTEtMS0xMTU0OTY_e283f97b-95f3-4d47-89cf-af97104585d4">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia976ce0a469f43dd8529daa7ded8f407_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNi0zLTEtMS0xMTU0OTY_46e83425-0784-4900-87f7-fadf6b7cf7ec">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ffc106e9c034ce0a4ec85dfbc149c80_D20220101-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNi01LTEtMS0xMTU0OTY_92bc237a-979e-4cf6-ae21-894fe1509d3f">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97c06ced3466414480ad4f43ed22809c_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNi03LTEtMS0xMTU0OTY_2a1930dd-c1ce-4612-bf46-299a8ca343e2">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10df804649bf4f5881d03f512c323aad_D20220701-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNy0xLTEtMS0xMTU0OTY_b569933a-ac01-489f-adcb-e748bc17fb4d">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82b33cfb43b446bb98d589fcf33582cd_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNy0zLTEtMS0xMTU0OTY_0280e7d3-a078-4fbb-b063-39fe8eba2191">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67742768ef2045548179b11e33a332c8_D20220101-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNy01LTEtMS0xMTU0OTY_1c03f81a-e685-4088-ba2f-50383e57c42c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6cd5647e0764102ae7a3f85ef3b6d57_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNy03LTEtMS0xMTU0OTY_a62cd4d3-c4c9-4603-9e76-393c74cab628">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7a804747bab486687e11ad36d58a3ce_D20220701-20220930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOC0xLTEtMS0xMTU0OTY_5ae966bc-f295-494e-a325-ae64c3728d69">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcaf85e03f214f0fa6d79c0c4f6af669_D20210701-20210930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOC0zLTEtMS0xMTU0OTY_6ed19a18-b879-45c9-9c4d-319c1e09cf49">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a294335166245f6a43fd1a87aa252a7_D20220101-20220930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOC01LTEtMS0xMTU0OTY_efa701a1-cabd-45bd-b40b-517ac4585834">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia51e5bcf01714c6fa740643677798f18_D20210101-20210930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOC03LTEtMS0xMTU0OTY_ff76a917-b9b2-427d-9074-04789de87ab6">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOS0xLTEtMS0xMTU0OTY_10d358d9-943e-42da-b295-a3dc9e25a1a3">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOS0zLTEtMS0xMTU0OTY_e5304569-41bd-4ca0-af14-ceb7396ae729">97.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOS01LTEtMS0xMTU0OTY_0fb650fc-626f-4df0-94ce-840984fc4e4c">98.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOS03LTEtMS0xMTU0OTY_167e62c8-d855-49da-b27b-a171a7d82ca5">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTEtMS0xLTEtMTE1NDk2_07914b5d-111d-41f7-a00f-b72fcf4df275">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTEtMy0xLTEtMTE1NDk2_940daec5-a334-4ea0-a895-ee544d1da7db">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTEtNS0xLTEtMTE1NDk2_6336d554-3ca5-4c60-9481-96da5148dda3">0.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTEtNy0xLTEtMTE1NDk2_42db7860-3bd8-45ca-9283-163799c239e3">1.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTItMS0xLTEtMTE1NDk2_e121b66a-905c-48c4-892c-9c3a6ec5f325">0.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTItMy0xLTEtMTE1NDk2_1bf5d9d2-dc1e-4085-bad1-f50ef11517d1">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTItNS0xLTEtMTE1NDk2_c362b2c5-3bd8-4cce-9ea1-dc809a6ff2a7">0.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTItNy0xLTEtMTE1NDk2_89f08395-5423-4641-ab40-49f85cdf364f">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTQtMS0xLTEtMTE1NDk2_57ccf48d-5a40-453c-b02e-87e060c0a604">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTQtMy0xLTEtMTE1NDk2_422a25fc-7a40-4691-a809-73fd3b498f8d">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTQtNS0xLTEtMTE1NDk2_86b0c850-8925-4328-ac9f-8d40a99426f8">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTQtNy0xLTEtMTE1NDk2_5ae43bf6-7d53-4cec-8e9f-b0851093e1b6">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iff439a36db274cfaa026518ede3eda49_712"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV83MTIvZnJhZzpmNDY1OWRmNDgzYzc0MzI3YjM2NGNjZDNiNjYwY2JjMi90ZXh0cmVnaW9uOmY0NjU5ZGY0ODNjNzQzMjdiMzY0Y2NkM2I2NjBjYmMyXzIxOTkwMjMyNjAwNjc_21fc4f3b-9505-43b6-bfd7-6c415b2117d8" continuedAt="i4f71c5f91e1a4c63ac29b4db9555452a" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4f71c5f91e1a4c63ac29b4db9555452a">On November 1, 2022, we acquired Diurnal Group plc in an all-cash transaction, for an aggregate value of approximately &#163;<ix:nonFraction unitRef="gbp" contextRef="if8ceebe0bfe84be1b0d7f9f9ae5831b9_D20221101-20221101" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV83MTIvZnJhZzpmNDY1OWRmNDgzYzc0MzI3YjM2NGNjZDNiNjYwY2JjMi90ZXh0cmVnaW9uOmY0NjU5ZGY0ODNjNzQzMjdiMzY0Y2NkM2I2NjBjYmMyXzU0OTc1NTgxODkxNw_a88c520e-b01b-4d2b-b227-b37d97822497">48.3</ix:nonFraction>&#160;million GBP, or approximately $<ix:nonFraction unitRef="usd" contextRef="if8ceebe0bfe84be1b0d7f9f9ae5831b9_D20221101-20221101" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV83MTIvZnJhZzpmNDY1OWRmNDgzYzc0MzI3YjM2NGNjZDNiNjYwY2JjMi90ZXh0cmVnaW9uOmY0NjU5ZGY0ODNjNzQzMjdiMzY0Y2NkM2I2NjBjYmMyXzU0OTc1NTgxODk1OA_3a69b14e-c8fc-4844-a89c-d90f8818a8d7">56</ix:nonFraction>&#160;million USD. We believe the transaction presents an opportunity to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders. We are currently in the process of finalizing the accounting for this transaction.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part II, Item&#160;1A under the caption &#8220;Risk Factors.&#8221; The interim financial statements and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&#160;31, 2021 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, which are contained in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 and our Quarterly Report on Form 10-Q for the six months ended June&#160;30, 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Neurocrine Biosciences, our purpose is simple: to relieve suffering for people with great needs, but few options. For three decades, we have applied our unique insight into neuroscience to advance medicines for neurology, neuroendocrinology and neuropsychiatry-related disorders and diseases. Our efforts have resulted in United States Food and Drug Administration, or FDA, approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis* and uterine fibroids* and a diversified portfolio of investigational therapies with the potential to address unmet clinical needs of patients worldwide living with neurological, endocrine and psychiatric disorders. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc., or AbbVie)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the United States in May 2017 as the first FDA-approved drug for the treatment of tardive dyskinesia and launched ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) in the United States in September 2020 as an FDA-approved add-on treatment for levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. INGREZZA net product sales represent the significant majority of our total net product sales.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner Mitsubishi Tanabe Pharma Corporation, or MTPC, launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan in June 2022 for the treatment of tardive dyskinesia. We receive royalties at tiered percentage rates on MTPC net sales of DYSVAL.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the United States in August 2018 for the treatment of moderate to severe pain associated with endometriosis and launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States in June 2020 for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Highlights</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2022, we submitted a supplemental new drug application, or sNDA, with the FDA for valbenazine for the treatment of chorea associated with Huntington disease.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On November 1, 2022, we acquired Diurnal Group plc in an all-cash transaction, for an aggregate value of approximately &#163;48.3&#160;million GBP, or approximately $56&#160;million USD. We believe the transaction presents an opportunity to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Impacts of Macro-Economic Factors on Our Business</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Global Pandemic.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the impact of the COVID-19 pandemic on our business, including our clinical trials, third-party manufacturers, suppliers and service providers. The extent to which COVID-19 may impact our financial condition and results of operations remains uncertain and is dependent on numerous evolving factors, including the measures being taken by authorities to mitigate against the spread of COVID-19, the emergence of new variants and the availability and successful administration of effective vaccines. For more information on the risks and uncertainties associated with the evolving effects of COVID-19 on our business, our ability to generate sales of and revenues from our approved products and our clinical development and regulatory efforts, refer to Part II Item 1A. Risk Factors.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Russia/Ukraine Conflict.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia commenced a military invasion of Ukraine. The ongoing geopolitical turmoil and continuing military action in the region, together with widening sanctions imposed on Russia, have caused us to suspend all planned clinical trial activities for valbenazine and luvadaxistat in Russia and Ukraine.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration and impact of the conflict between Russia and Ukraine is highly unpredictable and the extent to which the conflict may impact certain of our clinical development and regulatory efforts remains uncertain. For more information on the risks and uncertainties associated with the evolving effects of the conflict between Russia and Ukraine on our business and certain of our clinical development and regulatory efforts, refer to Part II Item 1A. Risk Factors.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations for the Three and Nine Months Ended September&#160;30, 2022 and 2021</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales by Sales Product. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INGREZZA net product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,028.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">780.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ONGENTYS net product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,036.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the increase in INGREZZA net product sales was driven by increased new patient starts and record total prescriptions, reflecting higher customer demand and increased commercial activities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues by Category.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of royalties earned at tiered percentage rates on AbbVie net sales of elagolix and, beginning in June 2022, MTPC net sales of DYSVAL.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of license fees earned under the terms of our license agreements with AbbVie and MTPC.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenue for the nine months ended September&#160;30, 2022 reflected the achievement of a $20.0 million milestone in connection with MTPC's first commercial sale of DYSVAL in Japan in June 2022. For the comparable period last year, milestone revenue reflected the achievement of a $15.0 million milestone in connection with MTPC's submission of a marketing authorization application for valbenazine for the treatment of tardive dyskinesia with the Ministry of Health and Welfare in Japan in April 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the increase in cost of revenues primarily reflected increased manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with MTPC and increased INGREZZA net product sales driven by increased new patient starts and record total prescriptions, reflecting higher customer demand and increased commercial activities.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development by Category. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs, and business development opportunities. Costs are reflected in the applicable development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same reporting period. For several of our programs, the research and development activities are part of our collaborative arrangements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Late stage</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Early stage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Late Stage.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of expenses incurred for product candidates in Phase II registrational studies and all subsequent activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, late-stage expenses primarily reflected increased investment in our Phase III programs for valbenazine in schizophrenia and crinecerfont in classic congenital adrenal hyperplasia, partially offset by lower spend related to the completion of the Phase III KINECT-HD study in the first quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Stage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of expenses incurred for product candidates after the approval of an investigational new drug application by the applicable regulatory agency through Phase II non-registrational studies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, early-stage expenses primarily reflected increased investment in support of our advancing Phase II programs in epilepsy and luvadaxistat and NBI-1117568 in schizophrenia.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Discovery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of expenses incurred prior to the approval of an investigational new drug application by the applicable regulatory agency.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, research and discovery expenses primarily reflected increased investment in our preclinical development programs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consists of milestone expenses incurred in connection with our collaborative arrangements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone expenses for the nine months ended September&#160;30, 2022 primarily reflected $5.0 million of expense recognized in connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in July 2022, $30.0 million of expense recognized in connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022 and $7.3 million of expense recognized in connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in January 2022. For the nine months ended September&#160;30, 2021, milestone expenses reflected $5.4 million of expense recognized in connection with the European Union's approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payroll and Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consists of costs incurred for salaries and wages, payroll taxes, benefits and stock-based compensation associated with employees involved in research and development activities. Stock-based compensation may fluctuate from period to period based on factors that are not within our control, such as our stock price on the dates stock-based grants are issued.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to the comparable period last year, payroll and benefits expenses for the nine months ended September&#160;30, 2022 primarily reflected higher headcount and an increase of $7.4 million in non-cash stock-based compensation expense primarily related to an August 2021 equity grant of approximately 0.5 million restricted stock units to our full-time employees other than our executive officers, which are vesting over a 2-year period, and unvested performance-based restricted stock units to our executive officers for which attainment of the performance-based criteria was determined to be probable. The nine months ended September&#160;30, 2021 included a non-cash stock-based compensation charge of $6.4 million related to the modification of certain stock-based awards.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the increase in sales, general and administrative expense was primarily driven by increased investment in ongoing commercial initiatives, including our TD Spotlight-branded direct-to-consumer INGREZZA advertising campaign, which launched in May 2021, and deployment of our expanded sales force. Compared with the comparable period last year, sales, general and administrative expense for the nine months ended September 30, 2022, also reflected increased personnel expenses driven by higher headcount and an increase of $23.6 million in non-cash stock-based compensation expense primarily related to an August 2021 equity grant of approximately 0.5 million restricted stock units to our full-time employees other than our executive officers, which are vesting over a 2-year period, and unvested performance-based restricted stock units to our executive officers for which attainment of the performance-based criteria was determined to be probable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the change in other income (expense), net, was driven by periodic fluctuations in the fair values of our equity security investments and decreased interest expense in connection with our adoption of ASU 2020-06 on January 1, 2022. Compared with the comparable period last year, other expense, net, for the nine months ended September 30, 2022, also reflected a $70.0 million loss on extinguishment in connection with the repurchase of $210.8 million aggregate principal amount of our convertible senior notes for an aggregate repurchase price of $279.0 million in cash in the second quarter of 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the three and nine months ended September 30, 2022, reflected an effective tax rate that differs from the federal and state statutory rates primarily due to credits generated for research activities and certain nondeductible expenses, including the premium paid on the repurchase of our convertible senior notes. The provision for income taxes for the three and nine months ended September 30, 2021, reflected an effective tax rate that was lower than the federal and statutory rates primarily due to excess tax benefits related to stock-based compensation. Based upon available Federal net operating losses and tax credits, we expect to begin making cash payments for Federal income tax beginning in 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Income.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the change in net income primarily reflected increased INGREZZA net product sales driven by increased new patient starts and record total prescriptions, reflecting higher customer demand and increased commercial activities, partially offset by increased investments in ongoing commercial initiatives and our expanded clinical portfolio. Compared to the comparable period last year, net income for the nine months ended September 30, 2022, also reflected a $70.0 million loss on extinguishment recognized in connection with the repurchase of our convertible senior notes in the second quarter of 2022 and increased milestone expenses incurred in connection with certain of our collaborative arrangements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources and anticipated revenues will be sufficient to satisfy our current and projected funding requirements for at least the next 12&#160;months. However, we cannot guarantee that our existing capital resources and anticipated revenues will be sufficient to conduct and complete all of our research and development programs or commercialization activities as planned. We may seek to access the public or private equity markets whenever conditions are favorable or pursue opportunities to obtain additional debt financing in the future. We may also seek additional funding through strategic alliances or other financing mechanisms. However, we cannot provide assurance that adequate funding will be available on terms acceptable to us, if at all. In addition, the disruption of global financial markets caused by the COVID-19 pandemic, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Information Regarding Our Financial Condition.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,162.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,272.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Working Capital:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,205.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total working capital</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">720.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Information Regarding Our Cash Flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(258.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable period last year, cash flows from operating activities primarily reflected increased INGREZZA net product sales driven by increased new patient starts and record total prescriptions, reflecting higher customer demand and increased commercial activities, partially offset by increased investments in ongoing commercial initiatives and our expanded clinical portfolio. In addition, we experienced an increase in accounts receivable due to extended customer payment terms attributed to the expansion of our distribution network at the end of fiscal 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic fluctuations in cash flows from investing activities primarily reflect timing differences related to purchases, sales and maturities of debt security investments and changes in our portfolio-mix.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable period last year, cash flows from financing activities primarily reflected the repurchase of $210.8 million aggregate principal amount of our convertible senior notes for an aggregate repurchase price of $279.0 million in cash in the second quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical industry, it can take a significant amount of time and capital resources to successfully complete all stages of research and development and commercialize a product candidate, which ultimate length of time and spend required cannot be accurately estimated as it varies substantially according to the type, complexity, novelty and intended use of a product candidate. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The funding necessary to execute our business strategies is subject to numerous uncertainties and we may be required to make substantial expenditures if unforeseen difficulties arise in certain areas of our business. In particular, our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, ORIAHNN and/or DYSVAL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our research and clinical development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including our advertising campaigns;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing of our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing factors, we have significant future capital requirements, including:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">External Business Developments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our independent efforts to develop and market products, we may enter into collaboration and license agreements or acquire businesses from time-to-time to enhance our drug development and commercial capabilities. With respect to our existing collaboration and license agreements, we may be required to make potential future payments of up to $10.8 billion upon the achievement of certain event-based milestones.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, we acquired Diurnal Group plc in an all-cash transaction, for an aggregate value of approximately &#163;48.3&#160;million GBP, or approximately $56&#160;million USD. We believe the transaction presents an opportunity to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 to the condensed consolidated financial statements for more information on our significant collaboration and license agreements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rated convertible senior notes due May&#160;15, 2024, or the 2024 Notes. In the fourth quarter of 2020 and second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million and $210.8 million, respectively, aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million and $279.0 million, respectively, in cash. As of September&#160;30, 2022, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our election, we may redeem all or any portion of the 2024 Notes under certain circumstances. Further, as the conditional conversion feature of the 2024 Notes was triggered as of September 30, 2022, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on October 3, 2022, and ending at the close of business on December 30, 2022</span><span style="background-color:#def3c0;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> With respect to the 2024 Notes, unless earlier converted, redeemed, or repurchased, we would be required to pay interest of $1.9 million in 2022, $3.8 million in 2023, and $1.9 million in 2024 and pay the aggregate principal amount outstanding of $170.4 million upon maturity of the 2024 Notes.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. There are customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the notes would become due and payable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 8 to the condensed consolidated financial statements for more information on the 2024 Notes.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters and expect to begin subleasing our existing leased facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7 to the condensed consolidated financial statements for more information on our leases, including a presentation of our approximate future minimum lease payments under non-cancelable operating leases.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to our critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a diversified investment portfolio consisting of low-risk, investment-grade debt securities with maturities of up to three years, including investments in commercial paper, securities of government-sponsored entities and corporate bonds that are subject to interest rate risk. The primary objective of our investment activities is to preserve principal and maintain liquidity. If a 1% unfavorable change in interest rates were to have occurred on September&#160;30, 2022, it would not have had a material effect on the fair value of our investment portfolio as of that date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;proforma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products, technology enhancements, possible changes in legislation and other statements that are not historical. These statements include but are not limited to statements under the captions &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as other sections in this report. You should be aware that the occurrence of any of the events discussed under the heading in Part II titled &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline and you could lose all or a part of the value of your shares of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future.</span></div><div id="iff439a36db274cfaa026518ede3eda49_64"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of our exposure to, and management of, market risk appears in Part I, Item&#160;2 of this Quarterly Report on Form&#160;10-Q&#160;under the heading &#8220;Interest Rate Risk.&#8221;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports required by the Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the timelines specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any changes to our internal control over financial reporting that occurred during our last fiscal quarter and that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our evaluation did not identify significant changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the quarter ended September&#160;30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div id="iff439a36db274cfaa026518ede3eda49_73"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second, third and fourth quarters of 2021 and the first, second and third quarters of 2022, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., (iv) Sandoz Inc. and (v) Zydus Pharmaceuticals (USA) Inc. that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by the manufacture, use or sale of the medicine for which the ANDA was submitted.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed suit in the United States District Court for the District of Delaware in July, August and October 2021 and January, April, May, July, August and September 2022, against (i) Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (entity dismissed), (ii) Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc. and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., (iv) Sandoz Inc., Sandoz International GmbH (entity dismissed) and Sandoz AG (entity dismissed) and (v) Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC (entity dismissed). Sandoz Inc. has been joined in the cases against Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. The cases filed in July, August and October 2021 and January and August 2022 have been consolidated in the United States District Court for the District of Delaware and the trial is currently scheduled for January 2, 2024.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also filed suit in the United States District Court for the District of New Jersey in July and October 2021 and April 2022 against Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC and these cases were dismissed in favor of continued prosecution of the Delaware proceedings against the same entities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we filed suit in the United States District Court for the District of Delaware and in the United States District Court for the District of New Jersey in September 2022, against Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><div id="iff439a36db274cfaa026518ede3eda49_76"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on Form 10-Q and those we may make from time to time. If any of the following risks actually occur, our business, operating results, prospects or financial condition could be harmed. Additional risks not presently known to us, or that we currently deem immaterial, may also affect our business operations. The risk factors set forth below with an asterisk (*) contain changes to the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties related to our business, many of which are beyond our control.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, risks associated with our business include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, which could also cause significant disruption in the operations of third-party manufacturers, contract research organizations, or CROs, or other third parties upon whom we rely.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may be delayed for safety or other reasons, or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Several of our planned clinical trial sites have been impacted and could be delayed or suspended as a result of the conflict between Russia and Ukraine.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to retain and recruit qualified scientists and other employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Company</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to produce INGREZZA revenues consistent with expectations ultimately depends on our ability to continue to successfully commercialize INGREZZA and secure adequate third-party reimbursement. Our experience in marketing and selling pharmaceutical products began with INGREZZA&#8217;s approval in 2017, when we hired our sales force and established our distribution and reimbursement capabilities, all of which are necessary to successfully commercialize our current and future products. We have continued to invest in our commercial infrastructure and distribution capabilities in the past four years, including the expansion of our specialty sales force, which we announced in the third quarter of 2021 and completed in April 2022. While our team members and consultants have experience marketing and selling pharmaceutical products, we may face difficulties related to managing the rapid growth of our personnel and infrastructure, and there can be no guarantee that we will be able to maintain the personnel, systems, arrangements and capabilities necessary to continue to successfully commercialize INGREZZA, or to successfully commercialize ONGENTYS or any product candidate approved by the FDA in the future. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business has been and may continue to be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic. In parts of the country where the pandemic is having a greater impact, some hospitals, community mental health facilities and other healthcare facilities continue to have policies that limit access of our sales representatives, medical affairs personnel and patients to such facilities. These policies are likely to change from time to time as communities or regions grapple with outbreaks. These facilities also may be facing staffing shortages that impact their ability to see patients and conduct necessary screenings. In addition, many health care practitioners have adopted telehealth for patient interactions, which may impact the ability of the health care practitioner to screen for and diagnose tardive dyskinesia. Further, during the COVID-19 pandemic, the use of physician telehealth services increased significantly, fueled by an expansion of coverage and reimbursement from government and other payors. The limitations that telehealth places on the ability to conduct a thorough visual and physical examination may impact the ability of providers to screen for movement disorders, leading to potentially fewer patients to be diagnosed and referred for treatment. The ultimate impact of the COVID-19 pandemic, including any lasting effects on the way we conduct our business, is highly uncertain and subject to continued change. If we fail to maintain successful marketing, sales and reimbursement capabilities, our product revenues may suffer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of INGREZZA or ONGENTYS will depend upon the acceptance of those products as safe and effective by the medical community and patients.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market acceptance of INGREZZA or ONGENTYS could be affected by a number of factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of receipt of marketing approvals for additional indications;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of healthcare payor coverage and adequate reimbursement for the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public perception regarding any products we may develop;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of existing competitor products addressing our target markets or the emergence of equivalent or superior products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost-effectiveness of the products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the medical community, patients and payors do not continue to accept our products as being safe, effective, superior and/or cost-effective, we may not generate sufficient revenue.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products or impose policies that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to commercialize INGREZZA successfully or to successfully commercialize ONGENTYS, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. The continuing efforts of government and third-party payors to contain or reduce the costs of health care and the price of prescription drugs through various means may impact our revenues. These payors&#8217; efforts could decrease the price that we receive for any products we may develop and sell in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the out-of-pocket cost of our products. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available regardless of whether they are approved by the FDA for that particular use. Coverage decisions by payors for our competitors' products may also impact coverage for our products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. In addition, communications from government officials regarding health care costs and pharmaceutical pricing could have a negative impact on our stock price, even if such communications do not ultimately impact coverage or reimbursement decisions for our products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs or indications, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize INGREZZA, ONGENTYS or any other product candidate for which we obtain marketing approval. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. Further, a majority of our current revenue is derived from federal healthcare program payors, including Medicare and Medicaid. Thus, changes in government reimbursement policies, reductions in payments and/or our suspension or exclusion from participation in federal healthcare programs could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, during the COVID-19 pandemic, the use of physician telehealth services has rapidly increased, fueled by an unprecedented expansion of coverage and reimbursement across insurers. The limitations that telehealth places on the ability to conduct a thorough physical examination may impact the ability of providers to screen for movement disorders, leading to fewer patients being diagnosed and/or treated.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, which could also cause significant disruption in the operations of third-party manufacturers CROs, or other third parties upon whom we rely.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics, which could also cause significant disruption in the operations of third-party manufacturers, CROs and other third parties upon whom we rely. As a result of the ongoing COVID-19 pandemic, we may experience disruptions that could severely impact our supply chain, ongoing and future clinical trials and commercialization of INGREZZA and ONGENTYS. For example, the COVID-19 pandemic has resulted in travel restrictions and the shutdown or delay of business activities in various regions. In response to the COVID-19 pandemic, we implemented a remote work model for all employees except certain key essential members involved in business-critical activities.&#160;Most of our field-based employees have resumed in-person interactions in accordance with location-specific guidance. Our office-based employees have returned to the office under flexible work guidelines to help balance business needs, employee health, well-being and safety and the evolving work environment. However, as the effects of the pandemic continue to rapidly evolve with the emergence of new COVID-19 variants and spikes or surges in infection and hospitalization rates, a remote work model may nevertheless need to be reinstated at some point in the future. The effects of a remote and flexible work model may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In addition, we may face several challenges or disruptions upon a return back to the workplace, including re-integration challenges by our employees and distractions to management related to such transition. These and similar, and perhaps more severe, disruptions in our operations due to the COVID-19 pandemic could negatively impact our business, operating results and financial condition. We continue to evaluate the impact of the COVID-19 pandemic on our business and will update our plans and policies as needed going forward.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, stay at home orders, travel restrictions and other state and local restrictions, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical site initiation and patient enrollment may be delayed due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient travel or interrupt healthcare services. Similarly, our ability to recruit and retain patients, principal investigators and site staff may be hindered, which would adversely impact our clinical trial operations. Increases in COVID-19 cases or hospitalizations in the future could cause us or any of our clinical sites to again limit or suspend our patient enrollment and screening activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic has caused disruption in the global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business and the value of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the COVID-19 pandemic continue to evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to continued change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations, or the operations of third parties on whom we rely.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other drug development technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods of preventing or reducing the incidence of disease, including vaccines; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new small molecule or other classes of therapeutic agents.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments by others (including the development of generic equivalents) may render our product candidates or technologies obsolete or noncompetitive.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are commercializing and performing research on or developing products for the treatment of several disorders including endometriosis, tardive dyskinesia, uterine fibroids, essential tremor, classic congenital adrenal hyperplasia, pain, Parkinson&#8217;s disease and other neurology, neuroendocrinology and neuropsychiatry-related diseases and disorders, and there are a number of competitors to our products and product candidates. If one or more of our competitors&#8217; products or programs are successful (including the development of generic equivalents), the market for our products may be reduced or eliminated.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA competes with AUSTEDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (deutetrabenazine), which was approved by the FDA for the treatment of tardive dyskinesia in adults in August 2017 and is marketed by Teva Pharmaceutical Industries, and several clinical development-stage programs targeting tardive dyskinesia and related movement disorders. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as XENAZINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ONGENTYS competes with two other FDA-approved COMT inhibitors and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson&#8217;s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications, including opioids.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the United States alone, there are more than two dozen companies manufacturing steroid-based products. In addition, there are several programs in clinical development targeting CAH and several companies developing medicinal treatments for CAH.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications and development-stage programs being pursued by several other companies. Commonly used anti-seizure medications include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol, among others. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathies SCN8A-DEE and EE-CSWS; however, a number of different anti-seizure medications are currently used in these patient populations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in schizophrenia and depression may in the future compete with several development-stage programs being pursued by other companies. Currently, there are no FDA-approved treatments specifically indicated for cognitive impairment associated with schizophrenia, or CIAS; however, there are a number of different anti-psychotic medications currently used in these patient populations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in neurology, neuroendocrinology and neuropsychiatry may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to us, many of our competitors and potential competitors have substantially greater:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital resources;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales and marketing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research and development resources, including personnel and technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study and clinical testing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing and distribution experience; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increased competition in certain disorders or therapies may make it more difficult for us to recruit or enroll patients in our clinical trials for similar disorders or therapies.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a small number of research and development programs ultimately result in commercially successful drugs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons. These reasons include the possibilities that the potential products may:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be found ineffective or cause harmful side effects during preclinical studies or clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to receive necessary regulatory approvals on a timely basis or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be precluded from commercialization by proprietary rights of third parties;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be difficult to manufacture on a large scale; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be uneconomical to commercialize or fail to achieve market acceptance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our clinical trials may be delayed for safety or other reasons or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of any of our potential products, we must subject these product candidates to extensive preclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete and the outcomes are uncertain.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the clinical trials of our product candidates, we face the risks that:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authority may not allow an IND or foreign equivalent filings required to initiate human clinical studies for our drug candidates or the FDA may require additional preclinical studies as a condition of the initiation of Phase I clinical studies, or additional clinical studies for progression from Phase&#160;I to Phase&#160;II, or Phase&#160;II to Phase&#160;III, or for NDA approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate may not prove to be effective or as effective as other competing product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may discover that a product candidate may cause harmful side effects or results of required toxicology or other studies may not be acceptable to the FDA;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results may not replicate the results of previous trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authorities may require use of new or experimental endpoints that may prove insensitive to treatment effects;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the FDA or similar foreign regulatory authorities may suspend the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not be statistically significant;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical site initiation or patient recruitment and enrollment may be slower or more difficult than expected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may not accept the data from any trial or trial site outside of the United States;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients may drop out of the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen disruptions or delays may occur, caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requirements may change.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks and uncertainties impact all of our clinical programs and any of the clinical, regulatory or operational events described above could change our planned clinical and regulatory activities. In addition, due to the impact of the COVID-19 pandemic, clinical site initiation and new patient enrollment has been negatively impacted. Additionally, any of these events described above could result in suspension of a program and/or obviate any filings for necessary regulatory approvals.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, late-stage clinical trials are often conducted with patients having the most advanced stages of disease. During the course of treatment, these patients can die or suffer other adverse medical effects for reasons that may not be related to the pharmaceutical agent being tested but which can nevertheless adversely affect clinical trial conduct, completion and results. Any failure or substantial delay in completing clinical trials for our product candidates may severely harm our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Several of our planned clinical trial sites have been impacted and could be delayed or suspended as a result of the conflict between Russia and Ukraine.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia commenced a military invasion of Ukraine. We have planned clinical trial sites in both Russia and Ukraine, but no patients yet enrolled. Ongoing geopolitical turmoil and continuing military action in the region, together with widening sanctions imposed on Russia, have caused us to suspend all planned clinical trial activities in Russia and Ukraine. Alternative clinical trial sites that would fully and timely compensate for our planned clinical trial activities in Ukraine and Russia may not be available and we may need to find other countries in which to conduct such activities. Our planned clinical development timelines for valbenazine and luvadaxistat could be significantly delayed, which would increase our development costs and delay the development and/or regulatory approval process of such product candidates and jeopardize our ability to commence product sales and generate revenues.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates. For example, we depend on AbbVie for the manufacture and commercialization of ORILISSA and ORIAHNN and for the continued development of elagolix. We collaborate with MTPC for the commercialization of DYSVAL in Japan and for the continued development and commercialization of valbenazine for movement disorders in other select Asian markets. We also rely on BIAL for the commercial supply of ONGENTYS. In addition, we collaborate with Xenon Pharmaceuticals, Inc. for the development of NBI-921352, Idorsia Pharmaceuticals Ltd for the development of NBI-827104, Takeda Pharmaceutical Company Limited for the development of luvadaxistat, NBI-1065845 and NBI-1065846 and Heptares Therapeutics Limited for the development of NBI-1117568.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future collaborations and licenses could subject us to a number of risks, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may sell, transfer or divest assets or programs related to our partnered product or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to undertake the expenditure of substantial operational, financial and management resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to assume substantial actual or contingent liabilities; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our products or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to influence our strategic collaborator&#8217;s decisions regarding the development and collaboration of our partnered product and product candidates, and as a result, our collaboration partners may not pursue or prioritize the development and commercialization of those partnered products and product candidates in a manner that is in our best interest;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not conduct collaborative activities in a timely manner, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements or disputes may arise between us and our strategic collaborators that result in delays or in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may experience financial difficulties; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and commercialization and may increase the cost of developing and commercializing our products or product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could develop, either alone or with others, products or product candidates that may compete with ours. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these issues arise, it may delay and/or negatively impact the development and commercialization of drug candidates and, ultimately, our generation of product revenues.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson&#8217;s disease patients, and in September 2020, we launched the commercial sale of ONGENTYS with our existing commercial infrastructure. The successful commercialization of ONGENTYS is subject to many risks, and there are numerous examples of unsuccessful product launches and failures, including by pharmaceutical companies with more experience and resources than us. If we are unable to effectively train our employees and equip them with effective materials, including medical and sales literature to help them inform and educate health care practitioners about the benefits of ONGENTYS and its proper administration, our commercialization of ONGENTYS may not be successful. Even if we are successful in effectively training and equipping our sales force, there are many factors that could cause the commercialization of ONGENTYS to be unsuccessful, including a number of factors that are outside our control. Health care practitioners may not prescribe ONGENTYS and patients may be unwilling to use ONGENTYS if insurance coverage is not provided or reimbursement is inadequate. In addition, our ability to train our employees and effectively communicate with potential prescribers could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, use of our approved products or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor adverse reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our products or those of our collaborators may be observed at any time, including after a product is commercialized, and reports of any such side effects or adverse events may negatively impact demand for our or our collaborators&#8217; products or affect our or our collaborators&#8217; ability to maintain regulatory approval for such products. Side effects or other safety issues associated with the use of our approved products or those of our collaborators could require us or our collaborators to modify or halt commercialization of these products or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional studies regarding the safety and efficacy of our products which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had more than 1,150 full-time employees. Although we have substantially increased the size of our organization, we may need to add additional qualified personnel and resources, especially with the recent increase in the size of our sales force. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on our organization, including the need to identify, recruit, maintain and integrate additional employees, and may take time away from running other aspects of our business, including development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize INGREZZA, ONGENTYS and any other product candidates that receive regulatory approval will depend, in part, on our ability to manage any future growth effectively. In particular, as we commercialize INGREZZA and ONGENTYS, we will need to support the training and ongoing activities of our sales force and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our development efforts effectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate additional management, administrative and manufacturing personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our marketing and sales organization; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compensate our employees on adequate terms in an increasingly competitive, inflationary market;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain personnel; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain sufficient administrative, accounting and management information systems and controls.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development and commercialization goals. Our failure to accomplish any of these goals could harm our financial results and prospects.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to retain and recruit qualified scientists and other employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management, commercial and scientific staff. The loss of any of these people could impede the achievement of our objectives, including the successful commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA. Furthermore, recruiting and retaining qualified scientific personnel to perform research and development work in the future, along with personnel with experience marketing and selling pharmaceutical products, is critical to our success. We may be unable to attract and retain personnel on acceptable terms given effects of the COVID-19 pandemic, as well as the competition among biotechnology, pharmaceutical and health care companies, universities and non-profit research institutions for experienced scientists and individuals with experience marketing and selling pharmaceutical products. We may face particular retention challenges in light of the recent rapid growth in our personnel and infrastructure and the perceived impact of those changes upon our corporate culture. In addition, we rely on a significant number of consultants to assist us in formulating our research and development strategy and our commercialization strategy. Our consultants may have commitments to, or advisory or consulting agreements with, other entities that may limit their availability to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past utilized, and intend to continue to utilize, third-party manufacturers to produce the drug compounds we use in our clinical trials and for the commercialization of our products. We have limited experience in manufacturing products for commercial purposes and do not currently have any manufacturing facilities. Establishing internal commercial manufacturing capabilities would require significant time and resources, and we may not be able to timely or successfully establish such capabilities. Consequently, we depend on, and will continue to depend on, several contract manufacturers for all production of products for development and commercial purposes, including INGREZZA and ONGENTYS. If we are unable to obtain or retain third-party manufacturers, we will not be able to develop or commercialize our products, including INGREZZA and ONGENTYS. The manufacture of our products for clinical trials and commercial purposes is subject to specific FDA regulations, including current Good Manufacturing Practice regulations. Our third-party manufacturers, including BIAL and its suppliers, might not comply with FDA regulations relating to manufacturing our products for clinical trials and commercial purposes or other regulatory requirements now or in the future. Our reliance on contract manufacturers also exposes us to the following risks:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturers may encounter difficulties in achieving volume production, quality control or quality assurance, and also may experience shortages in qualified personnel. As a result, our contract manufacturers might not be able to meet our clinical schedules or adequately manufacture our products in commercial quantities when required;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store or distribute our products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the United States Drug Enforcement Administration, and other agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current dependence upon third parties for the manufacture of our products may reduce our profit margin, if any, on the sale of INGREZZA, ONGENTYS, or our future products and our ability to develop and deliver products on a timely and competitive basis.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the active pharmaceutical ingredients, or API, the finished drug product and packaging in sufficient quantities while meeting detailed product specifications on a repeated basis. Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced United States, state and non-United States regulations, and disruptions or delays caused by man-made or natural disasters, pandemics or epidemics, or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine. We depend on a limited number of suppliers for the production and packaging of INGREZZA and its API. If our third-party suppliers for INGREZZA encounter these or any other manufacturing, quality or compliance difficulties, we may be unable to meet commercial demand for INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. In addition, under the terms of our agreement with BIAL, although we are responsible for the management of all ONGENTYS commercialization activities, we rely on BIAL and its suppliers to supply all drug product for the commercialization of ONGENTYS. BIAL relies on third-party contract manufacturers to produce ONGENTYS. These contract manufacturers may encounter difficulties in achieving volume production, quality control, or quality assurance. As a result, these contract manufacturers may not be able to adequately produce ONGENTYS in commercial quantities when required, which may impact our ability to deliver ONGENTYS on a timely basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our suppliers fail or refuse to supply us with INGREZZA or its API for any reason, it would take a significant amount of time and expense to qualify a new supplier. The FDA and similar international regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in pharmaceutical products. The loss of a supplier could require us to obtain regulatory clearance and to incur validation and other costs associated with the transfer of the API or product manufacturing processes. If there are delays in qualifying new suppliers or facilities or if a new supplier is unable to meet FDA or a similar international regulatory body&#8217;s requirements for approval, there could be a shortage of INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. If BIAL is unable or refuses to supply us with ONGENTYS drug product for any reason, or does not meet FDA or international regulators&#8217; requirements for approval, we have limited opportunity to qualify a new supplier. This could materially and adversely affect our ability to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The independent clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators and CROs to conduct our clinical trials under their agreements with us. The investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. If our independent investigators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, or not in compliance with Good Clinical Practices, it may delay or prevent the approval of our regulatory applications and our introduction of new treatments. The CROs we contract with for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. Failure of the CROs to meet their obligations could adversely affect clinical development of our products. Moreover, these independent investigators and CROs may also have relationships with other commercial entities, some of which may compete with us. If independent investigators and CROs assist our competitors at our expense, it could harm our competitive position.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not and will not have access to all information regarding the products and product candidates we licensed to AbbVie.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not and will not have access to all information regarding elagolix, including potentially material information about commercialization plans, medical information strategies, clinical trial design and execution, safety reports from clinical trials, safety reports, regulatory affairs, process development, manufacturing and other areas known by AbbVie. In addition, we have confidentiality obligations under our agreement with AbbVie. Thus, our ability to keep our shareholders informed about the status of elagolix will be limited by the degree to which AbbVie keeps us informed and allows us to disclose such information to the public. If AbbVie fails to keep us informed about commercialization efforts related to elagolix, or the status of the clinical development or regulatory approval pathway of other product candidates licensed to it, we may make operational and/or investment decisions that we would not have made had we been fully informed, which may materially and adversely affect our business and operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing obligations and continued regulatory review for INGREZZA. Additionally, our other product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approvals for any of our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. For example, with respect to the FDA&#8217;s approval of INGREZZA for tardive dyskinesia in April 2017, we are subject to certain post-marketing requirements and commitments. In addition, with respect to INGREZZA, and any product candidate that the FDA or a comparable foreign regulatory authority approves, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Clinical Practices for any clinical trials that we conduct post-approval. Failure to comply with these ongoing regulatory requirements, or later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, may result in, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, changes in the product&#8217;s label, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning or untitled letters or holds on clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse inspection findings or other activities that temporarily delay manufacture and distribution of our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events may adversely affect our business, prospects and ability to achieve or sustain profitability on a sustained basis.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our products and product candidates are smaller than we believe they are, our expected revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the diseases that INGREZZA, ONGENTYS and our other product candidates are being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for INGREZZA, ONGENTYS and our other product candidates may be smaller than we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on licenses from third parties for some of our key technologies. These licenses typically subject us to various commercialization, reporting and other obligations. If we fail to comply with these obligations, we could lose important rights. If we were to default on our obligations under any of our licenses, we could lose some or all of our rights to develop, market and sell products covered by these licenses. For example, BIAL may terminate our license agreement, pursuant to which we have rights to commercialize ONGENTYS, if we fail to use commercially reasonable efforts to comply with specified obligations under the license agreement, or if we otherwise breach the license agreement. In addition, several of our collaboration and license agreements allow our licensors to terminate such agreements if we challenge the validity or enforceability of certain intellectual property rights or if we commit a material breach in whole or in part of the agreement and do not cure such breach within the agreed upon cure period. In addition, if we were to violate any of the terms of our licenses, we could become subject to damages. Likewise, if we were to lose our rights under a license to use proprietary research tools, it could adversely affect our existing collaborations or adversely affect our ability to form new collaborations. We also face the risk that our licensors could, for a number of reasons, lose patent protection or lose their rights to the technologies we have licensed, thereby impairing or extinguishing our rights under our licenses with them.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*The conditional conversion feature of the 2024 Notes, if triggered, may adversely affect our financial condition, operating results, or liquidity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the conditional conversion feature of the 2024 Notes had been triggered, allowing holders of 2024 Notes to convert their 2024 Notes at any time during the period beginning on October 3, 2022 and ending at the close of business on December 30, 2022. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods, and as a result, it is possible that holders of 2024 Notes will continue to be entitled to convert their 2024 Notes at any time during specified periods at their option. If one or more of the holders of the 2024 Notes elects to convert their 2024 Notes, we would be required to settle the principal amount of our conversion obligation in cash, which could adversely affect our liquidity.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we sold $517.5&#160;million aggregate principal amount of the 2024 Notes. In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of September&#160;30, 2022, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our vulnerability to adverse economic and industry conditions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to obtain additional financing;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our flexibility to plan for, or react to, changes in our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the 2024 Notes; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the 2024 Notes and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant net losses and negative cash flow from operations. As of September&#160;30, 2022, we had an accumulated deficit of $495.8 million as a result of historical operating losses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval for INGREZZA for tardive dyskinesia in April 2017 and for ONGENTYS for Parkinson&#8217;s disease in April 2020. Our partner AbbVie received FDA approval for ORILISSA for endometriosis in July 2018 and for ORIAHNN for uterine fibroids in May 2020. Additionally, our partner MTPC received Japanese Ministry of Health, Labour and Welfare approval for DYSVAL for the treatment of tardive dyskinesia in March 2022. However, we have not yet obtained regulatory approvals for any other product candidates. Even if we continue to succeed in commercializing INGREZZA, or if we successfully commercialize ONGENTYS or are successful in developing and commercializing any of our other product candidates, we may not be able to sustain profitability. We also expect to continue to incur significant operating and capital expenditures as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize INGREZZA for tardive dyskinesia;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize ONGENTYS for Parkinson&#8217;s disease;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates or for additional indications for our current products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, formulate, manufacture and commercialize our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire new product development opportunities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implement additional internal systems and infrastructure; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, scientific, sales and marketing personnel.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to increase our expenses and other investments in the coming years as we fund our operations and capital expenditures. Thus, our future operating results and profitability may fluctuate from period to period due to the factors described above, and we will need to generate significant revenues to achieve and maintain profitability and positive cash flow on a sustained basis. We may not be able to generate these revenues, and we may never achieve profitability on a sustained basis in the future. Our failure to maintain or increase profitability on a sustained basis could negatively impact the market price of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is commonplace in the biotechnology industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Because our operating results may vary significantly in future periods, our stock price may decline.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenues, expenses and operating results have fluctuated in the past and are likely to fluctuate significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA, impact of the commercial launch of ONGENTYS and ORIAHNN, royalties from out-licensed products, the impact of Medicare Part D coverage, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments, fluctuations in our effective tax rate, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine. Because a majority of our costs are predetermined on an annual basis, due in part to our significant research and development costs, small declines in revenue could disproportionately affect financial results in a quarter. Thus, our future operating results and profitability may fluctuate from period to period, and even if we become profitable on a quarterly or annual basis, we may not be able to sustain or increase our profitability. Moreover, as our company and our market capitalization have grown, our financial performance has become increasingly subject to quarterly and annual comparisons with the expectations of securities analysts or investors. The failure of our financial results to meet these expectations, either in a single quarterly or annual period over a sustained period time, could cause our stock price to decline.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. Unless the United States Department of the Treasury issues regulations that narrow the application of this provision to a smaller subset of our research and development expenses or the provision is deferred, modified, or repealed by Congress, we expect a material decrease in our cash flows from operations and an offsetting similarly sized increase in our net deferred tax assets over these amortization periods. The actual impact of this provision will depend on multiple factors, including the amount of research and development expenses we will incur and whether we conduct our research and development activities inside or outside the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, new income, sales, use, excise or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, Tax Cut and Jobs Act of 2017, the Coronavirus Aid, Relief, and Economic Security Act and the Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. Furthermore, it is uncertain if and to what extent various states will conform to federal tax laws. Future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future United States tax expense.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss, or NOL, carryforwards generated in tax years beginning on or prior to December 31, 2017, are only permitted to be carried forward for 20 years under applicable United States tax law. Under current law, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We do not believe we have experienced any previous ownership changes, but the determination is complex and there can be no assurance we are correct. Furthermore, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our pre-2018 NOL carryforwards may expire prior to being used and our NOL carryforwards generated in tax years beginning after December 31, 2017, will be subject to a percentage limitation and, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use all of our pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each such place. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including the impact of stock-based compensation, changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on December 31, 2020, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against our deferred tax assets was released. Therefore, beginning in 2021, we commenced recording income tax expense at an estimated tax rate that will likely approximate statutory tax rates, which could result in a significant reduction in our net income and net income per share.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*The price of our common stock is volatile.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies historically have been highly volatile, and the market for these securities has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. The COVID-19 pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in significant volatility. Furthermore, especially as we and our market capitalization have grown, the price of our common stock has been increasingly affected by quarterly and annual comparisons with the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts&#8217; forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, which is based on assumptions that may be incorrect or that may change from quarter to quarter, the market price of our common stock could decline. Over the course of the last twelve months, the price of our common stock has ranged from approximately $72 per share to approximately $116 per share. The market price of our common stock may fluctuate in response to many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of INGREZZA and our other products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the status and cost of our post-marketing commitments for INGREZZA;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports of safety issues related to INGREZZA, ONGENTYS, ORILISSA, ORIAHNN, or DYSVAL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning new and existing collaboration agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products by us or others;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions, including economic and market conditions affecting the biotechnology industry;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to the FDA and foreign regulatory agencies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our common stock by us or our stockholders;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comments by securities analysts;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential litigation matters and developments in existing litigation matters, such as the ANDA litigation matters;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government regulation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and third-party payor coverage and reimbursement;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by man-made or natural disasters, pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of our drugs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a member of the S&amp;P MidCap 400 index. If we cease to be represented in the S&amp;P MidCap 400 index, or other indexes or indexed products, as a result of our market capitalization falling below the threshold for inclusion in the index, certain institutional shareholders may, due to their internal policies and investment guidelines, be required to sell their shareholdings. Such sales may result in further negative pressure on our stock price and, when combined with reduced trading volume and liquidity, could adversely affect the value of your investment and your ability to sell your shares.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors, and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 89% of our total product revenue for the nine months ended September&#160;30, 2022 and approximately 95% of our accounts receivable balance as of September&#160;30, 2022. If any of these significant customers becomes subject to bankruptcy, is unable to pay us for our products or is acquired by a company that wants to terminate the relationship with us, or if we otherwise lose any of these significant customers, our revenue, results of operations and cash flows would be adversely affected. Even if we replace the loss of a significant customer, we cannot predict with certainty that such transition would not result in a decline in our revenue, results of operations and cash flows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional funding to continue our research and development programs, to conduct preclinical studies and clinical trials, for operating expenses, to pursue regulatory approvals for our product candidates, for the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims, if any, and the cost of product in-licensing and any possible acquisitions. In addition, we may require additional funding to establish manufacturing and marketing capabilities in the future. We believe that our existing capital resources and anticipated revenues will be sufficient to satisfy our current and projected funding requirements for at least the next 12&#160;months. However, these resources might be insufficient to conduct research and development programs, the cost of product in-taking and possible acquisitions, fully commercialize products and operate the company to the full extent currently planned. If we cannot obtain adequate funds, we may be required to significantly curtail our commercial plans or one or more of our research and development programs or obtain funds through additional arrangements with corporate collaborators or others that may require us to relinquish rights to some of our technologies or product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, ORIAHNN and/or DYSVAL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt services obligations on the 2024 Notes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our R&amp;D and clinical development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including advertising campaigns;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of any strategic alliances, collaborations, product in-licensing, or acquisitions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek additional funding through strategic alliances and may seek additional funding through public or private sales of our securities, including equity securities. In addition, during the second quarter of 2017, we issued the 2024 Notes and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of September&#160;30, 2022, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding. Additional equity or debt financing might not be available on reasonable terms, if at all. In addition, disruptions due to the COVID-19 pandemic could make it more difficult for us to access capital. Any additional equity financings will be dilutive to our stockholders and any additional debt financings may involve operating covenants that restrict our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and Nasdaq rules, are creating uncertainty for companies such as ours. These laws, regulations and standards are subject to varying interpretations in some cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, our efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased selling, general and administrative expenses and management time related to compliance activities. If we fail to comply with these laws, regulations and standards, our reputation may be harmed and we might be subject to sanctions or investigation by regulatory authorities, such as the SEC. Any such action could adversely affect our financial results and the market price of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patent protection for our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve our trade secrets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent third parties from infringing upon our proprietary rights; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing upon the proprietary rights of others, both in the United States and internationally.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial length of time and expense associated with bringing new products through the development and regulatory approval processes in order to reach the marketplace, the pharmaceutical industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Accordingly, we intend to seek patent protection for our proprietary technology and compounds. However, we face the risk that we may not obtain any of these patents and that the breadth of claims we obtain, if any, may not provide adequate protection of our proprietary technology or compounds.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our commercial collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our commercial collaborators and consultants. However, if our employees, commercial collaborators or consultants breach these agreements, we may not have adequate remedies for any such breach, and our trade secrets may otherwise become known or independently discovered by our competitors.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we own a number of patents, the issuance of a patent is not conclusive as to its validity or enforceability, and third parties may challenge the validity or enforceability of our patents. We cannot assure you how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court or in other proceedings. It is possible that a competitor may successfully challenge our patents or that challenges will result in limitations of their coverage. Moreover, competitors may infringe our patents or successfully avoid them through design innovation. In addition, potential competitors have in the past and may in the future file an ANDA with the FDA seeking approval to market a generic version of our products, or our competitors&#8217; products, before the expiration of the patents covering our products or our competitors&#8217; products, as applicable. To prevent infringement or unauthorized use, we have in the past and may in the future need to file infringement claims, which are expensive and time-consuming. For example, we are currently engaged in various intellectual property litigation matters against potential competitors related to INGREZZA. Refer to Item 1. Legal Proceedings f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a more detailed description of these matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, in an infringement proceeding a court may decide that a patent of ours or a patent of a competitor is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. Derivation proceedings declared by the United States Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications (or those of our licensors) or a patent of a competitor. Litigation or derivation proceedings may fail and, even if successful, may result in substantial costs and be a distraction to management. Litigation or derivation proceedings, including proceedings of a competitor, may also result in a competitor entering the marketplace faster than expected. We cannot assure you that we will be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care and to lower drug prices. In the United States, comprehensive health care reform legislation has been enacted by the Federal government and we expect that there will continue to be a number of federal and state proposals to implement government control over the pricing of prescription pharmaceuticals. In addition, increasing emphasis on reducing the cost of health care in the United States will continue to put pressure on the pricing and reimbursement of prescription pharmaceuticals. Moreover, in some foreign jurisdictions, pricing of prescription pharmaceuticals is already subject to government control. Additionally, other federal and state legislation impose obligations on manufacturers of pharmaceutical products, among others, related to disclosure of new drug products introduced to the market and increases in drug prices above a specified threshold.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was signed into law, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our drug products and potential drug candidates are:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures, or imports, specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a Medicare Part&#160;D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive legal and political challenges to certain aspects of the ACA. For example, on June 17, 2021 the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, prior to the United States Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and any additional healthcare reform measures of the Biden administration will impact the ACA.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act, will remain in effect until 2031, except for a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequestration. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, which ended the use of the statutory formula, also referred to as the Sustainable Growth Rate, for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, the Centers for Medicare &amp; Medicaid Services, or CMS, issued a final rule finalizing the changes to the Quality Payment Program. At this time, it remains unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, on July 24, 2020, and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempted to implement several of the administration&#8217;s proposals. As a result, the FDA concurrently released a final rule and guidance in September 2020, providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the United States Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of which has been delayed until January 1, 2027. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. Additionally, the IRA will, among other things, allow the Secretary of HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare Part B and Medicare Part D, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, the IRA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs, particularly since the majority of our current revenue is derived from federal healthcare programs, including Medicare and Medicaid.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to enter into collaboration agreements for the further development and commercialization of our programs and products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such laws include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and Civil Monetary Penalties Laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability and Accountability Act, or HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans and healthcare clearinghouses, as well as their business associates and their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state, local and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state laws that require disclosure of price increases above certain identified thresholds as well as of new commercial launches in the state; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug take back&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals, including our speaker programs and other arrangements have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. For example, we maintain a patient assistance program to help eligible patients afford our products. These types of programs have become the subject of governmental scrutiny, and numerous organizations, including pharmaceutical manufacturers, have been subject to litigation, enforcement actions and settlements related to their patient assistance programs. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of our product once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could face liability if a regulatory authority determines that we are promoting INGREZZA, ONGENTYS or any of our product candidates that receives regulatory approval, for &#8220;off-label&#8221; uses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the United States or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability, including civil and criminal sanctions. We intend to comply with the requirements and restrictions of the FDA and other regulatory agencies with respect to our promotion of our products, including INGREZZA and ONGENTYS, but we cannot be sure that the FDA or other regulatory agencies will agree that we have not violated their restrictions. As a result, we may be subject to criminal and civil liability. In addition, our management&#8217;s attention could be diverted to handle any such alleged violations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any other governmental agency initiates an enforcement action against us, or if we are the subject of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit brought by a private plaintiff on behalf of the government, and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If our information technology systems or data is or were compromised, we could experience adverse impacts resulting from such compromise, including, but not limited to, interruptions to our operations such as our clinical trials, claims that we breached our data protection obligations, harm to our reputation, and a loss of customers or sales.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, use, safeguard, share, transfer and otherwise process confidential and sensitive electronic information on our networks and in our data centers. This information includes, among other things, our intellectual property and proprietary information, the confidential information of our collaborators and licensees, and the personal data of our employees. It is important to our operations and business strategy that this electronic information remains secure and is perceived to be secure. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches, ransomware attacks, social engineering attacks, supply-chain attacks, and other cyber-attacks. Ransomware attacks are becoming increasingly prevalent and severe. To alleviate the financial, operational and reputational impact of a ransomware attack, it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems and infrastructure or the information technology systems and infrastructure of third parties that support our operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if the COVID-19 pandemic requires us to reinstate a remote workforce model, our information technology systems and data will be at increased risk as more of our employees work from home, utilizing network connections outside our premises.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, natural disasters, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), terrorism, war and geopolitical conflicts (including, for example, the conflict between Russia and Ukraine) and telecommunication and electrical failures may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of confidential information, including intellectual property, proprietary business information and personal data. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign private parties and state actors.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. Our efforts to identify and remediate such vulnerabilities may not be successful and we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Further, we may be unable to detect such vulnerabilities in the future because such threats and techniques change frequently, are often sophisticated in nature and may not be detected until after a security breach has occurred.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although to our knowledge we have not experienced any material incident or disruption to date, we and our vendors have been the target of cybersecurity incidents of this nature and expect them to continue. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security breach or are perceived to have experienced a security breach, we may experience adverse consequences. Such consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to any patent protection, we rely on forms of regulatory exclusivity to protect our products such as orphan drug designation. A product candidate that receives orphan drug designation can benefit from a streamlined regulatory process as well as potential commercial benefits following approval. Currently, this designation provides market exclusivity in the United States for seven years and the European Union for 10 years if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, orphan exclusivity may be reduced to 6 years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is &#8220;clinically superior&#8221; to the original orphan drug. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not have adequate patent protection for our products, then the relative importance of obtaining regulatory exclusivity is even greater. We may not be successful obtaining orphan drug designations for any indications and, even if we succeed, such product candidates with such orphan drug designations may fail to achieve FDA approval. Even if a product candidate with orphan drug designation may receive marketing approval from the FDA, it may fail to result in or maintain orphan drug exclusivity upon approval, which would harm our competitive position.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third&#160;parties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us or our collaborators with respect to technologies used in potential products. If a patent infringement suit were brought against us or our collaborators, we or our collaborators could be forced to stop or delay developing, manufacturing or selling potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our collaborators rights to use its intellectual property. In such cases, we could be required to obtain licenses to patents or proprietary rights of others in order to continue to commercialize our products. However, we may not be able to obtain any licenses required under any patents or proprietary rights of third parties on acceptable terms, or at all. Even if our collaborators or we were able to obtain rights to the third party&#8217;s intellectual property, these rights may be non-exclusive, thereby giving our competitors access to the same intellectual property. Ultimately, we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result of patent infringement claims, which could severely harm our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in disputes, claims and lawsuits relating to our business operations. In particular, we may face claims related to the safety of our products, intellectual property matters, employment matters, tax matters, commercial disputes, competition, sales and marketing practices, environmental matters, personal injury, insurance coverage and acquisition or divestiture-related matters. Any dispute, claim or lawsuit may divert management&#8217;s attention away from our business, we may incur significant expenses in addressing or defending any dispute, claim or lawsuit, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial results. For example, we are currently engaged in various intellectual property litigation matters against potential competitors related to INGREZZA. Refer to Item 1. Legal Proceedings f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a more detailed description of these matters.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation related to these disputes may be costly and time-consuming and could materially and adversely impact our financial position and results of operations if resolved against us. In addition, the uncertainty associated with litigation could lead to increased volatility in our stock price.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal investigators, consultants, commercial partners and vendors, or by employees of our commercial partners could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial information or data accurately, to maintain the confidentiality of our trade secrets or the trade secrets of our commercial partners, or to disclose unauthorized activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Employee and independent contractor misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any action against our employees, independent contractors, principal investigators, consultants, commercial partners or vendors for violations of these laws could result in significant civil, criminal and administrative penalties, fines and imprisonment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our insurance coverage.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our potential products in clinical trials, and the sale of any approved products, including INGREZZA and ONGENTYS, may expose us to liability claims. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling our products. We have product liability insurance coverage for our clinical trials in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. In addition, we have product liability insurance related to the sale of INGREZZA and ONGENTYS in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability from any current or future clinical trials or approved products. A successful product liability claim, or series of claims, brought against us would decrease our cash reserves and could cause our stock price to fall. Furthermore, regardless of the eventual outcome of a product liability claim, any product liability claim against us may decrease demand for our approved products, including INGREZZA and ONGENTYS, damage our reputation, result in regulatory investigations that could require costly recalls or product modifications, cause clinical trial participants to withdrawal, result in costs to defend the related litigation, decrease our revenue, and divert management&#8217;s attention from managing our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities involve hazardous materials, and we may be liable for any resulting contamination or injuries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research activities involve the controlled use of hazardous materials. We cannot eliminate the risk of accidental contamination or injury from these materials. If an accident occurs, a court may hold us liable for any resulting damages, which may harm our results of operations and cause us to use a substantial portion of our cash reserves, which would force us to seek additional financing.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We are subject to stringent and changing obligations related to data privacy and information security. Our actual or perceived failure to comply with such obligations could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we process confidential and sensitive information, including personal data, proprietary and confidential business data, trade secrets, intellectual property, data we collect about clinical trial participants in connection with clinical trials, and sensitive third-party data, on our networks and in our data centers. We are subject to numerous federal, state, local and foreign laws, orders, codes, regulations and regulatory guidance regarding privacy, data protection, information security and the processing of personal information, the number and scope of which are expanding, changing, subject to differing applications and interpretations, and may be inconsistent among countries. Our data processing activities may also subject us to other data privacy and security obligations, such as industry standards, external and internal privacy and security policies, contracts and other obligations that govern the processing of data by us and by third parties on our behalf.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws in Europe regarding privacy, data protection, information security and the processing of personal data have been significantly reformed and continue to undergo reform. For example, the European Union&#8217;s General Data Protection Regulation, or the EU GDPR, and the United Kingdom&#8217;s GDPR, or the UK GDPR, impose strict requirements for processing the personal data of individuals located, respectively, within the European Economic Area, or EEA, and the United Kingdom, or the UK. The EU GDPR and the UK GDPR enhance data protection obligations for processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; and implementing safeguards to protect the security and confidentiality of personal data. The EU GDPR and the UK GDPR impose substantial fines for breaches of data protection requirements. For example, under the EU GDPR, such fines can be up to four percent of global revenue or 20 million euros, whichever is greater, and also confer a private right of action on data subjects for breaches of data protection requirements. The EU GDPR, the UK GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as EU regulations governing clinical trial data and other healthcare data, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions have enacted data localization laws and cross-border personal data transfers laws. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the EEA, such as the United States, which the European Commission does not consider to provide an adequate level of personal data protection. If we cannot implement a valid compliance mechanism for cross-border personal data transfers, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal data from Europe or elsewhere. The inability to import personal data to the United States may significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties subject to European and other data protection laws or requiring us to increase our personal data processing capabilities in Europe and/or elsewhere at significant expense.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws regarding privacy, data protection, information security and the processing of personal data are also becoming increasingly common in the United States at both the federal and state level. For example, the California Consumer Privacy Act, or CCPA, which went into effect in 2020, imposes obligations on businesses to which it applies. These obligations include, without limitation, providing specific disclosures in privacy notices, affording California residents certain rights related to their personal data, and requiring businesses subject to the CCPA to implement certain measures to effectuate California residents&#8217; personal data rights. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). In addition, it is anticipated that the California Privacy Rights Act of 2020, or the CPRA, effective January 1, 2023, will expand the CCPA. For example, the CPRA establishes a new California Privacy Protection Agency to implement and enforce the CCPA (as amended), which could increase the risk of an enforcement action. Other states have also enacted data privacy laws. For example, Virginia passed its Consumer Data Protection Act, Colorado passed the Colorado Privacy Act, and Utah passed the Utah Consumer Privacy Act, all of which become effective in 2023.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion. These obligations may be subject to differing applications and interpretations, which may be inconsistent among jurisdictions or in conflict. Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations may necessitate changes to our information technologies, systems and practices and those of any third parties that process personal data on our behalf. In addition, these obligations may even require us to change to our business model.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third-parties upon whom we rely may fail to comply such obligations that impacts our compliance posture. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions, litigation, additional reporting requirements and/or oversight, bans on processing personal data and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following exhibits are filed as part of, or incorporated by reference into, this report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459018026844/nbix-ex31_91.htm">Certificate of Incorporation, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 5, 2018</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit3_2.htm">Bylaws, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.2 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/0000898430-96-002108.txt">Form of Common Stock Certificate</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-03172)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex41.htm">Indenture, dated as of May&#160;2, 2017, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000013/nbix-20211231exhibit43.htm">First Supplemental Indenture, dated as of December 22, 2021, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Incorporated by reference to Exhibit 4.3 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2022</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex991.htm">Form of Note representing the Company&#8217;s 2.25% Convertible Notes due 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q3-2022xexhibit311.htm">Certification of Chief Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q3-2022xexhibit312.htm">Certification of Chief Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q3-2022xexhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document. &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as specifically noted above, the Company&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K have a Commission File Number of 000-22705. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="iff439a36db274cfaa026518ede3eda49_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November&#160;1, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Duly authorized officer and Principal Financial Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>q3-2022xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6c525b9d20f449e0a57ef771f419efdf_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; November&#160;1, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin C. Gorman&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>q3-2022xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3e6ada853687436581210737d5b1c09e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Matthew C. Abernethy, Chief Financial Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; November&#160;1, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew C. Abernethy&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>q3-2022xexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i85af85b78dda4c39aee855730edd51ea_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Kevin C. Gorman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Matthew C. Abernethy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew C. Abernethy&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nbix-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3520a338-fe51-42c9-b6ce-64a0958f0bdf,g:fc65d0f6-0ebc-4627-b8fe-1f4c71e82970-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.neurocrine.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeandComprehensiveIncome" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Income and Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>0000007 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000008 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecurities" roleURI="http://www.neurocrine.com/role/DebtSecurities">
        <link:definition>0000009 - Disclosure - Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.neurocrine.com/role/FairValueMeasurements">
        <link:definition>0000010 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.neurocrine.com/role/Inventories">
        <link:definition>0000011 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCash" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash">
        <link:definition>0000012 - Disclosure - Cash, Cash Equivalents and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.neurocrine.com/role/Leases">
        <link:definition>0000013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes">
        <link:definition>0000014 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.neurocrine.com/role/EarningsperShare">
        <link:definition>0000015 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.neurocrine.com/role/SubsequentEvents">
        <link:definition>0000016 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>0000017 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesTables" roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables">
        <link:definition>0000018 - Disclosure - Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables">
        <link:definition>0000019 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.neurocrine.com/role/InventoriesTables">
        <link:definition>0000020 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables">
        <link:definition>0000021 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.neurocrine.com/role/LeasesTables">
        <link:definition>0000022 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables">
        <link:definition>0000023 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.neurocrine.com/role/EarningsperShareTables">
        <link:definition>0000024 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000025 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>0000026 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails">
        <link:definition>0000027 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails">
        <link:definition>0000028 - Disclosure - Debt Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails">
        <link:definition>0000029 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>0000030 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail">
        <link:definition>0000031 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesSummaryofInventoriesDetails" roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails">
        <link:definition>0000032 - Disclosure - Inventories - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000033 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeInformationDetails" roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails">
        <link:definition>0000034 - Disclosure - Leases - Narrative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalInformationDetails" roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails">
        <link:definition>0000035 - Disclosure - Leases - Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityPaymentDueDetails" roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails">
        <link:definition>0000036 - Disclosure - Leases - Liability, Payment, Due (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityPaymentDueDetails_1" roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1">
        <link:definition>0000036 - Disclosure - Leases - Liability, Payment, Due (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails">
        <link:definition>0000037 - Disclosure - Convertible Senior Notes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes2024NotesDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails">
        <link:definition>0000038 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesInterestExpenseDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails">
        <link:definition>0000039 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareScheduleofNetIncomePerShareDetails" roleURI="http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails">
        <link:definition>0000040 - Disclosure - Earnings per Share - Schedule of Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.neurocrine.com/role/SubsequentEventsDetails">
        <link:definition>0000041 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AbbVieIncMember" abstract="true" name="AbbVieIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_XenonPharmaceuticalsIncMember" abstract="true" name="XenonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_PotentialMilestonePaymentReceipts" abstract="false" name="PotentialMilestonePaymentReceipts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionDomain" abstract="true" name="DebtInstrumentConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_NumberOfRenewalOptions" abstract="false" name="NumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionAxis" abstract="true" name="DebtInstrumentConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AnnualRentEscalationPercentage" abstract="false" name="AnnualRentEscalationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_IdorsiaPharmaceuticalsLtdMember" abstract="true" name="IdorsiaPharmaceuticalsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_SaleOfStockNumberOfSharesSoldInTransaction" abstract="false" name="SaleOfStockNumberOfSharesSoldInTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" abstract="false" name="FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_HeptaresTherapeuticsLimitedMember" abstract="true" name="HeptaresTherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_CarryingAmountOfLiabilityComponentAtSettlement" abstract="false" name="CarryingAmountOfLiabilityComponentAtSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_VoyagerTherapeuticsMember" abstract="true" name="VoyagerTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" abstract="false" name="DebtSecuritiesAvailableForSalePositionNumberOfPositions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_ConversionPeriodOneMember" abstract="true" name="ConversionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_InvestmentIncomeAndOtherNet" abstract="false" name="InvestmentIncomeAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtInstrumentConvertibleConversionPremium" abstract="false" name="DebtInstrumentConvertibleConversionPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" abstract="true" name="SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PatentTerm" abstract="false" name="PatentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_BIALPortelaCaSAMember" abstract="true" name="BIALPortelaCaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_CashAndMoneyMarketFundMember" abstract="true" name="CashAndMoneyMarketFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_PotentialMilestonePayments" abstract="false" name="PotentialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" abstract="false" name="IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PrincipalAmountOnConversionRate" abstract="false" name="PrincipalAmountOnConversionRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" abstract="false" name="LesseeOperatingLeaseOptionTermToConstructFifthBuilding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" abstract="false" name="MinimumPercentageOfTradingPriceToLastReportedSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_DebtInstrumentCouponInterest" abstract="false" name="DebtInstrumentCouponInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DiurnalGroupPlcMember" abstract="true" name="DiurnalGroupPlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_ConversionPeriodTwoMember" abstract="true" name="ConversionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbix_CarryingAmountOfLiabilityComponentUponIssuance" abstract="false" name="CarryingAmountOfLiabilityComponentUponIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_RentAbatementPeriod" abstract="false" name="RentAbatementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_RestrictedCashTextBlock" abstract="false" name="RestrictedCashTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" abstract="false" name="LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_UpfrontPaymentsMade" abstract="false" name="UpfrontPaymentsMade" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_A225ConvertibleSeniorNotesMember" abstract="true" name="A225ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nbix-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3520a338-fe51-42c9-b6ce-64a0958f0bdf,g:fc65d0f6-0ebc-4627-b8fe-1f4c71e82970-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_99e2f3f6-d2e9-4a9a-bf45-50372589657b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_74d3720e-587d-492c-a294-abdb06202a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_99e2f3f6-d2e9-4a9a-bf45-50372589657b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_74d3720e-587d-492c-a294-abdb06202a0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_b940dace-5bd3-4d4d-9e85-278ab408ad9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_99e2f3f6-d2e9-4a9a-bf45-50372589657b" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_b940dace-5bd3-4d4d-9e85-278ab408ad9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e3264e73-6113-4898-b248-109a4f50d3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_99e2f3f6-d2e9-4a9a-bf45-50372589657b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e3264e73-6113-4898-b248-109a4f50d3e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1aec3157-dfdf-470b-9c21-518bc579d562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_49aed73d-6daf-47a3-9942-8a43f5b60f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1aec3157-dfdf-470b-9c21-518bc579d562" xlink:to="loc_us-gaap_PreferredStockValue_49aed73d-6daf-47a3-9942-8a43f5b60f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1ea72870-975c-4621-9a11-4b748a4c2ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1aec3157-dfdf-470b-9c21-518bc579d562" xlink:to="loc_us-gaap_CommonStockValue_1ea72870-975c-4621-9a11-4b748a4c2ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_08623b17-bedf-40ee-befb-ff25b2d7f1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1aec3157-dfdf-470b-9c21-518bc579d562" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_08623b17-bedf-40ee-befb-ff25b2d7f1cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c8c056b3-ebd6-4f64-975d-eab35cc6f92e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1aec3157-dfdf-470b-9c21-518bc579d562" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c8c056b3-ebd6-4f64-975d-eab35cc6f92e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21f8d377-af2d-4a9d-ba90-c1b6b914a6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1aec3157-dfdf-470b-9c21-518bc579d562" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21f8d377-af2d-4a9d-ba90-c1b6b914a6e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7e8a3386-6448-4986-9db1-f2d71233dcef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_04961ec3-b763-46b0-b0e3-bec0310b515b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e8a3386-6448-4986-9db1-f2d71233dcef" xlink:to="loc_us-gaap_AssetsCurrent_04961ec3-b763-46b0-b0e3-bec0310b515b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_554efc92-11d5-40b8-a05d-94019c86c6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e8a3386-6448-4986-9db1-f2d71233dcef" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_554efc92-11d5-40b8-a05d-94019c86c6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4baa9137-84e9-473d-b0bd-09dded382c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e8a3386-6448-4986-9db1-f2d71233dcef" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4baa9137-84e9-473d-b0bd-09dded382c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d3f69bec-0664-4e9c-bf02-f73ded6ee4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e8a3386-6448-4986-9db1-f2d71233dcef" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d3f69bec-0664-4e9c-bf02-f73ded6ee4c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_8ea176a9-cd9c-4630-b3bc-1ef01c781374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e8a3386-6448-4986-9db1-f2d71233dcef" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_8ea176a9-cd9c-4630-b3bc-1ef01c781374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31f55612-0532-4162-a966-30385635fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e8a3386-6448-4986-9db1-f2d71233dcef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31f55612-0532-4162-a966-30385635fd07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0b6591ab-a6e3-4518-9dd1-3df229b13460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7e8a3386-6448-4986-9db1-f2d71233dcef" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0b6591ab-a6e3-4518-9dd1-3df229b13460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd2974b3-3fb5-4f32-be2f-0da64724fa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_80d2ad30-5788-4436-b3cf-54ab25e56f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd2974b3-3fb5-4f32-be2f-0da64724fa2a" xlink:to="loc_us-gaap_Liabilities_80d2ad30-5788-4436-b3cf-54ab25e56f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_18254baa-7863-42ed-8e74-d6ea8a85f078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd2974b3-3fb5-4f32-be2f-0da64724fa2a" xlink:to="loc_us-gaap_StockholdersEquity_18254baa-7863-42ed-8e74-d6ea8a85f078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_df1d607b-0d5e-4ec9-8198-89710f7f0874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_156d41cc-f753-46e9-96ba-9ab88f884c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df1d607b-0d5e-4ec9-8198-89710f7f0874" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_156d41cc-f753-46e9-96ba-9ab88f884c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e7cb2dcb-9e92-46e2-8d5f-17aeae3d2aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df1d607b-0d5e-4ec9-8198-89710f7f0874" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e7cb2dcb-9e92-46e2-8d5f-17aeae3d2aca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d84eb724-5328-478b-aa48-f24ac6c29cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df1d607b-0d5e-4ec9-8198-89710f7f0874" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d84eb724-5328-478b-aa48-f24ac6c29cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9910c0d5-ffcf-4edc-8286-e9349a992ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df1d607b-0d5e-4ec9-8198-89710f7f0874" xlink:to="loc_us-gaap_InventoryNet_9910c0d5-ffcf-4edc-8286-e9349a992ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9c170402-0b2f-4f33-933b-700d904f1008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df1d607b-0d5e-4ec9-8198-89710f7f0874" xlink:to="loc_us-gaap_OtherAssetsCurrent_9c170402-0b2f-4f33-933b-700d904f1008" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a2ea1526-c0d2-42a2-8ae5-4ac2f17884da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f0b8f72a-0126-4f8e-9b70-60045a663a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2ea1526-c0d2-42a2-8ae5-4ac2f17884da" xlink:to="loc_us-gaap_LiabilitiesCurrent_f0b8f72a-0126-4f8e-9b70-60045a663a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_ad1ee1a3-f662-403f-9c90-ec819e4f9576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2ea1526-c0d2-42a2-8ae5-4ac2f17884da" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_ad1ee1a3-f662-403f-9c90-ec819e4f9576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06f7af60-49de-4bf6-beec-3b21d4b63c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2ea1526-c0d2-42a2-8ae5-4ac2f17884da" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06f7af60-49de-4bf6-beec-3b21d4b63c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0defa660-c384-4c22-ba2f-436d686745d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2ea1526-c0d2-42a2-8ae5-4ac2f17884da" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0defa660-c384-4c22-ba2f-436d686745d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7bfdc0e1-3283-4ad8-b834-735424083e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dba524e9-cdef-4d04-a371-2ce6e9e4b21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7bfdc0e1-3283-4ad8-b834-735424083e7d" xlink:to="loc_us-gaap_NetIncomeLoss_dba524e9-cdef-4d04-a371-2ce6e9e4b21e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_09bf90a4-231b-4d99-985f-138660f1ffb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7bfdc0e1-3283-4ad8-b834-735424083e7d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_09bf90a4-231b-4d99-985f-138660f1ffb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b56e3b38-88da-4c9c-a902-ea91f269fbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3fec84ae-1f2b-41a9-8b46-34232849e072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b56e3b38-88da-4c9c-a902-ea91f269fbd4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3fec84ae-1f2b-41a9-8b46-34232849e072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_816d3c45-ef11-4d89-a2b5-f865290a81d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b56e3b38-88da-4c9c-a902-ea91f269fbd4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_816d3c45-ef11-4d89-a2b5-f865290a81d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_721a21d3-110a-4bc5-a456-c1d9e54d3100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b56e3b38-88da-4c9c-a902-ea91f269fbd4" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_721a21d3-110a-4bc5-a456-c1d9e54d3100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_10eb6223-4f76-4fd5-9ce8-600cf402e6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b56e3b38-88da-4c9c-a902-ea91f269fbd4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_10eb6223-4f76-4fd5-9ce8-600cf402e6da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_af44b62f-f573-461e-a501-418df6cc04a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a8c0fc5-d148-4389-9be6-3dda0347ff90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_af44b62f-f573-461e-a501-418df6cc04a6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a8c0fc5-d148-4389-9be6-3dda0347ff90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3672a8e3-2af5-4dc2-a548-0c74cd303bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_af44b62f-f573-461e-a501-418df6cc04a6" xlink:to="loc_us-gaap_CostsAndExpenses_3672a8e3-2af5-4dc2-a548-0c74cd303bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d4341448-003a-49b2-8ad2-c2247747f153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_88c6875b-b057-4cfd-96a9-e083e501bfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d4341448-003a-49b2-8ad2-c2247747f153" xlink:to="loc_us-gaap_OperatingIncomeLoss_88c6875b-b057-4cfd-96a9-e083e501bfd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_94c07da3-f833-4ea5-8e13-424ae88b13ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d4341448-003a-49b2-8ad2-c2247747f153" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_94c07da3-f833-4ea5-8e13-424ae88b13ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23d3b52d-06e5-4eb9-9bbe-9a406c738437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_720760cc-5c10-4108-838b-270afdb1aaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_23d3b52d-06e5-4eb9-9bbe-9a406c738437" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_720760cc-5c10-4108-838b-270afdb1aaf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3902f265-843f-4c75-bab4-da63355ce0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_23d3b52d-06e5-4eb9-9bbe-9a406c738437" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3902f265-843f-4c75-bab4-da63355ce0e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cb8c0cd4-6fe6-42d4-90b1-0ebd158ec748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e997c9f5-a5e5-4387-811c-e7672ff54275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cb8c0cd4-6fe6-42d4-90b1-0ebd158ec748" xlink:to="loc_us-gaap_InterestExpense_e997c9f5-a5e5-4387-811c-e7672ff54275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b1c498e6-091e-4c5f-9e3f-abf35e991ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cb8c0cd4-6fe6-42d4-90b1-0ebd158ec748" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b1c498e6-091e-4c5f-9e3f-abf35e991ce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_81812bcf-9efa-4cf9-a524-9f51afde2654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cb8c0cd4-6fe6-42d4-90b1-0ebd158ec748" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_81812bcf-9efa-4cf9-a524-9f51afde2654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_14e0ff6a-3de9-4d38-a17b-3dc4329eecfc" xlink:href="nbix-20220930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cb8c0cd4-6fe6-42d4-90b1-0ebd158ec748" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_14e0ff6a-3de9-4d38-a17b-3dc4329eecfc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_28dfe447-bbbc-4dd6-9aa0-21796bd3d90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b313d55-dd55-4fc1-b1f1-96525cb369f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_28dfe447-bbbc-4dd6-9aa0-21796bd3d90f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b313d55-dd55-4fc1-b1f1-96525cb369f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c91166f-5385-4612-889c-30b9618f2bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_28dfe447-bbbc-4dd6-9aa0-21796bd3d90f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c91166f-5385-4612-889c-30b9618f2bd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1edd4a83-e111-442a-b50f-9af339ac47d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_28dfe447-bbbc-4dd6-9aa0-21796bd3d90f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1edd4a83-e111-442a-b50f-9af339ac47d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_823dd4b1-359b-430d-bd77-b9c47777c612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e5e9ab31-8607-4020-93a2-fc79dbc85d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_823dd4b1-359b-430d-bd77-b9c47777c612" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e5e9ab31-8607-4020-93a2-fc79dbc85d0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1bfc8062-7f97-4953-8793-745465d29185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_823dd4b1-359b-430d-bd77-b9c47777c612" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1bfc8062-7f97-4953-8793-745465d29185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_abe90e29-e529-484a-8766-d5b8cff70b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_823dd4b1-359b-430d-bd77-b9c47777c612" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_abe90e29-e529-484a-8766-d5b8cff70b8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6ea56c06-60b6-4df8-b6d3-0e747edafd09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_823dd4b1-359b-430d-bd77-b9c47777c612" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6ea56c06-60b6-4df8-b6d3-0e747edafd09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5319070f-7fa9-4c57-bbca-8c17295a4e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_NetIncomeLoss_5319070f-7fa9-4c57-bbca-8c17295a4e52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_85c4c424-d46b-44a6-9cc5-205dd86992d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_ShareBasedCompensation_85c4c424-d46b-44a6-9cc5-205dd86992d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e785153f-d7b4-4474-8e5b-a24ef61240d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_Depreciation_e785153f-d7b4-4474-8e5b-a24ef61240d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8cd83c10-1531-4a4d-b826-6983ba172f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8cd83c10-1531-4a4d-b826-6983ba172f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_dc54b03e-fa35-43d6-8cf7-3f4479ba26a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_dc54b03e-fa35-43d6-8cf7-3f4479ba26a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c3d8d454-ea0f-4825-b13a-7fd64f0c0453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c3d8d454-ea0f-4825-b13a-7fd64f0c0453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_28f7addd-8984-4bdd-9ff0-c4bff1e6121d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_28f7addd-8984-4bdd-9ff0-c4bff1e6121d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fd199099-2d78-4669-b1ee-f5fc662d2fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fd199099-2d78-4669-b1ee-f5fc662d2fcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_ef10c454-b5ec-4866-97c9-8a0badf26ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_ef10c454-b5ec-4866-97c9-8a0badf26ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7d451283-d24d-4e9a-b65c-ac6f7aaa1089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7d451283-d24d-4e9a-b65c-ac6f7aaa1089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b8263ddf-ba35-4ec8-a601-9b2658f9ac0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b8263ddf-ba35-4ec8-a601-9b2658f9ac0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2efcce9f-f427-4a30-9ede-77c2df8cfb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2efcce9f-f427-4a30-9ede-77c2df8cfb7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_45b7a6e6-870d-48fd-b43e-30192aa88efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_df97d2ef-d535-4d0d-ad95-9b503cbb3613" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_45b7a6e6-870d-48fd-b43e-30192aa88efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fd6f3d8-927c-429e-b8f4-1c27f6343372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4b07d89e-8679-4eba-bebf-e2eff758dc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fd6f3d8-927c-429e-b8f4-1c27f6343372" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4b07d89e-8679-4eba-bebf-e2eff758dc6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_1829f4d5-a2ef-4dc2-af10-67da1447ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fd6f3d8-927c-429e-b8f4-1c27f6343372" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_1829f4d5-a2ef-4dc2-af10-67da1447ad01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_709a2007-24e3-4e33-ae39-2cbc1a03548c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_f9868d88-cf71-4097-ad08-dc79e40a39a0" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_709a2007-24e3-4e33-ae39-2cbc1a03548c" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_f9868d88-cf71-4097-ad08-dc79e40a39a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_34d3d68c-1e95-4dbe-b2a1-b688fb18f770" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_709a2007-24e3-4e33-ae39-2cbc1a03548c" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_34d3d68c-1e95-4dbe-b2a1-b688fb18f770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_73c71d53-3afa-4238-9732-2fe0be23bf51" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_709a2007-24e3-4e33-ae39-2cbc1a03548c" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_73c71d53-3afa-4238-9732-2fe0be23bf51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_e826d4c6-d080-4eec-9998-c741bf0fefe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_3b752e6d-233b-4976-8ded-135dc3e548aa" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_e826d4c6-d080-4eec-9998-c741bf0fefe1" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_3b752e6d-233b-4976-8ded-135dc3e548aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_3d6a80ee-5923-4805-bb3c-f0c5194d8cfe" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_e826d4c6-d080-4eec-9998-c741bf0fefe1" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_3d6a80ee-5923-4805-bb3c-f0c5194d8cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_666cf33a-45aa-40ee-a3ab-162ea936fc26" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_e826d4c6-d080-4eec-9998-c741bf0fefe1" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_666cf33a-45aa-40ee-a3ab-162ea936fc26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f4adc82d-111f-4f14-848b-b4f32b6c7edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_4952d3ca-c6c6-44e3-9d88-f3c3a2b85a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f4adc82d-111f-4f14-848b-b4f32b6c7edd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_4952d3ca-c6c6-44e3-9d88-f3c3a2b85a6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_da86eff0-a650-4259-93d4-6177477a117d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f4adc82d-111f-4f14-848b-b4f32b6c7edd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_da86eff0-a650-4259-93d4-6177477a117d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0772147e-06ef-4b0f-b008-70e46d210772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_af9786f4-2f8c-422d-8cda-9e29e9fb81c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0772147e-06ef-4b0f-b008-70e46d210772" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_af9786f4-2f8c-422d-8cda-9e29e9fb81c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_4edff297-c4ff-443e-aa5c-7d54d81b5329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0772147e-06ef-4b0f-b008-70e46d210772" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_4edff297-c4ff-443e-aa5c-7d54d81b5329" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#InventoriesSummaryofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2d2eb1f4-d8e7-440e-a445-0d65e17a85d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2f1b1262-edbe-4d46-810b-2d34b96960dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2d2eb1f4-d8e7-440e-a445-0d65e17a85d5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2f1b1262-edbe-4d46-810b-2d34b96960dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_15c674ee-cc1c-49c0-8730-5017ac70e188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2d2eb1f4-d8e7-440e-a445-0d65e17a85d5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_15c674ee-cc1c-49c0-8730-5017ac70e188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f5bb15c7-7a51-4aa0-ae65-a836e2bc087c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2d2eb1f4-d8e7-440e-a445-0d65e17a85d5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f5bb15c7-7a51-4aa0-ae65-a836e2bc087c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_15084650-c066-4606-8575-0cb533612dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47b4df83-d946-42d7-a7d1-01e672b7df88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_15084650-c066-4606-8575-0cb533612dd7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47b4df83-d946-42d7-a7d1-01e672b7df88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_4eed93ab-c45b-4622-9a00-374257dc66ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_15084650-c066-4606-8575-0cb533612dd7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_4eed93ab-c45b-4622-9a00-374257dc66ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#LeasesLiabilityPaymentDueDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0b8c3a5b-97d9-4d4e-af8f-c625147c9f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_81db85e4-03d0-42a9-9e17-3b35acd64e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0b8c3a5b-97d9-4d4e-af8f-c625147c9f24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_81db85e4-03d0-42a9-9e17-3b35acd64e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bae46f51-0790-4ac8-880b-c88fe2acb46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0b8c3a5b-97d9-4d4e-af8f-c625147c9f24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bae46f51-0790-4ac8-880b-c88fe2acb46e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f429f0d-4e6b-423f-9e49-f33e41bedb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f52fb7c2-bd2f-4713-88eb-b4868fcd75b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f429f0d-4e6b-423f-9e49-f33e41bedb3a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f52fb7c2-bd2f-4713-88eb-b4868fcd75b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b1648868-4d34-4477-bd00-0a4b9f4134f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f429f0d-4e6b-423f-9e49-f33e41bedb3a" xlink:to="loc_us-gaap_OperatingLeaseLiability_b1648868-4d34-4477-bd00-0a4b9f4134f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1" xlink:type="simple" xlink:href="nbix-20220930.xsd#LeasesLiabilityPaymentDueDetails_1"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_355a872c-4de8-498b-925e-686a2cac3345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c096c649-7299-4a3f-9c36-0477890a6831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_355a872c-4de8-498b-925e-686a2cac3345" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c096c649-7299-4a3f-9c36-0477890a6831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ae3af088-9c2e-4649-b0e6-5fb2d635bbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_355a872c-4de8-498b-925e-686a2cac3345" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ae3af088-9c2e-4649-b0e6-5fb2d635bbc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8f68a16a-f1e0-45c2-907e-77ca1d4e8bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_355a872c-4de8-498b-925e-686a2cac3345" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8f68a16a-f1e0-45c2-907e-77ca1d4e8bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3d92b012-9530-4fb9-967b-b793a4169f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_355a872c-4de8-498b-925e-686a2cac3345" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3d92b012-9530-4fb9-967b-b793a4169f7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f054f9a2-4368-4ccc-9255-3724008f96ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_355a872c-4de8-498b-925e-686a2cac3345" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f054f9a2-4368-4ccc-9255-3724008f96ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_2d44af0d-7d55-41d5-9242-da1b7e29a48c" xlink:href="nbix-20220930.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_355a872c-4de8-498b-925e-686a2cac3345" xlink:to="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_2d44af0d-7d55-41d5-9242-da1b7e29a48c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ad1b012b-cd68-4ce3-9dec-842978d2353c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest_9550d898-1e7d-4081-9113-c8e69e2a7e29" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_ad1b012b-cd68-4ce3-9dec-842978d2353c" xlink:to="loc_nbix_DebtInstrumentCouponInterest_9550d898-1e7d-4081-9113-c8e69e2a7e29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f982d927-ca2b-4a65-80df-0af0aa69655d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_ad1b012b-cd68-4ce3-9dec-842978d2353c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f982d927-ca2b-4a65-80df-0af0aa69655d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#EarningsperShareScheduleofNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81821e29-381e-48a5-98bb-183d35120c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_492f3221-c95f-4e0b-b393-bc354e2d31e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81821e29-381e-48a5-98bb-183d35120c37" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_492f3221-c95f-4e0b-b393-bc354e2d31e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cc922236-c3f8-4aba-a0f6-eaccfd652512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81821e29-381e-48a5-98bb-183d35120c37" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cc922236-c3f8-4aba-a0f6-eaccfd652512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_c405caac-c440-4eb9-ba4a-33ad34cf2ade" xlink:href="nbix-20220930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81821e29-381e-48a5-98bb-183d35120c37" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_c405caac-c440-4eb9-ba4a-33ad34cf2ade" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>nbix-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3520a338-fe51-42c9-b6ce-64a0958f0bdf,g:fc65d0f6-0ebc-4627-b8fe-1f4c71e82970-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome" xlink:type="extended" id="idd08e4431904401082eee826045a1d11_CondensedConsolidatedStatementsofIncomeandComprehensiveIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d6982ac0-e07c-4b87-af68-f001d7706a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_RevenuesAbstract_d6982ac0-e07c-4b87-af68-f001d7706a92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c181d1f-e6ca-495c-a246-4180e72236c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d6982ac0-e07c-4b87-af68-f001d7706a92" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c181d1f-e6ca-495c-a246-4180e72236c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ba0c2e9e-f649-4294-b73e-b5fa3bf309fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ba0c2e9e-f649-4294-b73e-b5fa3bf309fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eafd14ed-c90c-4e4f-a52e-abd93b9a29f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eafd14ed-c90c-4e4f-a52e-abd93b9a29f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b6320ded-4146-4441-8028-6fbce82ba3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b6320ded-4146-4441-8028-6fbce82ba3ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_27c1f5de-418f-4685-be7f-efaa08154789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_27c1f5de-418f-4685-be7f-efaa08154789" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_eb5f4b25-b215-4c1a-a25b-1e7bdee320b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_CostsAndExpenses_eb5f4b25-b215-4c1a-a25b-1e7bdee320b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_96ec5032-a6f2-4231-9402-ee2d1901620c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_OperatingIncomeLoss_96ec5032-a6f2-4231-9402-ee2d1901620c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_416afd92-0e2d-48f1-b841-840cc89ffc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_us-gaap_InterestExpense_416afd92-0e2d-48f1-b841-840cc89ffc4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6215b1bb-021d-4d9c-b052-d0743c71fbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6215b1bb-021d-4d9c-b052-d0743c71fbad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3bbe40bb-83bf-49e6-a420-03569f347f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3bbe40bb-83bf-49e6-a420-03569f347f5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_d5193b1c-9fa1-4c58-a7f9-ca3bc936ec58" xlink:href="nbix-20220930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_d5193b1c-9fa1-4c58-a7f9-ca3bc936ec58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_66da6c76-d3fc-4070-8c83-c5aa3905972c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_66da6c76-d3fc-4070-8c83-c5aa3905972c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dfdb8d81-367e-488f-a744-d63ac7eb1f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dfdb8d81-367e-488f-a744-d63ac7eb1f63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_82a97f6e-f3f0-4d3b-b30b-5ef375e2c0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_82a97f6e-f3f0-4d3b-b30b-5ef375e2c0c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_65a9647f-32eb-49c0-8307-29745e6b1b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_NetIncomeLoss_65a9647f-32eb-49c0-8307-29745e6b1b71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e47ebecc-702a-4ad2-b94e-a0cdd4efed2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e47ebecc-702a-4ad2-b94e-a0cdd4efed2e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1a938be6-8237-48cb-be7e-49dcf780fddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1a938be6-8237-48cb-be7e-49dcf780fddc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4dfa7480-4282-4d68-a880-bb2b60bf8b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_EarningsPerShareAbstract_4dfa7480-4282-4d68-a880-bb2b60bf8b78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ef7c54be-521d-413d-a75e-4667cc726c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4dfa7480-4282-4d68-a880-bb2b60bf8b78" xlink:to="loc_us-gaap_EarningsPerShareBasic_ef7c54be-521d-413d-a75e-4667cc726c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f03a435e-bc62-4b8a-ac77-cad78a6b20af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4dfa7480-4282-4d68-a880-bb2b60bf8b78" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f03a435e-bc62-4b8a-ac77-cad78a6b20af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3eb94850-8dec-4d7d-b99b-24c178c3b3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3eb94850-8dec-4d7d-b99b-24c178c3b3cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ff04354-b6d3-4b67-a58c-3b33bd5ffb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3eb94850-8dec-4d7d-b99b-24c178c3b3cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ff04354-b6d3-4b67-a58c-3b33bd5ffb2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c8c00428-c913-4e15-a84a-f19a0a80b4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3eb94850-8dec-4d7d-b99b-24c178c3b3cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c8c00428-c913-4e15-a84a-f19a0a80b4c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bd1ace4b-4290-4da5-b7f7-5348d9fa0bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_StatementTable_bd1ace4b-4290-4da5-b7f7-5348d9fa0bb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f946d20-fc17-45e3-a1de-0a670891d5d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bd1ace4b-4290-4da5-b7f7-5348d9fa0bb6" xlink:to="loc_srt_ProductOrServiceAxis_0f946d20-fc17-45e3-a1de-0a670891d5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f946d20-fc17-45e3-a1de-0a670891d5d5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0f946d20-fc17-45e3-a1de-0a670891d5d5" xlink:to="loc_srt_ProductsAndServicesDomain_0f946d20-fc17-45e3-a1de-0a670891d5d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fbf04429-2196-4689-b002-7fb05b44ec55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0f946d20-fc17-45e3-a1de-0a670891d5d5" xlink:to="loc_srt_ProductsAndServicesDomain_fbf04429-2196-4689-b002-7fb05b44ec55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_69c162f8-956a-427d-a496-e2e6b75c3d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fbf04429-2196-4689-b002-7fb05b44ec55" xlink:to="loc_us-gaap_ProductMember_69c162f8-956a-427d-a496-e2e6b75c3d6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_9a791642-eda6-472f-beb2-4539f4e5c86b" xlink:href="nbix-20220930.xsd#nbix_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fbf04429-2196-4689-b002-7fb05b44ec55" xlink:to="loc_nbix_CollaborationRevenueMember_9a791642-eda6-472f-beb2-4539f4e5c86b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i65545f9f3f40432eab80f6a1d5c80113_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_44d0a6c5-e982-415b-8902-3dcb201b31ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_44d0a6c5-e982-415b-8902-3dcb201b31ba" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c72fd61d-7d4b-426d-a792-fe0bce70f48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_SharesOutstanding_c72fd61d-7d4b-426d-a792-fe0bce70f48b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d85b255-8c25-4ede-b54c-b2c79a0497a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_StockholdersEquity_0d85b255-8c25-4ede-b54c-b2c79a0497a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_485bec11-72b9-4fb4-b53e-5c9e68869269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_NetIncomeLoss_485bec11-72b9-4fb4-b53e-5c9e68869269" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d66e21a9-1747-44ad-9b79-7169bf28337c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d66e21a9-1747-44ad-9b79-7169bf28337c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_436d1dab-6f80-46a1-a2d4-841519ba9436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_436d1dab-6f80-46a1-a2d4-841519ba9436" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9099c551-399f-41ea-bfe5-3ffb1d6ff1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9099c551-399f-41ea-bfe5-3ffb1d6ff1c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0eccd4eb-e3cd-4d46-a56a-3dc7d4736c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0eccd4eb-e3cd-4d46-a56a-3dc7d4736c94" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_557f1bd3-5023-4aa6-93aa-8c1fe6a7b09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_557f1bd3-5023-4aa6-93aa-8c1fe6a7b09a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e1bfd229-cbd1-4984-815b-2acfb0eb8a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc654580-b1f7-453b-9aa0-9ff5a0e952bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0dd5db0a-f479-49b1-a1c1-fb7fe845dd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_44d0a6c5-e982-415b-8902-3dcb201b31ba" xlink:to="loc_us-gaap_StatementTable_0dd5db0a-f479-49b1-a1c1-fb7fe845dd84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8a85f909-44ec-4f64-8157-34fd02c6b724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0dd5db0a-f479-49b1-a1c1-fb7fe845dd84" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8a85f909-44ec-4f64-8157-34fd02c6b724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8a85f909-44ec-4f64-8157-34fd02c6b724_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8a85f909-44ec-4f64-8157-34fd02c6b724" xlink:to="loc_us-gaap_EquityComponentDomain_8a85f909-44ec-4f64-8157-34fd02c6b724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8a85f909-44ec-4f64-8157-34fd02c6b724" xlink:to="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0f3c2d9c-cac9-4746-997c-69d03a010acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:to="loc_us-gaap_CommonStockMember_0f3c2d9c-cac9-4746-997c-69d03a010acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_846960be-ad42-4711-a632-9f6addb7db53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_846960be-ad42-4711-a632-9f6addb7db53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e43641-f3f9-45cf-93de-2fb5264ce0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e43641-f3f9-45cf-93de-2fb5264ce0c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d611502f-9d5e-4443-a991-d1a23e9676c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:to="loc_us-gaap_RetainedEarningsMember_d611502f-9d5e-4443-a991-d1a23e9676c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3ce9755f-7370-401c-81e9-4879e38b44c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0dd5db0a-f479-49b1-a1c1-fb7fe845dd84" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3ce9755f-7370-401c-81e9-4879e38b44c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3ce9755f-7370-401c-81e9-4879e38b44c3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3ce9755f-7370-401c-81e9-4879e38b44c3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3ce9755f-7370-401c-81e9-4879e38b44c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e83b714f-8ae6-4364-bb78-c50bd6d71117" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3ce9755f-7370-401c-81e9-4879e38b44c3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e83b714f-8ae6-4364-bb78-c50bd6d71117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5630c2f1-9014-4359-80a8-39941ee96dd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e83b714f-8ae6-4364-bb78-c50bd6d71117" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5630c2f1-9014-4359-80a8-39941ee96dd3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i806ea422a4da4ad898f7dbe51a6042ff_OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_bb5599bd-6792-4fdf-a78c-e79c9df81553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_bb5599bd-6792-4fdf-a78c-e79c9df81553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7572f6b3-c42c-4620-b3ab-4ea3d0e6ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7572f6b3-c42c-4620-b3ab-4ea3d0e6ad54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_d3f62e91-872e-42ed-8306-2aaeca0df9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_d3f62e91-872e-42ed-8306-2aaeca0df9bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2e9f6efb-2a38-41ff-842a-c43bdc235c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2e9f6efb-2a38-41ff-842a-c43bdc235c88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dd619f98-bb02-4437-b0e8-65f320b2e028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dd619f98-bb02-4437-b0e8-65f320b2e028" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb53e2e8-cf45-4709-8a74-26ce03d6d7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb53e2e8-cf45-4709-8a74-26ce03d6d7fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fb17b0c3-aef1-4801-bd5b-9f8d804ee55f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:to="loc_us-gaap_DebtInstrumentAxis_fb17b0c3-aef1-4801-bd5b-9f8d804ee55f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fb17b0c3-aef1-4801-bd5b-9f8d804ee55f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fb17b0c3-aef1-4801-bd5b-9f8d804ee55f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fb17b0c3-aef1-4801-bd5b-9f8d804ee55f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0536bd5c-8a4e-4574-9c4a-9368e64dca91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fb17b0c3-aef1-4801-bd5b-9f8d804ee55f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0536bd5c-8a4e-4574-9c4a-9368e64dca91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_75b38a41-111a-464e-a98f-9ee896637c5b" xlink:href="nbix-20220930.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0536bd5c-8a4e-4574-9c4a-9368e64dca91" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_75b38a41-111a-464e-a98f-9ee896637c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f271447-56c7-4018-b491-7087b4aecc38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f271447-56c7-4018-b491-7087b4aecc38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f271447-56c7-4018-b491-7087b4aecc38_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f271447-56c7-4018-b491-7087b4aecc38" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f271447-56c7-4018-b491-7087b4aecc38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9cc8ee9-8b40-40ed-928c-2ac4cc8df68f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f271447-56c7-4018-b491-7087b4aecc38" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9cc8ee9-8b40-40ed-928c-2ac4cc8df68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_850999eb-59ee-4d18-b4aa-858b70ad80c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9cc8ee9-8b40-40ed-928c-2ac4cc8df68f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_850999eb-59ee-4d18-b4aa-858b70ad80c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0fadd826-55dc-4a90-b7dd-df27f21e04c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0fadd826-55dc-4a90-b7dd-df27f21e04c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0fadd826-55dc-4a90-b7dd-df27f21e04c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0fadd826-55dc-4a90-b7dd-df27f21e04c4" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0fadd826-55dc-4a90-b7dd-df27f21e04c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a394ebe9-0fe5-48c2-8911-2be1b0d3f610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0fadd826-55dc-4a90-b7dd-df27f21e04c4" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a394ebe9-0fe5-48c2-8911-2be1b0d3f610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_16ec6eaa-0266-45c6-a18a-6cf54840d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a394ebe9-0fe5-48c2-8911-2be1b0d3f610" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_16ec6eaa-0266-45c6-a18a-6cf54840d1e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended" id="i9099efeb54fc4129bc489cdadf42a635_CollaborationandLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_23b18e24-5e74-441f-bc5e-c8c3256b775f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_23b18e24-5e74-441f-bc5e-c8c3256b775f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b566d9b6-4418-4138-87de-4869ab04f7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b566d9b6-4418-4138-87de-4869ab04f7b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_cbb19864-b75d-4db2-9d26-d6020f7173fe" xlink:href="nbix-20220930.xsd#nbix_PotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_PotentialMilestonePayments_cbb19864-b75d-4db2-9d26-d6020f7173fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_ded6693a-7027-4e33-9897-379125fb1ef2" xlink:href="nbix-20220930.xsd#nbix_UpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_UpfrontPaymentsMade_ded6693a-7027-4e33-9897-379125fb1ef2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_55595c87-1bad-4645-97e9-518a24bdbbf7" xlink:href="nbix-20220930.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_55595c87-1bad-4645-97e9-518a24bdbbf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6701e3c1-49d2-48a5-95d4-34f149788e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_SharePrice_6701e3c1-49d2-48a5-95d4-34f149788e8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_aff2a4f3-c45d-479a-a654-9b0bd3f09558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_aff2a4f3-c45d-479a-a654-9b0bd3f09558" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_40166697-2593-4a0f-b5a9-35d15254f8b3" xlink:href="nbix-20220930.xsd#nbix_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_MilestonePayment_40166697-2593-4a0f-b5a9-35d15254f8b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_ed369219-8e8a-4548-a45e-1aa849cf03a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_ed369219-8e8a-4548-a45e-1aa849cf03a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6c2d683-5e6e-4918-85de-cbe6179401c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6c2d683-5e6e-4918-85de-cbe6179401c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_32ebc7f1-5812-4b69-a9eb-1f9c7ef6b0c6" xlink:href="nbix-20220930.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_32ebc7f1-5812-4b69-a9eb-1f9c7ef6b0c6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_aa3153e4-a1c2-444e-b883-7811b2518533" xlink:href="nbix-20220930.xsd#nbix_PatentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_PatentTerm_aa3153e4-a1c2-444e-b883-7811b2518533" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_67cacc33-e2b3-477f-a513-b5d5d6816761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_67cacc33-e2b3-477f-a513-b5d5d6816761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67cacc33-e2b3-477f-a513-b5d5d6816761_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_67cacc33-e2b3-477f-a513-b5d5d6816761" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67cacc33-e2b3-477f-a513-b5d5d6816761_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5eb16fef-46f3-449e-aada-0b4a09ac01dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_67cacc33-e2b3-477f-a513-b5d5d6816761" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5eb16fef-46f3-449e-aada-0b4a09ac01dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9574bd51-15e2-4261-89a9-6199390902d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5eb16fef-46f3-449e-aada-0b4a09ac01dd" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9574bd51-15e2-4261-89a9-6199390902d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6567c01b-4078-46de-a2d1-24203120f333" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_srt_ProductOrServiceAxis_6567c01b-4078-46de-a2d1-24203120f333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6567c01b-4078-46de-a2d1-24203120f333_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6567c01b-4078-46de-a2d1-24203120f333" xlink:to="loc_srt_ProductsAndServicesDomain_6567c01b-4078-46de-a2d1-24203120f333_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bff02868-53e3-498c-ba99-2d38131c0e84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6567c01b-4078-46de-a2d1-24203120f333" xlink:to="loc_srt_ProductsAndServicesDomain_bff02868-53e3-498c-ba99-2d38131c0e84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b299ea4c-7dbf-46b2-a010-9d277541d0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bff02868-53e3-498c-ba99-2d38131c0e84" xlink:to="loc_us-gaap_RoyaltyMember_b299ea4c-7dbf-46b2-a010-9d277541d0b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ec7fd5c8-b0e9-44b3-a9b3-e328c5df5488" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_srt_CounterpartyNameAxis_ec7fd5c8-b0e9-44b3-a9b3-e328c5df5488" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec7fd5c8-b0e9-44b3-a9b3-e328c5df5488_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ec7fd5c8-b0e9-44b3-a9b3-e328c5df5488" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec7fd5c8-b0e9-44b3-a9b3-e328c5df5488_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ec7fd5c8-b0e9-44b3-a9b3-e328c5df5488" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember_ee004ae7-9630-47b1-b6a5-10f4ee427a5e" xlink:href="nbix-20220930.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_HeptaresTherapeuticsLimitedMember_ee004ae7-9630-47b1-b6a5-10f4ee427a5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_66d8f1f5-25e8-4498-bd4e-437ff7ff2a8e" xlink:href="nbix-20220930.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_66d8f1f5-25e8-4498-bd4e-437ff7ff2a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_b8cc94c2-a453-43cd-a2ee-da9522883371" xlink:href="nbix-20220930.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_b8cc94c2-a453-43cd-a2ee-da9522883371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_7bd8c1c6-cab4-4139-84e4-823a0f367d8d" xlink:href="nbix-20220930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_7bd8c1c6-cab4-4139-84e4-823a0f367d8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_d89a985a-9ba5-422e-8055-0e77584651bb" xlink:href="nbix-20220930.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_VoyagerTherapeuticsMember_d89a985a-9ba5-422e-8055-0e77584651bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_35bcc423-c98d-4b4b-b905-9bc04a8b9877" xlink:href="nbix-20220930.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_BIALPortelaCaSAMember_35bcc423-c98d-4b4b-b905-9bc04a8b9877" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_c07e0fe3-5cda-4b6f-aa2c-362cd6675c71" xlink:href="nbix-20220930.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_c07e0fe3-5cda-4b6f-aa2c-362cd6675c71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_0ef5adc7-cbee-4597-970e-48e0bcf7599d" xlink:href="nbix-20220930.xsd#nbix_AbbVieIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_AbbVieIncMember_0ef5adc7-cbee-4597-970e-48e0bcf7599d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d5e4dfc-7918-4aea-87cd-c17761808bc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_srt_RangeAxis_5d5e4dfc-7918-4aea-87cd-c17761808bc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d5e4dfc-7918-4aea-87cd-c17761808bc9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d5e4dfc-7918-4aea-87cd-c17761808bc9" xlink:to="loc_srt_RangeMember_5d5e4dfc-7918-4aea-87cd-c17761808bc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2d79353-ddec-4f96-8358-850379580dd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d5e4dfc-7918-4aea-87cd-c17761808bc9" xlink:to="loc_srt_RangeMember_d2d79353-ddec-4f96-8358-850379580dd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b9abba9-807f-422c-96a9-5de03f276093" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2d79353-ddec-4f96-8358-850379580dd7" xlink:to="loc_srt_MinimumMember_5b9abba9-807f-422c-96a9-5de03f276093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f53b98a0-320a-4901-9e5c-ea7219d0f8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f53b98a0-320a-4901-9e5c-ea7219d0f8d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f53b98a0-320a-4901-9e5c-ea7219d0f8d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f53b98a0-320a-4901-9e5c-ea7219d0f8d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f53b98a0-320a-4901-9e5c-ea7219d0f8d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0a140efc-fd50-4983-885c-d050ff01918d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f53b98a0-320a-4901-9e5c-ea7219d0f8d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0a140efc-fd50-4983-885c-d050ff01918d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_cb66f083-fd9e-4424-901a-82a9990dfd22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0a140efc-fd50-4983-885c-d050ff01918d" xlink:to="loc_us-gaap_PatentsMember_cb66f083-fd9e-4424-901a-82a9990dfd22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1ac6f7b3-fcaf-4638-9ea4-5085cc1717c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1ac6f7b3-fcaf-4638-9ea4-5085cc1717c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1ac6f7b3-fcaf-4638-9ea4-5085cc1717c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1ac6f7b3-fcaf-4638-9ea4-5085cc1717c0" xlink:to="loc_us-gaap_EquityComponentDomain_1ac6f7b3-fcaf-4638-9ea4-5085cc1717c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6faae5f8-72b3-4045-ba8d-b3f03a2f3d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1ac6f7b3-fcaf-4638-9ea4-5085cc1717c0" xlink:to="loc_us-gaap_EquityComponentDomain_6faae5f8-72b3-4045-ba8d-b3f03a2f3d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_232ac876-2cbc-47f1-8cec-0849d57bdf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6faae5f8-72b3-4045-ba8d-b3f03a2f3d97" xlink:to="loc_us-gaap_CommonStockMember_232ac876-2cbc-47f1-8cec-0849d57bdf72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended" id="i400ec8e7be334162b4a213a8091f797d_DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b48ae94d-611f-4ba7-998a-e8a242724fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b48ae94d-611f-4ba7-998a-e8a242724fea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_b553df5c-22d5-4990-9405-3cbc8f53050e" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_b553df5c-22d5-4990-9405-3cbc8f53050e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_2bd30b57-0f04-44ee-aa20-521148e76d59" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_2bd30b57-0f04-44ee-aa20-521148e76d59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_e02f020e-9b94-40ba-b6f0-d38c9089dc7b" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_e02f020e-9b94-40ba-b6f0-d38c9089dc7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_b4160294-44e9-4088-8cb0-060126f21713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_b4160294-44e9-4088-8cb0-060126f21713" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_2b00a6bc-66e8-464c-9fd3-b3ada5105a4a" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_2b00a6bc-66e8-464c-9fd3-b3ada5105a4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_7f035925-69ac-46a5-8903-0593bc408e01" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_7f035925-69ac-46a5-8903-0593bc408e01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_3ded51f7-4d02-4622-9832-b3d304157eba" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_3ded51f7-4d02-4622-9832-b3d304157eba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_954b8cbd-c077-40d6-b769-24122041c2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_954b8cbd-c077-40d6-b769-24122041c2b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a16e9151-c323-4ea2-8ef4-4bfb419c222c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_954b8cbd-c077-40d6-b769-24122041c2b5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a16e9151-c323-4ea2-8ef4-4bfb419c222c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16e9151-c323-4ea2-8ef4-4bfb419c222c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a16e9151-c323-4ea2-8ef4-4bfb419c222c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a16e9151-c323-4ea2-8ef4-4bfb419c222c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a16e9151-c323-4ea2-8ef4-4bfb419c222c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6d35cf57-6c38-4b8a-b8bf-cff1991c7365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:to="loc_us-gaap_CommercialPaperMember_6d35cf57-6c38-4b8a-b8bf-cff1991c7365" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b901c19f-fee6-4203-a845-9e90a3acafc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b901c19f-fee6-4203-a845-9e90a3acafc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5426ff1e-c1c7-4139-8ddd-e048261f029c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5426ff1e-c1c7-4139-8ddd-e048261f029c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended" id="i25f3d9c21c1e4d0aafa7327efddb142a_DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bf0d03e8-ccc3-4661-b54e-404d4aa66767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bf0d03e8-ccc3-4661-b54e-404d4aa66767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_69357c91-41aa-420d-8078-ab8ff35106d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_69357c91-41aa-420d-8078-ab8ff35106d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_931de01a-aad3-4227-b708-4337629e86b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_931de01a-aad3-4227-b708-4337629e86b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c6f7625d-294a-436b-bb13-9a2e775bd338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c6f7625d-294a-436b-bb13-9a2e775bd338" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1d622817-4582-455a-964b-6e3060fc588d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1d622817-4582-455a-964b-6e3060fc588d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0856911e-aa68-46cf-a258-dbb75e7a0070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0856911e-aa68-46cf-a258-dbb75e7a0070" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57aefb04-55e1-49f7-babd-daebe2978bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57aefb04-55e1-49f7-babd-daebe2978bb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_37357851-86b6-4e55-9cc0-b5cf6ea9b7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57aefb04-55e1-49f7-babd-daebe2978bb9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_37357851-86b6-4e55-9cc0-b5cf6ea9b7e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37357851-86b6-4e55-9cc0-b5cf6ea9b7e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37357851-86b6-4e55-9cc0-b5cf6ea9b7e7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37357851-86b6-4e55-9cc0-b5cf6ea9b7e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37357851-86b6-4e55-9cc0-b5cf6ea9b7e7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a159aaea-c925-4ff4-ac9c-a4b843b56b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:to="loc_us-gaap_CommercialPaperMember_a159aaea-c925-4ff4-ac9c-a4b843b56b3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ceae38fb-5f7f-47c9-9a9a-aa4f85677fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ceae38fb-5f7f-47c9-9a9a-aa4f85677fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2ed06010-9d44-4834-980c-2e49bb4fa21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2ed06010-9d44-4834-980c-2e49bb4fa21a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="nbix-20220930.xsd#FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="i38447248eff94d05a9be9b98c301f5b9_FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10309929-e547-4d7e-a58b-6d4a944f3b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_92b79725-f1d8-4915-b662-eacbdbb72d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10309929-e547-4d7e-a58b-6d4a944f3b90" xlink:to="loc_us-gaap_Investments_92b79725-f1d8-4915-b662-eacbdbb72d88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cef459d8-fe90-46ef-aed5-16393d706b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10309929-e547-4d7e-a58b-6d4a944f3b90" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_cef459d8-fe90-46ef-aed5-16393d706b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10309929-e547-4d7e-a58b-6d4a944f3b90" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7e7262ea-b455-4c93-b358-e94d4b139c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7e7262ea-b455-4c93-b358-e94d4b139c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7e7262ea-b455-4c93-b358-e94d4b139c89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7e7262ea-b455-4c93-b358-e94d4b139c89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7e7262ea-b455-4c93-b358-e94d4b139c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7e7262ea-b455-4c93-b358-e94d4b139c89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_2505bc26-b7df-4c28-bc50-1681da2a2d4d" xlink:href="nbix-20220930.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_2505bc26-b7df-4c28-bc50-1681da2a2d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a1f16e6b-fd6e-4ebc-953a-cee8dc6477f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a1f16e6b-fd6e-4ebc-953a-cee8dc6477f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f26345c8-2a15-4da5-b747-291b0630b87e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:to="loc_us-gaap_CommercialPaperMember_f26345c8-2a15-4da5-b747-291b0630b87e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6858c24c-4a45-442a-9848-6831577306aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6858c24c-4a45-442a-9848-6831577306aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6858c24c-4a45-442a-9848-6831577306aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6858c24c-4a45-442a-9848-6831577306aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6858c24c-4a45-442a-9848-6831577306aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6858c24c-4a45-442a-9848-6831577306aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_11355e0b-31a4-4e49-a55b-fbfcbd0fb90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_11355e0b-31a4-4e49-a55b-fbfcbd0fb90f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cbe5173a-9c45-4c79-8ce0-43c61f6db26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cbe5173a-9c45-4c79-8ce0-43c61f6db26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_2b2cab5d-5181-448a-b643-da6390d169ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:to="loc_us-gaap_EquitySecuritiesMember_2b2cab5d-5181-448a-b643-da6390d169ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_463d5cec-15bf-4e24-8520-bcfd84185b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_463d5cec-15bf-4e24-8520-bcfd84185b12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463d5cec-15bf-4e24-8520-bcfd84185b12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_463d5cec-15bf-4e24-8520-bcfd84185b12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_463d5cec-15bf-4e24-8520-bcfd84185b12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_463d5cec-15bf-4e24-8520-bcfd84185b12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_72098065-a9a1-4529-bff8-95aef32f104f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_72098065-a9a1-4529-bff8-95aef32f104f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ca4934b3-7670-422a-8693-9cb02776bd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ca4934b3-7670-422a-8693-9cb02776bd5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d9b2a72a-eae4-47df-9560-c7b6f3ed6ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d9b2a72a-eae4-47df-9560-c7b6f3ed6ccf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efffc08-2ce9-4424-90cd-64efec5dd7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efffc08-2ce9-4424-90cd-64efec5dd7e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5efffc08-2ce9-4424-90cd-64efec5dd7e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efffc08-2ce9-4424-90cd-64efec5dd7e6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5efffc08-2ce9-4424-90cd-64efec5dd7e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_142476a1-482b-4255-af1b-980e6926fbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efffc08-2ce9-4424-90cd-64efec5dd7e6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_142476a1-482b-4255-af1b-980e6926fbd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6a285b2f-a8d1-40cc-b6b0-76e58f1553ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_142476a1-482b-4255-af1b-980e6926fbd8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6a285b2f-a8d1-40cc-b6b0-76e58f1553ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="simple" xlink:href="nbix-20220930.xsd#FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="extended" id="i9d090341e684413aaa326de394e76b00_FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b762fcb7-c576-47f5-887f-91e465934d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b762fcb7-c576-47f5-887f-91e465934d33" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_40955853-caa4-4dae-b755-70e1cf9b00b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_40955853-caa4-4dae-b755-70e1cf9b00b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_120ece45-fa50-4eea-8113-ee239c009000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_120ece45-fa50-4eea-8113-ee239c009000" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_7f98ba05-e385-49ec-9129-8bd3df10460c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_7f98ba05-e385-49ec-9129-8bd3df10460c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_c6288a62-4449-4e90-85c3-ee250c50ad78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_c6288a62-4449-4e90-85c3-ee250c50ad78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_392b0bbb-4271-4e85-8f9f-8ade82d329ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b762fcb7-c576-47f5-887f-91e465934d33" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a02b77a2-e80b-40d7-811e-f355a93ea5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a02b77a2-e80b-40d7-811e-f355a93ea5e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a02b77a2-e80b-40d7-811e-f355a93ea5e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a02b77a2-e80b-40d7-811e-f355a93ea5e1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a02b77a2-e80b-40d7-811e-f355a93ea5e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_924a079a-8a3f-49e6-ad16-90d91d92a71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a02b77a2-e80b-40d7-811e-f355a93ea5e1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_924a079a-8a3f-49e6-ad16-90d91d92a71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0b3270d8-6f9c-480f-82e9-2ca915a0eea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_924a079a-8a3f-49e6-ad16-90d91d92a71f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0b3270d8-6f9c-480f-82e9-2ca915a0eea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9a6d1f46-5441-4b9d-92d3-fb5f232555b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9a6d1f46-5441-4b9d-92d3-fb5f232555b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a6d1f46-5441-4b9d-92d3-fb5f232555b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9a6d1f46-5441-4b9d-92d3-fb5f232555b8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a6d1f46-5441-4b9d-92d3-fb5f232555b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_636eeff4-e5b3-4295-b550-219251919328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9a6d1f46-5441-4b9d-92d3-fb5f232555b8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_636eeff4-e5b3-4295-b550-219251919328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2d567c13-1c5b-4571-af07-5ad3d3c8429a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_636eeff4-e5b3-4295-b550-219251919328" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2d567c13-1c5b-4571-af07-5ad3d3c8429a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fb97dea1-02f9-47e2-bcc9-ba66b52b1a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fb97dea1-02f9-47e2-bcc9-ba66b52b1a8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb97dea1-02f9-47e2-bcc9-ba66b52b1a8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fb97dea1-02f9-47e2-bcc9-ba66b52b1a8b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb97dea1-02f9-47e2-bcc9-ba66b52b1a8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbb37a12-449d-4fec-9b5d-1e6fcc8f277a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fb97dea1-02f9-47e2-bcc9-ba66b52b1a8b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbb37a12-449d-4fec-9b5d-1e6fcc8f277a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0698166d-465d-4092-a851-1ff018f3d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbb37a12-449d-4fec-9b5d-1e6fcc8f277a" xlink:to="loc_us-gaap_EquitySecuritiesMember_0698166d-465d-4092-a851-1ff018f3d83d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_fbc9bb52-8396-455f-97f1-20d4ad0bf3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:to="loc_us-gaap_CollateralAxis_fbc9bb52-8396-455f-97f1-20d4ad0bf3c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_fbc9bb52-8396-455f-97f1-20d4ad0bf3c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_fbc9bb52-8396-455f-97f1-20d4ad0bf3c9" xlink:to="loc_us-gaap_CollateralDomain_fbc9bb52-8396-455f-97f1-20d4ad0bf3c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_239c193b-e23e-418d-b4b7-24ea8e38a624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_fbc9bb52-8396-455f-97f1-20d4ad0bf3c9" xlink:to="loc_us-gaap_CollateralDomain_239c193b-e23e-418d-b4b7-24ea8e38a624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_9e3ef192-6da6-453f-b1d9-a2828f7dc665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_239c193b-e23e-418d-b4b7-24ea8e38a624" xlink:to="loc_us-gaap_EquitySecuritiesMember_9e3ef192-6da6-453f-b1d9-a2828f7dc665" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended" id="i180d8b68ed4b4d8aa5bb17f9ec8a3e95_ConvertibleSeniorNotesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7a4eb904-9431-4e74-8634-4fd662ea1439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7a4eb904-9431-4e74-8634-4fd662ea1439" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_da8ede5d-bfbd-41ab-81a5-b995cc1dbf02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_da8ede5d-bfbd-41ab-81a5-b995cc1dbf02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_82debecd-0033-4bdc-8b44-2b9604a2880a" xlink:href="nbix-20220930.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_82debecd-0033-4bdc-8b44-2b9604a2880a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_b89c2c82-30f8-43b1-aeb5-2649f7583366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_b89c2c82-30f8-43b1-aeb5-2649f7583366" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_df39160e-9b20-451b-a2ad-fab48de549fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_df39160e-9b20-451b-a2ad-fab48de549fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_8b616dbb-38d4-435f-8756-44d2d4461603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentTerm_8b616dbb-38d4-435f-8756-44d2d4461603" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e1f76351-9835-4f7f-9b32-7a995da446b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e1f76351-9835-4f7f-9b32-7a995da446b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_9d0b7980-33b9-4de6-95ac-8ce43bec8abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_9d0b7980-33b9-4de6-95ac-8ce43bec8abb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_0ff9e36d-7f8f-434c-b8e6-fe60a4ba9c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_RepaymentsOfDebt_0ff9e36d-7f8f-434c-b8e6-fe60a4ba9c5b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_e3d84714-fe00-4248-9eab-f26e0c5c55dd" xlink:href="nbix-20220930.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_e3d84714-fe00-4248-9eab-f26e0c5c55dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_7767822f-260c-46c1-8b6c-5fe2276d2585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_7767822f-260c-46c1-8b6c-5fe2276d2585" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_03ad7376-ce01-4855-85b9-984a62b8e51b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_03ad7376-ce01-4855-85b9-984a62b8e51b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_1430b127-5279-4a2e-bc64-475be70b0dfb" xlink:href="nbix-20220930.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_1430b127-5279-4a2e-bc64-475be70b0dfb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8e975141-448f-40d8-acd5-8466db44f8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8e975141-448f-40d8-acd5-8466db44f8bb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_a83056ff-7434-4c29-b0e9-17c7be693905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_a83056ff-7434-4c29-b0e9-17c7be693905" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_18c1ee7d-637a-4133-8bc9-b26cb0974307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_18c1ee7d-637a-4133-8bc9-b26cb0974307" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_8b4a028f-6cbd-4db5-b74a-87e6501bcee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_8b4a028f-6cbd-4db5-b74a-87e6501bcee2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3edcb4af-3650-44ec-b16a-1f0c682b9e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3edcb4af-3650-44ec-b16a-1f0c682b9e9c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_689de86f-abf2-4e34-b027-a76fb69561a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_689de86f-abf2-4e34-b027-a76fb69561a3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36ecb4ff-ff7a-4af7-981f-929b8dd48608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36ecb4ff-ff7a-4af7-981f-929b8dd48608" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_f0e022f7-663d-4ca7-ba9f-5becc3274352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_f0e022f7-663d-4ca7-ba9f-5becc3274352" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9b4409d9-b7cf-4cd6-bd70-587b1d493bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9b4409d9-b7cf-4cd6-bd70-587b1d493bbe" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_e08b3acd-1b44-44bb-9b61-28b11eea1d85" xlink:href="nbix-20220930.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_e08b3acd-1b44-44bb-9b61-28b11eea1d85" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7ce9ff63-c24c-4fa6-82d7-2f2c4352ea65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7ce9ff63-c24c-4fa6-82d7-2f2c4352ea65" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_30ce4c94-b177-4043-9c6b-de559bc76990" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_30ce4c94-b177-4043-9c6b-de559bc76990" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_bee2d3be-56b2-44ce-ada1-28a8eac19f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_SharePrice_bee2d3be-56b2-44ce-ada1-28a8eac19f59" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f7ac5095-2e6d-4392-a9e0-b8dc497e55e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f7ac5095-2e6d-4392-a9e0-b8dc497e55e1" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_4f4a87a5-7178-46dc-9f02-ed3b72585f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_4f4a87a5-7178-46dc-9f02-ed3b72585f7d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_984a70c1-e50b-4c61-b8ab-119f200eb294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_984a70c1-e50b-4c61-b8ab-119f200eb294" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_5060267f-388c-4c6e-b8a1-16f2b25fbdc7" xlink:href="nbix-20220930.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_5060267f-388c-4c6e-b8a1-16f2b25fbdc7" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_699342e5-041f-4b6a-82bf-a83fa7e4b64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_699342e5-041f-4b6a-82bf-a83fa7e4b64c" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_38009e25-1bc0-40ba-8174-60b80b5160be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_us-gaap_DebtInstrumentAxis_38009e25-1bc0-40ba-8174-60b80b5160be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_38009e25-1bc0-40ba-8174-60b80b5160be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_38009e25-1bc0-40ba-8174-60b80b5160be" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_38009e25-1bc0-40ba-8174-60b80b5160be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_de1da4dd-68eb-4883-9127-41c9eec33893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_38009e25-1bc0-40ba-8174-60b80b5160be" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_de1da4dd-68eb-4883-9127-41c9eec33893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_a2c154de-d83c-44f6-b4be-656d780bf3e5" xlink:href="nbix-20220930.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_de1da4dd-68eb-4883-9127-41c9eec33893" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_a2c154de-d83c-44f6-b4be-656d780bf3e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_33cf05ae-fd17-4d27-9ad9-6d990c0169c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_33cf05ae-fd17-4d27-9ad9-6d990c0169c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_33cf05ae-fd17-4d27-9ad9-6d990c0169c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_33cf05ae-fd17-4d27-9ad9-6d990c0169c3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_33cf05ae-fd17-4d27-9ad9-6d990c0169c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7232e6f6-1931-4dea-9c9f-9e65b3ccf270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_33cf05ae-fd17-4d27-9ad9-6d990c0169c3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7232e6f6-1931-4dea-9c9f-9e65b3ccf270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b3fcb09f-f719-44f0-8195-d68a8733c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7232e6f6-1931-4dea-9c9f-9e65b3ccf270" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b3fcb09f-f719-44f0-8195-d68a8733c32d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d3ab2434-c665-4bd1-b6c8-8ea92f6c05d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d3ab2434-c665-4bd1-b6c8-8ea92f6c05d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d3ab2434-c665-4bd1-b6c8-8ea92f6c05d0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d3ab2434-c665-4bd1-b6c8-8ea92f6c05d0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d3ab2434-c665-4bd1-b6c8-8ea92f6c05d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_220b77ff-198e-43a3-b702-c23817bca14b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d3ab2434-c665-4bd1-b6c8-8ea92f6c05d0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_220b77ff-198e-43a3-b702-c23817bca14b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1d2aa9fb-5b41-4a64-b693-2e6e9a208b21" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_220b77ff-198e-43a3-b702-c23817bca14b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1d2aa9fb-5b41-4a64-b693-2e6e9a208b21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e308c6fd-f021-4356-acdd-1e4f1bbba151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e308c6fd-f021-4356-acdd-1e4f1bbba151" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e308c6fd-f021-4356-acdd-1e4f1bbba151_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e308c6fd-f021-4356-acdd-1e4f1bbba151" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e308c6fd-f021-4356-acdd-1e4f1bbba151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d4cbd44a-aff1-4aca-ab72-7acbcf4a8b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e308c6fd-f021-4356-acdd-1e4f1bbba151" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d4cbd44a-aff1-4aca-ab72-7acbcf4a8b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_2c6864ab-f044-41c8-8038-d2792ec0342b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d4cbd44a-aff1-4aca-ab72-7acbcf4a8b5a" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_2c6864ab-f044-41c8-8038-d2792ec0342b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_08ed3473-988f-429c-9c3a-7b9405df0308" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_nbix_DebtInstrumentConversionAxis_08ed3473-988f-429c-9c3a-7b9405df0308" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_08ed3473-988f-429c-9c3a-7b9405df0308_default" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbix_DebtInstrumentConversionAxis_08ed3473-988f-429c-9c3a-7b9405df0308" xlink:to="loc_nbix_DebtInstrumentConversionDomain_08ed3473-988f-429c-9c3a-7b9405df0308_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_5069e0f3-c7b5-4918-92ca-7bde2ebdce67" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbix_DebtInstrumentConversionAxis_08ed3473-988f-429c-9c3a-7b9405df0308" xlink:to="loc_nbix_DebtInstrumentConversionDomain_5069e0f3-c7b5-4918-92ca-7bde2ebdce67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_46bb7428-e757-4acb-8ab3-644942c976a0" xlink:href="nbix-20220930.xsd#nbix_ConversionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_5069e0f3-c7b5-4918-92ca-7bde2ebdce67" xlink:to="loc_nbix_ConversionPeriodOneMember_46bb7428-e757-4acb-8ab3-644942c976a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_7c6a54d2-c30c-4c78-960a-66a1b21709d6" xlink:href="nbix-20220930.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_5069e0f3-c7b5-4918-92ca-7bde2ebdce67" xlink:to="loc_nbix_ConversionPeriodTwoMember_7c6a54d2-c30c-4c78-960a-66a1b21709d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#ConvertibleSeniorNotes2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="extended" id="id8f47535d7e748b183b26902b6139617_ConvertibleSeniorNotes2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_386c073a-8b76-47c9-85a9-2df7bd41dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_386c073a-8b76-47c9-85a9-2df7bd41dc67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_51d17679-699e-4a67-8b68-424a5548aefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_51d17679-699e-4a67-8b68-424a5548aefa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_37032510-f803-4d6a-a5a4-e3895aec6af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_37032510-f803-4d6a-a5a4-e3895aec6af9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_e3eaf26b-906f-4233-b936-f877be0f1aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_e3eaf26b-906f-4233-b936-f877be0f1aee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_1d7a9b54-8027-46de-8f47-3c237a648af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_1d7a9b54-8027-46de-8f47-3c237a648af9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3abfdf85-5d30-4ed5-9dc9-2f46722bd121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3abfdf85-5d30-4ed5-9dc9-2f46722bd121" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2723af42-a517-475e-9b31-8dfac1222850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_DebtInstrumentTable_2723af42-a517-475e-9b31-8dfac1222850" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_34028195-0d3e-493c-a603-c435e4efbfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2723af42-a517-475e-9b31-8dfac1222850" xlink:to="loc_us-gaap_DebtInstrumentAxis_34028195-0d3e-493c-a603-c435e4efbfa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_34028195-0d3e-493c-a603-c435e4efbfa1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_34028195-0d3e-493c-a603-c435e4efbfa1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_34028195-0d3e-493c-a603-c435e4efbfa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1e8f93a8-46f1-49f7-868f-b0083002df71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_34028195-0d3e-493c-a603-c435e4efbfa1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1e8f93a8-46f1-49f7-868f-b0083002df71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_9a05e9d4-75a4-411d-9f49-aecf072cb982" xlink:href="nbix-20220930.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1e8f93a8-46f1-49f7-868f-b0083002df71" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_9a05e9d4-75a4-411d-9f49-aecf072cb982" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#EarningsperShareScheduleofNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="extended" id="i98166ebf1bc540df9ad8b8070440d5ac_EarningsperShareScheduleofNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9e498ddb-4ad2-4d80-9c9b-317ef3ba4ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9e498ddb-4ad2-4d80-9c9b-317ef3ba4ec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_31ade67e-f286-4e41-8049-cf51743789e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_31ade67e-f286-4e41-8049-cf51743789e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_553c4149-d77b-42a3-a088-fa7627d30945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_553c4149-d77b-42a3-a088-fa7627d30945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ac9e70d1-0d1d-4630-9e0f-e8622422d559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_553c4149-d77b-42a3-a088-fa7627d30945" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ac9e70d1-0d1d-4630-9e0f-e8622422d559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_80b6781b-5e2d-44c4-ba13-5528f99ad943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_80b6781b-5e2d-44c4-ba13-5528f99ad943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_2a203a7d-1c28-4967-99e8-6e738a19df14" xlink:href="nbix-20220930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_2a203a7d-1c28-4967-99e8-6e738a19df14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_467562e4-7212-4661-b21a-06bbbfb17061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_467562e4-7212-4661-b21a-06bbbfb17061" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6d5b3635-aa71-445a-8d6c-4847c1812466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_EarningsPerShareBasic_6d5b3635-aa71-445a-8d6c-4847c1812466" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3f78e90e-9dbd-43ac-99c9-dfaf698c2df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3f78e90e-9dbd-43ac-99c9-dfaf698c2df7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_94674c6c-7abd-462b-b37d-f2bcb74ed3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_94674c6c-7abd-462b-b37d-f2bcb74ed3ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a507d986-dff1-4e7d-8e7c-280e97c13d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a507d986-dff1-4e7d-8e7c-280e97c13d2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ea7a3d6-c599-4ce5-92d7-9eaa897e97dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a507d986-dff1-4e7d-8e7c-280e97c13d2d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ea7a3d6-c599-4ce5-92d7-9eaa897e97dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ea7a3d6-c599-4ce5-92d7-9eaa897e97dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ea7a3d6-c599-4ce5-92d7-9eaa897e97dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ea7a3d6-c599-4ce5-92d7-9eaa897e97dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ac533ca-7928-4a53-bc8d-5c5d793be256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ea7a3d6-c599-4ce5-92d7-9eaa897e97dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ac533ca-7928-4a53-bc8d-5c5d793be256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5be1c69-3e5f-4673-a3bf-f2751c5abfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ac533ca-7928-4a53-bc8d-5c5d793be256" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5be1c69-3e5f-4673-a3bf-f2751c5abfdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7d444b07-9744-46c5-bf86-b18fa299cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ac533ca-7928-4a53-bc8d-5c5d793be256" xlink:to="loc_us-gaap_RestrictedStockMember_7d444b07-9744-46c5-bf86-b18fa299cf27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca0093e9-567f-44a7-916f-73bfe53b4196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a507d986-dff1-4e7d-8e7c-280e97c13d2d" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca0093e9-567f-44a7-916f-73bfe53b4196" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ca0093e9-567f-44a7-916f-73bfe53b4196_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca0093e9-567f-44a7-916f-73bfe53b4196" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ca0093e9-567f-44a7-916f-73bfe53b4196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_edbe7ec0-7a3c-4dff-8000-6dce2d74519c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca0093e9-567f-44a7-916f-73bfe53b4196" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_edbe7ec0-7a3c-4dff-8000-6dce2d74519c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_ab4bba64-c881-43de-b2c0-a11648ebae3d" xlink:href="nbix-20220930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edbe7ec0-7a3c-4dff-8000-6dce2d74519c" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_ab4bba64-c881-43de-b2c0-a11648ebae3d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/SubsequentEventsDetails" xlink:type="extended" id="ia89b65a292574099992bd42d9aacc3e0_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_aa6b0637-e80f-4529-953d-58393c31048f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ab7f7b73-7299-4c4d-b8bf-489e352cab71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_aa6b0637-e80f-4529-953d-58393c31048f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ab7f7b73-7299-4c4d-b8bf-489e352cab71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_6fdc7eed-d601-40cb-a65d-2ab3d58bf746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_aa6b0637-e80f-4529-953d-58393c31048f" xlink:to="loc_us-gaap_SubsequentEventTable_6fdc7eed-d601-40cb-a65d-2ab3d58bf746" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5fe98ecb-f0eb-493a-8cf1-26e085f54f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6fdc7eed-d601-40cb-a65d-2ab3d58bf746" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5fe98ecb-f0eb-493a-8cf1-26e085f54f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5fe98ecb-f0eb-493a-8cf1-26e085f54f5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5fe98ecb-f0eb-493a-8cf1-26e085f54f5f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5fe98ecb-f0eb-493a-8cf1-26e085f54f5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e02733c1-7109-4411-9e22-40cda9e8d9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5fe98ecb-f0eb-493a-8cf1-26e085f54f5f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e02733c1-7109-4411-9e22-40cda9e8d9fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3707c188-2582-47f2-98e8-bc53226fefac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e02733c1-7109-4411-9e22-40cda9e8d9fa" xlink:to="loc_us-gaap_SubsequentEventMember_3707c188-2582-47f2-98e8-bc53226fefac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e5e6b062-d1dd-438c-8289-160b22e6ae9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6fdc7eed-d601-40cb-a65d-2ab3d58bf746" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e5e6b062-d1dd-438c-8289-160b22e6ae9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5e6b062-d1dd-438c-8289-160b22e6ae9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e5e6b062-d1dd-438c-8289-160b22e6ae9a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5e6b062-d1dd-438c-8289-160b22e6ae9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af38eb92-d98c-4e48-b2a4-7039f0e33cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e5e6b062-d1dd-438c-8289-160b22e6ae9a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af38eb92-d98c-4e48-b2a4-7039f0e33cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember_27d9c42f-c6ef-476e-aca6-524cac991c31" xlink:href="nbix-20220930.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af38eb92-d98c-4e48-b2a4-7039f0e33cdc" xlink:to="loc_nbix_DiurnalGroupPlcMember_27d9c42f-c6ef-476e-aca6-524cac991c31" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nbix-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3520a338-fe51-42c9-b6ce-64a0958f0bdf,g:fc65d0f6-0ebc-4627-b8fe-1f4c71e82970-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d18ce987-cf58-4a7d-b276-e667da9c4334_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_0a27e185-943b-42ae-b748-32cc25031c0b_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionDomain" xlink:to="lab_nbix_DebtInstrumentConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_a82d0052-d619-4d23-9347-c893b90700b7_terseLabel_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of reconciliation of cash cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="nbix-20220930.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9f1a794-be7b-4928-801d-e27321f55e23_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe2a4d0f-b139-442d-b670-b8db662e7bb4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ce8a242-1e1f-4d35-b867-a85bbdc8a18c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_651a7aac-e218-4afe-be1e-ab5d850eb1cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_57e03f79-8aad-4e71-8b2b-5f8f7ce169b4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dec902da-c500-4483-be09-3bbfa43d933d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1d9bbbd4-2e27-456b-9399-f00458544a43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_a71ea559-60d5-4ba9-85e4-f8e5599051d4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_3b820e21-419a-4693-9579-0f698f42f870_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5b829f24-936c-4667-adc3-ca660f729f10_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_66cb0ef5-0ed5-41b1-843b-6934f82cba8a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_07b12b75-200d-47f4-86e2-853c63afa679_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7fbffe4e-90aa-4169-aea5-509201676ef3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b4cf31b1-7d2a-4e15-969a-a735acb2caa0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_83928a63-d4f6-4b3d-95e7-f5f8499815c6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_d3953975-c631-418d-abf5-98d7a97271e4_negatedLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_fb7483db-58d5-47fc-95f8-c96d36f39ce4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d27e41c1-2d80-488d-a0ae-f80d0cf43cb3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fe8527f7-8606-4dbf-8a2a-275ca271183c_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_46f967a3-17b5-49a8-91da-4621fddeac3f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a9f784b2-6d37-463a-8b0b-8265f45e201b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_3a78700b-3a1a-4e8f-83f7-6cf20a87e068_terseLabel_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of common stock price trigger</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_label_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percentage Of Trading Price To Last Reported Sale Price</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_documentation_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:href="nbix-20220930.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:to="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ab7cf0d6-80ea-489a-94f3-4ccd1b129a57_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7c2299c9-b784-46a8-b868-b929b9bbe7ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_7ceef146-46ea-4a46-ab36-e7c8a432ea95_terseLabel_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares</link:label>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_label_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares Therapeutics Limited [Member]</link:label>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares Therapeutics Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember" xlink:href="nbix-20220930.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_HeptaresTherapeuticsLimitedMember" xlink:to="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_UpfrontPaymentsMade_7a9b6fcb-5558-4951-ba9f-40d863ec951c_terseLabel_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_label_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_documentation_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade" xlink:href="nbix-20220930.xsd#nbix_UpfrontPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_UpfrontPaymentsMade" xlink:to="lab_nbix_UpfrontPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_530925a1-f1fc-498a-9c61-f5dc22ab3d0d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_0bda1259-8a0b-4fe0-8ba0-460f9e3eb5b3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_d6f5fdfe-6f82-43b0-9cca-4a81770ae45f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_52336365-0318-47c5-b6b5-f86daa298079_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_d94da78f-ac1c-454d-9ecd-0eff0308bf05_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_97b54dba-6dcb-42a8-8e76-589d52b070bb_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42ed9d24-c9a6-41cb-9028-c401a2b161cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_78d1966d-aa41-462d-9af3-70202a74073f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_65b16736-0676-4c35-aff7-d91fe6506eb8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost related to issuance of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b2a649a0-5c10-4c2c-a48c-8e457d684f70_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_7c8953a6-310b-4367-bf71-bfa56cb35ac7_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_ee3e352d-dcd3-4150-9178-2218c1f137e2_terseLabel_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other, net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_label_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income And Other Net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_documentation_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet" xlink:href="nbix-20220930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_InvestmentIncomeAndOtherNet" xlink:to="lab_nbix_InvestmentIncomeAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_eaf900ab-faed-49ad-97e0-4ff1dd7f0ba6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_afcb0a4b-8d43-43d1-9af7-4840e10c2294_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 220.0 million shares authorized; 96.1 million and 94.9 million shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6e2a4bc9-3470-4c20-9786-0f66be58eb2f_negatedLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_92b1834e-3997-4139-9a83-7efecd8b620c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_42c3c155-b923-4f19-86d4-df6636a79ad3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7f24afea-c19f-4812-9cca-54a9773ba5c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0dd1e0d-7cac-4d71-9320-bfd4fb50252f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_68c84412-fcc8-45c7-9e52-8afc4b4adfde_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f0a7a704-776f-4d63-bdcd-8803383ca4cb_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_9fd1a09d-34d5-421c-b9eb-459912189c6e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fe4f69cd-8fb0-4c56-a986-4d921eea871f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_d120cbe5-ad53-4b61-8629-f0b8461789dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_c995e878-8884-4e8e-9819-2079a62c71b0_terseLabel_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes (in shares)</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_label_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_documentation_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:href="nbix-20220930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:to="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d86a282c-9385-48f4-905c-b19adeeedba4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c4cea53c-9778-4c6a-8fa6-8deee9156ed8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18ddb5af-aa97-41a4-9872-4ca3d4fa9978_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a0794ac7-a6b9-46c8-ace3-561716dfe76a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_eb8a2fff-3ac1-4d90-81c0-5895e714a233_negatedTerseLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_723507d6-6d2c-4974-b223-49b108689189_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate repurchase price paid in cash</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CollaborationRevenueMember_caae3032-116e-404d-a51b-4c5076c523fc_terseLabel_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_label_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember" xlink:href="nbix-20220930.xsd#nbix_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CollaborationRevenueMember" xlink:to="lab_nbix_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8423a74b-4d20-45db-98dc-e7ee779c504c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6384d4b5-2ac0-4291-a0ba-3bf87cfeee63_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_333b6a45-b458-4eb2-bdba-6d3ec10f02d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6149e5d1-fde1-48e9-a7de-4c610432cf6c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_2ccf055f-d2ca-43e9-a741-931866b31f9e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_aba7d042-b869-4e87-8e7d-ad0380010f88_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b055153f-8765-4633-b52a-d1fb2c959c8b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_534b8991-b753-48db-9d10-90704924b10b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_12023d85-3607-4435-99a7-6ebe91bcbc09_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cb356add-9430-439f-9938-f2da07fe6c38_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_daaf25b0-ba18-4806-8b1e-ec5b0a00defa_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1e95cedf-1881-4a45-89da-834e3257cf04_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ce08e2a-b485-4765-8dff-6179c11dbe6b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_512bf9b0-f5ab-4d9b-9109-ecec18693108_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available for sale in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e1ad6ee9-d46a-465e-b7d1-045765f68df7_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ba05815a-738e-4948-b772-1cf6b80bb7b5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b7cd79c4-7d8b-48bb-bdcf-067332adb599_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4872b8f4-988d-4dc0-9db5-82c8e7168493_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_628ef356-e00f-4029-b658-8757e5a1dc94_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_66185115-46c0-425f-b803-1ce20ebd7c71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_872f646e-12d1-4b0e-b8dc-d5ba74e0a045_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_b6d6a08b-ade5-48ac-8d95-34308eb424ab_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_207ba6ab-bb6a-4743-9046-38accc30bf1e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets on recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_942b7f9a-eb05-4432-988e-7537a04c321a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_2110d107-d44c-414f-b406-ffc38479dc19_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f8e58fe3-9537-4478-81dd-bda1c33e3ad5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_2c9c5478-d98e-4627-acd1-ab789380dd7a_terseLabel_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_label_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Money Market Fund [Member]</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_documentation_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember" xlink:href="nbix-20220930.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CashAndMoneyMarketFundMember" xlink:to="lab_nbix_CashAndMoneyMarketFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_84a32ff3-775c-474f-bfe7-2a8a20b1096f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4d27a95e-3da5-41a9-a602-5355abbd69ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1ef8a489-cacc-4dff-982d-48b8d5efc0f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_c5db673d-9a02-4e94-a3e7-f3a46bd2969d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price trigger (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_7f00b03b-9622-4b09-b842-57f0cd1be726_terseLabel_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_label_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount On Conversion Rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_documentation_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate" xlink:href="nbix-20220930.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PrincipalAmountOnConversionRate" xlink:to="lab_nbix_PrincipalAmountOnConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_cf988ab2-74a6-4fd8-9613-ea60f15a4e33_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_753c5677-5ab6-481e-a5c9-780f180fa8bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (3 months remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_3cca32af-05d4-4af0-8ea9-2d4244fb4385_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease lessee option term for construction of fifth building</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Option Term To Construct Fifth Building</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of term of lessee's option for the construction of a fifth building under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:href="nbix-20220930.xsd#nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:to="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b1197ad1-34a7-4e21-98ac-dfd03b1efd12_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5a2ef1a2-5251-4a69-825a-28de1dda4fee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_6a6f3167-98a9-4fc4-a63b-2f0ce2d00323_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_aa8ebf44-7cf0-42af-9d66-3192fb61278c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_e7bba7ae-6a90-4057-a0a9-d7210ef88645_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_0034e6df-774a-4579-9ef2-8374d9b126c1_terseLabel_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_label_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A. [Member]</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_documentation_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember" xlink:href="nbix-20220930.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BIALPortelaCaSAMember" xlink:to="lab_nbix_BIALPortelaCaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0968df9e-d734-4215-83c1-46445a10f08a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RentAbatementPeriod_519c5bdc-b9af-4e2d-a3ae-61053c143358_terseLabel_en-US" xlink:label="lab_nbix_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus rent abatement period</link:label>
    <link:label id="lab_nbix_RentAbatementPeriod_label_en-US" xlink:label="lab_nbix_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Abatement Period</link:label>
    <link:label id="lab_nbix_RentAbatementPeriod_documentation_en-US" xlink:label="lab_nbix_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Abatement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RentAbatementPeriod" xlink:href="nbix-20220930.xsd#nbix_RentAbatementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RentAbatementPeriod" xlink:to="lab_nbix_RentAbatementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_0058cc60-afc9-4d20-b6a1-34a19d83459f_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2024</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:href="nbix-20220930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfRenewalOptions_67d63375-12fe-4247-b885-2db69c1bebe1_terseLabel_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease number of renewal options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_label_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Renewal Options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_documentation_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of renewal options under the terms of the lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions" xlink:href="nbix-20220930.xsd#nbix_NumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfRenewalOptions" xlink:to="lab_nbix_NumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_20caedc6-da30-4b25-acac-6335a3656037_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_9249161c-c73b-491f-8a8b-74afab5aaf85_terseLabel_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component upon issuance</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_label_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount Of Liability Component Upon Issuance</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_documentation_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of the liability component upon issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:href="nbix-20220930.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:to="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4e881621-d7f2-4184-a30a-8bc4d289c2aa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_70f692c1-d755-4ea5-b518-c5e06087fe2f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_605503e4-821d-4ea0-8759-4cb0b89773a5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_96b00f5a-5e8e-4a26-bcc7-b4665592dbef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current operating lease liabilities included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e9cf6989-5f99-4547-92ed-a4339bdbd985_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c75bd1b2-7bf4-4dd4-ac6b-dc2612d2003b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7a67b301-b83d-495c-9982-0177c3080d48_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_27ddce6d-a947-42cc-a9ed-ac66620b009d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_97f26d0e-bc51-486b-9b9e-eb09e8387590_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_9e0d46a8-76df-4648-9f80-e5eeffdd1229_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_91743bac-f12b-422d-b37e-0293712f5011_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8dce1420-8af1-45aa-bce6-5178fa94167b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_a05ac839-1c2e-49a3-af10-9410be93c960_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1bb5ebf2-9be8-4d33-ba30-42fdc3f075f7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4bdf0705-b661-4dc2-bc5f-1c454f2c59e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9d448982-d41a-488f-93b6-03fef961390d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_441f4c3f-b8cc-4622-96a5-5d27c078189a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_a6e24af0-cd8e-43d0-ac38-0e2236c307b1_verboseLabel_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:href="nbix-20220930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:to="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_771a9f14-477f-434e-891f-54a4d53b49ce_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d81e96be-e412-4db2-83dc-e9f41f37049f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d5cd14d9-0f0a-4b5b-9057-db5930c6dcb1_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9eef6bcd-7acb-41e2-bc57-341407611815_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_898fbad1-229c-43d5-8594-4e04aadb51b3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash in connection with operating leases</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa11429f-95b0-4a85-aeed-6693bc9624d4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d3232cf6-c323-4542-ab6a-f9a0dd582242_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3da42704-373b-4780-b1c0-cf1e1feafb75_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAxis_9fda9aa0-6ae1-4ec7-b6ba-dc85ede79b65_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral</link:label>
    <link:label id="lab_us-gaap_CollateralAxis_label_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis" xlink:to="lab_us-gaap_CollateralAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fb7aaa7b-02e5-482b-b825-f350cba7956f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1f55c3b0-ab0e-44c9-935d-be4e77975f23_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0d1b3d22-4467-4ba2-b1d4-5c5c1199b059_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ac72029c-44a8-450c-baf7-09055a9012b8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_aa92fea1-8772-44af-a87d-d7152efcfaf6_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_186a8d99-9147-4f7e-a9c1-a50972c1ff74_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4a66e23b-5029-4d7b-aacf-f30383d16e1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_1c47185a-979a-4312-a044-164edfb4f534_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_65661b40-33ea-4716-b737-a14950928bfb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MilestonePayment_846aa135-1c0a-4bbb-b547-aa583f93f3c5_terseLabel_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_label_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_documentation_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment" xlink:href="nbix-20220930.xsd#nbix_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MilestonePayment" xlink:to="lab_nbix_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_985303cc-e8a2-4d70-ab6f-7e511103c86a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a2282943-b057-421a-aaf2-df35b0f24ed3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fa550f4c-2189-4fe2-a580-bd6dfa294833_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_8bbb52a1-37bf-4380-a5a8-0fa7b3cf29c0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_71ab0d82-a550-4e57-9c39-3753f2451e4c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_815a09ff-e8c9-4726-b8ce-d438719d1d03_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_26cb1057-ce33-4100-9285-ced637e43d06_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2d78c271-7bbe-4bc8-9b4a-bbb08c1d3636_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_e460d7ce-8a5c-4aae-95c3-65953678a6c0_terseLabel_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTPC</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:href="nbix-20220930.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_dde52e8d-bbdd-4c99-8b69-14db076b6d87_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_90e07545-c75b-4ce0-a458-f0af971c0026_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_88ae5042-23d9-4029-ac8f-314eca3ddb0f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_f3466366-253e-40a4-b9ca-a1917dd96770_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) included in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_eca810d0-964d-4f24-bce5-c920327c8c23_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7f2dc2a5-cee2-41b9-b4df-4ff0e68e6847_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePayments_f0a2e89f-774a-4d49-be49-1ae30784ef5f_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_label_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payments under a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments" xlink:href="nbix-20220930.xsd#nbix_PotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePayments" xlink:to="lab_nbix_PotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PatentTerm_d5f19eb6-57f0-4a3d-850b-d24dead0a1bc_terseLabel_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_label_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_documentation_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm" xlink:href="nbix-20220930.xsd#nbix_PatentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PatentTerm" xlink:to="lab_nbix_PatentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_36c8c0ba-7c8e-4bf9-9f4c-8ef29879ba46_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_b5426a02-974e-42b4-9614-4bae4dfccd4f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_7a9f1bb7-c8b4-4b1a-9cad-5cec03f3f1fd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8bb7a57a-3851-496d-8ac6-f3d05aeee1c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_92076c54-ff94-4637-b5ee-a2cd04e3c9e4_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_e4500d70-1674-4c12-bfdd-af1f4c0af695_terseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available for sale</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Available For Sale Position Number Of Positions</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available for sale position number of positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:to="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_20bfa4be-e84a-40db-8174-3511ef9ec34a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_e9d157cc-e886-4fc8-9cb1-af54a4e7855a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_bdf0a016-18c6-40b9-8c0d-b41e14c8c273_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_817bea91-0fee-473e-a371-4427bcb44745_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_90baf352-2d09-430f-aa2b-955f19c07075_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_c10b429b-918e-4249-bb78-5619581ab766_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_95ed0739-3c85-48e4-bcce-4f43c1be8e43_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9a2db24a-0b64-446f-962d-f32abc036d95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2185ce96-7280-40ac-b59a-480144c62404_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46876a78-cc08-42b1-820b-97b26031a95c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_f8871afd-f440-4c01-8774-18b9e19fed00_terseLabel_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component at settlement</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_label_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount Of Liability Component At Settlement</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_documentation_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component at settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:href="nbix-20220930.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:to="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36fe92f6-76b4-4d04-8ea3-36530794901e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b57df5c-12ee-4149-aa41-d5bf573ae37b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2e0868eb-b84a-43e7-b877-22f6272f1dac_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8fe2c29b-0a7f-4843-9d99-76cb4906fa48_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DiurnalGroupPlcMember_baf27ae6-c434-41df-b87a-51391bc9b426_terseLabel_en-US" xlink:label="lab_nbix_DiurnalGroupPlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diurnal Group plc</link:label>
    <link:label id="lab_nbix_DiurnalGroupPlcMember_label_en-US" xlink:label="lab_nbix_DiurnalGroupPlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diurnal Group Plc [Member]</link:label>
    <link:label id="lab_nbix_DiurnalGroupPlcMember_documentation_en-US" xlink:label="lab_nbix_DiurnalGroupPlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diurnal Group Plc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember" xlink:href="nbix-20220930.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DiurnalGroupPlcMember" xlink:to="lab_nbix_DiurnalGroupPlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_82679bae-f21f-4772-a26c-5ee234dcb9cc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d9021518-70e3-4c93-8d92-af22bedf06a4_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05574d3e-4a21-45fc-a6dd-15648b43bb27_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fe3eb63f-25b4-4a0c-9be5-5bce5b1dd068_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_4faa8e67-f9d8-46ba-86a5-187b677408ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_45115bb9-ae56-4eff-8103-3544ea86e8c6_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4ef8386d-d13e-4575-a449-47d425b9e13d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2e843f51-d328-424a-b494-0f9d5c3dbe35_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of common stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_1ce1ca52-83e5-438d-86f7-9784d523fd6e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, stock price</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6b8b7fde-801f-46f6-b023-0c845221993f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AnnualRentEscalationPercentage_b3c7ab05-4205-46b1-aefc-14fed114918a_terseLabel_en-US" xlink:label="lab_nbix_AnnualRentEscalationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease annual rent escalation percentage</link:label>
    <link:label id="lab_nbix_AnnualRentEscalationPercentage_label_en-US" xlink:label="lab_nbix_AnnualRentEscalationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Escalation Percentage</link:label>
    <link:label id="lab_nbix_AnnualRentEscalationPercentage_documentation_en-US" xlink:label="lab_nbix_AnnualRentEscalationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Escalation Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AnnualRentEscalationPercentage" xlink:href="nbix-20220930.xsd#nbix_AnnualRentEscalationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AnnualRentEscalationPercentage" xlink:to="lab_nbix_AnnualRentEscalationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_69c34535-f266-4a99-b562-fe278c1326da_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0a04332e-1a3b-40c2-8e88-d113cbbc5094_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under benefit plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b01f3e5d-325d-4e04-b906-4e8f343a5d92_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2df35582-13f8-4d11-8eb4-3fdc5f87ef0e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_e9be69bc-938e-432c-bca9-16f1d2b277c2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c81f8a5c-942e-430f-ace4-dfcef4760ff2_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5bb21033-b9fb-447b-b3ec-cf56a40fd158_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_12d44790-b915-4903-9e84-37baa16d65c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_613e9864-f4ed-47cf-a9c8-071edcdfde3a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note carrying value of the equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7bed823b-f041-46c5-a665-dcfcbce5dab1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6c4ad8e2-ca37-484e-b63d-dadd1b9c1e33_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_4fb079ec-620b-4101-9762-9ba07464ed98_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount repurchased</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_e3bc9f9d-ee35-4acc-9bea-4e31d6c2d87e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a016a3cc-d8ab-47d1-a9ff-05487a14109e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_cdd2810f-2784-49fc-b6f8-69893a9f576f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_568a5ffe-4c2a-4701-9790-82f352700183_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cac70d2b-4596-4599-a625-124476cefd23_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0a7289fb-38fa-498d-9886-ae72f9513884_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_6dac0c16-04ba-4a59-8a3e-6f6cfc10ee57_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease monthly base rent per square foot</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Monthly Base Rent Per Square Foot</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Monthly Base Rent Per Square Foot</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:href="nbix-20220930.xsd#nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:to="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3ff7c26e-57cd-489a-95e8-7ba6a0f7fe2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_91f0e550-135d-4d42-97b8-e39ad52f0f78_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_031442bc-badf-4888-b807-89d215dfdbe8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c8b771ef-1a37-4d61-a093-baf8d7e0b42c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_91b9f8ce-184c-4fa2-a8d7-6b033c38c868_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7f324892-df14-44a7-b2ba-ad9508ef1049_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0de0673b-7092-4d0a-9f69-2dca9e58aa21_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_e7b4da12-c43a-4c44-bf55-c240894606f5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_de43ab8a-656e-42e4-88ce-4851865774c3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_8e2aaeaf-7acd-456f-b8da-57c46a929a15_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_95fecebc-a51b-464d-8084-402e367b2bf1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes convertible in to shares</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RestrictedCashTextBlock_20785920-ae1f-4152-8627-17b97f61d0cb_terseLabel_en-US" xlink:label="lab_nbix_RestrictedCashTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_nbix_RestrictedCashTextBlock_label_en-US" xlink:label="lab_nbix_RestrictedCashTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashTextBlock" xlink:href="nbix-20220930.xsd#nbix_RestrictedCashTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RestrictedCashTextBlock" xlink:to="lab_nbix_RestrictedCashTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9ed96970-deba-42c9-9da4-1ef844463d08_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8d2a9018-8d98-4409-b227-b9b82e2ad43e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_3f885f75-75bb-4eb1-b1ab-c01b1de7441d_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9194be5d-ddb1-4370-a14d-8c2064104121_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_9dd25395-15d7-46be-b568-658ac083e10e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ba65aa8f-907d-48d3-8723-2a207b263951_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt, Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9407b61d-386d-425f-babe-a4cd2b58662a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9018a5a3-8228-4919-8b01-d033294248d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_49209951-201b-4a9c-a0ca-fa7123ca400d_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_ba03940d-b681-418b-a5d0-76e61513d2b0_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price of common stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_43233b4f-055f-496a-880b-bf8644127830_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fcd30b74-847d-4e8f-a3ac-f22bc079f0ab_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_61c37fb8-335e-445e-8099-e80fc3f6c3ad_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_9d4b46c3-dcb2-4240-a2eb-a8fad6eecd8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c14b30af-8313-4e96-9b29-668399a16fc5_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_0979287d-4ebc-48de-9981-bb18dc2a68d7_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:href="nbix-20220930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_20f3e9ab-74b4-4108-a9ee-774c056f7af7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_6d454608-db7b-4a6f-a7b1-9ddc362cd604_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:href="nbix-20220930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_11b0bba8-8e03-4516-8959-1e94cdfd1253_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_81c820e2-5a9e-4493-9428-a8137ac55f78_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_82fb3092-d3e4-4cc3-83b2-de1e7764f34a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of repurchased convertible senior notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_54eb9c2a-9a06-4c5b-991d-d5499aa0c99e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_fab64c8b-53a8-4456-bacf-9359d1822ca3_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_34989d53-4f75-478d-afd1-39940d7f6ca0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_189e5310-c0fd-436d-a754-903236bfaebe_terseLabel_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible senior notes due 2024</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the 2.25% Convertible Senior Notes Due in May 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:href="nbix-20220930.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:to="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_276f45ba-0c15-4da1-97ff-4700d3e7b456_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accreted interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ea41c91c-9352-420f-b5dc-d57d668e144c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_07476fc3-037a-4594-bf93-d8a5005c4332_terseLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain, current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_3d0e8fc3-fd99-41d8-8e37-58e8834b2d91_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0e44134c-a090-4c1f-8956-196bf9a1994c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2b3ed4b6-0265-4d10-9165-4ff0492adee2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_b5240ef2-fa51-4d47-923f-6766e060106e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01ce460e-5480-4042-93f4-50937ec33938_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4e2e2491-192d-46f2-b0bb-05083cd00486_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralDomain_ebafe9dd-0091-4e57-b808-4769bc8d260c_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral</link:label>
    <link:label id="lab_us-gaap_CollateralDomain_label_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain" xlink:to="lab_us-gaap_CollateralDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_7ce47f56-5dfd-4ffd-b526-6d01f9413dc5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_20029603-049b-4807-be1b-5c8d8b190c01_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_cd6af683-006c-4e0b-ac65-59b230a9a4a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_769d3823-b9f2-4343-9676-f06d025645d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_75aee8db-a1ce-4bbd-9ae5-8641df674e28_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d625a2b2-2561-4206-b305-09a643821399_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f628236b-6a91-4ba9-96a6-0a97c497719c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_1aee7dd0-91bc-4747-931d-264ae957536c_terseLabel_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="nbix-20220930.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_d3775644-6157-48a3-9d45-cb1301ad15d7_terseLabel_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_label_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager Therapeutics [Member]</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_documentation_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager therapeutics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember" xlink:href="nbix-20220930.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_VoyagerTherapeuticsMember" xlink:to="lab_nbix_VoyagerTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_03b6b10f-a42d-41c7-a12d-b1d0f95ed106_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_c7b97063-3841-43d7-b291-d367e2553aad_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_6c9dc0e2-87c6-433c-9a30-5900eb38376b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_4a8d61a2-32ad-41d6-ad3f-ca03f35a83a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_f62e0449-20fe-4637-a62a-f0501deffe82_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities&#8211;biotechnology industry</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d709b2ae-d281-46ed-a3a7-50a93bdb94c0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8328f7db-1dc7-4f78-898f-c1a25cc2926b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9e8ed892-8a7f-4939-a26e-a1e3b651d794_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodOneMember_0064aa4d-5807-4a50-acd1-f89c6a2aee0d_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember" xlink:href="nbix-20220930.xsd#nbix_ConversionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodOneMember" xlink:to="lab_nbix_ConversionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_3a258cf4-4f3b-4ccc-ad6b-b476f89f790b_terseLabel_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_label_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Sold in Transaction</link:label>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_documentation_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares sold by the collaboration partner per stock transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:href="nbix-20220930.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:to="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_8750bbde-fee9-4fc5-9dab-e994a3db4526_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_11bcded2-e40d-47b3-bcb9-4e3c5d5b588b_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_63ac7740-3a6a-4d45-8dcc-0aa1f4dcc6a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a7cd4d24-9b90-4563-9c60-22e78505628a_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6bda2ff8-fc1b-4c60-bc84-be2d6c30554c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f5b63f1a-a17c-465b-9c92-1302e0ecc5d4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_33059bb6-6945-4cb3-bb9b-613fc185b5ef_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="nbix-20220930.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7f94680c-7678-4fff-8634-0eb2d6344685_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0cfc059c-c777-4189-a9ed-e7ca7aa65a73_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity security investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4eff63cc-9d79-4b0c-b499-9256c018f545_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_1b588586-268e-4bc7-93f3-86065211416e_terseLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain, noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5d026b78-4464-48f9-90fb-8ea25840b9a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b306e8c0-d0f3-471c-aa3f-4bc19dc523e1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_87cb6fff-87df-476d-8d17-11295708cc58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_eff5a334-5958-4c1c-872f-27dc654e7712_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_854f6182-e504-41a1-ae0e-a2a6d4a50004_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_07c5e00b-ecf8-4335-81be-292df6cb0aa7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ad563ecf-402e-430e-8454-739e77060615_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2cd2409f-ac89-488f-be4c-3fcf3191d474_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ada5da5c-267c-4808-b2dd-9ff686db2e7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_fe099406-9a91-4fef-a357-cb1b912c1a5d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_28d34e72-726d-41b7-ae0a-1d844252870b_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_7bebfbb3-9833-4f41-9101-34e2f2933bc0_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_badd0197-7540-4c3b-84cd-ab3d1a77829f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_ef5b765a-3f2b-4519-b5ea-08c3e8a4f715_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest</link:label>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_label_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Coupon Interest</link:label>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Coupon Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentCouponInterest" xlink:to="lab_nbix_DebtInstrumentCouponInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9d6e5238-842b-4bbc-a270-5d2321db8efc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2e7ce2e2-b13c-4656-a175-64e6ab45d9a8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3ca2ff79-a098-419c-a9aa-5ef92e0df464_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government-sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a01a133a-eb8e-40be-9834-7951f71beaef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_e61ea934-4f66-46f7-80dd-9e4dce497e8d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_09ea63ba-10bf-421d-996a-1c0d14d37265_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ea007ee9-4b1a-4707-b8fb-253082b4590a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Notes Net of Discount and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_45d28341-b58b-41bf-bf5e-6b19edefd414_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_84762383-d30c-43fa-adbd-a767b9bb8604_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_d964d75f-c9b8-45b8-ab55-1a76dadbeead_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_55dc2930-ae5f-4ea6-a046-579f8da18a83_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5da3adf8-e657-43bc-a272-024765b4ddfe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8038deab-9fc7-4d1d-9126-e3b112c2f6f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_f52c8850-00c1-4dbf-ab63-214bc3377402_terseLabel_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_label_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd. [Member]</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_documentation_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:href="nbix-20220930.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:to="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_01116732-a211-4e7c-bfdb-d5a9a9de1096_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Description of Operating Lease</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b9f2389f-32ea-4cd5-a48d-4c84f85e6456_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_e95e2532-d511-4ab0-b0b7-b5aeb1b38507_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_0cd59fc8-3bed-413c-bd54-3cfe114d39d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes redemption rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_1d065686-8486-4810-98b2-be5b0c47ccc2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5791841f-1750-467a-a2e4-8d897761bc2d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f3cfa092-f20f-4d99-bc21-be712b541345_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a269069b-f107-4f9c-b27a-d667e8b76df4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3ada4081-e47b-47e2-9f35-bb7d16ef855a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d64d18fe-e32d-46bd-bc5a-f9e53bb33a06_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_dd337c4d-0f15-463c-9710-d9e0d07495fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note assumed borrowing rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_029e93bf-c8c3-42e3-a4c6-29b6dd193476_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_355bc1d6-3557-4b02-9401-0a713d302c30_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9e1161ff-4eb8-4f5d-9073-143878eb8954_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_e3ffe772-e6c0-4f85-9ab2-714d1c48f1fc_terseLabel_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the liability component immediately before extinguishment</link:label>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_label_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Liability Component Immediately Before Extinguishment</link:label>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_documentation_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the liability component immediately before extinguishment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:href="nbix-20220930.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:to="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f8a55060-1765-433f-a6b1-858fc6560a7d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_67802d9f-9e9a-4b8c-a9c6-6fbb3407fb5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_f4c9dd7f-646f-4280-8b90-6777bfa57798_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_15457083-9e66-4cf7-b840-e03e51696855_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2a8fc523-4710-4a2b-b327-5554350715dd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_830d1a13-08bd-47db-a375-5d499fb56870_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d1b2fe53-c104-4f37-bdb6-e828ae589dd2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1532df96-0113-4d75-8d77-fcbc9ddb39f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_69c0c6b6-8580-42ed-9a85-2d422fe4bd14_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_label_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payment receipts under a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts" xlink:href="nbix-20220930.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePaymentReceipts" xlink:to="lab_nbix_PotentialMilestonePaymentReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_72995a65-8cb6-46ec-b65d-17bd0883fcca_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:href="nbix-20220930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2add1533-999b-4b3e-914c-28457915319a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf3db3f7-96f1-40e5-89af-acc28876427f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5ee209b8-90a3-44f1-8ded-6241874f6867_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1062a69f-c9c0-416f-9626-a6dea5a666a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate value of all cash transaction</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_69b66b25-3b9a-4b43-b8ce-af615212f058_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a8a564af-5b9c-4077-975e-6e2879d976ba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1d3be6dc-51cb-4798-970b-b33e2883b9c5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_8f239faa-7596-4a9d-a8cf-777d58c23426_terseLabel_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_label_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember" xlink:href="nbix-20220930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_XenonPharmaceuticalsIncMember" xlink:to="lab_nbix_XenonPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_8d231158-7cee-4f0a-b829-b8097923b3e4_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember" xlink:href="nbix-20220930.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodTwoMember" xlink:to="lab_nbix_ConversionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_324db70d-eb0c-4db9-a965-e5476ffa07f5_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a0e79a1b-ab05-4427-b894-c5d285f1bad6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_41092ca3-ad67-4bdd-a07d-1b6f270fdad7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_582d5a2d-881d-40f7-b01a-f64e109090e3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_20d3f1d9-99a5-4bca-86f5-8ca64e3c44a4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b37fc507-8146-4be0-b1cb-37096761cec2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_035d3dcf-6966-4e67-ae32-a89a59d58e86_terseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, current</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Current</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:to="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_db04d237-8d14-498a-bc26-9c0d1973d90a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0a373420-56d7-4747-b435-68ef90afc6fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a9733a1-b887-4378-992b-f68015dcd12c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e79007b0-598e-4470-a604-cee5326900e5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_96b08dc2-9615-4497-aa48-eb529c5646c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_19e3d2a2-6f1e-480d-b862-9c2a31e91453_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_088b794c-9cad-4927-809d-271e75b50df2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_223d4fb8-cc27-4c08-ad6f-7fa78a2abb52_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c0743685-d3a1-41ff-9511-d092379f48a7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4006ebf-0977-4eb9-9d0c-8dab923aa866_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AbbVieIncMember_6c71f380-4b86-4212-be92-8fff081012a4_terseLabel_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_label_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc. [Member]</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_documentation_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember" xlink:href="nbix-20220930.xsd#nbix_AbbVieIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AbbVieIncMember" xlink:to="lab_nbix_AbbVieIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_346d6367-e20b-4491-b358-ac8c1a4c658c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_77a4ee86-75c2-4dfd-8d72-a8737597b19a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_7e3ff93e-b322-45ae-84df-646cf7f15e44_verboseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, noncurrent</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Noncurrent</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:to="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_bca495d5-b123-4d63-b281-4ca10bd9fbfe_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_label_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Conversion Premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:to="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ff88fff9-5836-46cc-a1ce-85ebd9f1c07d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0fe71359-1556-4c47-9ae5-d6d1beae1b26_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2ac7f5c7-735b-4f93-a56b-f5e672415ad1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aaaee8c4-c460-4dd1-9b54-cf289cf16ea8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_951bf3b7-1e30-49e4-8def-47aa40b2e655_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_bf3c46d5-3703-4803-bdb0-ecf6faab82ba_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_af9ab09f-6552-46f1-beca-5aa98182cdba_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_73f38601-1647-4f09-8379-e8fd6e01b044_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt, Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e95badce-ff5e-4172-baca-669e532124d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cd1503ce-0133-4453-968e-6befacec8ad1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets acquired through operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_20bf173d-b046-42c2-86a1-8d996606debf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_022c844b-cfe4-41f9-a77c-60b7cad70e23_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionAxis" xlink:to="lab_nbix_DebtInstrumentConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ceaf9f77-5bd7-47c1-942d-3cdc69ee6bef_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f91ce5f8-1101-4ec2-83b5-b6f04dc40421_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_4df4c935-2533-4f4a-9d40-d51b1fe03aff_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nbix-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3520a338-fe51-42c9-b6ce-64a0958f0bdf,g:fc65d0f6-0ebc-4627-b8fe-1f4c71e82970-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5377055e-c952-41d5-9c8c-b04d2d8a8f79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_DocumentType_5377055e-c952-41d5-9c8c-b04d2d8a8f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ef956ec7-09ee-4215-b732-76646a6e4967" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_DocumentQuarterlyReport_ef956ec7-09ee-4215-b732-76646a6e4967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_66fcd899-f4f2-4e9d-b974-018e69cabea0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_DocumentPeriodEndDate_66fcd899-f4f2-4e9d-b974-018e69cabea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_47318dc2-da0d-4dd8-b018-0ee94e00c32f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_DocumentTransitionReport_47318dc2-da0d-4dd8-b018-0ee94e00c32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a58af225-6d3c-4f5e-a4e4-ad9e11313e14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityFileNumber_a58af225-6d3c-4f5e-a4e4-ad9e11313e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_49440a5e-f135-44ce-830e-533f2856f793" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityRegistrantName_49440a5e-f135-44ce-830e-533f2856f793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7b68f420-1f21-48c1-87ae-c8e1395e89a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7b68f420-1f21-48c1-87ae-c8e1395e89a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6e366cf4-a6ab-46d3-8feb-990d721af615" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityTaxIdentificationNumber_6e366cf4-a6ab-46d3-8feb-990d721af615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_178df6e1-ab8b-4c10-8790-10356a95cba0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityAddressAddressLine1_178df6e1-ab8b-4c10-8790-10356a95cba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_810369c7-e46f-43e5-8151-d30e487980de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityAddressCityOrTown_810369c7-e46f-43e5-8151-d30e487980de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3d417448-e717-46f3-b9dd-b8b41c6d5273" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityAddressStateOrProvince_3d417448-e717-46f3-b9dd-b8b41c6d5273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d359aec9-b117-4ea4-8c7a-8fcc479753b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityAddressPostalZipCode_d359aec9-b117-4ea4-8c7a-8fcc479753b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_033dffbe-d20b-4478-ab80-ca3f309205c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_CityAreaCode_033dffbe-d20b-4478-ab80-ca3f309205c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fb8800d5-ae82-4d87-8788-f45e26d90407" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_LocalPhoneNumber_fb8800d5-ae82-4d87-8788-f45e26d90407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b3365a80-d4b1-4996-bf27-caba7af7accd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_Security12bTitle_b3365a80-d4b1-4996-bf27-caba7af7accd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8ba7a55f-daea-4e91-8ce6-69a481114ebd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_TradingSymbol_8ba7a55f-daea-4e91-8ce6-69a481114ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1f15ee0e-0436-413d-88a1-aa4ee0b0c7ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_SecurityExchangeName_1f15ee0e-0436-413d-88a1-aa4ee0b0c7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1d8ec35f-74ce-4fca-baa6-91b52fa6c9bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityCurrentReportingStatus_1d8ec35f-74ce-4fca-baa6-91b52fa6c9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5e9a3fde-3214-4ac2-a85b-c9fd74bc93b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityInteractiveDataCurrent_5e9a3fde-3214-4ac2-a85b-c9fd74bc93b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_77f24ee3-4bb3-40f0-a499-5d048db0aa78" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityFilerCategory_77f24ee3-4bb3-40f0-a499-5d048db0aa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_619bf7bc-66f0-4b59-b9d1-fff295ac65fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntitySmallBusiness_619bf7bc-66f0-4b59-b9d1-fff295ac65fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6bc8159b-95f5-490d-8c57-7d62466ef1d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityEmergingGrowthCompany_6bc8159b-95f5-490d-8c57-7d62466ef1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a007fb9b-73b5-4e4a-bf65-e288a24131c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityShellCompany_a007fb9b-73b5-4e4a-bf65-e288a24131c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_dd3b4a26-4a53-4ca3-8d8d-a9e798b63056" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_dd3b4a26-4a53-4ca3-8d8d-a9e798b63056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0e0b359c-4339-4734-b181-f8b54f0a56eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_AmendmentFlag_0e0b359c-4339-4734-b181-f8b54f0a56eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b2c16b26-4564-478f-8439-e02378be27b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_DocumentFiscalYearFocus_b2c16b26-4564-478f-8439-e02378be27b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0b4c53f8-50a2-42d6-afe9-a86a97aa3f26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0b4c53f8-50a2-42d6-afe9-a86a97aa3f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0f9536b9-437d-4529-9d36-6b69142f0351" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_EntityCentralIndexKey_0f9536b9-437d-4529-9d36-6b69142f0351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_510fd193-39a8-43f9-bcc9-2e8e495382ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7622bd30-5a8a-47f6-b35d-3b61f3b10b50" xlink:to="loc_dei_CurrentFiscalYearEndDate_510fd193-39a8-43f9-bcc9-2e8e495382ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cfe241b4-a1c1-49e8-9cc2-a389fd437a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cfe241b4-a1c1-49e8-9cc2-a389fd437a5b" xlink:to="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bacd0be8-b3b2-4cb6-ad4a-16898fd43f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bacd0be8-b3b2-4cb6-ad4a-16898fd43f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d39a874f-a10e-4edd-8903-8e70a3a3141a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bacd0be8-b3b2-4cb6-ad4a-16898fd43f94" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d39a874f-a10e-4edd-8903-8e70a3a3141a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4c1f8679-616b-4ed0-a99f-ca34710e7e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bacd0be8-b3b2-4cb6-ad4a-16898fd43f94" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4c1f8679-616b-4ed0-a99f-ca34710e7e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5935ea0d-9257-45bc-959f-b8ea9d3061fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bacd0be8-b3b2-4cb6-ad4a-16898fd43f94" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5935ea0d-9257-45bc-959f-b8ea9d3061fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_22ed59b4-42f5-4e2f-8f7b-777a814bc5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bacd0be8-b3b2-4cb6-ad4a-16898fd43f94" xlink:to="loc_us-gaap_InventoryNet_22ed59b4-42f5-4e2f-8f7b-777a814bc5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0c535767-f82b-4525-9688-dfde61244293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bacd0be8-b3b2-4cb6-ad4a-16898fd43f94" xlink:to="loc_us-gaap_OtherAssetsCurrent_0c535767-f82b-4525-9688-dfde61244293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b5235532-5c21-4963-adff-9bc77e770933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bacd0be8-b3b2-4cb6-ad4a-16898fd43f94" xlink:to="loc_us-gaap_AssetsCurrent_b5235532-5c21-4963-adff-9bc77e770933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_4765c067-7961-4751-8505-532064655309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_4765c067-7961-4751-8505-532064655309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f1c0f052-5312-4032-9ec2-02ef21520159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f1c0f052-5312-4032-9ec2-02ef21520159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f4405690-6089-4b23-9910-af1f8415f9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f4405690-6089-4b23-9910-af1f8415f9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_a681474c-a0bc-4827-94d8-0777e2de863a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_a681474c-a0bc-4827-94d8-0777e2de863a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_93a1dfb0-d60f-48f0-986f-b1eec793c570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_93a1dfb0-d60f-48f0-986f-b1eec793c570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e0c812cc-7f32-4b8c-be66-66dd75ed1311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e0c812cc-7f32-4b8c-be66-66dd75ed1311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2503861c-d7e6-4a8c-89ba-73acfddb3021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_30f95db2-5aa8-4c17-a7d8-c35b8d91004b" xlink:to="loc_us-gaap_Assets_2503861c-d7e6-4a8c-89ba-73acfddb3021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a925e76-3a6a-463d-b654-07d513c49503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cfe241b4-a1c1-49e8-9cc2-a389fd437a5b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a925e76-3a6a-463d-b654-07d513c49503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d948b6bc-73d6-447c-b709-a77b1c608dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a925e76-3a6a-463d-b654-07d513c49503" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d948b6bc-73d6-447c-b709-a77b1c608dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e7a99d2a-1202-44ca-bde2-3fb32898e2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d948b6bc-73d6-447c-b709-a77b1c608dd2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e7a99d2a-1202-44ca-bde2-3fb32898e2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_b263581b-4100-4652-96c9-5a6ba33e1b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d948b6bc-73d6-447c-b709-a77b1c608dd2" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_b263581b-4100-4652-96c9-5a6ba33e1b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_fb417359-eb3a-4060-b6fb-0bb9b2d345b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d948b6bc-73d6-447c-b709-a77b1c608dd2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_fb417359-eb3a-4060-b6fb-0bb9b2d345b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_22e46f60-44b6-4f86-af44-518b95c908d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d948b6bc-73d6-447c-b709-a77b1c608dd2" xlink:to="loc_us-gaap_LiabilitiesCurrent_22e46f60-44b6-4f86-af44-518b95c908d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_e36b3edc-194c-4535-bad6-a80bfef6fc57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a925e76-3a6a-463d-b654-07d513c49503" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_e36b3edc-194c-4535-bad6-a80bfef6fc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b446454-ef10-4d70-a915-6d83e81e437a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a925e76-3a6a-463d-b654-07d513c49503" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b446454-ef10-4d70-a915-6d83e81e437a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_78cc07db-2415-4721-b959-7c674bfaf218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a925e76-3a6a-463d-b654-07d513c49503" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_78cc07db-2415-4721-b959-7c674bfaf218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6d2e1a3c-eb3b-4a83-a9fd-30ed72dc53ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a925e76-3a6a-463d-b654-07d513c49503" xlink:to="loc_us-gaap_Liabilities_6d2e1a3c-eb3b-4a83-a9fd-30ed72dc53ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_32c8a8c6-5901-41bb-a9d3-c2b4a494c3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a925e76-3a6a-463d-b654-07d513c49503" xlink:to="loc_us-gaap_StockholdersEquityAbstract_32c8a8c6-5901-41bb-a9d3-c2b4a494c3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a4553cb9-e806-41fb-b166-4b002c10f92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32c8a8c6-5901-41bb-a9d3-c2b4a494c3f9" xlink:to="loc_us-gaap_PreferredStockValue_a4553cb9-e806-41fb-b166-4b002c10f92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1be776ce-9156-4e92-8065-e3e397fe647d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32c8a8c6-5901-41bb-a9d3-c2b4a494c3f9" xlink:to="loc_us-gaap_CommonStockValue_1be776ce-9156-4e92-8065-e3e397fe647d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f54195c6-e830-4269-a370-6a603a0f1338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32c8a8c6-5901-41bb-a9d3-c2b4a494c3f9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f54195c6-e830-4269-a370-6a603a0f1338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e820bc6-fbf0-425e-86d7-eb3ab2b245a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32c8a8c6-5901-41bb-a9d3-c2b4a494c3f9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e820bc6-fbf0-425e-86d7-eb3ab2b245a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac00478f-28a9-41b5-b9e7-790884b64c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32c8a8c6-5901-41bb-a9d3-c2b4a494c3f9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac00478f-28a9-41b5-b9e7-790884b64c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dedb7669-2ea6-430f-8526-c4f908e7aea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32c8a8c6-5901-41bb-a9d3-c2b4a494c3f9" xlink:to="loc_us-gaap_StockholdersEquity_dedb7669-2ea6-430f-8526-c4f908e7aea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_377cd352-3f7e-4f43-a30d-0b5deb7a686e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a925e76-3a6a-463d-b654-07d513c49503" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_377cd352-3f7e-4f43-a30d-0b5deb7a686e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_60de41ec-0c5f-43a0-9157-8ea287028d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5bdee8db-1954-48b4-b09c-faafff442393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60de41ec-0c5f-43a0-9157-8ea287028d8a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5bdee8db-1954-48b4-b09c-faafff442393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_af4746a4-386d-4def-a3ce-d560f8a3c88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60de41ec-0c5f-43a0-9157-8ea287028d8a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_af4746a4-386d-4def-a3ce-d560f8a3c88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1f3de7f4-f13a-4dd2-90f4-1f9fff41c613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60de41ec-0c5f-43a0-9157-8ea287028d8a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1f3de7f4-f13a-4dd2-90f4-1f9fff41c613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0c80dc83-2646-4387-bc98-ffb192580ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60de41ec-0c5f-43a0-9157-8ea287028d8a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0c80dc83-2646-4387-bc98-ffb192580ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_020f8a29-7d65-486e-97ba-3ba745c32538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60de41ec-0c5f-43a0-9157-8ea287028d8a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_020f8a29-7d65-486e-97ba-3ba745c32538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_59d83e11-726a-4c6d-b6c5-019e7e91caad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60de41ec-0c5f-43a0-9157-8ea287028d8a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_59d83e11-726a-4c6d-b6c5-019e7e91caad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_36ad01dd-85e9-49c4-b32d-9d6200e9c537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60de41ec-0c5f-43a0-9157-8ea287028d8a" xlink:to="loc_us-gaap_CommonStockSharesIssued_36ad01dd-85e9-49c4-b32d-9d6200e9c537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_aa8216ac-e983-4ddc-af9e-2640d64e0430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60de41ec-0c5f-43a0-9157-8ea287028d8a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_aa8216ac-e983-4ddc-af9e-2640d64e0430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_666cc053-6f5b-4a4d-a3ec-aa6899ab99f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bd1ace4b-4290-4da5-b7f7-5348d9fa0bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_666cc053-6f5b-4a4d-a3ec-aa6899ab99f2" xlink:to="loc_us-gaap_StatementTable_bd1ace4b-4290-4da5-b7f7-5348d9fa0bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f946d20-fc17-45e3-a1de-0a670891d5d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bd1ace4b-4290-4da5-b7f7-5348d9fa0bb6" xlink:to="loc_srt_ProductOrServiceAxis_0f946d20-fc17-45e3-a1de-0a670891d5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fbf04429-2196-4689-b002-7fb05b44ec55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0f946d20-fc17-45e3-a1de-0a670891d5d5" xlink:to="loc_srt_ProductsAndServicesDomain_fbf04429-2196-4689-b002-7fb05b44ec55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_69c162f8-956a-427d-a496-e2e6b75c3d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fbf04429-2196-4689-b002-7fb05b44ec55" xlink:to="loc_us-gaap_ProductMember_69c162f8-956a-427d-a496-e2e6b75c3d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_9a791642-eda6-472f-beb2-4539f4e5c86b" xlink:href="nbix-20220930.xsd#nbix_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fbf04429-2196-4689-b002-7fb05b44ec55" xlink:to="loc_nbix_CollaborationRevenueMember_9a791642-eda6-472f-beb2-4539f4e5c86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bd1ace4b-4290-4da5-b7f7-5348d9fa0bb6" xlink:to="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d6982ac0-e07c-4b87-af68-f001d7706a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_RevenuesAbstract_d6982ac0-e07c-4b87-af68-f001d7706a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c181d1f-e6ca-495c-a246-4180e72236c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d6982ac0-e07c-4b87-af68-f001d7706a92" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c181d1f-e6ca-495c-a246-4180e72236c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ba0c2e9e-f649-4294-b73e-b5fa3bf309fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ba0c2e9e-f649-4294-b73e-b5fa3bf309fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eafd14ed-c90c-4e4f-a52e-abd93b9a29f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eafd14ed-c90c-4e4f-a52e-abd93b9a29f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b6320ded-4146-4441-8028-6fbce82ba3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b6320ded-4146-4441-8028-6fbce82ba3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_27c1f5de-418f-4685-be7f-efaa08154789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_27c1f5de-418f-4685-be7f-efaa08154789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_eb5f4b25-b215-4c1a-a25b-1e7bdee320b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_00085d2a-d8ee-4eb0-bedb-bef8f4d6e6dd" xlink:to="loc_us-gaap_CostsAndExpenses_eb5f4b25-b215-4c1a-a25b-1e7bdee320b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_96ec5032-a6f2-4231-9402-ee2d1901620c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_OperatingIncomeLoss_96ec5032-a6f2-4231-9402-ee2d1901620c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_416afd92-0e2d-48f1-b841-840cc89ffc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_us-gaap_InterestExpense_416afd92-0e2d-48f1-b841-840cc89ffc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6215b1bb-021d-4d9c-b052-d0743c71fbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6215b1bb-021d-4d9c-b052-d0743c71fbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3bbe40bb-83bf-49e6-a420-03569f347f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3bbe40bb-83bf-49e6-a420-03569f347f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_d5193b1c-9fa1-4c58-a7f9-ca3bc936ec58" xlink:href="nbix-20220930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_d5193b1c-9fa1-4c58-a7f9-ca3bc936ec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_66da6c76-d3fc-4070-8c83-c5aa3905972c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2cdc9032-0da5-427e-945c-8c3d2ebd6ab5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_66da6c76-d3fc-4070-8c83-c5aa3905972c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dfdb8d81-367e-488f-a744-d63ac7eb1f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dfdb8d81-367e-488f-a744-d63ac7eb1f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_82a97f6e-f3f0-4d3b-b30b-5ef375e2c0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_82a97f6e-f3f0-4d3b-b30b-5ef375e2c0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_65a9647f-32eb-49c0-8307-29745e6b1b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_NetIncomeLoss_65a9647f-32eb-49c0-8307-29745e6b1b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e47ebecc-702a-4ad2-b94e-a0cdd4efed2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e47ebecc-702a-4ad2-b94e-a0cdd4efed2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1a938be6-8237-48cb-be7e-49dcf780fddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1a938be6-8237-48cb-be7e-49dcf780fddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4dfa7480-4282-4d68-a880-bb2b60bf8b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_EarningsPerShareAbstract_4dfa7480-4282-4d68-a880-bb2b60bf8b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ef7c54be-521d-413d-a75e-4667cc726c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4dfa7480-4282-4d68-a880-bb2b60bf8b78" xlink:to="loc_us-gaap_EarningsPerShareBasic_ef7c54be-521d-413d-a75e-4667cc726c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f03a435e-bc62-4b8a-ac77-cad78a6b20af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4dfa7480-4282-4d68-a880-bb2b60bf8b78" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f03a435e-bc62-4b8a-ac77-cad78a6b20af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3eb94850-8dec-4d7d-b99b-24c178c3b3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_70510e85-886a-4aec-98fe-0dca1f01a1ec" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3eb94850-8dec-4d7d-b99b-24c178c3b3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ff04354-b6d3-4b67-a58c-3b33bd5ffb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3eb94850-8dec-4d7d-b99b-24c178c3b3cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ff04354-b6d3-4b67-a58c-3b33bd5ffb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c8c00428-c913-4e15-a84a-f19a0a80b4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3eb94850-8dec-4d7d-b99b-24c178c3b3cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c8c00428-c913-4e15-a84a-f19a0a80b4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6ae0456a-2c12-48c2-8f9e-d2934e36b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0dd5db0a-f479-49b1-a1c1-fb7fe845dd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6ae0456a-2c12-48c2-8f9e-d2934e36b2bb" xlink:to="loc_us-gaap_StatementTable_0dd5db0a-f479-49b1-a1c1-fb7fe845dd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8a85f909-44ec-4f64-8157-34fd02c6b724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0dd5db0a-f479-49b1-a1c1-fb7fe845dd84" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8a85f909-44ec-4f64-8157-34fd02c6b724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8a85f909-44ec-4f64-8157-34fd02c6b724" xlink:to="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0f3c2d9c-cac9-4746-997c-69d03a010acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:to="loc_us-gaap_CommonStockMember_0f3c2d9c-cac9-4746-997c-69d03a010acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_846960be-ad42-4711-a632-9f6addb7db53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_846960be-ad42-4711-a632-9f6addb7db53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e43641-f3f9-45cf-93de-2fb5264ce0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e43641-f3f9-45cf-93de-2fb5264ce0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d611502f-9d5e-4443-a991-d1a23e9676c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb4511f6-92a2-4b97-aac4-30f6d7c10f87" xlink:to="loc_us-gaap_RetainedEarningsMember_d611502f-9d5e-4443-a991-d1a23e9676c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3ce9755f-7370-401c-81e9-4879e38b44c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0dd5db0a-f479-49b1-a1c1-fb7fe845dd84" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3ce9755f-7370-401c-81e9-4879e38b44c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e83b714f-8ae6-4364-bb78-c50bd6d71117" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3ce9755f-7370-401c-81e9-4879e38b44c3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e83b714f-8ae6-4364-bb78-c50bd6d71117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5630c2f1-9014-4359-80a8-39941ee96dd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e83b714f-8ae6-4364-bb78-c50bd6d71117" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5630c2f1-9014-4359-80a8-39941ee96dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_44d0a6c5-e982-415b-8902-3dcb201b31ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0dd5db0a-f479-49b1-a1c1-fb7fe845dd84" xlink:to="loc_us-gaap_StatementLineItems_44d0a6c5-e982-415b-8902-3dcb201b31ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_44d0a6c5-e982-415b-8902-3dcb201b31ba" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c72fd61d-7d4b-426d-a792-fe0bce70f48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_SharesOutstanding_c72fd61d-7d4b-426d-a792-fe0bce70f48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d85b255-8c25-4ede-b54c-b2c79a0497a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_StockholdersEquity_0d85b255-8c25-4ede-b54c-b2c79a0497a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_485bec11-72b9-4fb4-b53e-5c9e68869269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_NetIncomeLoss_485bec11-72b9-4fb4-b53e-5c9e68869269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d66e21a9-1747-44ad-9b79-7169bf28337c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d66e21a9-1747-44ad-9b79-7169bf28337c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_436d1dab-6f80-46a1-a2d4-841519ba9436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_436d1dab-6f80-46a1-a2d4-841519ba9436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9099c551-399f-41ea-bfe5-3ffb1d6ff1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9099c551-399f-41ea-bfe5-3ffb1d6ff1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0eccd4eb-e3cd-4d46-a56a-3dc7d4736c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0eccd4eb-e3cd-4d46-a56a-3dc7d4736c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_557f1bd3-5023-4aa6-93aa-8c1fe6a7b09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_557f1bd3-5023-4aa6-93aa-8c1fe6a7b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e1bfd229-cbd1-4984-815b-2acfb0eb8a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_SharesOutstanding_e1bfd229-cbd1-4984-815b-2acfb0eb8a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc654580-b1f7-453b-9aa0-9ff5a0e952bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83fa98d0-63b9-4bb8-b422-d884a4d7d81a" xlink:to="loc_us-gaap_StockholdersEquity_dc654580-b1f7-453b-9aa0-9ff5a0e952bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_601134a7-9964-4dd7-a1b8-1350893e7c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36be8519-dcad-4d5e-a413-e8e587c078b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_601134a7-9964-4dd7-a1b8-1350893e7c2b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36be8519-dcad-4d5e-a413-e8e587c078b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eff61d51-4617-47e3-97d2-fda4fb9c8586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36be8519-dcad-4d5e-a413-e8e587c078b5" xlink:to="loc_us-gaap_NetIncomeLoss_eff61d51-4617-47e3-97d2-fda4fb9c8586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36be8519-dcad-4d5e-a413-e8e587c078b5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_32878b61-0d40-4e73-b514-f24365527d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:to="loc_us-gaap_ShareBasedCompensation_32878b61-0d40-4e73-b514-f24365527d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6ad5ff0b-91f8-476b-89a9-19d5c8c7c705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6ad5ff0b-91f8-476b-89a9-19d5c8c7c705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_954f4568-1560-4f2a-9ec3-3ee3cb4b5e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:to="loc_us-gaap_Depreciation_954f4568-1560-4f2a-9ec3-3ee3cb4b5e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_f83c2e4c-9f31-41ed-8bfd-1dcd3392bdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_f83c2e4c-9f31-41ed-8bfd-1dcd3392bdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ef6aab19-099d-4f84-8bcd-7f72bf73b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ef6aab19-099d-4f84-8bcd-7f72bf73b8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4d327b14-7165-4e1f-9295-f8bb5f348444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4d327b14-7165-4e1f-9295-f8bb5f348444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_86176d78-d1c4-4e97-9211-e26733b9982e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_86176d78-d1c4-4e97-9211-e26733b9982e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_7a3af322-bd3e-4f3d-b31a-bd48c5ab56df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_7a3af322-bd3e-4f3d-b31a-bd48c5ab56df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03ac2124-e05c-4eb5-8906-f56732fa7e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20ca7b80-61b4-44c0-9614-8ba6b4e0dc3f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03ac2124-e05c-4eb5-8906-f56732fa7e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_07f69e38-9bf2-4656-a39f-f9663b9975c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03ac2124-e05c-4eb5-8906-f56732fa7e30" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_07f69e38-9bf2-4656-a39f-f9663b9975c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a7057f26-5bd2-428e-a8cf-52195b128d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03ac2124-e05c-4eb5-8906-f56732fa7e30" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a7057f26-5bd2-428e-a8cf-52195b128d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_486e0138-abd6-4b71-8bed-3a97b8b0144f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03ac2124-e05c-4eb5-8906-f56732fa7e30" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_486e0138-abd6-4b71-8bed-3a97b8b0144f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_28113b96-a1c2-43b8-859a-447c91ae62fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03ac2124-e05c-4eb5-8906-f56732fa7e30" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_28113b96-a1c2-43b8-859a-447c91ae62fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_700965ac-f365-4a00-9136-2f8c8fac897f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36be8519-dcad-4d5e-a413-e8e587c078b5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_700965ac-f365-4a00-9136-2f8c8fac897f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f95a6125-5ad3-41de-9ff7-9fd787fc8202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_601134a7-9964-4dd7-a1b8-1350893e7c2b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f95a6125-5ad3-41de-9ff7-9fd787fc8202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b1991133-5992-4727-8383-37ffcf2d8a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f95a6125-5ad3-41de-9ff7-9fd787fc8202" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b1991133-5992-4727-8383-37ffcf2d8a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_68441299-2894-42ba-afef-28de08bd1e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f95a6125-5ad3-41de-9ff7-9fd787fc8202" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_68441299-2894-42ba-afef-28de08bd1e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_7ac94d0e-5bd4-4bc4-b674-9d51abf88712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f95a6125-5ad3-41de-9ff7-9fd787fc8202" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_7ac94d0e-5bd4-4bc4-b674-9d51abf88712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e1a67ac3-f5f6-4359-8a2e-f7014308d322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f95a6125-5ad3-41de-9ff7-9fd787fc8202" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e1a67ac3-f5f6-4359-8a2e-f7014308d322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23bcdbda-bb46-4412-8445-3c248d2d3e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f95a6125-5ad3-41de-9ff7-9fd787fc8202" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23bcdbda-bb46-4412-8445-3c248d2d3e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9462e26-7270-4985-a4e9-0f46f07d36b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_601134a7-9964-4dd7-a1b8-1350893e7c2b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9462e26-7270-4985-a4e9-0f46f07d36b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cfc6680c-6ed3-4ce3-a048-5bf0b3d3ff66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9462e26-7270-4985-a4e9-0f46f07d36b2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cfc6680c-6ed3-4ce3-a048-5bf0b3d3ff66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_8b719830-5f52-4ffd-9741-458471653e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9462e26-7270-4985-a4e9-0f46f07d36b2" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_8b719830-5f52-4ffd-9741-458471653e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13d663f6-459b-43d4-875f-7ba18a76f8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9462e26-7270-4985-a4e9-0f46f07d36b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13d663f6-459b-43d4-875f-7ba18a76f8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1517d3fa-5f9e-42e8-a46b-0c13055c89a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_601134a7-9964-4dd7-a1b8-1350893e7c2b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1517d3fa-5f9e-42e8-a46b-0c13055c89a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa534a82-c4bb-41ed-abf0-f4b5d8314ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_601134a7-9964-4dd7-a1b8-1350893e7c2b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa534a82-c4bb-41ed-abf0-f4b5d8314ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa71876c-df24-47f8-bfcd-039eb880c4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_601134a7-9964-4dd7-a1b8-1350893e7c2b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa71876c-df24-47f8-bfcd-039eb880c4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a4806bf7-2c0a-420b-bef5-9828d3406163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_601134a7-9964-4dd7-a1b8-1350893e7c2b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a4806bf7-2c0a-420b-bef5-9828d3406163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5e10041a-fbaf-4159-b55d-3668f02f83fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a4806bf7-2c0a-420b-bef5-9828d3406163" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5e10041a-fbaf-4159-b55d-3668f02f83fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e5914727-a64c-4eb6-a7a3-c0d4202af755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a4806bf7-2c0a-420b-bef5-9828d3406163" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e5914727-a64c-4eb6-a7a3-c0d4202af755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_17bba9cb-4737-4747-a884-22232d5b79b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a4806bf7-2c0a-420b-bef5-9828d3406163" xlink:to="loc_us-gaap_InterestPaidNet_17bba9cb-4737-4747-a884-22232d5b79b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_12782c37-71eb-4203-982a-d17e4e35522a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a4806bf7-2c0a-420b-bef5-9828d3406163" xlink:to="loc_us-gaap_IncomeTaxesPaid_12782c37-71eb-4203-982a-d17e4e35522a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20220930.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_089e14b9-769b-4708-bf7b-d0de1999edac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_431c82f7-9296-4f02-be26-7df1fc32381f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_089e14b9-769b-4708-bf7b-d0de1999edac" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_431c82f7-9296-4f02-be26-7df1fc32381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="nbix-20220930.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b8609c7c-b3ac-483a-a5a3-46c1290b7fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d22afe59-2cba-476f-bcc9-597068687ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b8609c7c-b3ac-483a-a5a3-46c1290b7fe9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d22afe59-2cba-476f-bcc9-597068687ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20220930.xsd#DebtSecurities"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f384f0a1-5b06-4b3c-81c0-8eb51d5045a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_2febac31-6305-471d-b7bc-c86d9690c262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f384f0a1-5b06-4b3c-81c0-8eb51d5045a6" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_2febac31-6305-471d-b7bc-c86d9690c262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_601d328e-572c-49d0-8086-b3e804b264db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c67c0324-8aa1-4ebf-bbd8-f31877517171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_601d328e-572c-49d0-8086-b3e804b264db" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c67c0324-8aa1-4ebf-bbd8-f31877517171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Inventories" xlink:type="simple" xlink:href="nbix-20220930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_81207947-2f4a-4869-b83b-777da88f574c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_cda5883d-29e4-441c-948a-1e25ed8832bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_81207947-2f4a-4869-b83b-777da88f574c" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_cda5883d-29e4-441c-948a-1e25ed8832bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nbix-20220930.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c065cbef-dec5-4b55-94ff-78b7eb762b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashTextBlock_e0d09fd3-a34e-4cc9-a6d8-5c67b604123f" xlink:href="nbix-20220930.xsd#nbix_RestrictedCashTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c065cbef-dec5-4b55-94ff-78b7eb762b2f" xlink:to="loc_nbix_RestrictedCashTextBlock_e0d09fd3-a34e-4cc9-a6d8-5c67b604123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20220930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3ebf5d66-eba5-490e-b1df-8cb4221803e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_456e57bb-ae9b-43d0-9555-e0b6b5234416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ebf5d66-eba5-490e-b1df-8cb4221803e1" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_456e57bb-ae9b-43d0-9555-e0b6b5234416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20220930.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5f529c5d-b3c0-42ac-8a30-405383ca0daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a53e5c60-6049-4fa6-9d36-8ada71a57a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f529c5d-b3c0-42ac-8a30-405383ca0daa" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a53e5c60-6049-4fa6-9d36-8ada71a57a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsperShare" xlink:type="simple" xlink:href="nbix-20220930.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6a438f56-a005-49bd-addb-627d8d246d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_57f8059b-aeed-4844-beef-c3767395f49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6a438f56-a005-49bd-addb-627d8d246d98" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_57f8059b-aeed-4844-beef-c3767395f49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SubsequentEvents" xlink:type="simple" xlink:href="nbix-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a8e39587-b4b8-4dd1-af5d-5d879fa10c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_a8930ee1-0002-4de6-bd85-a4c909cfca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a8e39587-b4b8-4dd1-af5d-5d879fa10c68" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_a8930ee1-0002-4de6-bd85-a4c909cfca1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20220930.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cc7acb1e-ad7e-4a6a-af93-253e11e362f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_920233c4-82b4-41d0-a0cc-c05856f90408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cc7acb1e-ad7e-4a6a-af93-253e11e362f0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_920233c4-82b4-41d0-a0cc-c05856f90408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b3ca0aff-52fd-4bc0-af22-cc7207b0794f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cc7acb1e-ad7e-4a6a-af93-253e11e362f0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b3ca0aff-52fd-4bc0-af22-cc7207b0794f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_171684d1-dd39-4f57-aa3b-7c81dbabd9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cc7acb1e-ad7e-4a6a-af93-253e11e362f0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_171684d1-dd39-4f57-aa3b-7c81dbabd9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20220930.xsd#DebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c02baa7a-de7a-4799-bbae-0a8b56207a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_093f56c8-0852-4162-9908-29c451cc5b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c02baa7a-de7a-4799-bbae-0a8b56207a34" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_093f56c8-0852-4162-9908-29c451cc5b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_0a6b094e-e89a-471d-a7e2-871149a4de3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c02baa7a-de7a-4799-bbae-0a8b56207a34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_0a6b094e-e89a-471d-a7e2-871149a4de3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_61f15f15-6cd6-4cab-9c7d-e83cbeb8794d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_eb90e42e-a3b8-4ec1-94ca-0166ee15ef37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61f15f15-6cd6-4cab-9c7d-e83cbeb8794d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_eb90e42e-a3b8-4ec1-94ca-0166ee15ef37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a4949dc9-305d-4da6-aee4-ba93e4eee92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61f15f15-6cd6-4cab-9c7d-e83cbeb8794d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a4949dc9-305d-4da6-aee4-ba93e4eee92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesTables" xlink:type="simple" xlink:href="nbix-20220930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a9c87e23-23a0-44d6-8012-7d9c5f6267a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_be83c9ea-f381-42c8-8af0-fdd2110a69b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a9c87e23-23a0-44d6-8012-7d9c5f6267a5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_be83c9ea-f381-42c8-8af0-fdd2110a69b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nbix-20220930.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_80abdec9-7f0b-45d8-b4dc-9398413c3eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_cc1cb37d-4ae7-49df-947c-a2454e78afd9" xlink:href="nbix-20220930.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_80abdec9-7f0b-45d8-b4dc-9398413c3eb9" xlink:to="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_cc1cb37d-4ae7-49df-947c-a2454e78afd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTables" xlink:type="simple" xlink:href="nbix-20220930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8e96e60d-8c27-4d45-8865-bd7211991636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_9ff9b951-0fe3-400b-b010-5f0a2f0c5eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e96e60d-8c27-4d45-8865-bd7211991636" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_9ff9b951-0fe3-400b-b010-5f0a2f0c5eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0b257308-65eb-48a4-a490-60c8dd80b307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e96e60d-8c27-4d45-8865-bd7211991636" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0b257308-65eb-48a4-a490-60c8dd80b307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20220930.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_454bb3c5-4cf3-4d19-b845-48e54e0e630b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_65010091-e4fa-4aee-9574-5cd3e7d60d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_454bb3c5-4cf3-4d19-b845-48e54e0e630b" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_65010091-e4fa-4aee-9574-5cd3e7d60d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="nbix-20220930.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2e2f8807-4241-4a4b-97ff-35030cc9877d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_727d777b-b7ec-4c7d-bea8-6b3e67594dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e2f8807-4241-4a4b-97ff-35030cc9877d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_727d777b-b7ec-4c7d-bea8-6b3e67594dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_17dafe31-291a-44c5-96af-8291880a86fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_17dafe31-291a-44c5-96af-8291880a86fa" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fb17b0c3-aef1-4801-bd5b-9f8d804ee55f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:to="loc_us-gaap_DebtInstrumentAxis_fb17b0c3-aef1-4801-bd5b-9f8d804ee55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0536bd5c-8a4e-4574-9c4a-9368e64dca91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fb17b0c3-aef1-4801-bd5b-9f8d804ee55f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0536bd5c-8a4e-4574-9c4a-9368e64dca91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_75b38a41-111a-464e-a98f-9ee896637c5b" xlink:href="nbix-20220930.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0536bd5c-8a4e-4574-9c4a-9368e64dca91" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_75b38a41-111a-464e-a98f-9ee896637c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f271447-56c7-4018-b491-7087b4aecc38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f271447-56c7-4018-b491-7087b4aecc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9cc8ee9-8b40-40ed-928c-2ac4cc8df68f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f271447-56c7-4018-b491-7087b4aecc38" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9cc8ee9-8b40-40ed-928c-2ac4cc8df68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_850999eb-59ee-4d18-b4aa-858b70ad80c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e9cc8ee9-8b40-40ed-928c-2ac4cc8df68f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_850999eb-59ee-4d18-b4aa-858b70ad80c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0fadd826-55dc-4a90-b7dd-df27f21e04c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0fadd826-55dc-4a90-b7dd-df27f21e04c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a394ebe9-0fe5-48c2-8911-2be1b0d3f610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0fadd826-55dc-4a90-b7dd-df27f21e04c4" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a394ebe9-0fe5-48c2-8911-2be1b0d3f610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_16ec6eaa-0266-45c6-a18a-6cf54840d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a394ebe9-0fe5-48c2-8911-2be1b0d3f610" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_16ec6eaa-0266-45c6-a18a-6cf54840d1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ce5f643-7a9b-4277-8280-f983b6668a80" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_bb5599bd-6792-4fdf-a78c-e79c9df81553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_bb5599bd-6792-4fdf-a78c-e79c9df81553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7572f6b3-c42c-4620-b3ab-4ea3d0e6ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7572f6b3-c42c-4620-b3ab-4ea3d0e6ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_d3f62e91-872e-42ed-8306-2aaeca0df9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_d3f62e91-872e-42ed-8306-2aaeca0df9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2e9f6efb-2a38-41ff-842a-c43bdc235c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2e9f6efb-2a38-41ff-842a-c43bdc235c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dd619f98-bb02-4437-b0e8-65f320b2e028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dd619f98-bb02-4437-b0e8-65f320b2e028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb53e2e8-cf45-4709-8a74-26ce03d6d7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_43da5318-2253-41f7-b0fc-2c6ba6a30ace" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb53e2e8-cf45-4709-8a74-26ce03d6d7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8e7ccc7b-318d-4e23-a5ae-c0c9fb8e0d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8e7ccc7b-318d-4e23-a5ae-c0c9fb8e0d4f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_67cacc33-e2b3-477f-a513-b5d5d6816761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_67cacc33-e2b3-477f-a513-b5d5d6816761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5eb16fef-46f3-449e-aada-0b4a09ac01dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_67cacc33-e2b3-477f-a513-b5d5d6816761" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5eb16fef-46f3-449e-aada-0b4a09ac01dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9574bd51-15e2-4261-89a9-6199390902d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5eb16fef-46f3-449e-aada-0b4a09ac01dd" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9574bd51-15e2-4261-89a9-6199390902d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6567c01b-4078-46de-a2d1-24203120f333" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_srt_ProductOrServiceAxis_6567c01b-4078-46de-a2d1-24203120f333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bff02868-53e3-498c-ba99-2d38131c0e84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6567c01b-4078-46de-a2d1-24203120f333" xlink:to="loc_srt_ProductsAndServicesDomain_bff02868-53e3-498c-ba99-2d38131c0e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b299ea4c-7dbf-46b2-a010-9d277541d0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bff02868-53e3-498c-ba99-2d38131c0e84" xlink:to="loc_us-gaap_RoyaltyMember_b299ea4c-7dbf-46b2-a010-9d277541d0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ec7fd5c8-b0e9-44b3-a9b3-e328c5df5488" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_srt_CounterpartyNameAxis_ec7fd5c8-b0e9-44b3-a9b3-e328c5df5488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ec7fd5c8-b0e9-44b3-a9b3-e328c5df5488" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember_ee004ae7-9630-47b1-b6a5-10f4ee427a5e" xlink:href="nbix-20220930.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_HeptaresTherapeuticsLimitedMember_ee004ae7-9630-47b1-b6a5-10f4ee427a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_66d8f1f5-25e8-4498-bd4e-437ff7ff2a8e" xlink:href="nbix-20220930.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_66d8f1f5-25e8-4498-bd4e-437ff7ff2a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_b8cc94c2-a453-43cd-a2ee-da9522883371" xlink:href="nbix-20220930.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_b8cc94c2-a453-43cd-a2ee-da9522883371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_7bd8c1c6-cab4-4139-84e4-823a0f367d8d" xlink:href="nbix-20220930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_7bd8c1c6-cab4-4139-84e4-823a0f367d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_d89a985a-9ba5-422e-8055-0e77584651bb" xlink:href="nbix-20220930.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_VoyagerTherapeuticsMember_d89a985a-9ba5-422e-8055-0e77584651bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_35bcc423-c98d-4b4b-b905-9bc04a8b9877" xlink:href="nbix-20220930.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_BIALPortelaCaSAMember_35bcc423-c98d-4b4b-b905-9bc04a8b9877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_c07e0fe3-5cda-4b6f-aa2c-362cd6675c71" xlink:href="nbix-20220930.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_c07e0fe3-5cda-4b6f-aa2c-362cd6675c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_0ef5adc7-cbee-4597-970e-48e0bcf7599d" xlink:href="nbix-20220930.xsd#nbix_AbbVieIncMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3ea67bf-9355-40ba-80bd-5c2d21421b23" xlink:to="loc_nbix_AbbVieIncMember_0ef5adc7-cbee-4597-970e-48e0bcf7599d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d5e4dfc-7918-4aea-87cd-c17761808bc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_srt_RangeAxis_5d5e4dfc-7918-4aea-87cd-c17761808bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2d79353-ddec-4f96-8358-850379580dd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d5e4dfc-7918-4aea-87cd-c17761808bc9" xlink:to="loc_srt_RangeMember_d2d79353-ddec-4f96-8358-850379580dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b9abba9-807f-422c-96a9-5de03f276093" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2d79353-ddec-4f96-8358-850379580dd7" xlink:to="loc_srt_MinimumMember_5b9abba9-807f-422c-96a9-5de03f276093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f53b98a0-320a-4901-9e5c-ea7219d0f8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f53b98a0-320a-4901-9e5c-ea7219d0f8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0a140efc-fd50-4983-885c-d050ff01918d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f53b98a0-320a-4901-9e5c-ea7219d0f8d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0a140efc-fd50-4983-885c-d050ff01918d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_cb66f083-fd9e-4424-901a-82a9990dfd22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0a140efc-fd50-4983-885c-d050ff01918d" xlink:to="loc_us-gaap_PatentsMember_cb66f083-fd9e-4424-901a-82a9990dfd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1ac6f7b3-fcaf-4638-9ea4-5085cc1717c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1ac6f7b3-fcaf-4638-9ea4-5085cc1717c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6faae5f8-72b3-4045-ba8d-b3f03a2f3d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1ac6f7b3-fcaf-4638-9ea4-5085cc1717c0" xlink:to="loc_us-gaap_EquityComponentDomain_6faae5f8-72b3-4045-ba8d-b3f03a2f3d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_232ac876-2cbc-47f1-8cec-0849d57bdf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6faae5f8-72b3-4045-ba8d-b3f03a2f3d97" xlink:to="loc_us-gaap_CommonStockMember_232ac876-2cbc-47f1-8cec-0849d57bdf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c79736fc-393c-4036-8112-e57e1699f1f2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_23b18e24-5e74-441f-bc5e-c8c3256b775f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_23b18e24-5e74-441f-bc5e-c8c3256b775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b566d9b6-4418-4138-87de-4869ab04f7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b566d9b6-4418-4138-87de-4869ab04f7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_cbb19864-b75d-4db2-9d26-d6020f7173fe" xlink:href="nbix-20220930.xsd#nbix_PotentialMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_PotentialMilestonePayments_cbb19864-b75d-4db2-9d26-d6020f7173fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_ded6693a-7027-4e33-9897-379125fb1ef2" xlink:href="nbix-20220930.xsd#nbix_UpfrontPaymentsMade"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_UpfrontPaymentsMade_ded6693a-7027-4e33-9897-379125fb1ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_55595c87-1bad-4645-97e9-518a24bdbbf7" xlink:href="nbix-20220930.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_55595c87-1bad-4645-97e9-518a24bdbbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6701e3c1-49d2-48a5-95d4-34f149788e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_SharePrice_6701e3c1-49d2-48a5-95d4-34f149788e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_aff2a4f3-c45d-479a-a654-9b0bd3f09558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_aff2a4f3-c45d-479a-a654-9b0bd3f09558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_40166697-2593-4a0f-b5a9-35d15254f8b3" xlink:href="nbix-20220930.xsd#nbix_MilestonePayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_MilestonePayment_40166697-2593-4a0f-b5a9-35d15254f8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_ed369219-8e8a-4548-a45e-1aa849cf03a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_ed369219-8e8a-4548-a45e-1aa849cf03a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6c2d683-5e6e-4918-85de-cbe6179401c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6c2d683-5e6e-4918-85de-cbe6179401c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_32ebc7f1-5812-4b69-a9eb-1f9c7ef6b0c6" xlink:href="nbix-20220930.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_32ebc7f1-5812-4b69-a9eb-1f9c7ef6b0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_aa3153e4-a1c2-444e-b883-7811b2518533" xlink:href="nbix-20220930.xsd#nbix_PatentTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f3365a6-ae14-4918-a294-e40795459ea0" xlink:to="loc_nbix_PatentTerm_aa3153e4-a1c2-444e-b883-7811b2518533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2ddfc66-3175-437f-95b6-a6501a6e8ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_954b8cbd-c077-40d6-b769-24122041c2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2ddfc66-3175-437f-95b6-a6501a6e8ca4" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_954b8cbd-c077-40d6-b769-24122041c2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a16e9151-c323-4ea2-8ef4-4bfb419c222c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_954b8cbd-c077-40d6-b769-24122041c2b5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a16e9151-c323-4ea2-8ef4-4bfb419c222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a16e9151-c323-4ea2-8ef4-4bfb419c222c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6d35cf57-6c38-4b8a-b8bf-cff1991c7365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:to="loc_us-gaap_CommercialPaperMember_6d35cf57-6c38-4b8a-b8bf-cff1991c7365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b901c19f-fee6-4203-a845-9e90a3acafc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b901c19f-fee6-4203-a845-9e90a3acafc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5426ff1e-c1c7-4139-8ddd-e048261f029c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89d1de81-c5d2-418e-a4b6-57061b497ecf" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5426ff1e-c1c7-4139-8ddd-e048261f029c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_954b8cbd-c077-40d6-b769-24122041c2b5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b48ae94d-611f-4ba7-998a-e8a242724fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b48ae94d-611f-4ba7-998a-e8a242724fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_b553df5c-22d5-4990-9405-3cbc8f53050e" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_b553df5c-22d5-4990-9405-3cbc8f53050e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_2bd30b57-0f04-44ee-aa20-521148e76d59" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_2bd30b57-0f04-44ee-aa20-521148e76d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_e02f020e-9b94-40ba-b6f0-d38c9089dc7b" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_e02f020e-9b94-40ba-b6f0-d38c9089dc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_b4160294-44e9-4088-8cb0-060126f21713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_b4160294-44e9-4088-8cb0-060126f21713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_2b00a6bc-66e8-464c-9fd3-b3ada5105a4a" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_2b00a6bc-66e8-464c-9fd3-b3ada5105a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_7f035925-69ac-46a5-8903-0593bc408e01" xlink:href="nbix-20220930.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_7f035925-69ac-46a5-8903-0593bc408e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_3ded51f7-4d02-4622-9832-b3d304157eba" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5fac266-db1f-4168-ae8a-d31bd21097e2" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_3ded51f7-4d02-4622-9832-b3d304157eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#DebtSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9d1143f-d818-420f-bbec-dfe468eba980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_8f96349c-922b-4157-8b8f-9b817d2865e5" xlink:href="nbix-20220930.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9d1143f-d818-420f-bbec-dfe468eba980" xlink:to="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_8f96349c-922b-4157-8b8f-9b817d2865e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bd5d03ad-6e56-4300-8b74-135c614f7cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9d1143f-d818-420f-bbec-dfe468eba980" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bd5d03ad-6e56-4300-8b74-135c614f7cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_f9c4ebb7-ac84-40b8-9f73-90b814eb5b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9d1143f-d818-420f-bbec-dfe468eba980" xlink:to="loc_us-gaap_InterestReceivableCurrent_f9c4ebb7-ac84-40b8-9f73-90b814eb5b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_f731894c-4569-4d0e-b715-f3532e4ca23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9d1143f-d818-420f-bbec-dfe468eba980" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_f731894c-4569-4d0e-b715-f3532e4ca23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a81f0f42-2331-43c7-9cd5-a058fa7023fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57aefb04-55e1-49f7-babd-daebe2978bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a81f0f42-2331-43c7-9cd5-a058fa7023fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57aefb04-55e1-49f7-babd-daebe2978bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_37357851-86b6-4e55-9cc0-b5cf6ea9b7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57aefb04-55e1-49f7-babd-daebe2978bb9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_37357851-86b6-4e55-9cc0-b5cf6ea9b7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37357851-86b6-4e55-9cc0-b5cf6ea9b7e7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a159aaea-c925-4ff4-ac9c-a4b843b56b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:to="loc_us-gaap_CommercialPaperMember_a159aaea-c925-4ff4-ac9c-a4b843b56b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ceae38fb-5f7f-47c9-9a9a-aa4f85677fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ceae38fb-5f7f-47c9-9a9a-aa4f85677fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2ed06010-9d44-4834-980c-2e49bb4fa21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bf8bc66-1d45-49b8-97d0-adc57fc42afa" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2ed06010-9d44-4834-980c-2e49bb4fa21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57aefb04-55e1-49f7-babd-daebe2978bb9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bf0d03e8-ccc3-4661-b54e-404d4aa66767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bf0d03e8-ccc3-4661-b54e-404d4aa66767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_69357c91-41aa-420d-8078-ab8ff35106d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_69357c91-41aa-420d-8078-ab8ff35106d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_931de01a-aad3-4227-b708-4337629e86b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_931de01a-aad3-4227-b708-4337629e86b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c6f7625d-294a-436b-bb13-9a2e775bd338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c6f7625d-294a-436b-bb13-9a2e775bd338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1d622817-4582-455a-964b-6e3060fc588d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1d622817-4582-455a-964b-6e3060fc588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0856911e-aa68-46cf-a258-dbb75e7a0070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a4d1430-2eee-4c7a-b66f-3ac893adebb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0856911e-aa68-46cf-a258-dbb75e7a0070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="nbix-20220930.xsd#FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_58db4ede-39a8-45e8-97f9-ad08ec6bc81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_58db4ede-39a8-45e8-97f9-ad08ec6bc81c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7e7262ea-b455-4c93-b358-e94d4b139c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7e7262ea-b455-4c93-b358-e94d4b139c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7e7262ea-b455-4c93-b358-e94d4b139c89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_2505bc26-b7df-4c28-bc50-1681da2a2d4d" xlink:href="nbix-20220930.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_2505bc26-b7df-4c28-bc50-1681da2a2d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a1f16e6b-fd6e-4ebc-953a-cee8dc6477f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a1f16e6b-fd6e-4ebc-953a-cee8dc6477f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f26345c8-2a15-4da5-b747-291b0630b87e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fab7fc24-1b3c-4911-8140-3039b0ef5960" xlink:to="loc_us-gaap_CommercialPaperMember_f26345c8-2a15-4da5-b747-291b0630b87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6858c24c-4a45-442a-9848-6831577306aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6858c24c-4a45-442a-9848-6831577306aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6858c24c-4a45-442a-9848-6831577306aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_11355e0b-31a4-4e49-a55b-fbfcbd0fb90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_11355e0b-31a4-4e49-a55b-fbfcbd0fb90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cbe5173a-9c45-4c79-8ce0-43c61f6db26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cbe5173a-9c45-4c79-8ce0-43c61f6db26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_2b2cab5d-5181-448a-b643-da6390d169ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153987f7-6ca2-424a-8eab-5f78439cfa07" xlink:to="loc_us-gaap_EquitySecuritiesMember_2b2cab5d-5181-448a-b643-da6390d169ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_463d5cec-15bf-4e24-8520-bcfd84185b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_463d5cec-15bf-4e24-8520-bcfd84185b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_463d5cec-15bf-4e24-8520-bcfd84185b12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_72098065-a9a1-4529-bff8-95aef32f104f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_72098065-a9a1-4529-bff8-95aef32f104f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ca4934b3-7670-422a-8693-9cb02776bd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ca4934b3-7670-422a-8693-9cb02776bd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d9b2a72a-eae4-47df-9560-c7b6f3ed6ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46cc3fd7-40d6-4554-8492-c2ffeb033665" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d9b2a72a-eae4-47df-9560-c7b6f3ed6ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efffc08-2ce9-4424-90cd-64efec5dd7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efffc08-2ce9-4424-90cd-64efec5dd7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_142476a1-482b-4255-af1b-980e6926fbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efffc08-2ce9-4424-90cd-64efec5dd7e6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_142476a1-482b-4255-af1b-980e6926fbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6a285b2f-a8d1-40cc-b6b0-76e58f1553ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_142476a1-482b-4255-af1b-980e6926fbd8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6a285b2f-a8d1-40cc-b6b0-76e58f1553ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10309929-e547-4d7e-a58b-6d4a944f3b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f51bde1f-762c-4304-a2f7-b837303942c0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10309929-e547-4d7e-a58b-6d4a944f3b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_92b79725-f1d8-4915-b662-eacbdbb72d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10309929-e547-4d7e-a58b-6d4a944f3b90" xlink:to="loc_us-gaap_Investments_92b79725-f1d8-4915-b662-eacbdbb72d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cef459d8-fe90-46ef-aed5-16393d706b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10309929-e547-4d7e-a58b-6d4a944f3b90" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_cef459d8-fe90-46ef-aed5-16393d706b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="simple" xlink:href="nbix-20220930.xsd#FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_616fdb31-164d-4f41-adc3-0ce88c932e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_616fdb31-164d-4f41-adc3-0ce88c932e0f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a02b77a2-e80b-40d7-811e-f355a93ea5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a02b77a2-e80b-40d7-811e-f355a93ea5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_924a079a-8a3f-49e6-ad16-90d91d92a71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a02b77a2-e80b-40d7-811e-f355a93ea5e1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_924a079a-8a3f-49e6-ad16-90d91d92a71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0b3270d8-6f9c-480f-82e9-2ca915a0eea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_924a079a-8a3f-49e6-ad16-90d91d92a71f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0b3270d8-6f9c-480f-82e9-2ca915a0eea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9a6d1f46-5441-4b9d-92d3-fb5f232555b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9a6d1f46-5441-4b9d-92d3-fb5f232555b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_636eeff4-e5b3-4295-b550-219251919328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9a6d1f46-5441-4b9d-92d3-fb5f232555b8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_636eeff4-e5b3-4295-b550-219251919328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2d567c13-1c5b-4571-af07-5ad3d3c8429a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_636eeff4-e5b3-4295-b550-219251919328" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2d567c13-1c5b-4571-af07-5ad3d3c8429a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fb97dea1-02f9-47e2-bcc9-ba66b52b1a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fb97dea1-02f9-47e2-bcc9-ba66b52b1a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbb37a12-449d-4fec-9b5d-1e6fcc8f277a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fb97dea1-02f9-47e2-bcc9-ba66b52b1a8b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbb37a12-449d-4fec-9b5d-1e6fcc8f277a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0698166d-465d-4092-a851-1ff018f3d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbb37a12-449d-4fec-9b5d-1e6fcc8f277a" xlink:to="loc_us-gaap_EquitySecuritiesMember_0698166d-465d-4092-a851-1ff018f3d83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_fbc9bb52-8396-455f-97f1-20d4ad0bf3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:to="loc_us-gaap_CollateralAxis_fbc9bb52-8396-455f-97f1-20d4ad0bf3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_239c193b-e23e-418d-b4b7-24ea8e38a624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_fbc9bb52-8396-455f-97f1-20d4ad0bf3c9" xlink:to="loc_us-gaap_CollateralDomain_239c193b-e23e-418d-b4b7-24ea8e38a624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_9e3ef192-6da6-453f-b1d9-a2828f7dc665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_239c193b-e23e-418d-b4b7-24ea8e38a624" xlink:to="loc_us-gaap_EquitySecuritiesMember_9e3ef192-6da6-453f-b1d9-a2828f7dc665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b762fcb7-c576-47f5-887f-91e465934d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28a63015-6bff-446b-8c4c-ba12c36261ad" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b762fcb7-c576-47f5-887f-91e465934d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b762fcb7-c576-47f5-887f-91e465934d33" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_40955853-caa4-4dae-b755-70e1cf9b00b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_40955853-caa4-4dae-b755-70e1cf9b00b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_120ece45-fa50-4eea-8113-ee239c009000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_120ece45-fa50-4eea-8113-ee239c009000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_7f98ba05-e385-49ec-9129-8bd3df10460c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_7f98ba05-e385-49ec-9129-8bd3df10460c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_c6288a62-4449-4e90-85c3-ee250c50ad78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_c6288a62-4449-4e90-85c3-ee250c50ad78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_392b0bbb-4271-4e85-8f9f-8ade82d329ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_71a5cc03-b137-4be8-b1ef-79d958726f44" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_392b0bbb-4271-4e85-8f9f-8ade82d329ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#InventoriesSummaryofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c9e0bd1b-89bd-4696-ad00-4428effb50da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_28cf5758-fa88-45a7-aa90-e56093a22659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c9e0bd1b-89bd-4696-ad00-4428effb50da" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_28cf5758-fa88-45a7-aa90-e56093a22659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0613fbb4-5397-4bc0-893f-30ae011babf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c9e0bd1b-89bd-4696-ad00-4428effb50da" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0613fbb4-5397-4bc0-893f-30ae011babf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3cad9229-0d12-4d83-a508-b56930dae9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c9e0bd1b-89bd-4696-ad00-4428effb50da" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3cad9229-0d12-4d83-a508-b56930dae9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d7e11a8c-1c26-450b-b23d-160bcca1cdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c9e0bd1b-89bd-4696-ad00-4428effb50da" xlink:to="loc_us-gaap_InventoryNet_d7e11a8c-1c26-450b-b23d-160bcca1cdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_dd31b429-de03-42f8-9cca-e4110b7e64b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ad3d8e72-5c79-4375-bd2e-017f845b900d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_dd31b429-de03-42f8-9cca-e4110b7e64b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ad3d8e72-5c79-4375-bd2e-017f845b900d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aa0b3d35-6a98-4372-b84d-8ca2cd79d051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_dd31b429-de03-42f8-9cca-e4110b7e64b3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aa0b3d35-6a98-4372-b84d-8ca2cd79d051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_940811da-4551-4a77-aa44-d810b6e0008f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_dd31b429-de03-42f8-9cca-e4110b7e64b3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_940811da-4551-4a77-aa44-d810b6e0008f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#LeasesNarrativeInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_edd47939-24e8-4786-8a7c-79bec07c8f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_0f186f8e-fd66-424d-801b-b99ffc7b34f6" xlink:href="nbix-20220930.xsd#nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edd47939-24e8-4786-8a7c-79bec07c8f61" xlink:to="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_0f186f8e-fd66-424d-801b-b99ffc7b34f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RentAbatementPeriod_6be49383-f7ac-4175-a3a5-aa7a25073aeb" xlink:href="nbix-20220930.xsd#nbix_RentAbatementPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edd47939-24e8-4786-8a7c-79bec07c8f61" xlink:to="loc_nbix_RentAbatementPeriod_6be49383-f7ac-4175-a3a5-aa7a25073aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_b347867e-0be1-4396-9d81-250d02add79e" xlink:href="nbix-20220930.xsd#nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edd47939-24e8-4786-8a7c-79bec07c8f61" xlink:to="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_b347867e-0be1-4396-9d81-250d02add79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AnnualRentEscalationPercentage_d5ffc647-c083-4be5-bb85-eec9f784f431" xlink:href="nbix-20220930.xsd#nbix_AnnualRentEscalationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edd47939-24e8-4786-8a7c-79bec07c8f61" xlink:to="loc_nbix_AnnualRentEscalationPercentage_d5ffc647-c083-4be5-bb85-eec9f784f431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ba4a0df5-0827-42d7-a2fc-58e2d879fcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edd47939-24e8-4786-8a7c-79bec07c8f61" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ba4a0df5-0827-42d7-a2fc-58e2d879fcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions_4fc8cfa0-424e-4511-8780-a183db7ffcc2" xlink:href="nbix-20220930.xsd#nbix_NumberOfRenewalOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edd47939-24e8-4786-8a7c-79bec07c8f61" xlink:to="loc_nbix_NumberOfRenewalOptions_4fc8cfa0-424e-4511-8780-a183db7ffcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_478c2a77-bc7b-4c2a-8189-4580b6340c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edd47939-24e8-4786-8a7c-79bec07c8f61" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_478c2a77-bc7b-4c2a-8189-4580b6340c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b19885d2-80ff-484d-9d5c-d907cad81ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edd47939-24e8-4786-8a7c-79bec07c8f61" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b19885d2-80ff-484d-9d5c-d907cad81ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#LeasesSupplementalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_60556363-3dd8-439c-a2d4-4dc5add95a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ce2ecb0d-0b04-4a27-a45b-84d7182519ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60556363-3dd8-439c-a2d4-4dc5add95a16" xlink:to="loc_us-gaap_OperatingLeaseCost_ce2ecb0d-0b04-4a27-a45b-84d7182519ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f53a26ba-1ba2-4b31-a841-2f98a9e91a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60556363-3dd8-439c-a2d4-4dc5add95a16" xlink:to="loc_us-gaap_OperatingLeasePayments_f53a26ba-1ba2-4b31-a841-2f98a9e91a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_af42ffb9-cfcd-4e78-b496-6cbcb8bf1b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60556363-3dd8-439c-a2d4-4dc5add95a16" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_af42ffb9-cfcd-4e78-b496-6cbcb8bf1b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4ce4a600-157b-4f1e-bb9b-7492b15303bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60556363-3dd8-439c-a2d4-4dc5add95a16" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4ce4a600-157b-4f1e-bb9b-7492b15303bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#LeasesLiabilityPaymentDueDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8533102a-9fc8-46a9-bc1c-1de6653cca2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8533102a-9fc8-46a9-bc1c-1de6653cca2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_49549389-fbb8-4f14-bc3d-23e465b73ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_49549389-fbb8-4f14-bc3d-23e465b73ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_08c599bb-abac-4464-945f-a25e50a920eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_08c599bb-abac-4464-945f-a25e50a920eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c78cd160-d524-413e-9e14-5dc4288a08d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c78cd160-d524-413e-9e14-5dc4288a08d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c3dc7033-70c5-49ed-af00-69d08fb6d64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c3dc7033-70c5-49ed-af00-69d08fb6d64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_0c073431-6b68-4916-b388-cfa9cec6f2ba" xlink:href="nbix-20220930.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_0c073431-6b68-4916-b388-cfa9cec6f2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79aa82eb-bd4e-487d-b152-5f2b6c1e7d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79aa82eb-bd4e-487d-b152-5f2b6c1e7d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5b04e2c8-e1de-47e9-b81d-5b7da594e079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5b04e2c8-e1de-47e9-b81d-5b7da594e079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_77d67143-6278-4d8b-955b-4aeba1928afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_OperatingLeaseLiability_77d67143-6278-4d8b-955b-4aeba1928afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5a6730b4-d618-49f4-9beb-589f4015ad02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5a6730b4-d618-49f4-9beb-589f4015ad02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_280c126f-40ad-4467-b84d-44d9ecb98ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_280c126f-40ad-4467-b84d-44d9ecb98ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_bc5c5d43-f863-4c44-8d17-3d2b33ea8e01" xlink:href="nbix-20220930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_bc5c5d43-f863-4c44-8d17-3d2b33ea8e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_aa298807-4073-4f0f-9641-67680bf158f9" xlink:href="nbix-20220930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_aa298807-4073-4f0f-9641-67680bf158f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_1fe4b94e-38aa-42bc-a168-98ab360a6a78" xlink:href="nbix-20220930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_1fe4b94e-38aa-42bc-a168-98ab360a6a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_38ecd668-36ff-47ea-be0d-2aa6ce2656bf" xlink:href="nbix-20220930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5b66940-9783-483e-829b-d7c0d608ec5e" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_38ecd668-36ff-47ea-be0d-2aa6ce2656bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1" xlink:type="simple" xlink:href="nbix-20220930.xsd#LeasesLiabilityPaymentDueDetails_1"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bb106612-c773-44dc-9a88-3123ea7e12d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb106612-c773-44dc-9a88-3123ea7e12d7" xlink:to="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_38009e25-1bc0-40ba-8174-60b80b5160be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_us-gaap_DebtInstrumentAxis_38009e25-1bc0-40ba-8174-60b80b5160be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_de1da4dd-68eb-4883-9127-41c9eec33893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_38009e25-1bc0-40ba-8174-60b80b5160be" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_de1da4dd-68eb-4883-9127-41c9eec33893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_a2c154de-d83c-44f6-b4be-656d780bf3e5" xlink:href="nbix-20220930.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_de1da4dd-68eb-4883-9127-41c9eec33893" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_a2c154de-d83c-44f6-b4be-656d780bf3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_33cf05ae-fd17-4d27-9ad9-6d990c0169c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_33cf05ae-fd17-4d27-9ad9-6d990c0169c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7232e6f6-1931-4dea-9c9f-9e65b3ccf270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_33cf05ae-fd17-4d27-9ad9-6d990c0169c3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7232e6f6-1931-4dea-9c9f-9e65b3ccf270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b3fcb09f-f719-44f0-8195-d68a8733c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7232e6f6-1931-4dea-9c9f-9e65b3ccf270" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b3fcb09f-f719-44f0-8195-d68a8733c32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d3ab2434-c665-4bd1-b6c8-8ea92f6c05d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d3ab2434-c665-4bd1-b6c8-8ea92f6c05d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_220b77ff-198e-43a3-b702-c23817bca14b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d3ab2434-c665-4bd1-b6c8-8ea92f6c05d0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_220b77ff-198e-43a3-b702-c23817bca14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1d2aa9fb-5b41-4a64-b693-2e6e9a208b21" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_220b77ff-198e-43a3-b702-c23817bca14b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1d2aa9fb-5b41-4a64-b693-2e6e9a208b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e308c6fd-f021-4356-acdd-1e4f1bbba151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e308c6fd-f021-4356-acdd-1e4f1bbba151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d4cbd44a-aff1-4aca-ab72-7acbcf4a8b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e308c6fd-f021-4356-acdd-1e4f1bbba151" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d4cbd44a-aff1-4aca-ab72-7acbcf4a8b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_2c6864ab-f044-41c8-8038-d2792ec0342b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d4cbd44a-aff1-4aca-ab72-7acbcf4a8b5a" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_2c6864ab-f044-41c8-8038-d2792ec0342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_08ed3473-988f-429c-9c3a-7b9405df0308" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_nbix_DebtInstrumentConversionAxis_08ed3473-988f-429c-9c3a-7b9405df0308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_5069e0f3-c7b5-4918-92ca-7bde2ebdce67" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionAxis_08ed3473-988f-429c-9c3a-7b9405df0308" xlink:to="loc_nbix_DebtInstrumentConversionDomain_5069e0f3-c7b5-4918-92ca-7bde2ebdce67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_46bb7428-e757-4acb-8ab3-644942c976a0" xlink:href="nbix-20220930.xsd#nbix_ConversionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_5069e0f3-c7b5-4918-92ca-7bde2ebdce67" xlink:to="loc_nbix_ConversionPeriodOneMember_46bb7428-e757-4acb-8ab3-644942c976a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_7c6a54d2-c30c-4c78-960a-66a1b21709d6" xlink:href="nbix-20220930.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_5069e0f3-c7b5-4918-92ca-7bde2ebdce67" xlink:to="loc_nbix_ConversionPeriodTwoMember_7c6a54d2-c30c-4c78-960a-66a1b21709d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b781ca9-cf10-460c-95a3-7a68d329c8ce" xlink:to="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7a4eb904-9431-4e74-8634-4fd662ea1439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7a4eb904-9431-4e74-8634-4fd662ea1439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_da8ede5d-bfbd-41ab-81a5-b995cc1dbf02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_da8ede5d-bfbd-41ab-81a5-b995cc1dbf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_82debecd-0033-4bdc-8b44-2b9604a2880a" xlink:href="nbix-20220930.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_82debecd-0033-4bdc-8b44-2b9604a2880a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_b89c2c82-30f8-43b1-aeb5-2649f7583366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_b89c2c82-30f8-43b1-aeb5-2649f7583366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_df39160e-9b20-451b-a2ad-fab48de549fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_df39160e-9b20-451b-a2ad-fab48de549fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_8b616dbb-38d4-435f-8756-44d2d4461603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentTerm_8b616dbb-38d4-435f-8756-44d2d4461603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e1f76351-9835-4f7f-9b32-7a995da446b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e1f76351-9835-4f7f-9b32-7a995da446b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_9d0b7980-33b9-4de6-95ac-8ce43bec8abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_9d0b7980-33b9-4de6-95ac-8ce43bec8abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_0ff9e36d-7f8f-434c-b8e6-fe60a4ba9c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_RepaymentsOfDebt_0ff9e36d-7f8f-434c-b8e6-fe60a4ba9c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_e3d84714-fe00-4248-9eab-f26e0c5c55dd" xlink:href="nbix-20220930.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_e3d84714-fe00-4248-9eab-f26e0c5c55dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_7767822f-260c-46c1-8b6c-5fe2276d2585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_7767822f-260c-46c1-8b6c-5fe2276d2585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_03ad7376-ce01-4855-85b9-984a62b8e51b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_03ad7376-ce01-4855-85b9-984a62b8e51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_1430b127-5279-4a2e-bc64-475be70b0dfb" xlink:href="nbix-20220930.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_1430b127-5279-4a2e-bc64-475be70b0dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8e975141-448f-40d8-acd5-8466db44f8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8e975141-448f-40d8-acd5-8466db44f8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_a83056ff-7434-4c29-b0e9-17c7be693905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_a83056ff-7434-4c29-b0e9-17c7be693905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_18c1ee7d-637a-4133-8bc9-b26cb0974307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_18c1ee7d-637a-4133-8bc9-b26cb0974307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_8b4a028f-6cbd-4db5-b74a-87e6501bcee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_8b4a028f-6cbd-4db5-b74a-87e6501bcee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3edcb4af-3650-44ec-b16a-1f0c682b9e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3edcb4af-3650-44ec-b16a-1f0c682b9e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_689de86f-abf2-4e34-b027-a76fb69561a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_689de86f-abf2-4e34-b027-a76fb69561a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36ecb4ff-ff7a-4af7-981f-929b8dd48608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36ecb4ff-ff7a-4af7-981f-929b8dd48608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_f0e022f7-663d-4ca7-ba9f-5becc3274352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_f0e022f7-663d-4ca7-ba9f-5becc3274352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9b4409d9-b7cf-4cd6-bd70-587b1d493bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9b4409d9-b7cf-4cd6-bd70-587b1d493bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_e08b3acd-1b44-44bb-9b61-28b11eea1d85" xlink:href="nbix-20220930.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_e08b3acd-1b44-44bb-9b61-28b11eea1d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7ce9ff63-c24c-4fa6-82d7-2f2c4352ea65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7ce9ff63-c24c-4fa6-82d7-2f2c4352ea65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_30ce4c94-b177-4043-9c6b-de559bc76990" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_30ce4c94-b177-4043-9c6b-de559bc76990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_bee2d3be-56b2-44ce-ada1-28a8eac19f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_SharePrice_bee2d3be-56b2-44ce-ada1-28a8eac19f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f7ac5095-2e6d-4392-a9e0-b8dc497e55e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f7ac5095-2e6d-4392-a9e0-b8dc497e55e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_4f4a87a5-7178-46dc-9f02-ed3b72585f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_4f4a87a5-7178-46dc-9f02-ed3b72585f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_984a70c1-e50b-4c61-b8ab-119f200eb294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_984a70c1-e50b-4c61-b8ab-119f200eb294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_5060267f-388c-4c6e-b8a1-16f2b25fbdc7" xlink:href="nbix-20220930.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_5060267f-388c-4c6e-b8a1-16f2b25fbdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_699342e5-041f-4b6a-82bf-a83fa7e4b64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10eca5d4-2c0d-401b-908b-cf609e3b581b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_699342e5-041f-4b6a-82bf-a83fa7e4b64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#ConvertibleSeniorNotes2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_45827f80-c92e-4b90-a7c7-ba9bc615923c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2723af42-a517-475e-9b31-8dfac1222850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45827f80-c92e-4b90-a7c7-ba9bc615923c" xlink:to="loc_us-gaap_DebtInstrumentTable_2723af42-a517-475e-9b31-8dfac1222850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_34028195-0d3e-493c-a603-c435e4efbfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2723af42-a517-475e-9b31-8dfac1222850" xlink:to="loc_us-gaap_DebtInstrumentAxis_34028195-0d3e-493c-a603-c435e4efbfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1e8f93a8-46f1-49f7-868f-b0083002df71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_34028195-0d3e-493c-a603-c435e4efbfa1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1e8f93a8-46f1-49f7-868f-b0083002df71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_9a05e9d4-75a4-411d-9f49-aecf072cb982" xlink:href="nbix-20220930.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1e8f93a8-46f1-49f7-868f-b0083002df71" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_9a05e9d4-75a4-411d-9f49-aecf072cb982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2723af42-a517-475e-9b31-8dfac1222850" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_386c073a-8b76-47c9-85a9-2df7bd41dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_386c073a-8b76-47c9-85a9-2df7bd41dc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_51d17679-699e-4a67-8b68-424a5548aefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_51d17679-699e-4a67-8b68-424a5548aefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_37032510-f803-4d6a-a5a4-e3895aec6af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_37032510-f803-4d6a-a5a4-e3895aec6af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_e3eaf26b-906f-4233-b936-f877be0f1aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_e3eaf26b-906f-4233-b936-f877be0f1aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_1d7a9b54-8027-46de-8f47-3c237a648af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_1d7a9b54-8027-46de-8f47-3c237a648af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3abfdf85-5d30-4ed5-9dc9-2f46722bd121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9661d0e0-c7e3-4c61-b6db-446fc385814f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3abfdf85-5d30-4ed5-9dc9-2f46722bd121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4573c987-a804-4ca2-8da9-77ba032ddc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest_851b11f0-a324-4e51-b2fb-c69eca36ab30" xlink:href="nbix-20220930.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4573c987-a804-4ca2-8da9-77ba032ddc84" xlink:to="loc_nbix_DebtInstrumentCouponInterest_851b11f0-a324-4e51-b2fb-c69eca36ab30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7798a801-5149-4c66-aa4e-812647ea2aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4573c987-a804-4ca2-8da9-77ba032ddc84" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7798a801-5149-4c66-aa4e-812647ea2aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b6d46c4a-1824-40d3-b849-80b34050f4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4573c987-a804-4ca2-8da9-77ba032ddc84" xlink:to="loc_us-gaap_InterestExpense_b6d46c4a-1824-40d3-b849-80b34050f4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#EarningsperShareScheduleofNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9119c6cf-1717-453a-beea-6938ba24bd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a507d986-dff1-4e7d-8e7c-280e97c13d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9119c6cf-1717-453a-beea-6938ba24bd15" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a507d986-dff1-4e7d-8e7c-280e97c13d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ea7a3d6-c599-4ce5-92d7-9eaa897e97dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a507d986-dff1-4e7d-8e7c-280e97c13d2d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ea7a3d6-c599-4ce5-92d7-9eaa897e97dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ac533ca-7928-4a53-bc8d-5c5d793be256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ea7a3d6-c599-4ce5-92d7-9eaa897e97dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ac533ca-7928-4a53-bc8d-5c5d793be256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5be1c69-3e5f-4673-a3bf-f2751c5abfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ac533ca-7928-4a53-bc8d-5c5d793be256" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5be1c69-3e5f-4673-a3bf-f2751c5abfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7d444b07-9744-46c5-bf86-b18fa299cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2ac533ca-7928-4a53-bc8d-5c5d793be256" xlink:to="loc_us-gaap_RestrictedStockMember_7d444b07-9744-46c5-bf86-b18fa299cf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca0093e9-567f-44a7-916f-73bfe53b4196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a507d986-dff1-4e7d-8e7c-280e97c13d2d" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca0093e9-567f-44a7-916f-73bfe53b4196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_edbe7ec0-7a3c-4dff-8000-6dce2d74519c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca0093e9-567f-44a7-916f-73bfe53b4196" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_edbe7ec0-7a3c-4dff-8000-6dce2d74519c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_ab4bba64-c881-43de-b2c0-a11648ebae3d" xlink:href="nbix-20220930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_edbe7ec0-7a3c-4dff-8000-6dce2d74519c" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_ab4bba64-c881-43de-b2c0-a11648ebae3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a507d986-dff1-4e7d-8e7c-280e97c13d2d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9e498ddb-4ad2-4d80-9c9b-317ef3ba4ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9e498ddb-4ad2-4d80-9c9b-317ef3ba4ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_31ade67e-f286-4e41-8049-cf51743789e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_31ade67e-f286-4e41-8049-cf51743789e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_553c4149-d77b-42a3-a088-fa7627d30945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_553c4149-d77b-42a3-a088-fa7627d30945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ac9e70d1-0d1d-4630-9e0f-e8622422d559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_553c4149-d77b-42a3-a088-fa7627d30945" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ac9e70d1-0d1d-4630-9e0f-e8622422d559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_80b6781b-5e2d-44c4-ba13-5528f99ad943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_80b6781b-5e2d-44c4-ba13-5528f99ad943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_2a203a7d-1c28-4967-99e8-6e738a19df14" xlink:href="nbix-20220930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_2a203a7d-1c28-4967-99e8-6e738a19df14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_467562e4-7212-4661-b21a-06bbbfb17061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0f7cb95c-9aa7-4bb9-a0a5-d1cf702aa1b2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_467562e4-7212-4661-b21a-06bbbfb17061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6d5b3635-aa71-445a-8d6c-4847c1812466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_EarningsPerShareBasic_6d5b3635-aa71-445a-8d6c-4847c1812466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3f78e90e-9dbd-43ac-99c9-dfaf698c2df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3f78e90e-9dbd-43ac-99c9-dfaf698c2df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_94674c6c-7abd-462b-b37d-f2bcb74ed3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_234e25b2-9bd8-4891-a4b8-43beb368d286" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_94674c6c-7abd-462b-b37d-f2bcb74ed3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nbix-20220930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_19e3c570-01ab-4c50-941b-d7b9b45c070b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_6fdc7eed-d601-40cb-a65d-2ab3d58bf746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_19e3c570-01ab-4c50-941b-d7b9b45c070b" xlink:to="loc_us-gaap_SubsequentEventTable_6fdc7eed-d601-40cb-a65d-2ab3d58bf746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5fe98ecb-f0eb-493a-8cf1-26e085f54f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6fdc7eed-d601-40cb-a65d-2ab3d58bf746" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5fe98ecb-f0eb-493a-8cf1-26e085f54f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e02733c1-7109-4411-9e22-40cda9e8d9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5fe98ecb-f0eb-493a-8cf1-26e085f54f5f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e02733c1-7109-4411-9e22-40cda9e8d9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3707c188-2582-47f2-98e8-bc53226fefac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e02733c1-7109-4411-9e22-40cda9e8d9fa" xlink:to="loc_us-gaap_SubsequentEventMember_3707c188-2582-47f2-98e8-bc53226fefac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e5e6b062-d1dd-438c-8289-160b22e6ae9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6fdc7eed-d601-40cb-a65d-2ab3d58bf746" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e5e6b062-d1dd-438c-8289-160b22e6ae9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af38eb92-d98c-4e48-b2a4-7039f0e33cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e5e6b062-d1dd-438c-8289-160b22e6ae9a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af38eb92-d98c-4e48-b2a4-7039f0e33cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember_27d9c42f-c6ef-476e-aca6-524cac991c31" xlink:href="nbix-20220930.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af38eb92-d98c-4e48-b2a4-7039f0e33cdc" xlink:to="loc_nbix_DiurnalGroupPlcMember_27d9c42f-c6ef-476e-aca6-524cac991c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_aa6b0637-e80f-4529-953d-58393c31048f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6fdc7eed-d601-40cb-a65d-2ab3d58bf746" xlink:to="loc_us-gaap_SubsequentEventLineItems_aa6b0637-e80f-4529-953d-58393c31048f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ab7f7b73-7299-4c4d-b8bf-489e352cab71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_aa6b0637-e80f-4529-953d-58393c31048f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ab7f7b73-7299-4c4d-b8bf-489e352cab71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>nbix-20220930_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20220930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MR:G++?KO,[ZZ=-["QGBEC:/'2X35&/LW**Y[OF]ZFI[;;NWH?=GBS]I;X>^
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M0+.< Y>UE3?-Z+\[GXK+PHXSIT7EN'QT?J[TM[2HE9[KEY7OU2=F?G)^Q?\
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MCO-6\(Z3<:??:A;?9)GDOIK@-'N#XP[$#D#D<UZ^,XCHXC!.C)/G:\K7^_\
M0_-N&_ W,\EXKI9G0JPEA:<W)7E+VG*TTDURVNKVOS:VOI>Q^;O_  4L_P"3
MVO&W^]:?^DD-7OV9O^"B_BK]ESX9_P#"+Z/H/A_4;/[7+>>=>&;S=TF,CY6
MP,>E??WQ4_X)^_"WXT>/=0\3>(=#NKS6-3*&XF34KB%7V(J+\JN%'RJ!P*Y[
M_AU;\%/^A:OO_!O=?_'*TAGN7SPL,/B(2ERI+96NE;N<>*\(>,\/Q!BLZR;$
MTJ3JSJ-/FES<LYN5FO9M7VOOKU/FW1?^"RWCS4];L;5_"GA%4NKF*%BIN,@,
MX4D?/[U^C=?/=E_P2X^"^GWL-Q%X;OEEMY%E0_VM='#*01_RT]17T)7@9KB,
M%5<?J<'&U[W^5NK\S]C\.\GXKP$:ZXHQ,:[ER\G*[VMS<U_<AO==]N@4445Y
M!^E'XK?\%D_@))\'?VU]5UB&$QZ3X^@36K9P/E\\ 17*9]=ZJY_Z["OEZWBR
MN#T/4&OW$_X*6?L:+^V3^SU-I^GK"OB[PZ[:EH,KG:'E"X>W9NRRK\N>@8(Q
M^[7XDW6DW6B:G<V-];7%G?64K6]S;SH4EMY$)5D=3R&!!!![U]AE6(56DEUC
MI_D?USX7\04\SRF%)O\ >T4HR76RTC+T:TOW3/I3]E3_ (*8>+/@'X37P?XE
MTVR^(WP]9?*.CZL0TMK'_<AE8,-@[1N&4?P[:]AM?B]^Q?\ $L_;+[2?&O@6
MZ<;I;.*.Y,(;N%\HRICZ;?H*^#@,"BN[ZJD^:FW%O?E=K^JV.;C3P-X+XJJ^
MWS?!1E4_F2C?\4UKU:2;ZMGZ-2?\%8OA7^RS\+&\*_!G0?$WB)D=Y+>36YI8
MK&V=NI_>,92N>=B*@)).0237P9\8OC)XD^/OQ"OO%/BS4Y=5UG4"-\C#;'"@
MSMBC0<)&N3A1ZDG)))YBD9@BEF(55&23VIT<)3I2<UK)[MZMGU'!_A]D?#%!
M8?)Z*@DE%/=J*VBMDEY127?8^@_^"6?P^F^(?[=O@5(U9H=$FFUBX8#A$AB;
M:3]9&C'U-87[;_CJ'X@_M>_$C5K:19;6;79X(74\.D.( 1['R\U]+_LH^&6_
MX)V_L/\ BKXQ>(8?L?CGX@6RZ;X7L9AMFBB<$PDJ>1N;,[ ](XDZ$XKX.DG9
MR6D=I)&)9G8Y9R>23[D\U&&E[3$3JK9+E7YO_(^#S:G'/<_J8BEK3HI4D^CD
MFY3:]&^6^SL+-<"-2S-A5&2?2OV:_P""4?P*G^!W['6A_;X6@U;Q7(^O7:,N
M&C$P40H?<0K'D=B37YW_ /!-+]BZX_:X^-D-WJ5J_P#P@OA:9+G5Y6&$O9!\
MT=FI[E^"^.B9Z%ES^T$:+$BJJJJJ,  8 %>3GV,32P\?5_HOZ\CX/Q+QU'#0
MAE%!^]I*?EI[L?76[_[=[CJ\#_X*AZE<Z/\ L!_$ZZL[BXL[F'2@T<T$K121
MGSH^0RD$?@:]\KY]_P""J?/_  3W^*7_ &"1_P"CHJ^9/Q\\F^ /_!+'P!\3
M?@3X+\1ZEXF^*G]I:_H5EJ-UY7BZZ2/S98$D?:N>!N8X'850;3/%_P#P3=_:
M\^&'ANQ\<>)?&OPM^*U^^BC3/$%V;R[T:Z&T(\4I&=N9$.!@$!P03M:M#]G?
MXX?M,Z5^S_X'M=#^!OA75-%M] L8K"]E\90P/=P+;H(Y6C*Y0LH#%3T)Q7,_
M"GQ1KGQU_P""@OA>3]HBWF\"^*_"\4UQX#\)1VV=)O92!YERM[O9;B8!00@V
MX**1TVD [[_@JAK5]I'Q&_9R6SOKZS6Z^(EI%.MO</$)T)3*N%(W+['(KV[]
MLG]J?2OV/?@3J7C#4H&O[E&6STS3T.)-2O),B*$'!P."S'!PJL<$X!\)_P""
ML'_)2?V:_P#LH]I_-*A_X*5HOB3]L7]ECP_J"B31+KQ3/>31OS'--%Y!C!'0
M]2/^!&@!G@;_ ()_^.OVK])A\5?M">/O%BWFJ*+B#P=X?OFTW3=%1L%8GV9+
MR <-W!ZLW6KOB;_@EA>_!^QDUKX$_$OQQX+\468\V&RU+57U#2=1(Y$4T<@.
M W3<=P']VOL:B@#P?]@O]K^Y_:E\":Q8^)-+7P]\1/ ]Z=)\3Z2,A8+A<@2H
M"2?+?:V!DX*L,D ,?!?"OA36O^"HW[1_Q.C\3>+O$F@_"OX;:RWAZP\/:'>M
M8MJL\>X//<2+\Q'&0/1@!MVDMT7PHC7PM_P6Y^)5GIJA;77O ]K?ZBB#"BX1
MK=5<C^\5[_[9]:L>/?V1OB]^S/\ M">*OB1\!K[P_K&F^.+@7NO^#M<<P1SW
M/):6"48"DLS'DK@N1\PP% ,+XV?\$YO$O[+6A+XX_9O\2>-+?Q-H\L<D_AB\
MU9[ZQUZ'>H:,K,V-P!S\S8(!P5;!KZ<\??M'6?P8_9@F^)'C;3[G01I^D17]
M_ICLK3P7#JO^B@@D,YE81@YP20>E>(:+_P %4&^&WB:QT7XX?#/Q5\)+B_D$
M$.JSXO\ 1I9._P#I$8&T?@V!R2!DUB_\%J=077/@%\.=+\Y)-"\2>.M,@O94
M;='+ 5D8<C@J>#Z< T 9_P *_P!F'XD?\%"]!M_'GQG\9>)O"OA775%UHG@?
MPY>-81P6K<Q/<R@;I'92#@\X(.5SL7HO$/\ P2&T+P?8R:A\*?B%\1OAYXIM
MU+6MTNN37EI(XZ+-$YRRD\'!Z=CTKZ]M[>.TMXXHD6..-0B(HPJ@<  >@I]
M'S-^P!^UOXJ^*^K^*OAK\4-/33?BA\/91%?2PQ%+;6;<G"W4? 7NN0O!#HP
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M9SRTLC=7D8\LQZGVP*ZJBBOGI2<G=[GXQ6K5*U256JW*4G=MZMM[ML*^??\
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M*/C9_P $]O@_^T5X]F\3^,O!\.M:Y<0QV\ERU]<Q%DC!"#;'(J\ GM7*V_\
MP2*_9XM+F.:/X=6JR0NLB'^T[WAE((/^N]10!Q7_  49_P"3TOV3_P#L:[O^
M5M7UAX^\":3\4/!.J^'==LH=0T?6K62SO+:4966-P01['G((Y! (Y%8OQ%^
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MY('-4?CO^PK\)?VEM3&H>,_ ^CZKJB@+]O0-;79 Z9EB*NV.VXG%<_\ "O\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440778464016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,134,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440778612672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 212.2<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities available-for-sale</a></td>
<td class="nump">587.2<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">301.2<span></span>
</td>
<td class="nump">185.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">67.9<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,205.5<span></span>
</td>
<td class="nump">972.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">319.4<span></span>
</td>
<td class="nump">315.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Debt securities available-for-sale</a></td>
<td class="nump">362.6<span></span>
</td>
<td class="nump">560.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">89.6<span></span>
</td>
<td class="nump">97.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">94.9<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">60.9<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,143.4<span></span>
</td>
<td class="nump">2,072.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">297.8<span></span>
</td>
<td class="nump">225.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">169.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">18.1<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">485.1<span></span>
</td>
<td class="nump">245.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">335.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">96.6<span></span>
</td>
<td class="nump">105.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">17.1<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">598.8<span></span>
</td>
<td class="nump">698.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 220.0 million shares authorized; 96.1 million and 94.9 million shares issued and outstanding, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,054.3<span></span>
</td>
<td class="nump">2,011.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(495.8)<span></span>
</td>
<td class="num">(635.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,544.6<span></span>
</td>
<td class="nump">1,374.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,143.4<span></span>
</td>
<td class="nump">$ 2,072.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440778432208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">220.0<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">96.1<span></span>
</td>
<td class="nump">94.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">96.1<span></span>
</td>
<td class="nump">94.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440776868608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income and Comprehensive Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 387.9<span></span>
</td>
<td class="nump">$ 296.0<span></span>
</td>
<td class="nump">$ 1,076.7<span></span>
</td>
<td class="nump">$ 821.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">107.7<span></span>
</td>
<td class="nump">92.7<span></span>
</td>
<td class="nump">345.8<span></span>
</td>
<td class="nump">240.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">186.3<span></span>
</td>
<td class="nump">154.6<span></span>
</td>
<td class="nump">569.8<span></span>
</td>
<td class="nump">426.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">300.1<span></span>
</td>
<td class="nump">251.5<span></span>
</td>
<td class="nump">931.1<span></span>
</td>
<td class="nump">682.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">87.8<span></span>
</td>
<td class="nump">44.5<span></span>
</td>
<td class="nump">145.6<span></span>
</td>
<td class="nump">138.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
<td class="num">(19.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(70.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_InvestmentIncomeAndOtherNet', window );">Investment income and other, net</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(49.6)<span></span>
</td>
<td class="num">(23.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
<td class="nump">96.0<span></span>
</td>
<td class="nump">115.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">68.5<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">65.5<span></span>
</td>
<td class="nump">96.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(12.3)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 66.7<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="nump">$ 53.2<span></span>
</td>
<td class="nump">$ 95.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">95.8<span></span>
</td>
<td class="nump">94.7<span></span>
</td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">94.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">98.3<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 379.3<span></span>
</td>
<td class="nump">$ 288.8<span></span>
</td>
<td class="nump">$ 1,036.3<span></span>
</td>
<td class="nump">$ 786.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 34.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_InvestmentIncomeAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment income and other net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_InvestmentIncomeAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440773898896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,126.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,849.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="num">$ (725.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">96.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">98.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">1,346.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,974.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(628.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2021</a></td>
<td class="nump">1,279.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,929.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(651.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">37.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">1,346.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,974.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(628.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">1,374.0<span></span>
</td>
<td class="num">$ (32.3)<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">2,011.4<span></span>
</td>
<td class="num">$ (106.8)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(635.8)<span></span>
</td>
<td class="nump">$ 74.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">65.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(12.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">129.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2022</a></td>
<td class="nump">1,544.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">2,054.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(495.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2022</a></td>
<td class="nump">1,423.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,999.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="num">(564.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">68.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">43.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 1,544.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 2,054.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14.0)<span></span>
</td>
<td class="num">$ (495.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440773849616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 65.5<span></span>
</td>
<td class="nump">$ 96.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">129.6<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Change in fair value of equity security investments</a></td>
<td class="num">(23.6)<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(115.7)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(6.5)<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">77.0<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(20.7)<span></span>
</td>
<td class="num">(21.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="nump">196.4<span></span>
</td>
<td class="nump">252.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities available-for-sale</a></td>
<td class="num">(387.9)<span></span>
</td>
<td class="num">(658.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of debt securities available-for-sale</a></td>
<td class="nump">348.8<span></span>
</td>
<td class="nump">523.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchases of equity securities</a></td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(14.7)<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash flows from investing activities</a></td>
<td class="num">(61.5)<span></span>
</td>
<td class="num">(153.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuances of common stock under benefit plans</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repurchase of convertible senior notes</a></td>
<td class="num">(279.0)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash flows from financing activities</a></td>
<td class="num">(258.9)<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(124.0)<span></span>
</td>
<td class="nump">124.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">220.0<span></span>
</td>
<td class="nump">314.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash capital expenditures</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired through operating leases</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779659776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">Organization and Significant Accounting Policies<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMTc2OQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjMyOQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjU3MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjg5NA_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440782635920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heptares Therapeutics Limited, or Heptares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which compounds we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase II clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing and commercialization costs of any collaboration product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Heptares $100.0 million upfront, which, including certain transaction-related costs, was expensed as in-process research and development, or IPR&amp;D, in 2021. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the United States Food and Drug Administration's, or FDA's, acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $30.0 million, which was expensed as research and development, or R&amp;D, in the second quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $2.6 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#8217; written notice to Heptares during the research collaboration term and upon 90 days&#8217; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early to mid-stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the 4 non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development and commercialization costs of any royalty-bearing product. With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase II clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical trial for such compound.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $120.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in July 2022, a milestone of $5.0 million was expensed as R&amp;D in the third quarter of 2022, which we expect to pay to Takeda in the fourth quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or in one or more (but not all) of the United States, Japan, the European Union and the United Kingdom, or, collectively, the major markets, upon six months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#8217; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Idorsia $45.0 million upfront, which was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Xenon $50.0 million upfront, including a purchase of approximately 1.4 million shares of Xenon common stock (at $14.196 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $14.1 million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $36.2 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the European Union&#8217;s approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021, we paid Xenon a regulatory milestone of $10.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $19.9755 per share). The purchased shares were recorded at a fair value of $4.6 million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $5.4 million of the milestone payment was expensed as R&amp;D in 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in January 2022, we paid Xenon a regulatory milestone of $15.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $31.855 per share). The purchased shares were recorded at a fair value of $7.7 million after considering Xenon&#8217;s stock price on the measurement date. The remaining $7.3 million of the milestone payment was expensed as R&amp;D in the first quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the United States and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#8217; written notice to Xenon, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Voyager, pursuant to which we acquired certain rights to develop and commercialize the NBIb-1817 for Parkinson&#8217;s disease program, Friedreich&#8217;s ataxia program and two undisclosed programs. We are responsible for all development costs of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program, which became effective August 2, 2021. The termination did not apply to any program other than the NBIb-1817 for Parkinson&#8217;s disease program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Voyager $165.0 million upfront, including a purchase of approximately 4.2 million shares of Voyager common stock (at $11.9625 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $54.7 million after considering Voyager&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $113.1 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019. In addition, we paid Voyager $5.0 million upfront, which was expensed as IPR&amp;D in 2019, to acquire the rights outside the United States to the Friedreich&#8217;s ataxia program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $1.3 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement. We may terminate the agreement upon 180 days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired the United States and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(opicapone) from BIAL in 2017, and launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We are responsible for all commercialization costs of ONGENTYS in the United States and Canada and rely on BIAL for the commercial supply of ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, BIAL may be entitled to receive potential future payments of up to $75.0 million upon the achievement of certain event-based milestones. In addition, with respect to ONGENTYS, in the event we fail to meet certain minimum sales requirements for a particular year in comparison to our annual sales forecast for such year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year. Further, upon our written request to BIAL 12 months prior to the estimated expiration of the term of a licensed product, we will negotiate the continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is no longer supplying such licensed product, BIAL would be entitled to receive a low double-digit royalty on our future quarterly net sales of such licensed product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until a generic product with respect to such licensed product is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement upon nine months&#8217; written notice to BIAL. BIAL may terminate the agreement in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#8217;s insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In December 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we agreed to supply MTPC with valbenazine drug product for commercial use in Japan and other select Asian markets. MTPC is responsible for all development, manufacturing and commercialization costs of valbenazine in such markets.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, MTPC launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan for the treatment of tardive dyskinesia. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $20.0 million in the second quarter of 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#8217;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in the second quarter of 2022. In addition, we receive royalties at tiered percentage rates on MTPC net sales of DYSVAL.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $30.0 million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of 10 years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the United States for the treatment of moderate to severe pain associated with endometriosis. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $6.1&#160;million and $15.5&#160;million, respectively, for the three and nine months ended September&#160;30, 2022 and $5.9 million and $16.3 million, respectively, for the three and nine months ended September&#160;30, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $366.0 million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of 10 years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440861446000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Debt Securities</a></td>
<td class="text">Debt Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, our security portfolio consisted of 193 debt securities available-for-sale, including 183 such securities that were in an unrealized loss position but of high credit quality. Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of September&#160;30, 2022 or December&#160;31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of September&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $3.9 million and $2.2 million, respectively, as of September&#160;30, 2022 and December&#160;31, 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the nine months ended September&#160;30, 2022 or 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779858624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of investments, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,264.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">949.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) included in earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440780478080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440866335632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_RestrictedCashTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted Cash<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_RestrictedCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_RestrictedCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779858624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters. This lease has not commenced for accounting purposes. Under the terms of the lease, on a building-by-building basis, base rent will be subject to a 10-month rent abatement period following the respective lease commencement date, which dates will be determined in the future based upon achievement of substantial completion of construction with respect to each such building in the condition suitable for the installation of our furniture, fixtures, and equipment, and on which date we will record a lease liability, corresponding right-of-use asset, and begin lease expense recognition with respect to each such building. After the rent abatement period, monthly base rent will be $6 per square foot, subject to annual escalations of 3% during the initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTY0OTI2NzQ0NDE5NQ_53c700d8-36e0-4b90-b6dc-fbf8018a13aa">13.6-year</span> lease term, which term we have the option to renew for two additional terms of five years each.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our operating leases, in lieu of a cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $7.8 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information for operating leases that have commenced.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate non-cancelable future minimum lease payments under operating leases as of September&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 (3 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities included in other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440780478080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance in effect at the time of issuance, we were required to separately account for the liability and equity components of the 2024 Notes. The initial carrying value of the liability component of $368.3 million was calculated using a 7.50% assumed borrowing rate, which reflected the market interest rate for a similar non-convertible instrument at the date of issuance. The equity component of $149.2 million, which was treated as a discount on the liability component and amortized over the seven-year term of the 2024 Notes using the effective interest rate method, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and recorded as an increase to additional paid-in capital on the issuance date. In addition, we allocated transaction costs of $14.7 million related to the issuance of the 2024 Notes to the liability and equity components based on their relative values on the issuance date. Transaction costs attributable to the liability component were being amortized over the seven-year term of the 2024 Notes using the effective interest rate method, while transaction costs attributable to the equity component were recorded as a reduction to additional paid-in capital on the issuance date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7 million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3 million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recorded as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4 million at settlement was recognized as a reduction to the 2024 Notes and resulted in an $18.4 million loss on extinguishment, which we recognized in the fourth quarter of 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjY4MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million, and reduced the accumulated deficit by $74.5 million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment, which resulted in the recognition of a $70.0 million loss on extinguishment in the second quarter of 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of September&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2024 Notes in cash upon conversion and to settle any conversion premium, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $1,000 principal amount and equivalent to an initial conversion price of approximately $75.92 per share, reflecting a conversion premium of approximately 42.5% above the closing price of $53.28 per share of our common stock on April&#160;26, 2017.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of September&#160;30, 2022) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of September&#160;30, 2022) on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;five business-day period immediately after any&#160;five&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the conditional conversion feature described under (i) above was triggered as of September 30, 2022, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on October 3, 2022, and ending at the close of business on December 30, 2022. Accordingly, the 2024 Notes have been classified as a current liability as of September 30, 2022. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes in cash and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440778371648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779858624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn November 1, 2022, we acquired Diurnal Group plc in an all-cash transaction, for an aggregate value of approximately &#163;48.3&#160;million GBP, or approximately $56&#160;million USD. We believe the transaction presents an opportunity to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders. We are currently in the process of finalizing the accounting for this transaction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440781772176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMTc2OQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjMyOQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjU3MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjg5NA_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">ASU 2020-06</span> on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779751472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of September&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779735040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Investments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of investments, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,264.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">949.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) included in earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779748448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779843280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of reconciliation of cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779658560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Description of Operating Lease</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information for operating leases that have commenced.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate non-cancelable future minimum lease payments under operating leases as of September&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 (3 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities included in other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779722688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Notes Net of Discount and Deferred Financing Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of September&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440781798064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440776604496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(635.8)<span></span>
</td>
<td class="num">$ (495.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">42.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">106.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440771744288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">387.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,076.7<span></span>
</td>
<td class="nump">821.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Heptares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Xenon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.9755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities, stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Xenon | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Voyager</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 113.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.9625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Voyager | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | BIAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | MTPC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | MTPC | Minimum | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="nump">366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie | Minimum | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Royalty | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PatentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PatentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePaymentReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payment receipts under a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePaymentReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments under a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares sold by the collaboration partner per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SaleOfStockNumberOfSharesSoldInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_UpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments made under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_UpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_HeptaresTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_HeptaresTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_AbbVieIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_AbbVieIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440771658672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">$ 595.6<span></span>
</td>
<td class="nump">$ 370.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">587.2<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">373.1<span></span>
</td>
<td class="nump">563.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Unrealized gain, noncurrent</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Unrealized loss, noncurrent</a></td>
<td class="num">(10.5)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent', window );">Fair value, noncurrent</a></td>
<td class="nump">362.6<span></span>
</td>
<td class="nump">560.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">97.5<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">260.5<span></span>
</td>
<td class="nump">128.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">257.3<span></span>
</td>
<td class="nump">128.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">270.8<span></span>
</td>
<td class="nump">358.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Unrealized gain, noncurrent</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Unrealized loss, noncurrent</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent', window );">Fair value, noncurrent</a></td>
<td class="nump">264.6<span></span>
</td>
<td class="nump">357.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">237.2<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">232.4<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">102.3<span></span>
</td>
<td class="nump">204.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Unrealized gain, noncurrent</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Unrealized loss, noncurrent</a></td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent', window );">Fair value, noncurrent</a></td>
<td class="nump">$ 98.0<span></span>
</td>
<td class="nump">$ 203.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSaleFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440776870768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions', window );">Number of debt securities available for sale | security</a></td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of debt securities available for sale in unrealized loss position | security</a></td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivables | $</a></td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff', window );">Accrued interest receivables write-off | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale position number of positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440776699344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">$ 52.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">52.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized Loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">251.1<span></span>
</td>
<td class="nump">$ 428.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">263.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="num">(4.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">514.8<span></span>
</td>
<td class="nump">428.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized Loss</a></td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">235.0<span></span>
</td>
<td class="nump">230.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">(6.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">92.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">327.9<span></span>
</td>
<td class="nump">230.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized Loss</a></td>
<td class="num">$ (9.1)<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440773776512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">$ 1,264.7<span></span>
</td>
<td class="nump">$ 1,338.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">314.9<span></span>
</td>
<td class="nump">396.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">949.8<span></span>
</td>
<td class="nump">931.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">521.9<span></span>
</td>
<td class="nump">485.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">521.9<span></span>
</td>
<td class="nump">485.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">330.4<span></span>
</td>
<td class="nump">240.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">330.4<span></span>
</td>
<td class="nump">240.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">94.9<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">94.9<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">212.2<span></span>
</td>
<td class="nump">340.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">212.2<span></span>
</td>
<td class="nump">340.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">97.5<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">97.5<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440774262752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail) - Level 3 - Fair Value, Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at beginning of period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">38.9<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Unrealized gain (loss) included in earnings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at end of period</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 35.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779022224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="nump">$ 30.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440779023088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 212.2<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
<td class="nump">$ 311.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in other assets</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440773787584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative Information (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>USD ($) </div>
<div>renewalOption</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding', window );">New campus lease lessee option term for construction of fifth building</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_RentAbatementPeriod', window );">New campus rent abatement period</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot', window );">New campus lease monthly base rent per square foot</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AnnualRentEscalationPercentage', window );">New campus lease annual rent escalation percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">New campus lease term</a></td>
<td class="text">13 years 7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NumberOfRenewalOptions', window );">New campus lease number of renewal options | renewalOption</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">New campus lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash in connection with operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AnnualRentEscalationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Rent Escalation Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AnnualRentEscalationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Monthly Base Rent Per Square Foot</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of term of lessee's option for the construction of a fifth building under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of renewal options under the terms of the lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_RentAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent Abatement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_RentAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440780899440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440778949312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Liability, Payment, Due (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (3 months remaining)</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">70.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">141.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less accreted interest</a></td>
<td class="nump">27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">113.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current operating lease liabilities included in other current liabilities</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">96.6<span></span>
</td>
<td class="nump">$ 105.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2024</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025</a></td>
<td class="nump">33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026</a></td>
<td class="nump">41.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter</a></td>
<td class="nump">$ 479.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440776585632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(635,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(495,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(495,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">42,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="nump">106,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">381,200,000<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
<td class="nump">170,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_CarryingAmountOfLiabilityComponentUponIssuance', window );">Carrying amount of the liability component upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Convertible senior note assumed borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Convertible senior note carrying value of the equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Convertible senior notes term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Transaction cost related to issuance of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Aggregate repurchase price paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment', window );">Fair value of the liability component immediately before extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of repurchased convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_CarryingAmountOfLiabilityComponentAtSettlement', window );">Carrying amount of the liability component at settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible senior notes convertible in to shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0131711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible senior notes conversion price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtInstrumentConvertibleConversionPremium', window );">Convertible senior notes premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price of common stock (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Convertible senior notes redemption rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Conversion Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive common stock trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger', window );">Common stock price trigger (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Conversion Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PrincipalAmountOnConversionRate', window );">Principal amount on conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice', window );">Minimum percentage of common stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_CarryingAmountOfLiabilityComponentAtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the liability component at settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_CarryingAmountOfLiabilityComponentAtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_CarryingAmountOfLiabilityComponentUponIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability component upon issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_CarryingAmountOfLiabilityComponentUponIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConvertibleConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConvertibleConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the liability component immediately before extinguishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PrincipalAmountOnConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount on conversion rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PrincipalAmountOnConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440778954480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - 2024 Notes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Net Carrying Amount</a></td>
<td class="nump">$ 169,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Net Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">170,400,000<span></span>
</td>
<td class="nump">381,200,000<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Unamortized Debt, Discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(43,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized Debt, Issuance Costs</a></td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="num">(2,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Net Carrying Amount</a></td>
<td class="nump">169,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value, Amount</a></td>
<td class="nump">$ 238,300,000<span></span>
</td>
<td class="nump">$ 464,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440778306592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtInstrumentCouponInterest', window );">Coupon interest</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentCouponInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Coupon Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentCouponInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440776613200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Schedule of Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income - basic</a></td>
<td class="nump">$ 68.5<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="nump">$ 65.5<span></span>
</td>
<td class="nump">$ 96.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income - diluted</a></td>
<td class="nump">$ 68.5<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="nump">$ 65.5<span></span>
</td>
<td class="nump">$ 96.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">95.8<span></span>
</td>
<td class="nump">94.7<span></span>
</td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">94.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">98.3<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in USD per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted (in USD per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares)</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities', window );">2024 Notes (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140440773848256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Nov. 01, 2022<br> &#163; in Millions, $ in Millions</strong></div></th>
<th class="th"><div>GBP (&#163;)</div></th>
<th class="th"><div>USD ($)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Diurnal Group plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Aggregate value of all cash transaction</a></td>
<td class="nump">&#163; 48.3<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>nbix-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nbix="http://www.neurocrine.com/20220930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20220930.xsd" xlink:type="simple"/>
    <context id="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if918665a526048bba62c5c916d1da24e_I20221028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-10-28</instant>
        </period>
    </context>
    <context id="i7f42127857b54a13aa343398bb2d541d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i63a36f8809514653892aaae462d392cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe44f84f3acc41678a991f68f4e0a4a0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c9497c79ced4aeaa7f1db18e0399893_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic95f1ad2e17045e4abe097728c7590d4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i19314b84529d46f99e5c461ac31afdc4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if7a0669f73bd42779f23c7b8c8b7807b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9814ecaf809a4416a7ffd9d41c7694f6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i401123ce4dd945a38b707d60c1882890_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibb49c8d270504eda9057c294777b76eb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ed395fe9cc1449bb7d939fd514068ba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia07d586d340f45f99771c0d7a421770b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib88cff710aa64f0db32eff49fd8b81ef_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8c6f9adf4a4f46229cbde98aedf63b35_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i44069ab866fd423cb33d0c69f2a3f908_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i324159b7704844d0ab9d10da3decc855_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6beacf8156fb48ea965024414adc5ab5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5825bdfeea8640ffa28b46a703daa81b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iba66c4f94fa34d49b8f74b725073fd80_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaaef5673cc82499992433df9a4170336_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4ec663ae2974473c932ec901d2279e45_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i14a6e7bfb09240da8df57c0b10f74e22_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6f55b27df0414697becfc3c88fdb3675_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie0d7237003994ddb914ef3572076e2d3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia1fb24b2c68e4e50a0786e67d741db84_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i031a6b6ce49a43efb4f5777c5cd53c63_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i78153a6965184d7c88703cc188594611_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9c7f36f1d6364a3ba48295705c5a6577_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ife1366392be644cdb1fdf15d68cc7c12_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i96745670dede4bf7b3baf9f45f84ddbe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i858eddcb9f684bed940a6fbd8a8477ad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9e66c6f25b84530a5fb28be5eae8546_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia5ae523d047d497ba5e50594b29cf3b2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i516ff9b620b94979821df492ffccf0d2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9adb983cdb174ff39bb4b981e7ce9650_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iedd9ce6e56184b7999d247c1dc25eabe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2d4f0a2cea8441e0b026692719475b64_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i72d0b3550c5e44f5be3613d00e3a1b13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65ee8e9be30b406da6b582097952f9d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b7d3cbd4ae44165b3954e2ed6ee365b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10242909a1074444b3e2545c393d3f32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9a3b29344c14dbe9ec425f46e47ae87_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i23c65102bd2e4adeb5ea816771ce177b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c1ded1a54114c989385f9d44f2fea9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifde886332b6d4f1ab3402bed3a5fc8fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i366ff930ea93441a960a632e36fee44b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38341b51bfd94d92bcf639e9e87abf56_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i567085fe5058473dabeb8fb3a2603864_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idc1223dc268f4291a7665d63b9b7a94b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic84e58872dfd4571bebfb56f5496b527_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id74d31171db5404580903e96807daec4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6fe17b0ffe694754b8dd32868036e3e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bac18c0efcf4ec5a02f7ce6edaaab4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e7fbc21c2904c9b893e0cbd3313df98_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide286c9ed2ab4936a7d1621b6a95fce8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie58820f78b294bfe91aa7c6ad11e3cd8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i70caea784a864bd89ac94bdd2e53e6b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="i4d3b20629a004abe8438fa321eae8513_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5df8b3da765848b7b1e13148e4a5f0ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic54ce1de757a4c65bf42b4362a4de196_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iee8c3876d62e426f8ca317331158e084_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i94db63ec77c8436ab4bc0f734a8773d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6afab7bf36d74de2bbf8ef61c544135a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1f569faa178b45c18012ecef36524f9f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i62cff9c5fde445f89dc7148fdddd5d1f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf4f4cb73b3749bbbf050c1a913538e0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i229c41a0bfa841e1a21acad7a1d13142_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7447780aa7a4acd84f15c1df4fd1ada_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i739f24694cca4f96aa40688cb5643a85_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i672c8742c0424d8e9899e8cf653e3879_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i436998f220e64b2d85633913fc679dd2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieca44e6f568f4cce81a0f0b62a9e6ed8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1fc719c24174081baf340c8e1ed9345_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic054d101780b4681bad0f8685e5eb620_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i651b70e3e4884c87b5c8f6c691e732c9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i14108dce2bd342338c0eaada7d66ed9f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id5c2d75942864117893c1167135a171c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb6ee5ada95b4566aa1c9a8b49eccd5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc36a091f0fb425ca083c03b1d5b9108_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i22270e6ff4f141aea1c8f066676c3e93_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9baa790a842c4e00b5d7aea97ed51955_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i704ab482b22e45fa8b591f730cc65111_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0635b37952e44f7286d405737fc817b2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4243abfeabbc4f8fb0fcb634ef8fc677_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iac2a51b5f62848819ec910c25d7f2308_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2d2fb655446647d285e1b13940b27b9a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iae6fe2cc66814ab7bb20abd508f23227_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c2e568d37774c2babc5f26a9b4a305b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5cf793309e7a403c9867c00418ded9b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i966fced94cdb4f9b9b690c806b6192f2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8edd28eddf194035b1e8ecf4e46d867d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if991653053864b2a904fed8d29ebc17e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if53c84fbe1cd4494b369d17f941323c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76a54806004342ca99ad41187b5f18ff_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbf2dc2b8842457aab96f17adc6e8854_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i33f86e14bc93493b8cdc4da223c47077_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4839e374f144412a9f7b6a7f7818e610_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8b0b098d67fd4b36b7ad36c659fff363_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id6de012629174382b73ae25ee390d53d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5dd7f53c0917469fb5aa137f42fa9641_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id71a72a0204343a2ba932bbdf699fd15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41a60cfe6cb248f28f728ecc7b0d9dac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3554cf0de1b74187a218d6f9def209e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i595e5cac95e64a078c1b2e3ba8fcad00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1d72cc605f044c39df6e8ac34e59455_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i092271effac144f483e64869aea849d1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2ca50849466f4f388fa755ae299a561f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibf1638a41bfc4a4188eb4b991772a3c5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i180afdb708d547789b9d9c373554692d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieca3d6e4dcde4876b83e7398f46fed0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i222b84b6200c4687ae6fad5eb6c114eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02faf276f4724aa4ad454f7424494fa8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fd7fbc215c547fe9905956a7d3b2d0b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i427d6d88fbf5403a90f978999cec31c1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6f1de29717fb412b8d0f3ede241f8bb3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4f0287a3f58248fd9c60960a29b9c6d7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2455f9d7a9344e94b5e44642abae8dec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7b9e17b5b754d4086db11dcfe954416_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c322608454a431fb44e4870cfcf20e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e7878b6282f4161a51f2ecb11e6ee6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icad8bd51420d47599a0bbb9a64c2debc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3c20de1be0b54d57a763e3ccf1e3ffd2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia4870a12f1c34345966751447c52154e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib0223e03f957402ba98f263591110328_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a1df5c5dc8a46219d57553226f03b5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebc376687d434b2f95f43d1c9e9eca69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6810cd7a4b24c838b72ecadd02e9522_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9d07e5ef45644257bbcfa85ae04c08a9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i36692663da7d47208855243ce31dfad4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i80aeccc4b4694ebd8b20044eeae2adc2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0dedc56fd35f4871bf88c063a6ff6849_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd7fa1d696ab44f8be8a258fb5120a82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4207c67f0d44accbd49d0bd44c9afb5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ife8bf998110245f8b80ff377a8f82542_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie08641e1abc544caad6433c0c27d62c6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i70f76ef824ec4b4c9f74fdf2aca12a07_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic1f93fe5331c425f98f7d5e731495d7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7146d8e9d0640aa93ae219f21de2a1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc1594a5b6774dc8b404800132ae9d9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bf809ef29d94cf38cf7aaf31b95dbc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ca0198fc8364c69827b4bcd85bfda5c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3c36d96155624c52aa5e2d8d06ca58f6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i99f5e98291034c5ebdd1aaa8e86213e7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic534f177a08b41618f86a8447e6aa13b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22d1bdea9d1346bc84bff185b75f4d8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16add8cd888840ba965b71e41d99d856_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3482a00ad8dd4f2e803c923b8f328ea5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i292aeff53ad84fc0ba0c70a3a9c01173_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibbd2750ce3bd433caa60ae155d4dae98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie49ac4b8f7504f74ae784614035b01ea_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i252ec6df430b4181b19dba818761eefa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b89d380f2a64113845905298e656b37_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie39d31443ce649c9b07f69bd9027d2fc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i32c048dc598a4c8d8d72fe8f04ccf8a4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i66dcf8a5e7154e9fadd29e9e4be560b2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i215cbb49fff34b958a3ad2dc5ab67b77_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifbf97cbe7b5a4eeca45e05f5d6e775d3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i88e35fa4d9f3455b80e4ddf1bb260920_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i293bb336d80d473eb69da7cf494b8713_D20220208-20220208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="i016360b58b9248388c5ea2f0970527a4_I20220208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i1203e4c8b5dc4172916025c8100cbdf2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77d2b40e50ad4aa48f0578112016e986_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4f1503bf3ac46d1b34a4f8bb6f92140_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifa8302f1e6814a9987ec49ca9af465a2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8a5bcc60ead14ba1ac643d19e4770911_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i66f160f54d404d8bb80d4edd382393c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i5d6487fd362c4e36a923415c3752b4f7_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="ib8b91f81d53147c9b20bab4e275695ef_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic03ac1eae74a42adac16fd393cd612f3_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i075bf5beb06a450d897f5554a7c9f675_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia976ce0a469f43dd8529daa7ded8f407_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7ffc106e9c034ce0a4ec85dfbc149c80_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i97c06ced3466414480ad4f43ed22809c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10df804649bf4f5881d03f512c323aad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i82b33cfb43b446bb98d589fcf33582cd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67742768ef2045548179b11e33a332c8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if6cd5647e0764102ae7a3f85ef3b6d57_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib7a804747bab486687e11ad36d58a3ce_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idcaf85e03f214f0fa6d79c0c4f6af669_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a294335166245f6a43fd1a87aa252a7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia51e5bcf01714c6fa740643677798f18_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if8ceebe0bfe84be1b0d7f9f9ae5831b9_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nbix:DiurnalGroupPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>nbix:security</measure>
    </unit>
    <unit id="renewaloption">
        <measure>nbix:renewalOption</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl8yLTEtMS0xLTExNTQ5Ng_8ec60db0-87fe-41ee-a9d8-4e0ed90778da">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl8zLTEtMS0xLTExNTQ5Ng_181feacb-6beb-494b-b5e9-3a8ef17513b1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl80LTEtMS0xLTExNTQ5Ng_ac1be5a7-a751-40e9-aeed-491c4c7080ea">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl81LTEtMS0xLTExNTQ5Ng_849eaa6d-51c8-4a5e-895e-618e15bb7b70">0000914475</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80L2ZyYWc6NWUxMTBhMzFlYzhlNDNkYWI2OWU3OTNiYjYwOTdlODYvdGFibGU6OTg0ZDAyNjJiN2QxNDg3MmJmNzlhODZmYzc0YjExOGYvdGFibGVyYW5nZTo5ODRkMDI2MmI3ZDE0ODcyYmY3OWE4NmZjNzRiMTE4Zl82LTEtMS0xLTExNTQ5Ng_3835d04f-77bd-4fb7-87d0-413e715a13f6">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjAtMC0xLTEtMTE1NDk2_1e393d84-1da2-402e-9cd4-e46f6dd5b945">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMTc2OQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjMyOQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjU3MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjg5NA_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTY0OTI2NzQ0NDE5NQ_53c700d8-36e0-4b90-b6dc-fbf8018a13aa">P13Y7M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i3dd50ff8e258426689131a522857f9fb_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjY4MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81NS9mcmFnOjMzOWU2YzViYzNiYjRiYTU5NTAxMmZkNTk4YmVkMTQ4L3RhYmxlOmQzOWUxYzYwNGVmYjRhNThhNDAyNDMyOGYwYmY0NWUxL3RhYmxlcmFuZ2U6ZDM5ZTFjNjA0ZWZiNGE1OGE0MDI0MzI4ZjBiZjQ1ZTFfMi0xLTEtMS0xMTU0OTY_4fa9c01f-9861-4a2e-aaed-4b01f34a4a48"
      unitRef="number">0.0131711</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk2_ca21bdca-583d-4c99-a035-6e69da2d401b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk3_e9e2c741-dec1-4c67-8480-177d688d6636">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yMjE_91e786b8-bdb4-4414-915d-b24403e09a9d">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg3_c043fb4e-b74a-4dfa-a305-09ef38bcb6c9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDgy_f9d34fc1-9b43-4754-8ad8-0bd6aa7a89fd">0-22705</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk4_f678eafe-2c79-423b-8a23-0bba07d16658">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk5_c03afa65-353d-414a-b5a4-b3f706d6b429">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNTAw_7553d6cc-7748-44e5-af92-1170ac5a08d5">12780 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDgz_e886a431-42c0-44ba-95fb-7af8c673ea6f">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg4_8c45ce85-e093-4c7c-b5c4-3c945ac377be">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg5_baf7fa77-8428-4e2e-a45d-0ffeb45cddd9">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDkw_1bb25b93-3ce9-402d-96cc-5e6bf004adc1">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDkx_7c19b2b6-0e34-430c-ac36-73f15af54646">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg0_5c83621e-1c07-43cb-bd2d-33e5ad349973">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGFibGU6ZWUyYWQyNzYyYTQ5NDBkZmE0ZGRhMTJlZDc3MmY1M2YvdGFibGVyYW5nZTplZTJhZDI3NjJhNDk0MGRmYTRkZGExMmVkNzcyZjUzZl8xLTAtMS0xLTExNTQ5Ng_6392a969-b39b-455a-899f-73d4d24f7c51">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGFibGU6ZWUyYWQyNzYyYTQ5NDBkZmE0ZGRhMTJlZDc3MmY1M2YvdGFibGVyYW5nZTplZTJhZDI3NjJhNDk0MGRmYTRkZGExMmVkNzcyZjUzZl8xLTItMS0xLTExNTQ5Ng_5d9dab63-1415-4215-834c-88a09c3fb0a8">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGFibGU6ZWUyYWQyNzYyYTQ5NDBkZmE0ZGRhMTJlZDc3MmY1M2YvdGFibGVyYW5nZTplZTJhZDI3NjJhNDk0MGRmYTRkZGExMmVkNzcyZjUzZl8xLTQtMS0xLTExNTQ5Ng_1e1621b1-9af9-414f-b9e0-6c5ac0be11a1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDkz_5e051790-d1f8-4de6-b369-ef9d09ab2a0c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg1_82f706f7-3ad1-4d57-9a8c-53653d6e9b19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk0_b22649a8-710b-4118-9b1e-09c7ce774fd5">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDg2_5d577bed-7caa-4a83-a0a8-d8daf2f41765">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDk1_13fcf187-3c51-4d59-84a9-b7761b2ae5e5">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDky_7417608a-d8da-4ed1-89bb-35f8d7994b8c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if918665a526048bba62c5c916d1da24e_I20221028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xL2ZyYWc6OGRhNmM4ODAzMTJiNDY1Yjg0NjI3MDk1MWZjODliYjgvdGV4dHJlZ2lvbjo4ZGE2Yzg4MDMxMmI0NjViODQ2MjcwOTUxZmM4OWJiOF8yNDY5_25b3ce56-6a81-458e-9503-5eb0ece2322c"
      unitRef="shares">96134388</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMy0xLTEtMS0xMTU0OTY_c8b6adbe-3363-401e-8264-c12161500fe2"
      unitRef="usd">212200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMy0zLTEtMS0xMTU0OTY_2997440a-bb9d-4dda-ba61-e0fe9db023e8"
      unitRef="usd">340800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNC0xLTEtMS0xMTU0OTY_b6a5c7ea-9cde-4ea8-aa0c-c1a393701313"
      unitRef="usd">587200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNC0zLTEtMS0xMTU0OTY_0a21d8fc-b82f-459a-aa92-e7cd059b1277"
      unitRef="usd">370500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNS0xLTEtMS0xMTU0OTY_dc8a575c-25cb-4519-a8dc-7bafabc79282"
      unitRef="usd">301200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNS0zLTEtMS0xMTU0OTY_d143d0a1-0136-44ba-ae58-d0a85ae2f8b4"
      unitRef="usd">185500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNi0xLTEtMS0xMTU0OTY_2acf3527-8f6a-45da-843d-245483464d71"
      unitRef="usd">37000000.0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNi0zLTEtMS0xMTU0OTY_de5683a0-b4c9-4f89-a5a7-2b927ec47616"
      unitRef="usd">30500000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNy0xLTEtMS0xMTU0OTY_f726eadf-411b-4bfa-a9db-9d993da9b17f"
      unitRef="usd">67900000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfNy0zLTEtMS0xMTU0OTY_b8852866-ada0-4f85-8704-0ec5672e2247"
      unitRef="usd">45500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfOC0xLTEtMS0xMTU0OTY_c485c2bd-ce74-4492-a52a-b6c959c3102e"
      unitRef="usd">1205500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfOC0zLTEtMS0xMTU0OTY_ca39c333-81e4-4ff5-b414-03e21270bd3f"
      unitRef="usd">972800000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfOS0xLTEtMS0xMTU0OTY_3974f56f-f0f4-4f7e-be78-d7ba97ebb662"
      unitRef="usd">319400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfOS0zLTEtMS0xMTU0OTY_c1e6bf69-6ff1-4ce0-a792-9dbc8b303957"
      unitRef="usd">315100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTAtMS0xLTEtMTE1NDk2_41ebe3e1-97fb-4ca4-a3f4-38d90b618794"
      unitRef="usd">362600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTAtMy0xLTEtMTE1NDk2_e177eed6-f2b2-4172-be30-5e76414616a7"
      unitRef="usd">560700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTEtMS0xLTEtMTE1NDk2_1403e698-f837-402e-afeb-9a95563ce0c6"
      unitRef="usd">89600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTEtMy0xLTEtMTE1NDk2_10446065-604e-42ff-b718-5cd4af6d1fe8"
      unitRef="usd">97200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTItMS0xLTEtMTE1NDk2_90e88d90-99ef-4b92-acf8-8e8226d9da1f"
      unitRef="usd">94900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTItMy0xLTEtMTE1NDk2_8467f0b7-4dac-4297-897b-fe720ceba2d8"
      unitRef="usd">63700000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTMtMS0xLTEtMTE1NDk2_b205b02c-6222-4670-a43b-0a1df9726ba4"
      unitRef="usd">60900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTMtMy0xLTEtMTE1NDk2_7c384ecd-ac96-41a2-9d6c-8eba2a0d8c08"
      unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTQtMS0xLTEtMTE1NDk2_7c205957-24a4-40c3-9886-ae199b842e2c"
      unitRef="usd">10500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTQtMy0xLTEtMTE1NDk2_bfbbac6e-3482-4ca9-b96d-0df2fa682ac6"
      unitRef="usd">4400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTUtMS0xLTEtMTE1NDk2_af59cbe0-e930-4dea-8dbd-a4f0bbdc86a3"
      unitRef="usd">2143400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTUtMy0xLTEtMTE1NDk2_2d1a7446-b333-4937-89b7-63f73ff024d3"
      unitRef="usd">2072500000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTktMS0xLTEtMTE1NDk2_b8f27331-796f-466d-aabc-d16a579a10bc"
      unitRef="usd">297800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMTktMy0xLTEtMTE1NDk2_92b27d74-3f1e-44cb-85f6-c5ab3707449b"
      unitRef="usd">225800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjAtMS0xLTEtMTE1NDk2_a6fcdd7a-2384-45ee-8f63-00ee55ebe659"
      unitRef="usd">169200000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjAtMy0xLTEtMTE1NDk2_695e13a9-6853-41c7-88dd-78c3f578d27a"
      unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjEtMS0xLTEtMTE1NDk2_59299c0b-108c-4676-bc7f-b6e8820267f2"
      unitRef="usd">18100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjEtMy0xLTEtMTE1NDk2_7fdedcda-8672-46d1-b1af-b86e5a1ec1ab"
      unitRef="usd">20000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjItMS0xLTEtMTE1NDk2_fee87665-af10-43ae-a7ce-5bd429752505"
      unitRef="usd">485100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjItMy0xLTEtMTE1NDk2_48b3cb71-2734-460f-8002-daf264125afa"
      unitRef="usd">245800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjMtMS0xLTEtMTE1NDk2_8ffca999-e8ee-4dde-8f50-e03a1dd8b789"
      unitRef="usd">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjMtMy0xLTEtMTE1NDk2_3195a3fb-d9a0-4856-af85-8c4410be56e6"
      unitRef="usd">335100000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjQtMS0xLTEtMTE1NDk2_97a10809-530d-4248-a842-a45bfe3d801b"
      unitRef="usd">96600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjQtMy0xLTEtMTE1NDk2_79bbec1f-7c77-4a33-8738-d206c53dcf8a"
      unitRef="usd">105300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjUtMS0xLTEtMTE1NDk2_023f5c24-75b2-4901-b599-e2301a2f6c95"
      unitRef="usd">17100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjUtMy0xLTEtMTE1NDk2_6bed4028-197e-44f1-80e7-a6431a2f2787"
      unitRef="usd">12300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjYtMS0xLTEtMTE1NDk2_24b66448-0535-476d-869b-479a22597511"
      unitRef="usd">598800000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjYtMy0xLTEtMTE1NDk2_cccfa236-8265-4e29-bdc8-e742b4d7809c"
      unitRef="usd">698500000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfMjE_3dfeb356-d101-46cf-81ca-b0c1fcd35025"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfMjE_d8a0dcbd-6fcd-407d-978a-fde372253bd4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfMzU_2187fa67-02f8-4142-89a9-3b2ae1dfa0bf"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfMzU_9595a44d-6bb8-4353-8478-900703c78af3"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfNTc_4c6e34ab-49bc-47c9-bf8b-59d0a41dbf16"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfNTc_5497a515-2009-4189-b650-a7bfeaef19ac"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfNTc_dce86cb3-04f1-4aad-a590-d7b7440f1e71"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMC0xLTEtMTE1NDk2L3RleHRyZWdpb246ZDllZDc1Nzc3MzgwNDJmYTkxYjUzNTkyYTMzMTViY2NfNTc_e25c1c2e-d334-4ad5-ab2f-aeb8e753fb4c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMS0xLTEtMTE1NDk2_28b6119e-7177-45a0-84e4-e01f6e8a0aae"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMjktMy0xLTEtMTE1NDk2_23e97a46-2de7-4ebe-96aa-109147469501"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfMTg_48760c82-34fb-4093-978d-7dd2b75e15fe"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfMTg_9fe717fc-1665-4f71-b6ea-b2434da6eb09"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfMzI_09ea582f-8a7d-49ad-a508-e794306cbce8"
      unitRef="shares">220000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfMzI_a025a65b-02e6-463f-b164-b5161f0ef196"
      unitRef="shares">220000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfODQ_57ed3050-6ce8-4d8c-a27c-1a8e6dad5a1f"
      unitRef="shares">96100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfODQ_f82c8773-9541-4704-88b5-795bd5fdf4d1"
      unitRef="shares">96100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfOTc_978b0d99-94aa-45fd-9a01-9d99d4dc0891"
      unitRef="shares">94900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMC0xLTEtMTE1NDk2L3RleHRyZWdpb246M2I2NDJhNWI0ODE4NDYwOWFlZDkwYTRhYjE0NzdhYTdfOTc_b0f4a36a-19c1-403e-8366-42fc9a5c4886"
      unitRef="shares">94900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMS0xLTEtMTE1NDk2_442ac603-7ea8-4783-9916-4ed7f09832fe"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzAtMy0xLTEtMTE1NDk2_1ddd3c53-400d-4615-9cb6-9b77dc4a8cf4"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzEtMS0xLTEtMTE1NDk2_cfbb4437-3665-478a-8aac-fcd9ea6e2d7d"
      unitRef="usd">2054300000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzEtMy0xLTEtMTE1NDk2_6dd54054-a0f3-4980-86eb-802f89e3aba5"
      unitRef="usd">2011400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzItMS0xLTEtMTE1NDk2_d3355d80-c7dd-4b2e-a93e-aba4aa432677"
      unitRef="usd">-14000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzItMy0xLTEtMTE1NDk2_dd742540-65d5-484d-83c9-af6cde88f16b"
      unitRef="usd">-1700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzMtMS0xLTEtMTE1NDk2_9614e04d-7050-4855-9591-d091747046e9"
      unitRef="usd">-495800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzMtMy0xLTEtMTE1NDk2_0228c96c-2031-418e-b71c-82c0524bc8d9"
      unitRef="usd">-635800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzQtMS0xLTEtMTE1NDk2_eaded246-79c4-4333-958e-914d280a3e73"
      unitRef="usd">1544600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzQtMy0xLTEtMTE1NDk2_dac379a7-e52d-492f-ab65-3a2f0eadd377"
      unitRef="usd">1374000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzUtMS0xLTEtMTE1NDk2_febd102f-ff21-4bf2-80eb-068b46b636ea"
      unitRef="usd">2143400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xNi9mcmFnOmYzMTNlN2RjMTBhMDRhN2ViMTg4YWRiNDFiN2NjZmRjL3RhYmxlOjFiYjAwMTg1MjQzNjRmMWQ4ZTI1YmE2OTlkZjMwYjFiL3RhYmxlcmFuZ2U6MWJiMDAxODUyNDM2NGYxZDhlMjViYTY5OWRmMzBiMWJfMzUtMy0xLTEtMTE1NDk2_fad62869-019f-4072-9a56-53e244cf7463"
      unitRef="usd">2072500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe44f84f3acc41678a991f68f4e0a4a0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMy0xLTEtMS0xMTU0OTY_f4e0a268-4a66-4347-93de-25ebbf5364a4"
      unitRef="usd">379300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c9497c79ced4aeaa7f1db18e0399893_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMy0zLTEtMS0xMTU0OTY_d19f659c-b473-436c-af4e-46d6185fa645"
      unitRef="usd">288800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic95f1ad2e17045e4abe097728c7590d4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMy01LTEtMS0xMTU0OTY_702b0ecc-9841-47b9-bafb-38210d56803a"
      unitRef="usd">1036300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19314b84529d46f99e5c461ac31afdc4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMy03LTEtMS0xMTU0OTY_67c2c7d9-2fd2-4d44-a980-fe1925cb3ede"
      unitRef="usd">786600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7a0669f73bd42779f23c7b8c8b7807b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNC0xLTEtMS0xMTU0OTY_4278fb1c-571b-436d-905e-c19a620c0f06"
      unitRef="usd">8600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9814ecaf809a4416a7ffd9d41c7694f6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNC0zLTEtMS0xMTU0OTY_88106d89-58e6-4598-8035-932cfa85acc7"
      unitRef="usd">7200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i401123ce4dd945a38b707d60c1882890_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNC01LTEtMS0xMTU0OTY_513420ae-a2d8-4f67-a096-127b1e842cb0"
      unitRef="usd">40400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb49c8d270504eda9057c294777b76eb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNC03LTEtMS0xMTU0OTY_d8953838-3afd-464e-82b5-a16387e5c3d7"
      unitRef="usd">34900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNS0xLTEtMS0xMTU0OTY_0562b7ab-23ce-4b71-9b83-8d3726503db0"
      unitRef="usd">387900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNS0zLTEtMS0xMTU0OTY_da2a495b-0be1-448b-a44d-c2b65f6ad24c"
      unitRef="usd">296000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNS01LTEtMS0xMTU0OTY_04587b01-ce62-4615-a4b3-2f33b955600e"
      unitRef="usd">1076700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNS03LTEtMS0xMTU0OTY_9b860406-79b5-4c8a-a8cb-4ae203caf1f4"
      unitRef="usd">821500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNy0xLTEtMS0xMTU0OTY_30521e5e-ca80-4f62-adab-4434fe1cef64"
      unitRef="usd">6100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNy0zLTEtMS0xMTU0OTY_7381b8c2-026b-42e7-b83c-d20464459499"
      unitRef="usd">4200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNy01LTEtMS0xMTU0OTY_03c4ee2f-8cac-4660-9a51-bc0b7d45bc84"
      unitRef="usd">15500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfNy03LTEtMS0xMTU0OTY_12059404-a3b0-46aa-9234-542cae82a51a"
      unitRef="usd">10200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOC0xLTEtMS0xMTU0OTY_fd842791-6571-4332-a9cf-13b815115bf0"
      unitRef="usd">107700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOC0zLTEtMS0xMTU0OTY_ff9ca6e5-7a43-4683-b27e-f34979c79074"
      unitRef="usd">92700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOC01LTEtMS0xMTU0OTY_677447cc-0bfa-4dce-a2b5-da81567c44b6"
      unitRef="usd">345800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOC03LTEtMS0xMTU0OTY_31226472-5538-4640-bf9d-aa4ffbb4015d"
      unitRef="usd">240700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOS0xLTEtMS0xMTU0OTY_454a3ee4-fecb-403f-a45f-d55f30dac13e"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOS0zLTEtMS0xMTU0OTY_d16ce717-e171-4378-b053-e5898dc04c11"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOS01LTEtMS0xMTU0OTY_5e58c864-20cc-4251-9fb8-8088b9b3222a"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfOS03LTEtMS0xMTU0OTY_3a40b12c-bb1a-41f0-814e-dcd0c6146f8e"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTAtMS0xLTEtMTE1NDk2_22a2ce11-7577-408d-8e52-afaaa65a9386"
      unitRef="usd">186300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTAtMy0xLTEtMTE1NDk2_b3e638f7-c6ec-47c3-b64a-cec366e002c6"
      unitRef="usd">154600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTAtNS0xLTEtMTE1NDk2_f597090e-b2dd-4655-a8e4-3174afb6170a"
      unitRef="usd">569800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTAtNy0xLTEtMTE1NDk2_1194b80d-79bc-491e-9c2e-b51ec9fdd983"
      unitRef="usd">426800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTEtMS0xLTEtMTE1NDk2_f39bc802-4478-48a2-acf7-7523b1234d7b"
      unitRef="usd">300100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTEtMy0xLTEtMTE1NDk2_800c3684-09da-4b64-bdb8-35d8c8caadff"
      unitRef="usd">251500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTEtNS0xLTEtMTE1NDk2_56f2b1ff-8bb3-4bcc-8a48-759fb5bdab7d"
      unitRef="usd">931100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTEtNy0xLTEtMTE1NDk2_2e8960d7-7193-4ba4-aa64-0b6468fb3cfd"
      unitRef="usd">682700000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTItMS0xLTEtMTE1NDk2_933bd2da-4a7b-496a-bf5e-038b8c284be6"
      unitRef="usd">87800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTItMy0xLTEtMTE1NDk2_2ecb2837-105e-4194-9b95-a8e405d4d415"
      unitRef="usd">44500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTItNS0xLTEtMTE1NDk2_384d74ba-9e45-4be8-a6c5-bdd594676f70"
      unitRef="usd">145600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTItNy0xLTEtMTE1NDk2_0d762584-2a87-4ea0-aee4-2168740b5e72"
      unitRef="usd">138800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTQtMS0xLTEtMTE1NDk2_5172cc68-c032-45c0-b396-05f3d6065712"
      unitRef="usd">1200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTQtMy0xLTEtMTE1NDk2_7cdcb526-52f5-4955-93bc-4d5e570b2cff"
      unitRef="usd">6600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTQtNS0xLTEtMTE1NDk2_84a17b6c-c1e1-4e25-81b5-c3784a5d98c2"
      unitRef="usd">6000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTQtNy0xLTEtMTE1NDk2_001b748c-c2d3-4ae1-ae64-0ce5ba0eedb0"
      unitRef="usd">19200000</us-gaap:InterestExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTUtMS0xLTEtMTE1NDk2_79a5704f-8ea3-4f4a-a2df-65b29e48551f"
      unitRef="usd">11100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTUtMy0xLTEtMTE1NDk2_83be080f-5ad6-4e5c-a406-72420d925b77"
      unitRef="usd">-8200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTUtNS0xLTEtMTE1NDk2_fe0820a4-4d9f-4f77-8cae-50797d502ea6"
      unitRef="usd">23600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTUtNy0xLTEtMTE1NDk2_2dfcb9e1-2ebf-4de7-9ec7-f147d916029e"
      unitRef="usd">-7500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTYtMS0xLTEtMTE1NDk2_8f2ce059-011e-4cfc-85ea-2571f14dd781"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTYtMy0xLTEtMTE1NDk2_695616c7-9c33-490f-8f0a-d923542fc33a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTYtNS0xLTEtMTE1NDk2_4fd765ce-5cda-4e6e-9d48-8576a7517045"
      unitRef="usd">-70000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTYtNy0xLTEtMTE1NDk2_f3f8f4fc-55e2-4c6b-a416-83acfd4fb352"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTctMS0xLTEtMTE1NDk2_15e4d388-e50c-43f8-8de1-b5837c2d3536"
      unitRef="usd">200000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTctMy0xLTEtMTE1NDk2_ead5c851-5e04-40a1-baf4-34beaa0d4995"
      unitRef="usd">800000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTctNS0xLTEtMTE1NDk2_7af0dfdf-26e9-4eb4-8cc0-90b9857d9692"
      unitRef="usd">2800000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTctNy0xLTEtMTE1NDk2_f39052cc-bf4d-49be-8776-75f2aad310c1"
      unitRef="usd">3100000</nbix:InvestmentIncomeAndOtherNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTgtMS0xLTEtMTE1NDk2_876278ef-a962-4d34-aa5a-7eb8d7129e62"
      unitRef="usd">10100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTgtMy0xLTEtMTE1NDk2_d8528b9d-9fb7-4fbb-b608-c0a6680b55a7"
      unitRef="usd">-14000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTgtNS0xLTEtMTE1NDk2_5b33d3be-ab45-481d-aee1-3d505d8afe96"
      unitRef="usd">-49600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTgtNy0xLTEtMTE1NDk2_831dc846-08ff-40ca-9d8f-19ec239d8d19"
      unitRef="usd">-23600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTktMS0xLTEtMTE1NDk2_09f5dcca-4a33-4b47-b369-70cd7edcfed6"
      unitRef="usd">97900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTktMy0xLTEtMTE1NDk2_103e9f48-37d7-4de2-9adf-bbd186c73eb3"
      unitRef="usd">30500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTktNS0xLTEtMTE1NDk2_deebfaee-455c-43fd-8a63-414c3acb47af"
      unitRef="usd">96000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMTktNy0xLTEtMTE1NDk2_60655422-c92d-4a25-ac46-14621c712a2e"
      unitRef="usd">115200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjAtMS0xLTEtMTE1NDk2_808cc7cd-be91-4213-a1cc-05849cd21a4f"
      unitRef="usd">29400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjAtMy0xLTEtMTE1NDk2_fde93efa-c1f3-42ee-83ba-60e43e4a4ba9"
      unitRef="usd">8000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjAtNS0xLTEtMTE1NDk2_2fe37e83-0a30-4009-9d88-9e626c182d1b"
      unitRef="usd">30500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjAtNy0xLTEtMTE1NDk2_00e618c2-0626-41ae-a4ca-26b125744f6f"
      unitRef="usd">18300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjEtMS0xLTEtMTE1NDk2_d165bd12-0af6-4bd3-bf84-e36b589ccd9b"
      unitRef="usd">68500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjEtMy0xLTEtMTE1NDk2_bc5b4feb-6033-4dd0-84cb-56f7b9205d07"
      unitRef="usd">22500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjEtNS0xLTEtMTE1NDk2_5005142b-ac6d-4c39-965e-9a18d4976e1f"
      unitRef="usd">65500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjEtNy0xLTEtMTE1NDk2_343ed79c-6daf-4d35-95f7-8d3746fdbc03"
      unitRef="usd">96900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjItMS0xLTEtMTE1NDk2_9df9aa12-d91a-4fb3-aba5-b010b9a77b19"
      unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjItMy0xLTEtMTE1NDk2_32154ca1-f4ab-45ec-befb-d51938b0a4d8"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjItNS0xLTEtMTE1NDk2_a98720fd-f7cc-4d32-a0c7-1bc7a7190454"
      unitRef="usd">-12300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjItNy0xLTEtMTE1NDk2_f4dad365-2d6c-4916-ba79-5eb5adec3734"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjMtMS0xLTEtMTE1NDk2_ca56db13-40e8-40b4-8827-0bede05fb854"
      unitRef="usd">66700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjMtMy0xLTEtMTE1NDk2_7493a26e-8e38-47ec-b0ff-c5ba8d8780cc"
      unitRef="usd">22200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjMtNS0xLTEtMTE1NDk2_fdcc6c53-8928-4b63-bb7f-3cbd15d70191"
      unitRef="usd">53200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjMtNy0xLTEtMTE1NDk2_dd185b8c-b97a-459b-bbab-d2989f3fefe5"
      unitRef="usd">95500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjUtMS0xLTEtMTE1NDk2_7ff4463e-2408-4053-bd59-8394a73a5fb9"
      unitRef="usdPerShare">0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjUtMy0xLTEtMTE1NDk2_5b7563d2-c365-4b2c-a853-8d19e6b0589f"
      unitRef="usdPerShare">0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjUtNS0xLTEtMTE1NDk2_771d20eb-c450-48af-8121-6df08025e468"
      unitRef="usdPerShare">0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjUtNy0xLTEtMTE1NDk2_81cc0c2e-3cfd-4a03-afe6-b2ccac956b24"
      unitRef="usdPerShare">1.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjYtMS0xLTEtMTE1NDk2_c596af9f-c370-4809-8d76-c7613c3700c8"
      unitRef="usdPerShare">0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjYtMy0xLTEtMTE1NDk2_d91598bb-1d39-42c0-b5bf-3bd8749e3b3d"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjYtNS0xLTEtMTE1NDk2_96085df6-6d00-48af-ac3a-c29b72de220d"
      unitRef="usdPerShare">0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjYtNy0xLTEtMTE1NDk2_9ffa606a-e1e7-45aa-81ef-6f575b092053"
      unitRef="usdPerShare">0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjgtMS0xLTEtMTE1NDk2_f0cedefb-764d-4219-ad88-7b768e7f0ff4"
      unitRef="shares">95800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjgtMy0xLTEtMTE1NDk2_df66b321-6202-45b0-9ede-60601a897ccf"
      unitRef="shares">94700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjgtNS0xLTEtMTE1NDk2_ff0bdab6-77e4-4e62-a237-08994ea9fb9c"
      unitRef="shares">95600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjgtNy0xLTEtMTE1NDk2_bb1b6241-8870-469d-bfc0-3019bf4de0e9"
      unitRef="shares">94500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjktMS0xLTEtMTE1NDk2_b2c439d2-b493-4d63-adfc-52f5831e0bda"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjktMy0xLTEtMTE1NDk2_b603c4e7-4ebf-4662-b3c7-24b9653d01ee"
      unitRef="shares">97700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjktNS0xLTEtMTE1NDk2_ff5db5dc-2c2e-402f-bfaf-0c447e83930f"
      unitRef="shares">98300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8xOS9mcmFnOjE0Nzk5NDM1MDA5ZTRkZGE4YmQxMDgzZjdlZWZlN2JiL3RhYmxlOjc2YjRkZDUxZDBjZTRkNTdhZDA4MGM0NDJjMGJjOWZkL3RhYmxlcmFuZ2U6NzZiNGRkNTFkMGNlNGQ1N2FkMDgwYzQ0MmMwYmM5ZmRfMjktNy0xLTEtMTE1NDk2_547ab153-89ad-4e9b-bcec-b3e18a6fe1d7"
      unitRef="shares">97900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i4ed395fe9cc1449bb7d939fd514068ba_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy0xLTEtMS0xMTU0OTY_0317bbec-ee71-417f-b945-58e8106dfbb2"
      unitRef="shares">95600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4ed395fe9cc1449bb7d939fd514068ba_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy0zLTEtMS0xMTU0OTY_da6251b5-f553-4a3d-a852-926d09299dbe"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia07d586d340f45f99771c0d7a421770b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy01LTEtMS0xMTU0OTY_4000fc33-9f8d-4837-96cf-7ec906d23e75"
      unitRef="usd">1999800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib88cff710aa64f0db32eff49fd8b81ef_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy03LTEtMS0xMTU0OTY_340a2f7c-d6ec-4e61-bece-3afa77d5be42"
      unitRef="usd">-12200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c6f9adf4a4f46229cbde98aedf63b35_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy05LTEtMS0xMTU0OTY_0ff4a175-b3ff-4453-852e-219262ca4ab0"
      unitRef="usd">-564300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44069ab866fd423cb33d0c69f2a3f908_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMy0xMS0xLTEtMTE1NDk2_b0c2b9b2-ee32-4a68-b901-ed4278f14e0e"
      unitRef="usd">1423400000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i324159b7704844d0ab9d10da3decc855_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNC05LTEtMS0xMTU0OTY_0eb0cd7e-9a8f-4819-9261-38c16daf4173"
      unitRef="usd">68500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNC0xMS0xLTEtMTE1NDk2_a12d8120-73cb-40ec-bf63-39794b67f822"
      unitRef="usd">68500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6beacf8156fb48ea965024414adc5ab5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNS03LTEtMS0xMTU0OTY_9d143a23-eb88-4bc3-a621-77e58cab393e"
      unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNS0xMS0xLTEtMTE1NDk2_3966ac36-2d4f-427c-bc30-e5bd9f987c42"
      unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5825bdfeea8640ffa28b46a703daa81b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNi01LTEtMS0xMTU0OTY_8dcabc5f-4e0b-4167-8c02-55c22ccc5106"
      unitRef="usd">43100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNi0xMS0xLTEtMTE1NDk2_d85ef80e-8e03-42db-ae60-4d6bd234854e"
      unitRef="usd">43100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iba66c4f94fa34d49b8f74b725073fd80_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNy0xLTEtMS0xMTU0OTY_943ea159-cf33-4dfa-b695-6943ad72f40d"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5825bdfeea8640ffa28b46a703daa81b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNy01LTEtMS0xMTU0OTY_653b430d-7e5a-48d8-af58-fbd1189fff82"
      unitRef="usd">11400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfNy0xMS0xLTEtMTE1NDk2_a4614402-9a6f-4cae-adb7-a630e487c534"
      unitRef="usd">11400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="iaaef5673cc82499992433df9a4170336_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC0xLTEtMS0xMTU0OTY_55a4a076-f446-4a27-b417-b640fd2a40bf"
      unitRef="shares">96100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaaef5673cc82499992433df9a4170336_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC0zLTEtMS0xMTU0OTY_e887345f-2ced-4773-845d-990a73cc1d27"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ec663ae2974473c932ec901d2279e45_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC01LTEtMS0xMTU0OTY_753566a3-f04d-4775-8ca3-efe4dc1fdb51"
      unitRef="usd">2054300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14a6e7bfb09240da8df57c0b10f74e22_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC03LTEtMS0xMTU0OTY_c37d4124-2675-42af-991f-a94dc249c44d"
      unitRef="usd">-14000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f55b27df0414697becfc3c88fdb3675_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC05LTEtMS0xMTU0OTY_f45461dd-944a-4613-8923-39da261365a8"
      unitRef="usd">-495800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfOC0xMS0xLTEtMTE1NDk2_b660c7fe-80c4-473e-9042-2ec840e4ce94"
      unitRef="usd">1544600000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ie0d7237003994ddb914ef3572076e2d3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtMS0xLTEtMTE1NDk2_f619a80b-5ee4-4ecb-b21b-e510e6eb77e4"
      unitRef="shares">94600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie0d7237003994ddb914ef3572076e2d3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtMy0xLTEtMTE1NDk2_2495c4db-f0b5-43f4-95ec-c0739728731d"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1fb24b2c68e4e50a0786e67d741db84_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtNS0xLTEtMTE1NDk2_0502752a-7f01-416e-ba4a-df7da44d5167"
      unitRef="usd">1929400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i031a6b6ce49a43efb4f5777c5cd53c63_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtNy0xLTEtMTE1NDk2_2ab0e412-1191-41b6-af5a-55357dc9696e"
      unitRef="usd">700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78153a6965184d7c88703cc188594611_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtOS0xLTEtMTE1NDk2_9f16b92e-4064-478d-b2bf-6b0327769fb5"
      unitRef="usd">-651000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c7f36f1d6364a3ba48295705c5a6577_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTAtMTEtMS0xLTExNTQ5Ng_f71a8cf0-e43c-4819-806b-a85e34f9cfab"
      unitRef="usd">1279200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ife1366392be644cdb1fdf15d68cc7c12_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTEtOS0xLTEtMTE1NDk2_31fd1479-8557-4583-af3e-2aeba1800fb1"
      unitRef="usd">22500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTEtMTEtMS0xLTExNTQ5Ng_90e5d7d5-aed5-4746-a186-f28c367ef68a"
      unitRef="usd">22500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i96745670dede4bf7b3baf9f45f84ddbe_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTItNy0xLTEtMTE1NDk2_5078c081-a1de-49fb-b868-4df5f270a935"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTItMTEtMS0xLTExNTQ5Ng_4300d0bb-e518-4961-966a-33d7cdaa8536"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i858eddcb9f684bed940a6fbd8a8477ad_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTMtNS0xLTEtMTE1NDk2_b764f469-3644-498a-b71d-7d5f36cb2808"
      unitRef="usd">37100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTMtMTEtMS0xLTExNTQ5Ng_f04a3768-904c-4bb0-9b7d-2ac3bfd3b65e"
      unitRef="usd">37100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic9e66c6f25b84530a5fb28be5eae8546_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTQtMS0xLTEtMTE1NDk2_f7cc4b37-92e2-4383-9073-ad8cda4365d5"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i858eddcb9f684bed940a6fbd8a8477ad_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTQtNS0xLTEtMTE1NDk2_f21c6305-a62d-42f4-bd5c-3c66aa714683"
      unitRef="usd">7500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTQtMTEtMS0xLTExNTQ5Ng_c4d551b3-d459-4471-b8ae-e1aec20305f2"
      unitRef="usd">7500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="ia5ae523d047d497ba5e50594b29cf3b2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtMS0xLTEtMTE1NDk2_2eefda1f-8641-4448-abe2-bd319d5072a6"
      unitRef="shares">94800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia5ae523d047d497ba5e50594b29cf3b2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtMy0xLTEtMTE1NDk2_da1b59e2-5a6c-4126-95ab-5a6d3c6557d6"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i516ff9b620b94979821df492ffccf0d2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtNS0xLTEtMTE1NDk2_1b014b59-e0b3-41bf-9747-9f38fd9438de"
      unitRef="usd">1974000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9adb983cdb174ff39bb4b981e7ce9650_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtNy0xLTEtMTE1NDk2_754c25a2-46c6-48a9-b59c-3e24bc27b109"
      unitRef="usd">400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedd9ce6e56184b7999d247c1dc25eabe_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtOS0xLTEtMTE1NDk2_787a1fbf-41bb-42f5-afc1-cd4a2e77bcc2"
      unitRef="usd">-628500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTUtMTEtMS0xLTExNTQ5Ng_aafd9c3d-cdac-4542-871a-935b965c16d6"
      unitRef="usd">1346000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i72d0b3550c5e44f5be3613d00e3a1b13_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctMS0xLTEtMTE1NDk2_b92abf76-9309-4488-9791-69e4defa4ab7"
      unitRef="shares">94900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i72d0b3550c5e44f5be3613d00e3a1b13_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctMy0xLTEtMTE1NDk2_1e9560e1-3bdb-47d9-b468-5bb3f8a546b9"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65ee8e9be30b406da6b582097952f9d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctNS0xLTEtMTE1NDk2_3ed78212-f588-484d-871a-b2491214f68c"
      unitRef="usd">2011400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b7d3cbd4ae44165b3954e2ed6ee365b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctNy0xLTEtMTE1NDk2_cf690b87-f6cf-4a1b-8193-8a28fc3f36c6"
      unitRef="usd">-1700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i10242909a1074444b3e2545c393d3f32_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctOS0xLTEtMTE1NDk2_8cd5ab37-e8cf-4c47-9018-9220af3e7176"
      unitRef="usd">-635800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTctMTEtMS0xLTExNTQ5Ng_0caf46d5-efda-43ec-89da-3ee0d6936bcf"
      unitRef="usd">1374000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia9a3b29344c14dbe9ec425f46e47ae87_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTgtOS0xLTEtMTE1NDk2_b8526c83-6c98-46a2-a0a7-2f18dae272fc"
      unitRef="usd">65500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTgtMTEtMS0xLTExNTQ5Ng_ea022516-225d-4d6d-87f5-a09570a87bb3"
      unitRef="usd">65500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i23c65102bd2e4adeb5ea816771ce177b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTktNy0xLTEtMTE1NDk2_0f9a7885-63a0-48cd-93ea-cd882bff9d9b"
      unitRef="usd">-12300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMTktMTEtMS0xLTExNTQ5Ng_33f85228-8047-4e6f-8cef-9e972121938e"
      unitRef="usd">-12300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i9c1ded1a54114c989385f9d44f2fea9e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjAtNS0xLTEtMTE1NDk2_3223897c-6a05-4bff-8931-7cc63606cd8e"
      unitRef="usd">-106800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifde886332b6d4f1ab3402bed3a5fc8fc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjAtOS0xLTEtMTE1NDk2_603d4105-1a4e-4d32-9688-7948b2b55da6"
      unitRef="usd">74500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i366ff930ea93441a960a632e36fee44b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjAtMTEtMS0xLTExNTQ5Ng_d0f2b6f2-e722-412e-a170-256ab87c5965"
      unitRef="usd">-32300000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i38341b51bfd94d92bcf639e9e87abf56_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjEtNS0xLTEtMTE1NDk2_18d6520a-2e21-4586-87b2-05a715f86a75"
      unitRef="usd">129600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjEtMTEtMS0xLTExNTQ5Ng_7b3b13cf-8c02-42c0-a21d-6389235b67d8"
      unitRef="usd">129600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i567085fe5058473dabeb8fb3a2603864_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjItMS0xLTEtMTE1NDk2_9ace3d95-772c-4f06-a1ed-424a5ddfcceb"
      unitRef="shares">1200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i38341b51bfd94d92bcf639e9e87abf56_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjItNS0xLTEtMTE1NDk2_6ba0b635-e0f6-4054-aff1-3e973452c330"
      unitRef="usd">20100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjItMTEtMS0xLTExNTQ5Ng_98f180f4-026e-479a-bd4f-6289cf531d08"
      unitRef="usd">20100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="iaaef5673cc82499992433df9a4170336_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtMS0xLTEtMTE1NDk2_11112210-d9d8-4576-9793-d7ce4b0070aa"
      unitRef="shares">96100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaaef5673cc82499992433df9a4170336_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtMy0xLTEtMTE1NDk2_d7d59f16-85ed-4857-a668-31d6d68d2e8d"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ec663ae2974473c932ec901d2279e45_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtNS0xLTEtMTE1NDk2_078c1165-e86a-42c6-bec5-bb1257a3ac92"
      unitRef="usd">2054300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14a6e7bfb09240da8df57c0b10f74e22_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtNy0xLTEtMTE1NDk2_d3abecdf-d001-4e39-8fca-d90acae3482a"
      unitRef="usd">-14000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f55b27df0414697becfc3c88fdb3675_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtOS0xLTEtMTE1NDk2_13fa274e-454d-442b-a1ba-61ecd1a52f68"
      unitRef="usd">-495800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjMtMTEtMS0xLTExNTQ5Ng_3c9f8b60-8a24-4685-9379-914a45b1901f"
      unitRef="usd">1544600000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="idc1223dc268f4291a7665d63b9b7a94b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtMS0xLTEtMTE1NDk2_7c624106-d413-4b47-9f95-aabf1226ca5c"
      unitRef="shares">93500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idc1223dc268f4291a7665d63b9b7a94b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtMy0xLTEtMTE1NDk2_371b7315-3997-430e-8692-105dcb99249a"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic84e58872dfd4571bebfb56f5496b527_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtNS0xLTEtMTE1NDk2_cbf60a6d-66ed-4827-b57e-109bd7224bfc"
      unitRef="usd">1849700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id74d31171db5404580903e96807daec4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtNy0xLTEtMTE1NDk2_0170b05d-c8da-4563-9833-722bfbb37e7a"
      unitRef="usd">1800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6fe17b0ffe694754b8dd32868036e3e1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtOS0xLTEtMTE1NDk2_fd5db390-91dd-4234-8e3a-14826fadfa9c"
      unitRef="usd">-725400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6bac18c0efcf4ec5a02f7ce6edaaab4e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjUtMTEtMS0xLTExNTQ5Ng_88ca0f80-68f2-45da-a759-202274aadd8f"
      unitRef="usd">1126200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5e7fbc21c2904c9b893e0cbd3313df98_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjYtOS0xLTEtMTE1NDk2_47c35b01-74d9-4a72-a3c6-247dac7b04a9"
      unitRef="usd">96900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjYtMTEtMS0xLTExNTQ5Ng_111b3d25-ecb5-4ba4-923b-d3a944e43ba1"
      unitRef="usd">96900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ide286c9ed2ab4936a7d1621b6a95fce8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjctNy0xLTEtMTE1NDk2_42f7ed2e-894a-4ac4-8e30-0804c0e159c6"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjctMTEtMS0xLTExNTQ5Ng_165c9b38-f30b-4dee-a409-4c7d20315b9a"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie58820f78b294bfe91aa7c6ad11e3cd8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjgtNS0xLTEtMTE1NDk2_828cbc3f-fe6e-4a5c-b690-b1d536c9d281"
      unitRef="usd">98600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjgtMTEtMS0xLTExNTQ5Ng_8dbceab1-7d81-494f-b0a0-12f70a916420"
      unitRef="usd">98600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i70caea784a864bd89ac94bdd2e53e6b8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjktMS0xLTEtMTE1NDk2_5ded6f7c-a747-4192-a1ef-e16b64ce23d0"
      unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie58820f78b294bfe91aa7c6ad11e3cd8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjktNS0xLTEtMTE1NDk2_e30cb695-d590-4968-ae83-87d52251115b"
      unitRef="usd">25700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMjktMTEtMS0xLTExNTQ5Ng_ffbbdd63-4305-4e57-9702-b8f88154deae"
      unitRef="usd">25700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="ia5ae523d047d497ba5e50594b29cf3b2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtMS0xLTEtMTE1NDk2_f18ee2d4-5dc7-482c-8327-1f2a98932b78"
      unitRef="shares">94800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia5ae523d047d497ba5e50594b29cf3b2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtMy0xLTEtMTE1NDk2_3e39b9a6-7f7a-447e-a2dd-b0f596e3d4f1"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i516ff9b620b94979821df492ffccf0d2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtNS0xLTEtMTE1NDk2_8086e5fd-118e-452d-ab3d-d41a6380e4df"
      unitRef="usd">1974000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9adb983cdb174ff39bb4b981e7ce9650_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtNy0xLTEtMTE1NDk2_ae4e7356-d22f-4c40-a764-61e50924a6ce"
      unitRef="usd">400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedd9ce6e56184b7999d247c1dc25eabe_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtOS0xLTEtMTE1NDk2_5decca5f-aa0c-4f1b-9fa6-818c5aec4d53"
      unitRef="usd">-628500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yMi9mcmFnOjg0ZWZlOGYyZjhhNDRiOTFhYjQyZGNmNmQ0YTcwMDZlL3RhYmxlOjA3MjkxOTZhYzY4ODRjNmE5NjNjODU1YjY4ZTI1YmE0L3RhYmxlcmFuZ2U6MDcyOTE5NmFjNjg4NGM2YTk2M2M4NTViNjhlMjViYTRfMzAtMTEtMS0xLTExNTQ5Ng_c8d691ea-edf9-4978-aa78-b4a6d1a11e97"
      unitRef="usd">1346000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMy0xLTEtMS0xMTU0OTY_1c1e8760-6156-4c21-b340-8afed23f19fe"
      unitRef="usd">65500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMy0zLTEtMS0xMTU0OTY_02d82184-8904-40fb-a9e2-255c2658689b"
      unitRef="usd">96900000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNS0xLTEtMS0xMTU0OTY_c8084eeb-0a69-4f77-a46a-465b6e80adfd"
      unitRef="usd">129600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNS0zLTEtMS0xMTU0OTY_eb1427a9-68d5-43d6-8dc8-39bcc37a0aec"
      unitRef="usd">98600000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNi0xLTEtMS0xMTU0OTY_9f62d3a9-e784-400f-b899-d1e3fd4c697b"
      unitRef="usd">-70000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNi0zLTEtMS0xMTU0OTY_e03dc57d-2449-4136-ac28-f4f26774f6b1"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:Depreciation
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNy0xLTEtMS0xMTU0OTY_bc5ed9cd-9d18-44b2-a175-29ab6370131a"
      unitRef="usd">11200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfNy0zLTEtMS0xMTU0OTY_f3b74cd8-3095-4e85-87fd-d23a7209c46f"
      unitRef="usd">7900000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfOC0xLTEtMS0xMTU0OTY_434fae77-6904-4a04-9115-b1f58b85e719"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfOC0zLTEtMS0xMTU0OTY_603bae7f-d9d3-401e-85ca-b7804ae8fe62"
      unitRef="usd">12100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfOS0xLTEtMS0xMTU0OTY_d9b51c55-36ad-46b1-b298-cba3dc1f6857"
      unitRef="usd">1000000.0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfOS0zLTEtMS0xMTU0OTY_bfd22372-2a2d-4afc-971a-dd849769f1f6"
      unitRef="usd">800000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTAtMS0xLTEtMTE1NDk2_12b72872-414b-4427-8723-5a4dc2ee4747"
      unitRef="usd">23600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTAtMy0xLTEtMTE1NDk2_24f8ae84-f49b-4d70-946b-1a8156c13ff9"
      unitRef="usd">-7500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTEtMS0xLTEtMTE1NDk2_54dbd905-7484-4f84-bebb-cddc0c9cf820"
      unitRef="usd">5600000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTEtMy0xLTEtMTE1NDk2_2e021f41-baa7-4c73-b66a-c6185f613857"
      unitRef="usd">9000000.0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTItMS0xLTEtMTE1NDk2_b510fe00-78cc-4e97-88b7-377a116de4c5"
      unitRef="usd">3000000.0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTItMy0xLTEtMTE1NDk2_1b3e07df-8548-4e21-b2e9-28d1bc3f9c9a"
      unitRef="usd">7700000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTQtMS0xLTEtMTE1NDk2_2deb35de-d34b-414e-ba32-56e7be097646"
      unitRef="usd">115700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTQtMy0xLTEtMTE1NDk2_c5b00af0-7258-4898-a71a-512b4b2516cd"
      unitRef="usd">6700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTUtMS0xLTEtMTE1NDk2_24a4b6f4-fa17-4308-a142-4979ba7d9c8e"
      unitRef="usd">6500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTUtMy0xLTEtMTE1NDk2_becfd72f-3acf-4b49-a7d1-95d751cb6554"
      unitRef="usd">-2500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTYtMS0xLTEtMTE1NDk2_c2523147-30d9-4163-98a8-de35122727d1"
      unitRef="usd">77000000.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTYtMy0xLTEtMTE1NDk2_a2098cf7-eba1-4287-8d08-1bc792104c82"
      unitRef="usd">37700000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTctMS0xLTEtMTE1NDk2_1b06df28-9114-4769-93a2-c183aa2a2e84"
      unitRef="usd">20700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTctMy0xLTEtMTE1NDk2_66eb57ff-8d98-42cc-9632-8db75ef11b5e"
      unitRef="usd">21700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTgtMS0xLTEtMTE1NDk2_ba871aeb-c10f-4d1b-b331-c091bc177ff2"
      unitRef="usd">196400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMTgtMy0xLTEtMTE1NDk2_80be3042-a84b-415b-8d1c-85aa527e20b5"
      unitRef="usd">252300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjEtMS0xLTEtMTE1NDk2_b27bec77-036d-44aa-87bf-f352d7762cc9"
      unitRef="usd">387900000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjEtMy0xLTEtMTE1NDk2_1c3ba597-2e0e-4ca7-8d48-081053a96733"
      unitRef="usd">658700000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjItMS0xLTEtMTE1NDk2_78772e24-97e2-4b42-83cf-3474b7efb9f9"
      unitRef="usd">348800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjItMy0xLTEtMTE1NDk2_ea97b75b-63d4-4cbe-a884-8662aa8df9e4"
      unitRef="usd">523900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjMtMS0xLTEtMTE1NDk2_97a9b58b-861d-46b5-ac6c-a91743140be6"
      unitRef="usd">7700000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjMtMy0xLTEtMTE1NDk2_a4ca32e6-674f-475a-95fd-0c204e27a5d6"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjQtMS0xLTEtMTE1NDk2_f9f7406e-6942-42df-9b06-e4ec466c2617"
      unitRef="usd">14700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjQtMy0xLTEtMTE1NDk2_bf8bfe41-3ff0-4ae3-93d8-5ce4681f5ec8"
      unitRef="usd">14500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjUtMS0xLTEtMTE1NDk2_dabae256-81e4-4bd0-b67a-d5c4d63f9514"
      unitRef="usd">-61500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjUtMy0xLTEtMTE1NDk2_eb21e8f3-2bc3-48d4-8889-d3c4ff149151"
      unitRef="usd">-153900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjgtMS0xLTEtMTE1NDk2_9085e880-f4e1-455a-a4ca-7ee725168a67"
      unitRef="usd">20100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjgtMy0xLTEtMTE1NDk2_ce1df91f-0437-4f81-a677-2d2276994e9e"
      unitRef="usd">25700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjktMS0xLTEtMTE1NDk2_9f8a4ace-5420-44d5-b76d-dd5b108c8ba2"
      unitRef="usd">279000000.0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMjktMy0xLTEtMTE1NDk2_8f99fee3-5f4c-451c-8938-5e3c04799692"
      unitRef="usd">100000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzAtMS0xLTEtMTE1NDk2_e7fbbc77-d6a3-4630-9b8e-3d0c3d449167"
      unitRef="usd">-258900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzAtMy0xLTEtMTE1NDk2_2aa398fd-3835-410a-9f4e-f2be220cefcb"
      unitRef="usd">25600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzEtMS0xLTEtMTE1NDk2_25ce5e0f-18d6-4ba5-aa61-18e90f511ef6"
      unitRef="usd">-124000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzEtMy0xLTEtMTE1NDk2_d8425f94-9102-4a24-82f8-efaf828a38b8"
      unitRef="usd">124000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzItMS0xLTEtMTE1NDk2_7b69bd07-7514-4268-a145-b4439fd751ea"
      unitRef="usd">344000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6bac18c0efcf4ec5a02f7ce6edaaab4e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzItMy0xLTEtMTE1NDk2_16bd4e0f-f52e-459a-b165-0bbb4d2f16ac"
      unitRef="usd">190300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzMtMS0xLTEtMTE1NDk2_f7815c9c-e0b6-4a43-b058-c52d5176f12b"
      unitRef="usd">220000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzMtMy0xLTEtMTE1NDk2_996c595c-c04e-4336-a8ff-daf8a182c0b1"
      unitRef="usd">314300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzYtMS0xLTEtMTE1NDk2_a1db4d0e-bcc1-4223-b778-13d4d6b96dc1"
      unitRef="usd">700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzYtMy0xLTEtMTE1NDk2_102e5766-496a-4ed2-a8ef-7777ce5caa8e"
      unitRef="usd">300000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzctMS0xLTEtMTE1NDk2_487e67bd-cf1b-4642-90d9-2d8aed5af79c"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzctMy0xLTEtMTE1NDk2_b611385f-8a60-4259-8560-1e5b3c38e26b"
      unitRef="usd">21600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzgtMS0xLTEtMTE1NDk2_fd71ed82-3be7-4a3b-a714-e126a7853db8"
      unitRef="usd">4600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzgtMy0xLTEtMTE1NDk2_334394f2-8d16-4539-8e74-a21f1e1b0f15"
      unitRef="usd">4300000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzktMS0xLTEtMTE1NDk2_bacfb1a7-80d6-4b9a-b3f7-0514ab223e0b"
      unitRef="usd">4300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8yNS9mcmFnOjViOTBlY2UxMDY5NDRmZmE5ZTUzZDg5Y2RlNjNjYjZhL3RhYmxlOjU0YTdkNjg3ZTY5NjRhYWVhYjlmMTliYjIxZWY3N2U3L3RhYmxlcmFuZ2U6NTRhN2Q2ODdlNjk2NGFhZWFiOWYxOWJiMjFlZjc3ZTdfMzktMy0xLTEtMTE1NDk2_e369bc07-93d1-44c2-940a-5e023b219765"
      unitRef="usd">3400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzMzNQ_62f9a57f-ec40-4534-a2a7-156a53051d56">Organization and Significant Accounting Policies&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMTc2OQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856"&gt;ASU 2020-06&lt;/span&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjMyOQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856"&gt;ASU 2020-06&lt;/span&gt; removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjU3MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856"&gt;ASU 2020-06&lt;/span&gt; prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjg5NA_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856"&gt;ASU 2020-06&lt;/span&gt; on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzMzNw_f95d1718-7729-464c-b772-b4bd29218011">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzMzOA_308a7a41-84d0-49e5-908f-5786b34760a8">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMTc2OQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856"&gt;ASU 2020-06&lt;/span&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjMyOQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856"&gt;ASU 2020-06&lt;/span&gt; removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjU3MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856"&gt;ASU 2020-06&lt;/span&gt; prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjg5NA_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856"&gt;ASU 2020-06&lt;/span&gt; on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMjgyNQ_f1039814-97ea-4016-af7e-82d16e67cdd1"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzIwOA_3fadbf96-fab2-4a82-9eb0-63ce21e29837"
      unitRef="usd">42200000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzI0OA_cf096fb4-0369-4106-b684-b56c27e6f653"
      unitRef="usd">-9900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzI5MA_c3d58a77-1cb2-4f4c-ba05-6c06fe4c9975"
      unitRef="usd">-106800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zMS9mcmFnOjM5MWNlZjNhMzAxZjQzNjdiYzliMGE0YzU1Yjg2OWFhL3RleHRyZWdpb246MzkxY2VmM2EzMDFmNDM2N2JjOWIwYTRjNTViODY5YWFfMzMzMg_5f4baac4-e767-43f4-9684-8d5a56c1dbfa"
      unitRef="usd">74500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjE1MDU_20d66ece-2443-4a73-b370-3079ca72ba94">Collaboration and License Agreements&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Heptares Therapeutics Limited, or Heptares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which compounds we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase II clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing and commercialization costs of any collaboration product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Heptares $100.0 million upfront, which, including certain transaction-related costs, was expensed as in-process research and development, or IPR&amp;amp;D, in 2021. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the United States Food and Drug Administration's, or FDA's, acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $30.0 million, which was expensed as research and development, or R&amp;amp;D, in the second quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $2.6 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#x2019; written notice to Heptares during the research collaboration term and upon 90 days&#x2019; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited, or Takeda.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early to mid-stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the 4 non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development and commercialization costs of any royalty-bearing product. With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase II clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical trial for such compound.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Takeda $120.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in July 2022, a milestone of $5.0 million was expensed as R&amp;amp;D in the third quarter of 2022, which we expect to pay to Takeda in the fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement in its entirety or in one or more (but not all) of the United States, Japan, the European Union and the United Kingdom, or, collectively, the major markets, upon six months&#x2019; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#x2019; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Idorsia Pharmaceuticals Ltd., or Idorsia.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development and commercialization costs of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Idorsia $45.0 million upfront, which was expensed as IPR&amp;amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#x2019; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Xenon Pharmaceuticals Inc., or Xenon. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Xenon $50.0 million upfront, including a purchase of approximately 1.4 million shares of Xenon common stock (at $14.196 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $14.1 million after considering Xenon&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $36.2 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;amp;D in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the European Union&#x2019;s approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021, we paid Xenon a regulatory milestone of $10.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $19.9755 per share). The purchased shares were recorded at a fair value of $4.6 million after considering Xenon&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $5.4 million of the milestone payment was expensed as R&amp;amp;D in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the FDA's acceptance of our amended KAYAK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;study protocol in January 2022, we paid Xenon a regulatory milestone of $15.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $31.855 per share). The purchased shares were recorded at a fair value of $7.7 million after considering Xenon&#x2019;s stock price on the measurement date. The remaining $7.3 million of the milestone payment was expensed as R&amp;amp;D in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the United States and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#x2019; written notice to Xenon, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voyager Therapeutics, Inc., or Voyager.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we entered into a collaboration and license agreement with Voyager, pursuant to which we acquired certain rights to develop and commercialize the NBIb-1817 for Parkinson&#x2019;s disease program, Friedreich&#x2019;s ataxia program and two undisclosed programs. We are responsible for all development costs of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#x2019;s disease program, which became effective August 2, 2021. The termination did not apply to any program other than the NBIb-1817 for Parkinson&#x2019;s disease program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Voyager $165.0 million upfront, including a purchase of approximately 4.2 million shares of Voyager common stock (at $11.9625 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $54.7 million after considering Voyager&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $113.1 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;amp;D in 2019. In addition, we paid Voyager $5.0 million upfront, which was expensed as IPR&amp;amp;D in 2019, to acquire the rights outside the United States to the Friedreich&#x2019;s ataxia program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $1.3 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement. We may terminate the agreement upon 180 days&#x2019; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIAL &#x2013; Portela &amp;amp; Ca, S.A., or BIAL.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We acquired the United States and Canada rights to ONGENTYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(opicapone) from BIAL in 2017, and launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We are responsible for all commercialization costs of ONGENTYS in the United States and Canada and rely on BIAL for the commercial supply of ONGENTYS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the license agreement, BIAL may be entitled to receive potential future payments of up to $75.0 million upon the achievement of certain event-based milestones. In addition, with respect to ONGENTYS, in the event we fail to meet certain minimum sales requirements for a particular year in comparison to our annual sales forecast for such year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year. Further, upon our written request to BIAL 12 months prior to the estimated expiration of the term of a licensed product, we will negotiate the continuation of BIAL&#x2019;s supply of such licensed product after the term. After the term, and if BIAL is no longer supplying such licensed product, BIAL would be entitled to receive a low double-digit royalty on our future quarterly net sales of such licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until a generic product with respect to such licensed product is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement upon nine months&#x2019; written notice to BIAL. BIAL may terminate the agreement in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#x2019;s insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mitsubishi Tanabe Pharma Corporation, or MTPC.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In December 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we agreed to supply MTPC with valbenazine drug product for commercial use in Japan and other select Asian markets. MTPC is responsible for all development, manufacturing and commercialization costs of valbenazine in such markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, MTPC launched DYSVAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) in Japan for the treatment of tardive dyskinesia. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $20.0 million in the second quarter of 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#x2019;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in the second quarter of 2022. In addition, we receive royalties at tiered percentage rates on MTPC net sales of DYSVAL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $30.0 million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of 10 years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#x2019; written notice to us. In such event, all out-licensed product rights would revert to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Inc., or AbbVie.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, AbbVie launched ORILISSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(elagolix tablets) in the United States for the treatment of moderate to severe pain associated with endometriosis. In June 2020, AbbVie launched ORIAHNN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $6.1&#160;million and $15.5&#160;million, respectively, for the three and nine months ended September&#160;30, 2022 and $5.9 million and $16.3 million, respectively, for the three and nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $366.0 million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of 10 years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#x2019; written notice to us. In such event, all out-licensed product rights would revert to us.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i5df8b3da765848b7b1e13148e4a5f0ac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTMxMQ_a718ce03-7fe2-4a1d-bedc-67fb1431c0d0"
      unitRef="usd">100000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic54ce1de757a4c65bf42b4362a4de196_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfNTQ5NzU1ODM4ODU3_c2ccea06-5e25-4131-a9de-55a8581c73fc"
      unitRef="usd">30000000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments
      contextRef="iee8c3876d62e426f8ca317331158e084_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA0MQ_f08bae6f-f777-419d-9d0a-34713e79b7d3"
      unitRef="usd">2600000000</nbix:PotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i94db63ec77c8436ab4bc0f734a8773d3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfNTQ5NQ_600b112f-2d90-4be5-91ed-c66172155082"
      unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:PotentialMilestonePayments
      contextRef="i6afab7bf36d74de2bbf8ef61c544135a_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfNTgxMQ_c69931f1-ac8f-470d-b1b1-e7312d6e3fb9"
      unitRef="usd">1900000000</nbix:PotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1f569faa178b45c18012ecef36524f9f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfNTQ5NzU1ODQ0Njg1_66151077-556c-4a41-86fe-48c5212d87dc"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i62cff9c5fde445f89dc7148fdddd5d1f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfOTIwMw_3fb226b1-a2eb-4fd4-9299-d85fa7bc890c"
      unitRef="usd">45000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:PotentialMilestonePayments
      contextRef="ibf4f4cb73b3749bbbf050c1a913538e0_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfOTQ3NA_abd2e36c-0adb-457c-9e24-83360761ea36"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="i229c41a0bfa841e1a21acad7a1d13142_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA1MzQ_abaaf02e-ec1b-4389-a771-56d3b3269eec"
      unitRef="usd">50000000</nbix:UpfrontPaymentsMade>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="ic7447780aa7a4acd84f15c1df4fd1ada_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA1ODQ_6e309a4d-4a96-456f-a2a6-707ec96ec46e"
      unitRef="shares">1400000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="i229c41a0bfa841e1a21acad7a1d13142_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA2MjA_44537838-efad-4142-857e-40903261ebca"
      unitRef="usdPerShare">14.196</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i229c41a0bfa841e1a21acad7a1d13142_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA4MDc_2e7ba1d2-f128-4e9b-b495-1ee673f06a69"
      unitRef="usd">14100000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i739f24694cca4f96aa40688cb5643a85_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTA5NDY_c17d1f70-ba79-4641-939c-ed58da411bd4"
      unitRef="usd">36200000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:MilestonePayment
      contextRef="i672c8742c0424d8e9899e8cf653e3879_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTEyNjI_1638fd7e-cb32-45aa-b6ad-d8e5bd10a93f"
      unitRef="usd">10000000</nbix:MilestonePayment>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="i436998f220e64b2d85633913fc679dd2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTEzMDQ_d6ee462e-2a59-4822-827c-02379124ec79"
      unitRef="shares">300000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="i672c8742c0424d8e9899e8cf653e3879_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTEzNDA_8b1de6c1-8f03-44fe-b371-0b466609fe82"
      unitRef="usdPerShare">19.9755</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i672c8742c0424d8e9899e8cf653e3879_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE0MDk_ab654c71-918a-4e24-8137-aa283e0482ce"
      unitRef="usd">4600000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ieca44e6f568f4cce81a0f0b62a9e6ed8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE1NDg_f6d74feb-8160-4d28-9700-24faf954fedf"
      unitRef="usd">5400000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:MilestonePayment
      contextRef="ie1fc719c24174081baf340c8e1ed9345_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE3NDA_b1d83f44-89b1-48e9-a3fd-2d0c2e1f5787"
      unitRef="usd">15000000</nbix:MilestonePayment>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="ic054d101780b4681bad0f8685e5eb620_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE3ODI_9b6e0e9a-0abc-424e-89ad-c1ec6990d79e"
      unitRef="shares">300000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="ie1fc719c24174081baf340c8e1ed9345_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE4MTg_b7a3a213-7257-44a0-a03e-066eff35c363"
      unitRef="usdPerShare">31.855</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ie1fc719c24174081baf340c8e1ed9345_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE4ODc_37689116-54eb-47d8-9314-39fab9a0c057"
      unitRef="usd">7700000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i651b70e3e4884c87b5c8f6c691e732c9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTE5Njc_a75fdc01-3be3-41a2-8d7b-d6c330525cdf"
      unitRef="usd">7300000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments
      contextRef="i14108dce2bd342338c0eaada7d66ed9f_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTIxNDc_96642a96-c350-432d-be07-b964863dc91e"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="id5c2d75942864117893c1167135a171c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQzMzE_69e62237-c636-46a6-9961-ca847751a6e6"
      unitRef="usd">165000000</nbix:UpfrontPaymentsMade>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="icb6ee5ada95b4566aa1c9a8b49eccd5d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQzODE_e213be40-4d1c-4e03-930c-df5254133490"
      unitRef="shares">4200000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="id5c2d75942864117893c1167135a171c_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQ0MTk_b65db9e3-ca22-49c8-bd51-0ff4e01735b0"
      unitRef="usdPerShare">11.9625</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="id5c2d75942864117893c1167135a171c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQ2MDY_780a383a-2c40-4c95-9a18-20c15e2116ef"
      unitRef="usd">54700000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ifc36a091f0fb425ca083c03b1d5b9108_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQ3NDc_f43091ea-65f2-4d71-a645-7c54ed5b63b5"
      unitRef="usd">113100000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i22270e6ff4f141aea1c8f066676c3e93_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTQ4ODM_4a416ca6-e294-4198-9017-55a904ce8b35"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:PotentialMilestonePayments
      contextRef="i9baa790a842c4e00b5d7aea97ed51955_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTUxMjA_1413ce7e-7abf-4bdd-8c5f-2a086973e48f"
      unitRef="usd">1300000000</nbix:PotentialMilestonePayments>
    <nbix:PotentialMilestonePayments
      contextRef="i704ab482b22e45fa8b591f730cc65111_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTY0Mjk_63004f0b-3caa-4bf9-877c-49eef1d1c976"
      unitRef="usd">75000000</nbix:PotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0635b37952e44f7286d405737fc817b2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTg4OTU_6b79f97c-b997-4814-985d-c9ec0b7bfdde"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="i4243abfeabbc4f8fb0fcb634ef8fc677_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMTk4NTY_e40002d2-1847-46d0-906e-e5547d83b734"
      unitRef="usd">30000000</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="iac2a51b5f62848819ec910c25d7f2308_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjAwMzc_f6d4e0ca-862f-4254-bdf1-e74612cf5dc6">P10Y</nbix:PatentTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d2fb655446647d285e1b13940b27b9a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA5MDk_d387630d-7f2e-4c1e-bb21-93a950ecd93b"
      unitRef="usd">6100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae6fe2cc66814ab7bb20abd508f23227_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA5MTY_796e0b72-6b70-4b8e-9fc9-9239c08bbb67"
      unitRef="usd">15500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c2e568d37774c2babc5f26a9b4a305b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA5NjU_b5229f6a-ca08-4134-be45-5ff2a3d7eb4e"
      unitRef="usd">5900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cf793309e7a403c9867c00418ded9b8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjA5NzI_58817195-245f-4075-bd40-5730a067c262"
      unitRef="usd">16300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="i966fced94cdb4f9b9b690c806b6192f2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjExMzc_8b557a26-768e-4767-a93b-d3da9c5cad5e"
      unitRef="usd">366000000</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="i8edd28eddf194035b1e8ecf4e46d867d_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNC9mcmFnOmE1MWQ5MjkxMGYxMjQ5NjE5ZDZlMDIyNzQ0YjFhY2ZmL3RleHRyZWdpb246YTUxZDkyOTEwZjEyNDk2MTlkNmUwMjI3NDRiMWFjZmZfMjEzMTc_9a0a4aaf-ad37-492f-a223-8c2cf5eb098e">P10Y</nbix:PatentTerm>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTc5Mw_ade95ea4-1f06-4fc5-b1af-8f837e53c494">Debt Securities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;595.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;587.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, our security portfolio consisted of 193 debt securities available-for-sale, including 183 such securities that were in an unrealized loss position but of high credit quality. Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of September&#160;30, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of September&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables on debt securities available-for-sale totaled $3.9 million and $2.2 million, respectively, as of September&#160;30, 2022 and December&#160;31, 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the nine months ended September&#160;30, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTc5NA_6932090e-6132-4cfb-a4bf-f5becfa2ebe1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;595.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;587.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0zLTEtMS0xMTU0OTY_7dab9c0b-8d56-4959-8b36-8680b40552fb"
      unitRef="usd">97900000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi01LTEtMS0xMTU0OTY_bae4c493-8f01-4d7f-a87a-21702d29a2d4"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi03LTEtMS0xMTU0OTY_29e516ec-cae3-48fb-b82c-78c3821022f5"
      unitRef="usd">400000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi05LTEtMS0xMTU0OTY_02ab5b9b-f08a-4d20-a830-133f7921b86c"
      unitRef="usd">97500000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="if53c84fbe1cd4494b369d17f941323c3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0xMS0xLTEtMTE1NDk2_9ce8e4cf-edc4-4c55-865a-00d89209112c"
      unitRef="usd">204800000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="if53c84fbe1cd4494b369d17f941323c3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0xMy0xLTEtMTE1NDk2_cfc314c6-5014-4bc1-841c-7bd6fc05385b"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="if53c84fbe1cd4494b369d17f941323c3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0xNS0xLTEtMTE1NDk2_ffe7fe15-ba84-4c11-8044-a2915facd779"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="if53c84fbe1cd4494b369d17f941323c3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMi0xNy0xLTEtMTE1NDk2_9feae00f-92f9-491a-a76a-47f483337c99"
      unitRef="usd">204800000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0zLTEtMS0xMTU0OTY_87d858af-afee-42fd-9df5-a48bc42ab385"
      unitRef="usd">260500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy01LTEtMS0xMTU0OTY_d428b901-21d9-4106-8462-d9ce0a8e9688"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy03LTEtMS0xMTU0OTY_2d4bcf74-ae67-473c-b9ee-f8f504f6f857"
      unitRef="usd">3200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy05LTEtMS0xMTU0OTY_e5433f29-8a32-4fbd-9bad-4de6912d00db"
      unitRef="usd">257300000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0xMS0xLTEtMTE1NDk2_1cf4dfd3-3af0-4757-ae96-ef81fc2483b3"
      unitRef="usd">128200000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0xMy0xLTEtMTE1NDk2_fe9f794d-5080-4e20-9a79-b0893fde91bc"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0xNS0xLTEtMTE1NDk2_79c541a0-0106-4437-9afd-379b2edf2dbb"
      unitRef="usd">100000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfMy0xNy0xLTEtMTE1NDk2_b5f7fe5e-7136-40f8-8f93-3590afc1a086"
      unitRef="usd">128100000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0zLTEtMS0xMTU0OTY_473f22d5-2ac6-499f-9f47-908d22f21d20"
      unitRef="usd">237200000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC01LTEtMS0xMTU0OTY_6c5c4d33-8b10-42d8-8fbc-930be3afaff8"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC03LTEtMS0xMTU0OTY_d6a88a9a-22c5-427e-8978-7899ae493017"
      unitRef="usd">4800000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC05LTEtMS0xMTU0OTY_4aa9758e-a6ed-40bc-85c5-946e66d65000"
      unitRef="usd">232400000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0xMS0xLTEtMTE1NDk2_2eb624ba-cb49-4c16-9e3d-9e77de2b1093"
      unitRef="usd">37600000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0xMy0xLTEtMTE1NDk2_8de0aba1-85a3-4b05-ba41-69eb5f7f3ef3"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0xNS0xLTEtMTE1NDk2_608a270d-0f5d-4224-9311-ffa6a6b92a1c"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNC0xNy0xLTEtMTE1NDk2_9d0d803c-08b6-44b4-8395-7862f84ac84f"
      unitRef="usd">37600000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0zLTEtMS0xMTU0OTY_03fb1589-5729-494f-80d8-40d0e1afe333"
      unitRef="usd">595600000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS01LTEtMS0xMTU0OTY_4614bcdc-bb31-44c2-b467-97f6aeab1b14"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS03LTEtMS0xMTU0OTY_59276614-4255-4955-9dbf-a795b5952089"
      unitRef="usd">8400000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS05LTEtMS0xMTU0OTY_68f73d94-f38a-4afd-b8d4-070418e2a33b"
      unitRef="usd">587200000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0xMS0xLTEtMTE1NDk2_f0bc1683-6f2e-47bb-9208-ca9917bb07db"
      unitRef="usd">370600000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0xMy0xLTEtMTE1NDk2_246c677c-67de-4bfe-b16b-f43a82d4926f"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0xNS0xLTEtMTE1NDk2_1eec525a-1405-47ea-862d-2b1474c2f2f6"
      unitRef="usd">100000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNS0xNy0xLTEtMTE1NDk2_e9972dad-6e4e-44a0-8406-b4316cfb2d39"
      unitRef="usd">370500000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0zLTEtMS0xMTU0OTY_52005b43-f4ea-491d-b607-1bb44488d1f8"
      unitRef="usd">270800000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy01LTEtMS0xMTU0OTY_99d60e45-d74e-4b1d-998e-47714a234506"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy03LTEtMS0xMTU0OTY_d9360b8f-7826-436d-acda-bacb20d5da22"
      unitRef="usd">6200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy05LTEtMS0xMTU0OTY_80158ac2-ffbd-48b1-81fe-c047e81b570b"
      unitRef="usd">264600000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0xMS0xLTEtMTE1NDk2_58fbf18e-5197-49c1-a52b-e0a4439a051d"
      unitRef="usd">358900000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0xMy0xLTEtMTE1NDk2_4411ca76-ed3f-428b-bf95-e3d331dd346a"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0xNS0xLTEtMTE1NDk2_4c57e54d-20ed-4362-bd3d-176a0fb9b98a"
      unitRef="usd">1500000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfNy0xNy0xLTEtMTE1NDk2_abe59a87-1b94-4387-94ba-46ba983b9caf"
      unitRef="usd">357400000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0zLTEtMS0xMTU0OTY_44483ab0-5ebb-442f-ba76-f603d011a82f"
      unitRef="usd">102300000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC01LTEtMS0xMTU0OTY_623aad95-f01b-418c-943d-2b5c87b7dfac"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC03LTEtMS0xMTU0OTY_033d0f67-5eb3-4704-836b-c5e640e79cef"
      unitRef="usd">4300000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC05LTEtMS0xMTU0OTY_d6fc9b08-fb07-4d10-b37b-d107264b017d"
      unitRef="usd">98000000.0</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0xMS0xLTEtMTE1NDk2_64e5c6d2-11a9-43b5-b9c6-7629837e1e4d"
      unitRef="usd">204300000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0xMy0xLTEtMTE1NDk2_40a5df63-88e7-4bfd-90a5-78b96728050f"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0xNS0xLTEtMTE1NDk2_db5310df-2c16-4c55-ba25-3319a1d0a37f"
      unitRef="usd">1000000.0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOC0xNy0xLTEtMTE1NDk2_2ae01b1b-f9ea-4177-81f4-340326b573c3"
      unitRef="usd">203300000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0zLTEtMS0xMTU0OTY_3409b7ad-5edd-4045-b372-1a289887797d"
      unitRef="usd">373100000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS01LTEtMS0xMTU0OTY_64e04e23-9143-4d09-b120-4ab0c6ce4398"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS03LTEtMS0xMTU0OTY_9776778a-8fad-4845-9a7f-19f1b7e54528"
      unitRef="usd">10500000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS05LTEtMS0xMTU0OTY_b052f942-05c9-4ab1-9346-56f406eb6ea0"
      unitRef="usd">362600000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0xMS0xLTEtMTE1NDk2_2d07447b-c28e-4936-8e60-7235c74f0fe7"
      unitRef="usd">563200000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0xMy0xLTEtMTE1NDk2_ebb6f63e-d9d8-4a54-b94e-5fb10e455cb6"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0xNS0xLTEtMTE1NDk2_202c102e-4a7c-40e7-9994-b8d1a85cbb94"
      unitRef="usd">2500000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmY0NWQyMjQ1YjExNzRlOGY5ODc5ZWU3ZDQ4NTMwYjY0L3RhYmxlcmFuZ2U6ZjQ1ZDIyNDViMTE3NGU4Zjk4NzllZTdkNDg1MzBiNjRfOS0xNy0xLTEtMTE1NDk2_c902b8e8-6486-4adc-a92b-5d43e720d412"
      unitRef="usd">560700000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMzIw_2d324ab9-e65f-4170-badd-bd501d9794c8"
      unitRef="security">193</nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMzY5_975b9ae3-4df8-40e3-b96c-c09ee54765b5"
      unitRef="security">183</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTc5NQ_2143d720-b852-4f03-bad3-287df5e8e7ee">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of September&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi0xLTEtMS0xMTU0OTY_e977366f-e17c-4161-b502-8d13d33c1ae8"
      unitRef="usd">52900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi0zLTEtMS0xMTU0OTY_9166a5a1-aa2a-4dec-8f3d-33e6c712c9d7"
      unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi01LTEtMS0xMTU0OTY_e6274b13-5f28-46e8-bf5e-781ba40e4897"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi03LTEtMS0xMTU0OTY_f9c969c6-e344-4328-bf87-278e1eec417a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi05LTEtMS0xMTU0OTY_1ec33bc1-a567-4997-96f2-fa0b02042881"
      unitRef="usd">52900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if991653053864b2a904fed8d29ebc17e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMi0xMS0xLTEtMTE1NDk2_f170bd8b-9c3e-4f9c-a6fb-0b2fdc9fdc53"
      unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy0xLTEtMS0xMTU0OTY_0b535cba-6c29-464b-9bcf-f107d8c7b1d0"
      unitRef="usd">251100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy0zLTEtMS0xMTU0OTY_a3239ef2-2d2e-4b5c-919a-52fcf4ec8a21"
      unitRef="usd">4800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy01LTEtMS0xMTU0OTY_403dbb65-0b91-441a-a881-df38d583505b"
      unitRef="usd">263700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy03LTEtMS0xMTU0OTY_1a845006-2bc7-4155-90da-1560bceec24c"
      unitRef="usd">4600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy05LTEtMS0xMTU0OTY_53fa3d54-7504-471f-b058-7b37d448d469"
      unitRef="usd">514800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfMy0xMS0xLTEtMTE1NDk2_5b075ffb-e5eb-4e78-ad8e-8358c91bb159"
      unitRef="usd">9400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC0xLTEtMS0xMTU0OTY_d19679cc-cf6f-40ce-a1e7-47211a24709f"
      unitRef="usd">235000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC0zLTEtMS0xMTU0OTY_563eed60-37a3-443f-af6f-614820827782"
      unitRef="usd">6000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC01LTEtMS0xMTU0OTY_a716f66e-125f-45b8-8d08-7c2fea47bdf7"
      unitRef="usd">92900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC03LTEtMS0xMTU0OTY_88fbb261-ff6b-4c80-9eb3-95bec250e672"
      unitRef="usd">3100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC05LTEtMS0xMTU0OTY_4b57fcd7-51b8-48b1-90fc-678688e9a30c"
      unitRef="usd">327900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOjAxMThkOTFiOTE1YjRiYTFiMjgyMWZlZDc4NDI3ZDI4L3RhYmxlcmFuZ2U6MDExOGQ5MWI5MTViNGJhMWIyODIxZmVkNzg0MjdkMjhfNC0xMS0xLTEtMTE1NDk2_b98f53fb-d85f-4603-800d-50acfc4eeb4f"
      unitRef="usd">9100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi0xLTEtMS0xMTU0OTY_d84aa91d-c816-4ed5-a3eb-24d701d4eeca"
      unitRef="usd">428600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi0zLTEtMS0xMTU0OTY_20091dad-d21d-4b46-818e-e9e24daf6129"
      unitRef="usd">1600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi01LTEtMS0xMTU0OTY_534a0ca9-caf5-49aa-8436-4cf88ab38382"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi03LTEtMS0xMTU0OTY_c0f37a01-1a9f-4820-a9df-1e0281f76828"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi05LTEtMS0xMTU0OTY_e4f8a26f-d4f4-4922-9500-6bbc0cc35c14"
      unitRef="usd">428600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMi0xMS0xLTEtMTE1NDk2_04f93284-aa52-4fef-a5dc-e1ccfc87a6dd"
      unitRef="usd">1600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy0xLTEtMS0xMTU0OTY_d6944973-01af-4b64-9f08-fcf3db87dffd"
      unitRef="usd">230500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy0zLTEtMS0xMTU0OTY_94c89936-22e6-449c-be54-3c72f2d4d1d2"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy01LTEtMS0xMTU0OTY_bf9694d5-ff4b-4cf6-a368-3412e445ab23"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy03LTEtMS0xMTU0OTY_33831746-8adc-47b0-b1ef-e6f0d62801b3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy05LTEtMS0xMTU0OTY_26d0ee54-374f-468f-ab4b-bcd7942bfb11"
      unitRef="usd">230500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RhYmxlOmU4M2NkMWViNzBkOTRhZGU4NTk1Y2IzYTI1NjQ3MjlmL3RhYmxlcmFuZ2U6ZTgzY2QxZWI3MGQ5NGFkZTg1OTVjYjNhMjU2NDcyOWZfMy0xMS0xLTEtMTE1NDk2_73622ca9-af86-4c45-8ccf-ed29d0c741af"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:InterestReceivableCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTI2MA_18c9a994-b34b-4d53-98d2-1715e2f3fc7d"
      unitRef="usd">3900000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTI2Nw_c18b8a74-631e-47e4-b69c-8862aedc0de2"
      unitRef="usd">2200000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTcwOA_13a96779-be18-49b4-96ee-373ce8af070c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV8zNy9mcmFnOjU3MjhhMjBkYWM2YzRkYjA5MGIxNjYyMmRiNzk3YWVkL3RleHRyZWdpb246NTcyOGEyMGRhYzZjNGRiMDkwYjE2NjIyZGI3OTdhZWRfMTcwOA_72b21827-9b98-406d-bc8d-9e69257fc617"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RleHRyZWdpb246MzhlZmY1NGYxNTJiNDlmMmEzOTgyMjJiZjFlOGNkNzNfMTQ0Mg_8eebf1b3-1447-4a30-82de-af23b40d7022">Fair Value Measurements&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of investments, which were measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,264.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;949.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gain (loss) included in earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RleHRyZWdpb246MzhlZmY1NGYxNTJiNDlmMmEzOTgyMjJiZjFlOGNkNzNfMTQ0Mw_07bb592a-6717-467c-9960-91676dda0612">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RleHRyZWdpb246MzhlZmY1NGYxNTJiNDlmMmEzOTgyMjJiZjFlOGNkNzNfMTQ0NA_7b346606-2a60-43ff-a2f5-69547c3f0a1a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of investments, which were measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,264.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;949.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:Investments
      contextRef="i4839e374f144412a9f7b6a7f7818e610_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0xLTEtMS0xMTU0OTY_cb5f0c26-b7d4-46ad-89cb-d4c69c8d8342"
      unitRef="usd">212200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b0b098d67fd4b36b7ad36c659fff363_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0zLTEtMS0xMTU0OTY_f0e8fe0d-4b9a-4568-8974-a4fef9c0dfb1"
      unitRef="usd">212200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id6de012629174382b73ae25ee390d53d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC01LTEtMS0xMTU0OTY_e8ca826d-1406-4ba7-9933-a8a6b86422ca"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5dd7f53c0917469fb5aa137f42fa9641_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC03LTEtMS0xMTU0OTY_f4fdd5a0-369f-4678-8c67-104328726d54"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="id71a72a0204343a2ba932bbdf699fd15_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC05LTEtMS0xMTU0OTY_ba288bf1-3465-48d4-bc34-1a4cf0ecd27c"
      unitRef="usd">340800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i41a60cfe6cb248f28f728ecc7b0d9dac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0xMS0xLTEtMTE1NDk2_32a7b167-c278-4cbc-adef-875bad55196c"
      unitRef="usd">340800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3554cf0de1b74187a218d6f9def209e1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0xMy0xLTEtMTE1NDk2_9a423eea-2d5d-4f7e-8a6f-5b9dc3c77988"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i595e5cac95e64a078c1b2e3ba8fcad00_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNC0xNS0xLTEtMTE1NDk2_1291d758-41ec-445b-bc6b-c7e07b870389"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="id1d72cc605f044c39df6e8ac34e59455_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0xLTEtMS0xMTU0OTY_a336e972-a9d9-47a0-9ea6-21102ccf25f1"
      unitRef="usd">7800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i092271effac144f483e64869aea849d1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0zLTEtMS0xMTU0OTY_93255296-6fd9-4e8b-a194-875f256eb20f"
      unitRef="usd">7800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ca50849466f4f388fa755ae299a561f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi01LTEtMS0xMTU0OTY_f8678d42-acce-46c7-8be0-f41fd687c309"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf1638a41bfc4a4188eb4b991772a3c5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi03LTEtMS0xMTU0OTY_18321ea9-c177-41fc-9d8b-b145b3b7e62c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i180afdb708d547789b9d9c373554692d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi05LTEtMS0xMTU0OTY_2600323b-e461-4df9-b90f-61ba4c07ac28"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieca3d6e4dcde4876b83e7398f46fed0e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0xMS0xLTEtMTE1NDk2_3e6bc78f-da67-4bce-90df-79c194147c22"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i222b84b6200c4687ae6fad5eb6c114eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0xMy0xLTEtMTE1NDk2_cf51c173-1aff-40da-bd67-c5558ca31201"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i02faf276f4724aa4ad454f7424494fa8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfNi0xNS0xLTEtMTE1NDk2_e231869c-d5ca-49d1-95a0-da98808d0a1c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i9fd7fbc215c547fe9905956a7d3b2d0b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0xLTEtMS0xMTU0OTY_f79ec0a1-ebb5-4158-ad2d-f5ccfa85c37b"
      unitRef="usd">97500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i427d6d88fbf5403a90f978999cec31c1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0zLTEtMS0xMTU0OTY_f4ef8f4b-cddb-4fe6-834a-940fd7c8a14a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f1de29717fb412b8d0f3ede241f8bb3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC01LTEtMS0xMTU0OTY_7cad3680-7900-44fb-aeb2-8156d308b935"
      unitRef="usd">97500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4f0287a3f58248fd9c60960a29b9c6d7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC03LTEtMS0xMTU0OTY_ff6d2ac2-7b3c-4683-aeeb-290ece3d834c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i2455f9d7a9344e94b5e44642abae8dec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC05LTEtMS0xMTU0OTY_549ba19c-bca5-426a-9473-2ffe33d82814"
      unitRef="usd">204800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if7b9e17b5b754d4086db11dcfe954416_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0xMS0xLTEtMTE1NDk2_2cfdfa61-5db3-4042-902b-24fdd0bd4e88"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c322608454a431fb44e4870cfcf20e0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0xMy0xLTEtMTE1NDk2_c378e402-4feb-4e56-bbe7-3ee6317a4e90"
      unitRef="usd">204800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e7878b6282f4161a51f2ecb11e6ee6a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOC0xNS0xLTEtMTE1NDk2_6b9ad549-1ba3-4be9-a9b4-d009dbd20120"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i76a54806004342ca99ad41187b5f18ff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0xLTEtMS0xMTU0OTY_b791975d-b672-420c-8f65-6c825fc59036"
      unitRef="usd">521900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icad8bd51420d47599a0bbb9a64c2debc_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0zLTEtMS0xMTU0OTY_fc6147d4-5432-491f-80b7-abb58f118037"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3c20de1be0b54d57a763e3ccf1e3ffd2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS01LTEtMS0xMTU0OTY_c469b009-41d0-42f4-96ff-cbe6fb345d0e"
      unitRef="usd">521900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia4870a12f1c34345966751447c52154e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS03LTEtMS0xMTU0OTY_1c5bdfaa-00a7-4964-9ada-710c75370cc5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ic94f8e4d5b6f4d038bb335a8d9952a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS05LTEtMS0xMTU0OTY_ebcadee1-94c3-4777-a6bc-898ab0e2f6eb"
      unitRef="usd">485500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0223e03f957402ba98f263591110328_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0xMS0xLTEtMTE1NDk2_bb2c8b1c-1ea7-4cf6-b2fe-6974b6288119"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3a1df5c5dc8a46219d57553226f03b5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0xMy0xLTEtMTE1NDk2_3003c12d-bd62-43e2-9ec6-e6f43fa8cb29"
      unitRef="usd">485500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iebc376687d434b2f95f43d1c9e9eca69_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfOS0xNS0xLTEtMTE1NDk2_4e119bdd-94fe-4fd0-a04d-c56ae0db2c6e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ibbf2dc2b8842457aab96f17adc6e8854_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMS0xLTEtMTE1NDk2_529036ed-d97a-4f69-8b8b-8997d6769a6f"
      unitRef="usd">330400000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib6810cd7a4b24c838b72ecadd02e9522_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMy0xLTEtMTE1NDk2_11c60723-e2a6-48ac-ae7d-8a8e81ec1759"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9d07e5ef45644257bbcfa85ae04c08a9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtNS0xLTEtMTE1NDk2_3b953b94-3636-43b3-ae2e-d18f24f476ac"
      unitRef="usd">330400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i36692663da7d47208855243ce31dfad4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtNy0xLTEtMTE1NDk2_82988261-9ad2-4bf2-b972-d4b15d04d610"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i33f86e14bc93493b8cdc4da223c47077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtOS0xLTEtMTE1NDk2_3442d97a-908b-4261-b146-5ecc670b5a4a"
      unitRef="usd">240900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i80aeccc4b4694ebd8b20044eeae2adc2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMTEtMS0xLTExNTQ5Ng_46bfe878-54ba-420b-9231-bf8c1cdfa197"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0dedc56fd35f4871bf88c063a6ff6849_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMTMtMS0xLTExNTQ5Ng_962b4e66-9813-4798-a219-8b5cfc47a794"
      unitRef="usd">240900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idd7fa1d696ab44f8be8a258fb5120a82_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTAtMTUtMS0xLTExNTQ5Ng_533529c9-e405-46e2-a932-2598b33d1a86"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ic4207c67f0d44accbd49d0bd44c9afb5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMS0xLTEtMTE1NDk2_af9e532c-6cb7-4227-b3d0-2c8ada46b062"
      unitRef="usd">94900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ife8bf998110245f8b80ff377a8f82542_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMy0xLTEtMTE1NDk2_558d0053-fa09-47b8-94ec-7a88d4a03b3b"
      unitRef="usd">94900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie08641e1abc544caad6433c0c27d62c6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItNS0xLTEtMTE1NDk2_a3e0db6d-b6a1-4d8e-b8a6-d216fda2676e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i70f76ef824ec4b4c9f74fdf2aca12a07_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItNy0xLTEtMTE1NDk2_b529c133-58d5-4fb1-99c7-c0a7726035a8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ic1f93fe5331c425f98f7d5e731495d7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItOS0xLTEtMTE1NDk2_2de3516c-3bcb-42ec-b9c1-1d9682229c0a"
      unitRef="usd">63700000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia7146d8e9d0640aa93ae219f21de2a1c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMTEtMS0xLTExNTQ5Ng_f55bc9dd-e011-46aa-bcea-ce51bb1aa55d"
      unitRef="usd">52700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc1594a5b6774dc8b404800132ae9d9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMTMtMS0xLTExNTQ5Ng_bf7f94c6-6c14-4862-a9d2-f4632613c9e2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2bf809ef29d94cf38cf7aaf31b95dbc9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTItMTUtMS0xLTExNTQ5Ng_08d5fe62-857d-4470-af3f-6cecd53616c1"
      unitRef="usd">11000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMS0xLTEtMTE1NDk2_25dccb5a-b780-40b5-b715-3aaa6b4a612e"
      unitRef="usd">1264700000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4ca0198fc8364c69827b4bcd85bfda5c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMy0xLTEtMTE1NDk2_79e6d13d-92ba-44e3-8495-2f8daa5ecdbf"
      unitRef="usd">314900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3c36d96155624c52aa5e2d8d06ca58f6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtNS0xLTEtMTE1NDk2_d37a6923-0941-45e2-bedb-883af725415c"
      unitRef="usd">949800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i99f5e98291034c5ebdd1aaa8e86213e7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtNy0xLTEtMTE1NDk2_e833a971-b5a1-4011-8f6d-1385ce3e6a0f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtOS0xLTEtMTE1NDk2_250fb384-3e0f-42c6-a31b-92df63754489"
      unitRef="usd">1338900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic534f177a08b41618f86a8447e6aa13b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMTEtMS0xLTExNTQ5Ng_c6e48aa2-72dc-4e87-bb33-a74c31d511e9"
      unitRef="usd">396700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i22d1bdea9d1346bc84bff185b75f4d8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMTMtMS0xLTExNTQ5Ng_a89301a9-1c5c-41c1-9e0f-ceac6aeef91e"
      unitRef="usd">931200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i16add8cd888840ba965b71e41d99d856_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOmJjYTJjODVhNTY1ZjQxNDI5YmNhMDRkM2MzYTQ1NzQxL3RhYmxlcmFuZ2U6YmNhMmM4NWE1NjVmNDE0MjliY2EwNGQzYzNhNDU3NDFfMTMtMTUtMS0xLTExNTQ5Ng_1638d710-e989-40c8-b8b3-20b78fcec4b6"
      unitRef="usd">11000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RleHRyZWdpb246MzhlZmY1NGYxNTJiNDlmMmEzOTgyMjJiZjFlOGNkNzNfMTQ0NQ_bca77f9d-d9d5-4c68-8ae0-1a94e536f6ae">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gain (loss) included in earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i3482a00ad8dd4f2e803c923b8f328ea5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMi0xLTEtMS0xMTU0OTY_7dd7a58f-ee98-4965-91fb-b112eed81668"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i292aeff53ad84fc0ba0c70a3a9c01173_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMi0zLTEtMS0xMTU0OTY_cb2951e6-92ba-443c-aa70-41088f670e15"
      unitRef="usd">38900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2bf809ef29d94cf38cf7aaf31b95dbc9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMi01LTEtMS0xMTU0OTY_e246f295-a87d-45fc-ab60-5311bd184558"
      unitRef="usd">11000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ibbd2750ce3bd433caa60ae155d4dae98_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMi03LTEtMS0xMTU0OTY_a0d28a12-eb47-493e-8aa6-7ff1568bb3dc"
      unitRef="usd">38200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="ie49ac4b8f7504f74ae784614035b01ea_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMy0xLTEtMS0xMTU0OTY_6925d69d-fb99-47f0-960f-c1738a6d9133"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i252ec6df430b4181b19dba818761eefa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMy0zLTEtMS0xMTU0OTY_0881b0e6-c4d7-4b56-b536-1e331e6060db"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i4b89d380f2a64113845905298e656b37_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMy01LTEtMS0xMTU0OTY_83f23ffe-973b-406e-ba5a-ad785120e980"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="ie39d31443ce649c9b07f69bd9027d2fc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfMy03LTEtMS0xMTU0OTY_da524543-48bf-4d69-8c46-11f9e3cf8683"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i32c048dc598a4c8d8d72fe8f04ccf8a4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNC0xLTEtMS0xMTU0OTY_ac63dd22-584f-421b-bb73-4a88495629db"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i66dcf8a5e7154e9fadd29e9e4be560b2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNC0zLTEtMS0xMTU0OTY_49a37e97-0c97-41ed-b235-a89c764d01b5"
      unitRef="usd">-8200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i215cbb49fff34b958a3ad2dc5ab67b77_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNC01LTEtMS0xMTU0OTY_7833498b-f731-4ed8-855b-7b4f6abc646e"
      unitRef="usd">20800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ifbf97cbe7b5a4eeca45e05f5d6e775d3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNC03LTEtMS0xMTU0OTY_decbaa24-c7c9-456b-ba2a-466625f5c62b"
      unitRef="usd">-7500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i32c048dc598a4c8d8d72fe8f04ccf8a4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNS0xLTEtMS0xMTU0OTY_70101c6e-0378-498d-b751-61ddef4b5ff0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i66dcf8a5e7154e9fadd29e9e4be560b2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNS0zLTEtMS0xMTU0OTY_47d6a0f3-2e53-4fdb-bd8d-b6000d9b3507"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i215cbb49fff34b958a3ad2dc5ab67b77_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNS01LTEtMS0xMTU0OTY_7f1c6c41-6c51-4042-83c2-2ed1cd68df0c"
      unitRef="usd">31800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ifbf97cbe7b5a4eeca45e05f5d6e775d3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNS03LTEtMS0xMTU0OTY_ee02eec1-53de-4d26-8b58-02ef2560c17a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i70f76ef824ec4b4c9f74fdf2aca12a07_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNi0xLTEtMS0xMTU0OTY_36c2c17a-3166-47af-8cf5-5052756ceb5d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i88e35fa4d9f3455b80e4ddf1bb260920_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNi0zLTEtMS0xMTU0OTY_fbff2102-a8c0-47e8-88a6-17ac60e893a5"
      unitRef="usd">35300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i70f76ef824ec4b4c9f74fdf2aca12a07_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNi01LTEtMS0xMTU0OTY_7952e29e-1c35-49f9-9d66-7035124e5ecb"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i88e35fa4d9f3455b80e4ddf1bb260920_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80MC9mcmFnOjM4ZWZmNTRmMTUyYjQ5ZjJhMzk4MjIyYmYxZThjZDczL3RhYmxlOjM5NTZhY2Y0YmI3ZjRkNGE4YWFlODRhYzcxOGFkNjY5L3RhYmxlcmFuZ2U6Mzk1NmFjZjRiYjdmNGQ0YThhYWU4NGFjNzE4YWQ2NjlfNi03LTEtMS0xMTU0OTY_b488d04d-2ef4-4006-a386-fd8ed3152949"
      unitRef="usd">35300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RleHRyZWdpb246NmM2ZDNhODNlYzI3NGM4NGJjOTk5NDQ4YmJjOWFiMWZfNjE_71af5f0d-97fd-4bf9-8ad5-e041420d9c15">Inventories&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RleHRyZWdpb246NmM2ZDNhODNlYzI3NGM4NGJjOTk5NDQ4YmJjOWFiMWZfNjI_d0e47ac7-a080-4802-8e96-664602c1f9d8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMS0xLTEtMS0xMTU0OTY_dfbd8100-d59d-418b-9034-7623c5dac2a8"
      unitRef="usd">15000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMS0zLTEtMS0xMTU0OTY_5e6b678e-cde9-4db4-b823-d51279e28de9"
      unitRef="usd">11200000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMi0xLTEtMS0xMTU0OTY_6c0b1aa3-42f2-45c8-9565-f8669897066d"
      unitRef="usd">5000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMi0zLTEtMS0xMTU0OTY_d88d6ea7-9b0b-4404-8792-78bbaee18078"
      unitRef="usd">3600000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMy0xLTEtMS0xMTU0OTY_cbc35e78-37dd-4b32-930f-916737b66a49"
      unitRef="usd">17000000.0</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfMy0zLTEtMS0xMTU0OTY_8b234c9d-3c27-40b5-b109-45fb79554f4e"
      unitRef="usd">15700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfNC0xLTEtMS0xMTU0OTY_76d5e915-ce11-4c0f-86f6-827cd48b8278"
      unitRef="usd">37000000.0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i63a36f8809514653892aaae462d392cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80My9mcmFnOjZjNmQzYTgzZWMyNzRjODRiYzk5OTQ0OGJiYzlhYjFmL3RhYmxlOmYxMWVkY2VhMWI5MDQxNjFhNDU2MjI5YjQzMzUyN2ZjL3RhYmxlcmFuZ2U6ZjExZWRjZWExYjkwNDE2MWE0NTYyMjliNDMzNTI3ZmNfNC0zLTEtMS0xMTU0OTY_e2d468ee-a26e-44e6-b441-331b509f0c2b"
      unitRef="usd">30500000</us-gaap:InventoryNet>
    <nbix:RestrictedCashTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RleHRyZWdpb246ZWY1ZGNmYWJlNGNiNDBiYTlkZTg3NDk0NWVlODA1MThfMjE3_8b91401a-2437-4e02-b513-0b9a60625e65">Cash, Cash Equivalents and Restricted Cash&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:RestrictedCashTextBlock>
    <nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RleHRyZWdpb246ZWY1ZGNmYWJlNGNiNDBiYTlkZTg3NDk0NWVlODA1MThfMjE4_f89a0682-7fed-4ca1-9a49-64569d8da984">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMS0xLTEtMS0xMTU0OTY_b6c81e59-5367-46fa-8938-f2e1341ef784"
      unitRef="usd">212200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMS0zLTEtMS0xMTU0OTY_9949752e-04f3-4ea6-9cc8-16934f89ecbb"
      unitRef="usd">311100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMi0xLTEtMS0xMTU0OTY_c4318502-144d-4b27-be8d-f3e86ab0587a"
      unitRef="usd">7800000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMi0zLTEtMS0xMTU0OTY_0733febf-5d2d-489b-b3b6-33202a5cfe12"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMy0xLTEtMS0xMTU0OTY_ecd90947-ebe6-4e2f-8b9c-0036a7869d72"
      unitRef="usd">220000000.0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80Ni9mcmFnOmVmNWRjZmFiZTRjYjQwYmE5ZGU4NzQ5NDVlZTgwNTE4L3RhYmxlOjA1MGMyMTIwZTY4MzQxOTM5MDIyYWUzNWI1ZjkzZGRhL3RhYmxlcmFuZ2U6MDUwYzIxMjBlNjgzNDE5MzkwMjJhZTM1YjVmOTNkZGFfMy0zLTEtMS0xMTU0OTY_28344a86-3f59-4ddc-af24-6a628527358b"
      unitRef="usd">314300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUyMQ_12737661-a932-455b-938b-47b7280a8854">Leases&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters. This lease has not commenced for accounting purposes. Under the terms of the lease, on a building-by-building basis, base rent will be subject to a 10-month rent abatement period following the respective lease commencement date, which dates will be determined in the future based upon achievement of substantial completion of construction with respect to each such building in the condition suitable for the installation of our furniture, fixtures, and equipment, and on which date we will record a lease liability, corresponding right-of-use asset, and begin lease expense recognition with respect to each such building. After the rent abatement period, monthly base rent will be $6 per square foot, subject to annual escalations of 3% during the initial &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTY0OTI2NzQ0NDE5NQ_53c700d8-36e0-4b90-b6dc-fbf8018a13aa"&gt;13.6-year&lt;/span&gt; lease term, which term we have the option to renew for two additional terms of five years each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our operating leases, in lieu of a cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $7.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental operating lease information for operating leases that have commenced.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents approximate non-cancelable future minimum lease payments under operating leases as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022 (3 months remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding
      contextRef="i293bb336d80d473eb69da7cf494b8713_D20220208-20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUxMw_87d6db83-3ef5-4b40-84ea-07186292b9d5">P6Y</nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding>
    <nbix:RentAbatementPeriod
      contextRef="i293bb336d80d473eb69da7cf494b8713_D20220208-20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUxNA_cd09db41-08fd-4a00-a625-6612f5315fae">P10M</nbix:RentAbatementPeriod>
    <nbix:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot
      contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTY4MA_f62e04d5-ad94-4041-98f0-0ca8f504d0d3"
      unitRef="usd">6</nbix:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot>
    <nbix:AnnualRentEscalationPercentage
      contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTczMw_bda942e5-1d07-49ed-b693-272a4aa30bae"
      unitRef="number">0.03</nbix:AnnualRentEscalationPercentage>
    <nbix:NumberOfRenewalOptions
      contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUxNw_9f9bfd8b-9ac6-4db7-a3af-cb2578ee5646"
      unitRef="renewaloption">2</nbix:NumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i016360b58b9248388c5ea2f0970527a4_I20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMTg0MQ_504f7af5-f9b6-49b5-9916-a0982e3b786a">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjAzMQ_7488bcca-5578-4638-a5d5-55c406a33727"
      unitRef="usd">7800000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUxOA_d35e25db-4669-4408-b58d-f1aabd4d407e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental operating lease information for operating leases that have commenced.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfMi0xLTEtMS0xMTU0OTY_0d57b3da-df05-4df5-b685-63bfb2feab56"
      unitRef="usd">12500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfMi0zLTEtMS0xMTU0OTY_5fe33ccd-28b1-471a-a132-da02050835a1"
      unitRef="usd">11200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfMy0xLTEtMS0xMTU0OTY_754914f7-fb8c-467d-9968-c438ca97e798"
      unitRef="usd">12200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfMy0zLTEtMS0xMTU0OTY_c1bcb0ac-5df9-41eb-9934-23fee462babe"
      unitRef="usd">9100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfNi0xLTEtMS0xMTU0OTY_7e9ffde3-670e-421d-8a2c-3c820baada4e">P8Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfNi0zLTEtMS0xMTU0OTY_cac40119-d5e0-4594-afb1-57c9234523f5">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfNy0xLTEtMS0xMTU0OTY_16548bf5-d526-473c-814f-392c10257cbe"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2d4f0a2cea8441e0b026692719475b64_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjRiNTYxOGZiZmU1MTQwNGY4ZTIxZGU5NDA3N2I5YWU1L3RhYmxlcmFuZ2U6NGI1NjE4ZmJmZTUxNDA0ZjhlMjFkZTk0MDc3YjlhZTVfNy0zLTEtMS0xMTU0OTY_e81c4e22-cd4a-40c5-b13d-f0929de0c20a"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjUyMw_c7c496a3-5af8-49a3-9eb2-74ced93874c0">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents approximate non-cancelable future minimum lease payments under operating leases as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022 (3 months remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMS0xLTEtMS0xMTU0OTY_ffb3cc40-f876-4725-ae86-b59441f17b18"
      unitRef="usd">4400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMi0xLTEtMS0xMTU0OTY_218eaca2-3484-45df-ba88-e64fe4a83d0e"
      unitRef="usd">17900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMy0xLTEtMS0xMTU0OTY_2ce60205-d86e-4c9a-a599-8912ad7dd8c4"
      unitRef="usd">17400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfNC0xLTEtMS0xMTU0OTY_e0e26c3b-b98a-43d9-9f6c-bc85b3cbea8b"
      unitRef="usd">15900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfNS0xLTEtMS0xMTU0OTY_7953f148-d796-446c-a665-da841bfaea40"
      unitRef="usd">15700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfNi0xLTEtMS0xMTU0OTY_4cfa9607-add0-4937-9982-27ee189826e9"
      unitRef="usd">70400000</nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfNy0xLTEtMS0xMTU0OTY_203d2735-cd1e-427d-af36-9116ac5d2688"
      unitRef="usd">141700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfOC0xLTEtMS0xMTU0OTY_ce9f7795-4a82-42de-92c0-26bd96a52590"
      unitRef="usd">27800000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfOS0xLTEtMS0xMTU0OTY_ce7060fc-5e4d-4ffa-8427-cb7346362878"
      unitRef="usd">113900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMTAtMS0xLTEtMTE1NDk2_d898a7f1-5dc9-45ec-b081-cac3a1c6a894"
      unitRef="usd">17300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RhYmxlOjFhNjc3YjQ2YzEwNDQ5ZDY5MzI0NTdlNzJiYjkxYjg3L3RhYmxlcmFuZ2U6MWE2NzdiNDZjMTA0NDlkNjkzMjQ1N2U3MmJiOTFiODdfMTEtMS0xLTEtMTE1NDk2_6a0f5201-9bd0-441b-b720-7da804628f09"
      unitRef="usd">96600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjM0NQ_4bb3b5d8-058f-44ea-86ed-bd4e46eb3139"
      unitRef="usd">17200000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjM1OA_5f03a482-42d3-42c1-baed-ef0a571cf0ba"
      unitRef="usd">33300000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjM3MQ_73b81380-74e0-445c-b399-9b4969b2ecbb"
      unitRef="usd">41900000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive
      contextRef="i7f42127857b54a13aa343398bb2d541d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV80OS9mcmFnOjFjMDBjYzg4MzU5ODQ4YTRiZmQ3M2Y3ODUwMDgwZDhmL3RleHRyZWdpb246MWMwMGNjODgzNTk4NDhhNGJmZDczZjc4NTAwODBkOGZfMjM4OA_7cf84875-67b4-472c-9060-6795961eb325"
      unitRef="usd">479700000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwMw_8102aff9-5a08-4715-934c-812e51e956bf">Convertible Senior Notes&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with authoritative guidance in effect at the time of issuance, we were required to separately account for the liability and equity components of the 2024 Notes. The initial carrying value of the liability component of $368.3 million was calculated using a 7.50% assumed borrowing rate, which reflected the market interest rate for a similar non-convertible instrument at the date of issuance. The equity component of $149.2 million, which was treated as a discount on the liability component and amortized over the seven-year term of the 2024 Notes using the effective interest rate method, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and recorded as an increase to additional paid-in capital on the issuance date. In addition, we allocated transaction costs of $14.7 million related to the issuance of the 2024 Notes to the liability and equity components based on their relative values on the issuance date. Transaction costs attributable to the liability component were being amortized over the seven-year term of the 2024 Notes using the effective interest rate method, while transaction costs attributable to the equity component were recorded as a reduction to additional paid-in capital on the issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7 million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3 million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recorded as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4 million at settlement was recognized as a reduction to the 2024 Notes and resulted in an $18.4 million loss on extinguishment, which we recognized in the fourth quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjY4MQ_23a4d3d8-f809-4fc2-a1ec-3aa2e7730856"&gt;ASU 2020-06&lt;/span&gt; using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million, and reduced the accumulated deficit by $74.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment, which resulted in the recognition of a $70.0 million loss on extinguishment in the second quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the interest expense of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2024 Notes in cash upon conversion and to settle any conversion premium, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $1,000 principal amount and equivalent to an initial conversion price of approximately $75.92 per share, reflecting a conversion premium of approximately 42.5% above the closing price of $53.28 per share of our common stock on April&#160;26, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of September&#160;30, 2022) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt"&gt;during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of September&#160;30, 2022) on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt"&gt;during the&#160;five business-day period immediately after any&#160;five&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt"&gt;upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt"&gt;if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the conditional conversion feature described under (i) above was triggered as of September 30, 2022, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on October 3, 2022, and ending at the close of business on December 30, 2022. Accordingly, the 2024 Notes have been classified as a current liability as of September 30, 2022. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, holders will receive the principal amount of their 2024 Notes in cash and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwNQ_ef8f04f5-41e3-4904-9590-625dd3555ec1"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTEy_f1039814-97ea-4016-af7e-82d16e67cdd1"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <nbix:CarryingAmountOfLiabilityComponentUponIssuance
      contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTAy_05c132a7-8b9c-4fc6-921c-e5ee96192abc"
      unitRef="usd">368300000</nbix:CarryingAmountOfLiabilityComponentUponIssuance>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTI4_d419db2e-ffb8-4d3d-af28-24e1760f7799"
      unitRef="number">0.0750</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjg2_f4d90fe0-7912-4edd-b4dc-dd8e8df05861"
      unitRef="usd">149200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwNg_62e356d3-16f9-413a-b2d0-69ea430b501a">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTA2Mw_048b9a22-7240-4174-9ab0-47c0cb3d1071"
      unitRef="usd">14700000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwNw_1ab501c3-438f-405b-bf1f-c5ae86a6e19f">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i1203e4c8b5dc4172916025c8100cbdf2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTYyMw_d5031a6b-4ca9-4527-a11e-dd42a1729c43"
      unitRef="usd">136200000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTcwMA_9335aed7-d0cc-475d-af8d-c37fd0b790fd"
      unitRef="usd">186900000</us-gaap:RepaymentsOfDebt>
    <nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment
      contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMTgxNQ_85003fd5-1f47-4065-b8d5-6c896a4df574"
      unitRef="usd">130700000</nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i77d2b40e50ad4aa48f0578112016e986_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjA5OA_e9c70af4-7b4b-4ff5-a1ed-1429f1a52e66"
      unitRef="number">0.0337</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjE5Ng_9d533d65-1a5a-4712-b625-888e1736d877"
      unitRef="usd">56300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <nbix:CarryingAmountOfLiabilityComponentAtSettlement
      contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjQ5Ng_eb6b7b4f-70fc-45cd-95d0-447b5ac97d10"
      unitRef="usd">112400000</nbix:CarryingAmountOfLiabilityComponentAtSettlement>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9178f3af8fe54ff3adfd9b2d4ddec577_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjU3Mg_097364e0-7e52-447d-949e-2fe857c4ad15"
      unitRef="usd">-18400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMjk4OA_3fadbf96-fab2-4a82-9eb0-63ce21e29837"
      unitRef="usd">42200000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzAyOA_cf096fb4-0369-4106-b684-b56c27e6f653"
      unitRef="usd">-9900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzA3MA_c3d58a77-1cb2-4f4c-ba05-6c06fe4c9975"
      unitRef="usd">-106800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4d3b20629a004abe8438fa321eae8513_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzExMw_5f4baac4-e767-43f4-9684-8d5a56c1dbfa"
      unitRef="usd">74500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ia4f1503bf3ac46d1b34a4f8bb6f92140_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzI2MQ_c70a5d9c-7681-469e-9c65-4dad1e872684"
      unitRef="usd">210800000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="ifa8302f1e6814a9987ec49ca9af465a2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzM0Ng_c943e8fd-4717-4134-b8ae-62e32a61a37b"
      unitRef="usd">279000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifa8302f1e6814a9987ec49ca9af465a2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfMzQ4MQ_b8055ecf-d8cf-4446-8843-99e898968530"
      unitRef="usd">-70000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODEwOA_2a43db28-e856-420b-b272-ce55bba37383">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the interest expense of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi0xLTEtMS0xMTU0OTY_de93fb2d-bd68-4e0b-be2c-eeff71377af4"
      unitRef="usd">170400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi0zLTEtMS0xMTU0OTY_0887833b-d041-4156-b008-480e92212d1f"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi01LTEtMS0xMTU0OTY_7d24b9bf-8183-44ff-a698-cb04b3e95797"
      unitRef="usd">1200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi03LTEtMS0xMTU0OTY_1b5daa40-b446-4045-ba8a-d1149dd601d5"
      unitRef="usd">169200000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i8a5bcc60ead14ba1ac643d19e4770911_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjlhZmI3YTJlNmUwNTRkYmU4YzEzNTU1ZTU5ZjgyZDFlL3RhYmxlcmFuZ2U6OWFmYjdhMmU2ZTA1NGRiZThjMTM1NTVlNTlmODJkMWVfMi05LTEtMS0xMTU0OTY_086836e8-c49e-4844-9b0d-09969b74916e"
      unitRef="usd">238300000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi0xLTEtMS0xMTU0OTY_129df4b4-e022-41f7-9aa7-ae19ee61f9b9"
      unitRef="usd">381200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi0zLTEtMS0xMTU0OTY_46508e92-a0d4-48f6-b7b5-770654887507"
      unitRef="usd">43200000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi01LTEtMS0xMTU0OTY_72e8fc48-9e8f-46d2-baa6-caf7786e86dd"
      unitRef="usd">2900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi03LTEtMS0xMTU0OTY_84d1c285-1e6d-4fab-81d4-3d916ec27d7b"
      unitRef="usd">335100000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i66f160f54d404d8bb80d4edd382393c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOjRkNmMxM2IxM2ZkNDQwMWY5YTZkMTE5NzkyOTkxZDJjL3RhYmxlcmFuZ2U6NGQ2YzEzYjEzZmQ0NDAxZjlhNmQxMTk3OTI5OTFkMmNfMi05LTEtMS0xMTU0OTY_715ae0a8-c637-49d5-bc8a-98ed9ae7d866"
      unitRef="usd">464700000</us-gaap:DebtInstrumentFairValue>
    <nbix:DebtInstrumentCouponInterest
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMi0xLTEtMS0xMTU0OTY_6c788a80-8438-49a5-b7f0-658e632e4176"
      unitRef="usd">1000000.0</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMi0zLTEtMS0xMTU0OTY_1c777305-4a4b-45d0-a2ae-522ee2bbf026"
      unitRef="usd">2200000</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMi01LTEtMS0xMTU0OTY_df1418d2-0e56-4646-b10c-ca933c773681"
      unitRef="usd">5000000.0</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMi03LTEtMS0xMTU0OTY_be89cbf4-4f6e-415a-9b75-6d5f979aaab2"
      unitRef="usd">6300000</nbix:DebtInstrumentCouponInterest>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMy0xLTEtMS0xMTU0OTY_c032c65c-47c1-4f64-a397-0de7ab9203ee"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMy0zLTEtMS0xMTU0OTY_ffc53860-722f-4e9b-9e9b-702566a06aad"
      unitRef="usd">4400000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMy01LTEtMS0xMTU0OTY_bbee3bb9-46a4-4fad-91fb-2864be65e2d2"
      unitRef="usd">1000000.0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfMy03LTEtMS0xMTU0OTY_75b375b9-bb58-4b8e-b9d5-bb3c60254ef4"
      unitRef="usd">12900000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpense
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfNC0xLTEtMS0xMTU0OTY_e171ddd5-939e-498f-9c52-4f94e7b813b7"
      unitRef="usd">1200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfNC0zLTEtMS0xMTU0OTY_8e04450f-234f-4a50-9bb3-72a9df18248a"
      unitRef="usd">6600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfNC01LTEtMS0xMTU0OTY_415d1e2c-4f28-4cde-9bc8-391ec6e43dc9"
      unitRef="usd">6000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RhYmxlOmZjNTU1YzlhNDZiMTRiMDM4MjBkZTJlZmRiYjExYzg5L3RhYmxlcmFuZ2U6ZmM1NTVjOWE0NmIxNGIwMzgyMGRlMmVmZGJiMTFjODlfNC03LTEtMS0xMTU0OTY_c27028c7-e478-42ff-9305-a9c934eea6be"
      unitRef="usd">19200000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNDU4MA_71a207e0-6b22-4f0b-9752-e61f72ccbc99"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i5d6487fd362c4e36a923415c3752b4f7_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNDg3NA_ad79e3a5-cf3d-47bb-b457-e6ebdb22a5b2"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNDk1Nw_6e7c5540-6ddf-4e25-9d32-beb18298bc2a"
      unitRef="usdPerShare">75.92</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nbix:DebtInstrumentConvertibleConversionPremium
      contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTAyMA_1a4342af-18d1-4633-8abb-d2eae8020329"
      unitRef="number">0.425</nbix:DebtInstrumentConvertibleConversionPremium>
    <us-gaap:SharePrice
      contextRef="i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTA1MA_7242e294-674f-4c29-a036-c9007a4c519e"
      unitRef="usdPerShare">53.28</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTIyOA_b65e7df1-9cbb-404a-b4e0-85be383f5c23"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="ib8b91f81d53147c9b20bab4e275695ef_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTI4MA_9fe7e6d9-d5c5-4e90-b038-af7fc6ca5dd4"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTMwNg_f16a96d8-4d75-4365-a502-dd4175d000ff"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTM2Mg_71a207e0-6b22-4f0b-9752-e61f72ccbc99"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTgwNg_f16a96d8-4d75-4365-a502-dd4175d000ff"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTg3MA_71a207e0-6b22-4f0b-9752-e61f72ccbc99"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTk5MQ_b65e7df1-9cbb-404a-b4e0-85be383f5c23"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="ib8b91f81d53147c9b20bab4e275695ef_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjAyOA_9fe7e6d9-d5c5-4e90-b038-af7fc6ca5dd4"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ic03ac1eae74a42adac16fd393cd612f3_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjA4NA_7b8e6d1f-7b02-4e38-9655-3a5bd0312451"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ic03ac1eae74a42adac16fd393cd612f3_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjEyOQ_7b8e6d1f-7b02-4e38-9655-3a5bd0312451"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i5d6487fd362c4e36a923415c3752b4f7_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjI0Mg_ad79e3a5-cf3d-47bb-b457-e6ebdb22a5b2"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice
      contextRef="ic03ac1eae74a42adac16fd393cd612f3_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNjMzMw_b6c6eb49-b4d9-4488-8e07-8fc1b7d1ae92"
      unitRef="number">0.98</nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="id02698bb2a6546b787a20f88bacf5509_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNTQ5NzU1ODI1OTY4_71a207e0-6b22-4f0b-9752-e61f72ccbc99"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfNzA1NA_21ae2697-8db1-406e-9f4b-ae21716ac2c5"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i4114e95b28fa4442bb77b9fa476745f4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81Mi9mcmFnOmY4MDRmZDUxMGU4NDQyYjFiNzVhZTczZGFjYmM3YWU1L3RleHRyZWdpb246ZjgwNGZkNTEwZTg0NDJiMWI3NWFlNzNkYWNiYzdhZTVfODAwMA_21ae2697-8db1-406e-9f4b-ae21716ac2c5"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RleHRyZWdpb246ZDY0ZWU3YTZkYWFlNDFjOGE5OGZhMWQxN2U2MzEyYTRfODc_28054010-cf6a-4c80-99ce-0a3ba3a13ac8">Earnings per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares excluded from diluted per share amounts because their effect would have been anti-dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RleHRyZWdpb246ZDY0ZWU3YTZkYWFlNDFjOGE5OGZhMWQxN2U2MzEyYTRfODg_96fcc8e4-38f1-4f5f-b2db-a0cf36e97d64">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares excluded from diluted per share amounts because their effect would have been anti-dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi0xLTEtMS0xMTU0OTY_3ebc5759-ee58-4fc9-bdda-d493086fc4f4"
      unitRef="usd">68500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi0xLTEtMS0xMTU0OTY_4c09bcfe-b01f-41cf-a3cb-f82236210625"
      unitRef="usd">68500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi0zLTEtMS0xMTU0OTY_41450c54-7e9d-4fb5-bf04-9c55077f0137"
      unitRef="usd">22500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi0zLTEtMS0xMTU0OTY_e13a42d1-494b-4a1e-b731-283032badaa9"
      unitRef="usd">22500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi01LTEtMS0xMTU0OTY_7bb0bd91-3b0b-43f2-8177-6ac5a653d1e7"
      unitRef="usd">65500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi01LTEtMS0xMTU0OTY_dfd9483c-c195-461b-be53-5e89bc51d664"
      unitRef="usd">65500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi03LTEtMS0xMTU0OTY_c2d92018-f677-4bce-baeb-8a9af6c6e4f1"
      unitRef="usd">96900000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMi03LTEtMS0xMTU0OTY_d18b3d3c-0b1a-40bd-9056-220697e7276d"
      unitRef="usd">96900000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNC0xLTEtMS0xMTU0OTY_b041e636-0195-404c-b708-5f9942b6c4c5"
      unitRef="shares">95800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNC0zLTEtMS0xMTU0OTY_f67856ff-da54-4467-8e03-2c970cb28bbd"
      unitRef="shares">94700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNC01LTEtMS0xMTU0OTY_2efb94e3-ed3a-4f23-8bd8-bb660a5da969"
      unitRef="shares">95600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNC03LTEtMS0xMTU0OTY_3de27984-7796-46a1-a02f-63ada51da9b2"
      unitRef="shares">94500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i075bf5beb06a450d897f5554a7c9f675_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNi0xLTEtMS0xMTU0OTY_e283f97b-95f3-4d47-89cf-af97104585d4"
      unitRef="shares">1900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia976ce0a469f43dd8529daa7ded8f407_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNi0zLTEtMS0xMTU0OTY_46e83425-0784-4900-87f7-fadf6b7cf7ec"
      unitRef="shares">1800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7ffc106e9c034ce0a4ec85dfbc149c80_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNi01LTEtMS0xMTU0OTY_92bc237a-979e-4cf6-ae21-894fe1509d3f"
      unitRef="shares">1700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i97c06ced3466414480ad4f43ed22809c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNi03LTEtMS0xMTU0OTY_2a1930dd-c1ce-4612-bf46-299a8ca343e2"
      unitRef="shares">1900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i10df804649bf4f5881d03f512c323aad_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNy0xLTEtMS0xMTU0OTY_b569933a-ac01-489f-adcb-e748bc17fb4d"
      unitRef="shares">800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i82b33cfb43b446bb98d589fcf33582cd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNy0zLTEtMS0xMTU0OTY_0280e7d3-a078-4fbb-b063-39fe8eba2191"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i67742768ef2045548179b11e33a332c8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNy01LTEtMS0xMTU0OTY_1c03f81a-e685-4088-ba2f-50383e57c42c"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if6cd5647e0764102ae7a3f85ef3b6d57_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfNy03LTEtMS0xMTU0OTY_a62cd4d3-c4c9-4603-9e76-393c74cab628"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="ib7a804747bab486687e11ad36d58a3ce_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOC0xLTEtMS0xMTU0OTY_5ae966bc-f295-494e-a325-ae64c3728d69"
      unitRef="shares">600000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="idcaf85e03f214f0fa6d79c0c4f6af669_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOC0zLTEtMS0xMTU0OTY_6ed19a18-b879-45c9-9c4d-319c1e09cf49"
      unitRef="shares">1000000.0</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i0a294335166245f6a43fd1a87aa252a7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOC01LTEtMS0xMTU0OTY_efa701a1-cabd-45bd-b40b-517ac4585834"
      unitRef="shares">500000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="ia51e5bcf01714c6fa740643677798f18_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOC03LTEtMS0xMTU0OTY_ff76a917-b9b2-427d-9074-04789de87ab6"
      unitRef="shares">1100000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOS0xLTEtMS0xMTU0OTY_10d358d9-943e-42da-b295-a3dc9e25a1a3"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOS0zLTEtMS0xMTU0OTY_e5304569-41bd-4ca0-af14-ceb7396ae729"
      unitRef="shares">97700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOS01LTEtMS0xMTU0OTY_0fb650fc-626f-4df0-94ce-840984fc4e4c"
      unitRef="shares">98300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfOS03LTEtMS0xMTU0OTY_167e62c8-d855-49da-b27b-a171a7d82ca5"
      unitRef="shares">97900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTEtMS0xLTEtMTE1NDk2_07914b5d-111d-41f7-a00f-b72fcf4df275"
      unitRef="usdPerShare">0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTEtMy0xLTEtMTE1NDk2_940daec5-a334-4ea0-a895-ee544d1da7db"
      unitRef="usdPerShare">0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTEtNS0xLTEtMTE1NDk2_6336d554-3ca5-4c60-9481-96da5148dda3"
      unitRef="usdPerShare">0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTEtNy0xLTEtMTE1NDk2_42db7860-3bd8-45ca-9283-163799c239e3"
      unitRef="usdPerShare">1.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTItMS0xLTEtMTE1NDk2_e121b66a-905c-48c4-892c-9c3a6ec5f325"
      unitRef="usdPerShare">0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTItMy0xLTEtMTE1NDk2_1bf5d9d2-dc1e-4085-bad1-f50ef11517d1"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTItNS0xLTEtMTE1NDk2_c362b2c5-3bd8-4cce-9ea1-dc809a6ff2a7"
      unitRef="usdPerShare">0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTItNy0xLTEtMTE1NDk2_89f08395-5423-4641-ab40-49f85cdf364f"
      unitRef="usdPerShare">0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTQtMS0xLTEtMTE1NDk2_57ccf48d-5a40-453c-b02e-87e060c0a604"
      unitRef="shares">4900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if2ee3b71fa4b4c198c42ffb8cbeeac53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTQtMy0xLTEtMTE1NDk2_422a25fc-7a40-4691-a809-73fd3b498f8d"
      unitRef="shares">4500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTQtNS0xLTEtMTE1NDk2_86b0c850-8925-4328-ac9f-8d40a99426f8"
      unitRef="shares">5500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6f120356cb534c0facb53901ae3a8a38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV81OC9mcmFnOmQ2NGVlN2E2ZGFhZTQxYzhhOThmYTFkMTdlNjMxMmE0L3RhYmxlOjMwMmUxZjhhZDZkYTRhY2I5OTkzYzc1MGE1M2ZlMDE1L3RhYmxlcmFuZ2U6MzAyZTFmOGFkNmRhNGFjYjk5OTNjNzUwYTUzZmUwMTVfMTQtNy0xLTEtMTE1NDk2_5ae43bf6-7d53-4cec-8e9f-b0851093e1b6"
      unitRef="shares">4000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV83MTIvZnJhZzpmNDY1OWRmNDgzYzc0MzI3YjM2NGNjZDNiNjYwY2JjMi90ZXh0cmVnaW9uOmY0NjU5ZGY0ODNjNzQzMjdiMzY0Y2NkM2I2NjBjYmMyXzIxOTkwMjMyNjAwNjc_21fc4f3b-9505-43b6-bfd7-6c415b2117d8">Subsequent EventsOn November 1, 2022, we acquired Diurnal Group plc in an all-cash transaction, for an aggregate value of approximately &#xa3;48.3&#160;million GBP, or approximately $56&#160;million USD. We believe the transaction presents an opportunity to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders. We are currently in the process of finalizing the accounting for this transaction.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="if8ceebe0bfe84be1b0d7f9f9ae5831b9_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV83MTIvZnJhZzpmNDY1OWRmNDgzYzc0MzI3YjM2NGNjZDNiNjYwY2JjMi90ZXh0cmVnaW9uOmY0NjU5ZGY0ODNjNzQzMjdiMzY0Y2NkM2I2NjBjYmMyXzU0OTc1NTgxODkxNw_a88c520e-b01b-4d2b-b227-b37d97822497"
      unitRef="gbp">48300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="if8ceebe0bfe84be1b0d7f9f9ae5831b9_D20221101-20221101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmNDM5YTM2ZGIyNzRjZmFhMDI2NTE4ZWRlM2VkYTQ5L3NlYzpmZjQzOWEzNmRiMjc0Y2ZhYTAyNjUxOGVkZTNlZGE0OV83MTIvZnJhZzpmNDY1OWRmNDgzYzc0MzI3YjM2NGNjZDNiNjYwY2JjMi90ZXh0cmVnaW9uOmY0NjU5ZGY0ODNjNzQzMjdiMzY0Y2NkM2I2NjBjYmMyXzU0OTc1NTgxODk1OA_3a69b14e-c8fc-4844-a89c-d90f8818a8d7"
      unitRef="usd">56000000</us-gaap:BusinessCombinationConsiderationTransferred1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MXW&G\I7.AQWE?(:Q4 O3,'\!!;T$<Q"O>&)/+2Y8#7H.X\-*X\-PW[)/Y%)
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MSHT'%9I1OT5'U<\>?X.BVQK1RN? 'K3IOU<F/3^?,SJ^L#\GJR;)B;3<RJ'
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M&"I3.$JAH&M5".7HZY88Y"(Z+(&;] ;"TTI58I5=R_[FLB4YB+'1%!B[42L
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MIPKK"\$.U;&Y.R8$VU=?=S3=T%(!Y._WC(FG"]7 ^6SG\C]02P,$%     @
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MJ3&[Z<;TK;HSHDBM[\R:BY&HU&0]5,Z(#7PA12T/J#,"I2ULA3,RTK^0 DV
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M/CUY*,HE+R^5D2934@L/+83B#UX4\H;$@L@(A+.2#ON4B8I=CMV$B@E%?&^
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M+E0Z$,963PS%;TK &&55*G1>&"%%TIDB\U/(, 58?#&OB S$S5PG<S%1B5P
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ME6M)F[4$$\6(H6>5)2XP3&QRXN314;3F =G;J[=QR>(%8W4C'@C '0L>$>=
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MD%^T#(]P-GMCL'%'NR0S?B/A;V[G]/..R6;M:Z+JWWZW -AS[RQ>K;=J8D,
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M$D4%Q3PO_9:B<1!(NJA3'P>2*ZU WTPRO%7-"L2.7%(NAD8+C)ZXG%$UU6L
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M#EG3=A^&8:"EL\65(E62LNO]^MU1+Y:2.-T*+$ LOAR?>^YX=R0O=MI\L1F
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ME"74@*^E0(IDQ_EA*M<*]HU'UZ5*+7O.HC *HL[7ATGTJM>*9]-@WOD^E/F
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MAV\@W\SPT0F&!'!^K;'.U1U2T#YCE_\ 4$L#!!0    ( %"!854@&]J&:P(
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MRI(G_;2F1Q"U*Z#U4BF["]P&P[.Z^ =02P,$%     @ 4(%A546'TM/4 @
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M&I\>1V"Z9MH93M>A@2VTHW88IA7]?]!X!]HOM78;PP?H_VC3OU!+ P04
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M)LE3RJ.^ ^D2T5NS;T9-9K2II\D@YZ9"6(SIR>4X:<1H6")I/#(;AX##T1G
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M#6$9=WN$!N*0X8<*%G5'<5YKMR*H&XOK8!^'JC-$5#0Q3H"<DU[X1*H/L/Z
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M.Q8?6HU_+KO2@1O8]T"I-TT$?4^Q_@O'^@&XC'*X0VYSV53OFM3\A@N"ZV#
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M]X*7-1?>5/PQW-QX<,L_5THB6&D!GB\,!(H7=$#[=>35?P%02P,$%     @
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M]["X8L^HJ95TL0Q0$S*60"C%.:P]9#8)9Y"-PVNG39TV@=NRI!X!JNR"49<
M@WFKN>5(:6^LRI] -:Z+&$@H7D(8"4$X_1'I'/'<433>,*;%.$SIF] W<LF-
MX5Y9XA-3Q"2,_5(2)O"YSRW+:#*[=J1FY$%:=J(TE_VN7)#_=>H%(3LQS4@0
M\.BDU]L.]I;D-^I&UUYD67<<C"N7:%T52ZWJP?&M>JQ6K;0&MIBSUB#8"KD&
M[/9OKUI10$4UH'6DABLMOQIV=$PYN<UV91M3NJ=N2G30QVK4.]^MZ3BZH%U+
M&V:'!^&FZX-OYMUK<L?TCE.Y!);D2ALV"4!W';H;6-7XKKA5EGJL5RMZU% [
M UHO%96L'[@ PS.Y^A=02P,$%     @ 4(%A54=RE7H& P  B08  !D   !X
M;"]W;W)K<VAE971S+W-H965T,38N>&ULE55M3]LP$/XKIVS:)]:4M#!>VDH4
M&)LFMHJ*\6':!R>Y)A:.;6RGA?WZW3FE*Q(@)E6I[;M[[KG'N<MH9=RMKQ$#
MW#=*^W%2AV"/TM07-3;"]XQ%39:%<8T(M'55ZJU#4<:@1J59O[^?-D+J9#**
M9S,W&9DV**EQYL"W32/<PQ2568V3W>3QX$I6=>"#=#*RHL(YAFL[<[1+-RBE
M;%![:30X7(R3D]VCZ9#]H\-/B2N_M0:N)#?FEC=?RW'29T*HL B,(.AOB:>H
M% ,1C;LU9K))R8';ZT?TS[%VJB47'D^-NI%EJ,?)00(E+D2KPI59?<%U/7N,
M5QCEXQ-6G6]VF$#1^F":=3 Q:*3N_L7]6H>M@(/^"P'9.B"+O+M$D>69"&(R
M<F8%CKT)C1>QU!A-Y*3F2YD'1U9)<6$R;W./=RWJ .=+>OI1&@B6C6FQAIAV
M$-D+$(=P:72H/9SK$LNG\2G1V7#*'CE-LU<!YVA[,.CO0-;/LE?P!IL:!Q%O
M\-8:X==)[H.C-^+W<^5V:,/GT;A+CKP5!8X3:@./;HG)Y,.[W?W^\2M<AQNN
MP]?0WW8?_PGQ0\-WL\0F1P>[G:H[L$+JB+M6.BSA3+9."P47SK06K"I 4K_0
M3ZF/A? UD%;:B]A'.T"3(!JKRF$E L)2J!;!+$!8Z\R]I%Y!]0"LR>!X>- ;
M=.HT4BENQ(OI; <8XXGW^[W]IV[7\[,>W"#DJ"0N$4*-VSP@BL^725R,M<:%
M5LOP ,%0806UO6-N'(4^B%Q)7S>L"?$TK8."9),%%5T2N#(VVH0NH3!-@ZZ0
M9"J$%;E4,DCT+ F#75,2DNR;U%5I&L[&ISEJ7,@(;@6Y$Q;C,"..95Q#?C0-
M@[C%VJ@2G8_E"8?4Y\Y1"*FP3D+"%.@]PRTDW8S\0^FBA4HSK0Z\Y7L(M?3;
MJO2>>P73K?% I55Q"'J(0-VDV)QNYNQ)-U[^N7=#^E*X2FH/"A<4VN]]VDO
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MER0#=R]W#UK<HV[W!_P9>8'Q]D=-;Q<@5Z2#BG20RX5GY'Z#.5 '*@6'ZYC
M)-(*"8D66\PWQ!!KF%$>TXP1]-<'$$3WFJ3J[S:41>O]]M9-^KA1&8[)S('\
MH(A\)L[\IQ_\H?=S&UB;8I$EL0;UL*(>=JG/:RB7&KYO+!.%GK($:R#Z_D6;
M#+8"NA^HTJU87R\/7YUW[0W;\':*7HK7DE@#;[_"V^^,?R'X,Y$Z1Z@(I_ 9
M<Z%)ZUPOE(:YDBE'S_,P'/1@7C_7T116DYJ5U[2(.GOTRG@'5;R#_QOO7;IC
M,+R)J2Z0$G5;J(7(J!;$]1!B'1_%.C@A<MV?G)A%G5UZ9<##*N!A]P 7X4)M
M1N_7:RC65^B12"H2)-90"41F<O\57/T#M<JD,O0%O6Y2W'5VY-($9E,LLB36
M&(!1-0"C[UHV1C:IVQ2++(DUJ(\KZF-K>6U\,MG[02\XFNJ=S5U*QI)8@\RD
M(C/I)!.1-9$2TI_&+XA1O*(,5H/M9"8G9":]R1&8SM8N!6-)K '&]PY+::^[
M.!P6QAFFB9F2,<ZHQJQUZ>N=T/&]X4F-Z&[S4D"VU)J$:IL-WT;Y+%7J:$;]
MWN"83&=;%Y.QI-8D<]@<^)VKX#EDC,&/Z%S:0<DN+YW]5EI65_Y6U2);:DVJ
MA\6_'W[7XNG;7,@OK*I%MM2:Z \; [][9W#/-0%=C:19]F5$QL <;T@K1DM+
M^A*C3;6H5//]^HZDYP7!(1TU"1VV$G[W7N*2-89_NE5HVSQUMWAQZ%8W'F[M
MD,H<*3Y@N:%<(4;6(._U1M":+$[IBALMLOS<:B6T%FE^N24X(=(8P/NU %KE
MC3D*J\Y*YU\!4$L#!!0    ( %"!854TCB)/0PX  "C?   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;,7=[V^;2 +&\7\%Y5:G76G7,=@X<2^-U(8?
M TQU5;/=.^ET+Z@S25!MX\4DW4KWQQ^V:?#89&+2;Y4W;>)Z/H,-3PSD*9Q]
MR8O/RUNE2NNOV72^?'UT6Y:+5\?'R\FMFJ7+7KY0\^I?KO-BEI;5M\7-\7)1
MJ/1J/6@V/7;Z_='Q+,WF1^=GZ\?>%^=G^5TYS>;J?6$M[V:SM/CZ5DWS+Z^/
M[*-O#WS(;F[+U0/'YV>+]$9=JO+CXGU1?7?\H%QE,S5?9OG<*M3UZZ,W]BLY
M6@]8/^./3'U9;GUMK5[*ISS_O/HFNGI]U%\MD9JJ2;DBTNJO>W6AIM.55"W'
MGS5Z]##G:N#VU]_T8/WBJQ?S*5VJBWSZK^RJO'U]='ID7:GK]&Y:?LB_"%6_
M('?E3?+I<OVG]:5^;O_(FMPMRWQ6#ZZ68);--W^G?]5OQ-: RFD?X-0#G-T!
MPT<&#.H!@T,'#.L!PT,'N/4 ]] !HWK Z- !)_6 DT/?I=-ZP.FA,XSK >/=
M :/'5ES_VYKK'SJ'_;"R]];VHT.^K6Y[O;Z/-QO6>JOTTC(]/ROR+U:Q>G[E
MK;Y8;]KK\=7&F,U7*;PLB^I?LVI<>5YMO=/T4UZDFTS,KRR93:J0*>O-3:%4
ME;=R:?UFO;FZRE;/2*=6--]D?_7\GSU5IMET^4OUE(^7GO7S3[]8/UG'UO(V
M+=32RN;6QWE6+G_=>N!=-IU60ZO'?MK^]NRXK%[-:IF.)_62O]TLN?/(D@^L
M=_F\O%U:_OQ*7;6,%^;QXZ?&Q^;QMF, CJO5\+ NG&_KXJUC%"_5HF<-^K]:
M3M]Q6A;HPCP\OIL;AWOFX>_2HAIN/SK</WSA[9;AP<$+;X];AH<'+WSK</%]
M[WST?:\]-@_WU.3AG6\;GAP^O-\R7!X\?/>MT[;BP<-/E,':&SS]$^6^^BE2
M%.G\9OUS9/W39?O[?Y:WJK#*VW1NZ8/^(RO3BDHU6_ZW[0?#9@&&[0NPVF]Y
MM5RD$_7ZJ-HQ6:KB7AV=__UO]JC_C[90D9A'8CZ)!206DI@@L8C$8A)+2$Q"
MF!;PX4/ AR;]_,WDS[NL4%?5Q_=OBR*?J.726LV2%I/;=<:OU'VU=[]89;PM
MO1M]O-97!PGWY]5/K?OM2!KG[QI)$O.?7/: G"XD,?'DLD?[SW#U9\3D B4D
M)B%,2X3[D C7F(@/U08_OU.M.[&;D2=;[^G@]*0WWMGBC7[7+9[$_ WF;BV_
M,Q[M;//DA"&)B?UWW^Z?C'HG.QO^_M-.';NWN_&32Y:0F(0P;>,?/6S\(^/&
M__C^WO\LH1;EZL"O+1A&M>M.'(EY).:36$!B(8D)$HM(+":QA,0DA&FI/7E(
M[<E+'Z6=D $G,8_$?!(+2"PD,4%B$8G%)):0F(0P+>"G#P$__:%':4:]:WI)
MS",QG\0"$@M)3)!81&+QZ=XQI]W?.2Y-R DEA&FA'#^$<OS$@>+A 31*70,X
MWGN7!SMOLD?.YY-80&(AB0D2BT@L)K&$Q"2$:?FS^\VO._O&!+[/RRIO63JU
M9ME4+<N\VH5=I%_7O^=L_1UD?__\QVCW!]2%>=*N'W"HYJ-:@&HAJHF#UE6$
MSAFC6H)JDM+TJ&TU"^QGGQCZ/?VLKM+6P!G1KI][J.:AFH]J :J%J"90+4*U
M&-425).4I@?8:0+LO/0YHGH)J+23FH=J/JH%J!:BFD"U"-5B5$M035*:GO:F
MMF,;2P/??<+(S'>.,EK+034?U0)4"U%-H%J$:C&J);6FG8=R=@X=)#6EGM"F
M=V.;BS==SA[5U/:QD+M[T(K6;%#-1[4 U4)4$Z@6H5J,:@FJ24K3L]@T?FQS
MY:?S>:3]'HT]WC^/A/: 4,U'M0#50E03!ZVK")TS1K4$U22EZ5%K^D7V\PM&
MT55>++/V$TEHP0C5/%3S42U M1#5!*I%J!:C6H)JDM+T!#==(_O%RT8VVC9"
M-0_5?%0+4"U$-8%J$:K%J):@FJ0T/>U-\<C^L<TC,]\YRFCW"-5\5 M0+40U
M@6H1JL6HEMC[A::ANWL>Z4=TD.RFA&2;6TB=CUW'^\=#)_O'KF1+Q$,U']4"
M5 M131RTKB)TSAC5$E23E*;_A_ZF;N28ZT:F8]=_JWD^;\N;V>SZ 8AJ'JKY
MJ!:@6HAJ M4B5(M1+4$U26EZ?IL.DV._])&K@Q:>4,U#-1_5 E0+44V@6H1J
M,:HEJ"8I34][4WARC!6+[SYR-?.=HXRVF5#-1[4 U4)4$Z@6H5J,:@FJR5H;
M;1V(#$8]Y^% 1(]HTU)RS"VE+AT(,]4YCF@CJ=:VWYZ3WD _3//1*0-4"U%-
MH%J$:G'+JG)[PYW_HH9.*2E-#UE3-'+,1:.N)XB<_;)1RPDB\Z2= X3VC5 M
M0+40U<1!ZRI"YXQ1+4$U26EZU)H>D6/N$7U<7!=Y=?A8QZLU7629XP+5/%3S
M42U M1#5!*I%J!:C6H)JLM:T2Y3U']FG; I&CKE@=+FZ.*VU*+*)LGY>7;/V
MTK,6JMA<M/:7UDBBW2)4\VKM='O'V^Z=NN[NSB7:&D*U$-4$JD6H%M>:[6Q_
M'H][XY/=]96@\\J6K<0>]NRM2[OI86JZ/HZQ77 >I%EAW:?3.V7EUY;Z\RXK
MOUI+-;DKLC)KOQ*86>R<)K2[@VH^J@6H%J*:0+4(U>):VSZ@&_9&NW%#*SDM
M4Z[B]DC8FJJ-8Z[:O-L]/&N-%]JG037/:;G\R]X'%=J20;40U02J1:@6MZVI
MW>OTH#-*2M.SU;1D''-+QM_]Z/K5JJ(V^;S946P-&GK)'E3S:DT_WWBRFS2T
M)H-J(:H)5(M0+4:U!-4DI>EW%FCJ-(/OK--4?U_DLUGUQ>4JJVTI-4_1-:6H
MYJ&:CVH!JH6H)E M0K48U1)4DY2FQ[EIUPQ>O%TS0-LUJ.:AFH]J :J%J"90
M+4*U&-425).4IJ>]:=<,S.V:RW2Z/B>TV8M>G6C=W!6L]0RKV>J<6[1*4VO;
MMPOH[_WN'ITR0+40U02J1:@6'[*J$G1*V3*EO547T,.S=5,M<^_%M.?[1_XU
MO5%%:XS86V6Q]\IB;Y;%WBV+O5T6>[\L]H99[!VSV%MFL??,^A&EFD%3JAD,
M7WQGEVQ&7*":AVH^J@6H%J*:0+4(U6)42U!-4IJ>]J;7,S#W>KZW2F[F.T<9
M+?V@FH]JP:"E(*+O[H7U4[3?Q=F#K5_&U<%#*SJH%J-:@FJ2TO3@-66>@;G,
MT[6[6G-:'W*PUUTU3]HY0.CE?U M0+40U<1!ZRI"YXQ1+4$U26EZU)JJS\!<
M]3F@NVH6.G^,H=4>5/-1+4"U$-4$JD6H%J-:@FJRUK0&Q<A]Y,104P$:F"M
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M93_RVN3>*ILHS89Q*;FZ&BD_.7^@SQ(LZ>K (QE1 0;@/F%<1O_1-5@P(>_
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MY_G&UV"[4\D-=S:)Z186H)[B1Z%';H:R#D*(9, C)& S=3[AFSGI)PZIQ?<
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MW<K)V;,GMF>]:0L5D9@6.&<7. =3;P2N;9C;ME[5MOSJN3VSN2>F_LGLMCF
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M5EK,1.!.W8Z<!LJR<<SJS.GB6_T(;L=[,YXX(C4]-L!RMC^NK"=%02HU/7@
M@S:*3(_Z?@_ZO]\Q$]UCH# ;Q[#^I6#$]7AOQK-)I*9OR@#J<6M42X&3<B*5
MFAX\X$2.HM1CED*MW'=U:#%#K@Z\L1F'0UK_DC"B?[PWXUD=8KN- PUR9UQ+
M@A0HJ=3TX %0<GQ+\#%+0O1>'5 3W6.@.(Y3W 7D?N'Q=7HKLZ3<O7^5K],D
M3\M9+CYUW@[@ZL:S-\3.' =HY-ZX4I^4*JG4]. !57)\BQ"_':@;:]N2CC45
M#S-\WXP+JVNCG@.U<9S:#++\N!L$O'_CJ1QBVXX#,?+YN-8!*5)2J>GE*D!*
M!]\]?,0EH%;&+@&HB>XQ<)R#<]PQB\/HE@'OWW1^J=3T: $[.N.JY#JD<$FE
MI@>O4<P]H)I[Y.)P#KJ"M)@A5Q 'R,[!R>Z816)T$X'W;SS/0^P-.D"5SKC*
MPPXIAE*IZ<$##'4&*Q'7RN@5!#/1/0;V<W#V^^/G)E+WC?OH9T\";MMO+J-4
MR<5-DL;I]3V+DN4F5]E]J^.D>X14:GHX@#:=<56,'5+XI%+3@P?PZ1Q0->Y^
MX*>M,CR=6XW_[(<)O]_$<[H>B!# >0+G/+.</^ZN G?!^'FA(;8+!6"F&%=9
M69!2)Y6:'CR@3C%86;E6-EDR+4U<WKED@/X$3G]'+AFC>PW<!>-9'V([430>
M,!Q7?5K0/I\X!(,*8%!Q0'WZR"7C]F(4:J)[#. G</ [<GT8W6;@+AA/\1![
MC@*X4XRKDBU(*95*30\>4*H8K)(M^BO9+29=3RH)8$/14\H.\YMJ[E9I(N_9
M*LQ^2,6N-LFRW4W2?44J-?UY:^!-=URE:I>4/:G4]. !>[H'E*H[;RK<_3(S
MMWGC0=)Z#/MFCK :3Z7JS@';N3W5Z.ZL/NZV >_/>.J&V#)T 1K=<=6C75*
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M+T:+1X7K]"I]-#[QKV[\BO&I?81([[G/]-D+QBU56!HTX;!$55ZKAV%1V:-
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M76[PMP/2..#Y2@C]:IC)UOW(TC]02P,$%     @ 4(%A58&!:]F] @  90@
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M IHRKDZ0]'Z6D..C$W)$6$EN&.?(I\:N1G$F13=MA%S50H(7A,R@&I+0&Y#
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MQD2E+F:8?((T#?"YV1(?*R9;:=/9Y!=02P,$%     @ 4(%A57'LDM3Q @
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MU;&_&FAQ*$_.:Z'A'%Y>[BF!))@)\'PKA'X9F,-X\^?+\E]02P,$%     @
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M+A["]5)^29^9J"O4+WFS=)E7_Y/G^KV]#IFM<YG&=>'B".(HV?P,?]0G8J>
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M(T']_@\4JAMH=*V1WI[01 U%4S?\:1(UYUV)FM:$9E1;$T)I7DU3_GQ'=A"
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M42\F[#V9&X6[#'%F-)5B"\JP!0<R!\&D(I^E 4W>D6MA0($V9/:(MU(#N8S
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MK$4/BA6O\A5;)U8\! \X87L*O"2$H83?[>>?]O#K7'NE"JT/%:ZL7L -/ S
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M%     @ 4(%A59>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
M?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2V
MBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=S
MI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YV
MX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)
M#^Q^ %!+ P04    " !0@6%5<Y1'P]T#  ">&P  #P   'AL+W=O<FMB;V]K
M+GAM;,6945/;.!" _XK&3^T,7&(YT)8AG>$:VLL,1QG2\GJCV)M$4UE*)3D4
M?OVM;$)E"#M]$7E)8LE6/J_M_5;RZ:VQ/^;&_&"_:J7=.%MYOSX9#%RY@EJX
MO\P:-/8LC*V%QTV['+BU!5&Y%8"OU8 /A\>#6DB=?3S=CG5E!_&&\5!Z:30V
MAH8;";?N=W_89!OIY%PJZ>_&6?M;0<9JJ64M[Z$:9\.,N96Y_<=8>6^T%VI6
M6J/4.,N[CANP7I;/FF<!\IN8N[;%B_FU0)!Q=CS$ 1?2.M_NT8XOD'$#N'.W
MU7CS62H/=B(\?+&F64N]#,/@60RBTVCCL/WN@GAB_R2,9K&0)4Q,V=2@?1='
M"RH :K>2:Y<Q+6H89Y_,!BR[$DL()X7_,JVZ$_1(%H7+GDCLL-.J94S)HRO0
M#BJ&OYQ1LD*.BOTME- EL B2$Y!\CY#_\0BR(""+O4#. @X>&D&.",C1'B%[
MD3PB((_V"5E$D,<$Y'%:R*]V*;2\;SN8T(@GEUKBP4)[=E9&D.\(R'>I(ZF4
MF!O[F_("#\30LK.EA3@%O2<@WZ>%G,#<LQF4C95>@HN@/A!0'])"?1;2LANA
M&F#_@G"-#<^PC^'R(96UAVGQIGJ#.Z! >_'*29&D-HEPJP,6/MGYST9NA H!
M:V^Z:W ^QJ14DB=VR05>S7[0*&?DZ:6Q"=4._BL^ EH:RRZQPNKQ4;K($_OB
M7%B-I9)C:ZQ:9BMA>V4+Y8@\L21FS=S!SP9W8N>;IX\FY85\GV+H*3:GS) G
M5L.3K,O>8+&LP+V-^2@IY(FM\$("WG+&F)0F\L2>B!+QKA!R2A(\L23(C-R[
M$SDE#IY8'%U&WAD]<LZ1?M*Q,S4_@,:8E$%X8H,\S] [(TE)A">6")T1XWJ>
M4T;AR:<=1+'<?UPHO_#$?GF:N _966WP/KUOYTMQ8N247_@K^P4QJTJ&W81B
MTW@ZS"G-\->=?"#F%VN<8]^U!:%DC$EIAN]G.H*X04#Q12\HXQ2)C?,RYC64
M)K[H!66<(K%Q8FD?LEE3U\+>,;-@74>,21FH2&T@TM]QWBS(=:_$!GKP]R&[
M%#8DSPU@'+N10B*-,2D+%8DM](@Y:]9KU=Z8;29Z((TQ*0L5B2WTB'DA1;>(
M?L"NQ%TXZH!-FAB3LE"1V$(O5D==GH\Q*0L5R1? 7L3DP[8H>L2D+%0DMA"!
M.=4^KC4+RD)%8@OMJ#7Q<<*!JP;!3;S$35EHE-A"SY8&V)L)>"%5KR0>408:
M=:^&MN^#*EA(#=4E#N^PO12JO+(L?'7K6:.C, E=-$I]PK:O^L*(:OMZ:?MJ
M[./_4$L#!!0    ( %"!854I78B@DP$  .(8   :    >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'/-V4V.@D 0AN&K& Y@6U7X-U%7LW$[\0)$6S&"$+HG
MH[<?HPO]R"QF8_I;D6Y"\8;%$P*++U\5\=B<0WELP^!25^>PS,H8VP_GPK;T
M=1&&3>O/MS/[IJN+>%MV!]<6VU-Q\$Y'HXGK7F=DJ\7KS,'FVOK_3&SV^^/6
M?S;;[]J?XQ^#W4_3G4+I?<P&FZ([^+C,W*5Z;@=W/\CP-CD;K'?+K%OO)'.I
M@Q2"-'V009"E#\HA*$\?-(:@<?J@"01-T@=-(6B:/F@&0;/T07,(FJ</DA'*
M.")(ZF%-H+4@UT+@M2#80B"V(-E"8+8@VD*@MB#;0N"V(-Q"(+<@W4)@MR#>
M0J"WHMY*H+>BWDJ@M_9>M@GT5M1;"?16U%L)]%;46PGT5M1;"?16U%L)]%;4
M6PGT5M1;"?0VU-L(]#;4VPCT-M3;"/2VWL<2 KT-]38"O0WU-@*]#?4V KT-
M]38"O0WU-@*]#?4V KUSU#LGT#M'O?-WZAWBM?+AV?-8X_W?276\7>N?M[\O
M'YN]AW#'V<$OC=4O4$L#!!0    ( %"!856(C*DWI0$  "\9   3    6T-O
M;G1E;G1?5'EP97-=+GAM;,V9S6Z#,!"$7P5QC8)C.TU_E.32]MKFT!=P80DH
M@"W;29.WKR$_4JL4-4JES@4+O#LS>*7O -.WG2$7;>NJ<;.X\-X\,.;2@FKE
M$FVH"3NYMK7RX=8NF5'I2BV)B=%HPE+=>&K\T+<:\7SZ1+E:5SYZWH;'KM3-
M++94N3AZW!>V7K-8&5.5J?)AGVV:[)O+\."0A,ZNQA6E<8-0$+.S#NW.SP:'
MOM<-65MF%"V4]2^J#E5L6S'G=Q6YI%_B3$:=YV5*F4[7=6A)G+&D,E<0^;I*
M]J*#?F<?3ICV5WZU?R?39Q@J%U8;%R9FZ7*[XTC:[J$)0F1]V?^*)\<@??7[
M43OMC+)?>H?C_=!VU<W#L6ZY_HR_SOBD?V$. 9)#@N08@^2X <DQ <EQ"Y+C
M#B3'/4@./D()@D)4CH)4CL)4C@)5CD)5CH)5CL)5C@)6CD)6@4)6@4)6@4)6
M@4)6@4)6@4)6@4)6@4)6@4)6@4)6B4)6B4)6B4)6B4)6B4)6B4)6B4)6B4)6
MB4)6B4+6,0I9Q_])UG>M5W_]";]=DUJ5S=&?=?])YI]02P$"% ,4    " !0
M@6%5!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P
M+GAM;%!+ 0(4 Q0    ( %"!855D.$)#[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %"!85697)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ 4(%A5<:-:UG7!0  S1X  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %"!857;)(5H"P8
M +L9   8              " @1H.  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " !0@6%5=?5=_P,#  !V"@  &               @(%;
M%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 4(%A50Z2
MR,2C!P  YRD  !@              ("!E!<  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( %"!8562.Q\;W@D  &EL   8
M  " @6T?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !0
M@6%5T>\\'.,&  "A'@  &               @(&!*0  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ 4(%A5?N]]!*S!0  -0X  !@
M         ("!FC   'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( %"!855Z_W3E%18  -];   8              " @8,V  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !0@6%59$_4[RH&  "?$0
M&               @('.3   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ 4(%A55T**FW2!0  T@X  !D              ("!+E,  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !0@6%5(!O:AFL"
M  !B!0  &0              @($W60  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( %"!855%A]+3U (  -T&   9              "
M@=E;  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 4(%A
M50N#M S<!@  VQ   !D              ("!Y%X  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " !0@6%5H?8#%>L,   I*0  &0
M        @('W90  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( %"!854OK4=^. ,  #('   9              " @1ES  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 4(%A54=RE7H& P  B08
M !D              ("!B'8  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " !0@6%5%?Q(S.H&  #J$0  &0              @('%>0
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %"!857$A%?<
MW00  "$.   9              " @>:   !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ 4(%A5;\ 3XP0!0  . T  !D
M ("!^H4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !0
M@6%5JA$=A'D"  !J!0  &0              @(%!BP  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( %"!8574QKA_Z (  -D&   9
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M970R-2YX;6Q02P$"% ,4    " !0@6%5-(XB3T,.   HWP  &0
M    @(&SH   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M %"!854<=)-P1P4  &<=   9              " @2VO  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ 4(%A53V])2 9 P  >@H  !D
M             ("!J[0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " !0@6%56(]P=G@$  #R%@  &0              @('[MP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %"!856)0*@JCP@
M *M6   9              " @:J\  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ 4(%A5?"H'3M%!   IA$  !D              ("!
M<,4  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !0@6%5
M[\%[PHT"  #4!@  &0              @('LR0  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( %"!856!@6O9O0(  &4(   9
M      " @;#,  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ 4(%A53[F=7"& P  V@X  !D              ("!I,\  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !0@6%5<>R2U/$"   7"
M&0              @(%ATP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( %"!855<$4;.X@,  (@1   9              " @8G6  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 4(%A5;P7+XT=
M#   5(D  !D              ("!HMH  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " !0@6%5R<CB7VH#  "3#P  &0
M@('VY@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %"!
M857X[2;I$P,  *\)   9              " @9?J  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ 4(%A513&G@10!0  "QX  !D
M         ("!X>T  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    " !0@6%5\SH''%@"   A!@  &0              @(%H\P  >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( %"!855-DL@T=@,  /D7
M   -              "  ??U  !X;"]S='EL97,N>&UL4$L! A0#%     @
M4(%A59>*NQS     $P(   L              ( !F/D  %]R96QS+RYR96QS
M4$L! A0#%     @ 4(%A57.41\/= P  GAL   \              ( !@?H
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %"!854I78B@DP$  .(8   :
M              "  8O^  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( %"!856(C*DWI0$  "\9   3              "  58  0!;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Q #$ 3@T  "P" 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>193</ContextCount>
  <ElementCount>240</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Income and Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income and Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecurities</Role>
      <ShortName>Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Cash, Cash Equivalents and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesTables</Role>
      <ShortName>Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/DebtSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Inventories</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/EarningsperShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails</Role>
      <ShortName>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Debt Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Debt Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails</Role>
      <ShortName>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Inventories - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails</Role>
      <ShortName>Inventories - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Leases - Narrative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesNarrativeInformationDetails</Role>
      <ShortName>Leases - Narrative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Leases - Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesSupplementalInformationDetails</Role>
      <ShortName>Leases - Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Leases - Liability, Payment, Due (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails</Role>
      <ShortName>Leases - Liability, Payment, Due (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Convertible Senior Notes - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails</Role>
      <ShortName>Convertible Senior Notes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails</Role>
      <ShortName>Convertible Senior Notes - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails</Role>
      <ShortName>Convertible Senior Notes - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Earnings per Share - Schedule of Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails</Role>
      <ShortName>Earnings per Share - Schedule of Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nbix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/SubsequentEvents</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:LesseeOperatingLeaseTermOfContract -  nbix-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="nbix-20220930.htm">nbix-20220930.htm</File>
    <File>nbix-20220930.xsd</File>
    <File>nbix-20220930_cal.xml</File>
    <File>nbix-20220930_def.xml</File>
    <File>nbix-20220930_lab.xml</File>
    <File>nbix-20220930_pre.xml</File>
    <File>q3-2022xexhibit311.htm</File>
    <File>q3-2022xexhibit312.htm</File>
    <File>q3-2022xexhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20220930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="612">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20220930.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 193,
   "dts": {
    "calculationLink": {
     "local": [
      "nbix-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbix-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nbix-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 368,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 13
   },
   "keyCustom": 34,
   "keyStandard": 206,
   "memberCustom": 15,
   "memberStandard": 24,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.neurocrine.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Fair Value Measurements",
     "role": "http://www.neurocrine.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Inventories",
     "role": "http://www.neurocrine.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Cash, Cash Equivalents and Restricted Cash",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash",
     "shortName": "Cash, Cash Equivalents and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Leases",
     "role": "http://www.neurocrine.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Convertible Senior Notes",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Earnings per Share",
     "role": "http://www.neurocrine.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Subsequent Events",
     "role": "http://www.neurocrine.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Debt Securities (Tables)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesTables",
     "shortName": "Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Inventories (Tables)",
     "role": "http://www.neurocrine.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Leases (Tables)",
     "role": "http://www.neurocrine.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.neurocrine.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i63a36f8809514653892aaae462d392cf_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Organization and Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i5df8b3da765848b7b1e13148e4a5f0ac_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
     "shortName": "Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Debt Securities - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails",
     "shortName": "Debt Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "if991653053864b2a904fed8d29ebc17e_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
     "shortName": "Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "if991653053864b2a904fed8d29ebc17e_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "ie49ac4b8f7504f74ae784614035b01ea_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireRestrictedInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
     "shortName": "Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "ie49ac4b8f7504f74ae784614035b01ea_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireRestrictedInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Inventories - Summary of Inventories (Details)",
     "role": "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails",
     "shortName": "Inventories - Summary of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i2d4f0a2cea8441e0b026692719475b64_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i293bb336d80d473eb69da7cf494b8713_D20220208-20220208",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Leases - Narrative Information (Details)",
     "role": "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails",
     "shortName": "Leases - Narrative Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i293bb336d80d473eb69da7cf494b8713_D20220208-20220208",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Leases - Supplemental Information (Details)",
     "role": "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails",
     "shortName": "Leases - Supplemental Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Leases - Liability, Payment, Due (Details)",
     "role": "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails",
     "shortName": "Leases - Liability, Payment, Due (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Convertible Senior Notes - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
     "shortName": "Convertible Senior Notes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i807d39638b3a4a3cb6c632e59cd7c3aa_I20170502",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbix:CarryingAmountOfLiabilityComponentUponIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7f42127857b54a13aa343398bb2d541d_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
     "shortName": "Convertible Senior Notes - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i8a5bcc60ead14ba1ac643d19e4770911_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtInstrumentCouponInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Convertible Senior Notes - Interest Expense (Details)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
     "shortName": "Convertible Senior Notes - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtInstrumentCouponInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Income and Comprehensive Income",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Income and Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Earnings per Share - Schedule of Net Income Per Share (Details)",
     "role": "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails",
     "shortName": "Earnings per Share - Schedule of Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "icd9a09353dcc4875b7d9990985cd8d8d_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "if8ceebe0bfe84be1b0d7f9f9ae5831b9_D20221101-20221101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbp",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.neurocrine.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "if8ceebe0bfe84be1b0d7f9f9ae5831b9_D20221101-20221101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbp",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "idc1223dc268f4291a7665d63b9b7a94b_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "idc1223dc268f4291a7665d63b9b7a94b_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Significant Accounting Policies",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.neurocrine.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Debt Securities",
     "role": "http://www.neurocrine.com/role/DebtSecurities",
     "shortName": "Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220930.htm",
      "contextRef": "i7c9adcc9c69a4301a7c94a60848b38d6_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nbix_A225ConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Convertible Senior Notes.",
        "label": "2.25% Convertible Senior Notes [Member]",
        "verboseLabel": "2024 Notes"
       }
      }
     },
     "localname": "A225ConvertibleSeniorNotesMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AbbVieIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbbVie Inc.",
        "label": "AbbVie Inc. [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieIncMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AnnualRentEscalationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Rent Escalation Percentage",
        "label": "Annual Rent Escalation Percentage",
        "terseLabel": "New campus lease annual rent escalation percentage"
       }
      }
     },
     "localname": "AnnualRentEscalationPercentage",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current",
        "terseLabel": "Unrealized gain, current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent",
        "terseLabel": "Unrealized gain, noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current",
        "negatedTerseLabel": "Unrealized loss, current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent",
        "negatedLabel": "Unrealized loss, noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_BIALPortelaCaSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIAL \u2013 Portela &amp; Ca, S.A.",
        "label": "BIAL \u2013 Portela &amp; Ca, S.A. [Member]",
        "terseLabel": "BIAL"
       }
      }
     },
     "localname": "BIALPortelaCaSAMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_CarryingAmountOfLiabilityComponentAtSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the liability component at settlement.",
        "label": "Carrying Amount Of Liability Component At Settlement",
        "terseLabel": "Carrying amount of the liability component at settlement"
       }
      }
     },
     "localname": "CarryingAmountOfLiabilityComponentAtSettlement",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_CarryingAmountOfLiabilityComponentUponIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the liability component upon issuance.",
        "label": "Carrying Amount Of Liability Component Upon Issuance",
        "terseLabel": "Carrying amount of the liability component upon issuance"
       }
      }
     },
     "localname": "CarryingAmountOfLiabilityComponentUponIssuance",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_CashAndMoneyMarketFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Cash And Money Market Fund [Member]",
        "terseLabel": "Cash and money market funds"
       }
      }
     },
     "localname": "CashAndMoneyMarketFundMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenues"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ConversionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period One",
        "label": "Conversion Period One [Member]",
        "terseLabel": "Conversion Period One"
       }
      }
     },
     "localname": "ConversionPeriodOneMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ConversionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period Two",
        "label": "Conversion Period Two [Member]",
        "terseLabel": "Conversion Period Two"
       }
      }
     },
     "localname": "ConversionPeriodTwoMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_DebtInstrumentConversionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Axis]",
        "terseLabel": "Debt Instrument, Conversion [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionAxis",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_DebtInstrumentConversionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Domain]",
        "terseLabel": "Debt Instrument, Conversion [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionDomain",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_DebtInstrumentConvertibleConversionPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.",
        "label": "Debt Instrument Convertible Conversion Premium",
        "terseLabel": "Convertible senior notes premium"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_DebtInstrumentCouponInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Coupon Interest",
        "label": "Debt Instrument, Coupon Interest",
        "terseLabel": "Coupon interest"
       }
      }
     },
     "localname": "DebtInstrumentCouponInterest",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtSecuritiesAvailableForSaleFairValueCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Current",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Current",
        "terseLabel": "Fair value, current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueCurrent",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Noncurrent",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Noncurrent",
        "verboseLabel": "Fair value, noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueNoncurrent",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities available for sale position number of positions.",
        "label": "Debt Securities Available For Sale Position Number Of Positions",
        "terseLabel": "Number of debt securities available for sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePositionNumberOfPositions",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_DiurnalGroupPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diurnal Group Plc",
        "label": "Diurnal Group Plc [Member]",
        "terseLabel": "Diurnal Group plc"
       }
      }
     },
     "localname": "DiurnalGroupPlcMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the liability component immediately before extinguishment.",
        "label": "Fair Value Of Liability Component Immediately Before Extinguishment",
        "terseLabel": "Fair value of the liability component immediately before extinguishment"
       }
      }
     },
     "localname": "FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_HeptaresTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heptares Therapeutics Limited",
        "label": "Heptares Therapeutics Limited [Member]",
        "terseLabel": "Heptares"
       }
      }
     },
     "localname": "HeptaresTherapeuticsLimitedMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IdorsiaPharmaceuticalsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idorsia Pharmaceuticals Ltd.",
        "label": "Idorsia Pharmaceuticals Ltd. [Member]",
        "terseLabel": "Idorsia"
       }
      }
     },
     "localname": "IdorsiaPharmaceuticalsLtdMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities",
        "terseLabel": "2024 Notes (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_InvestmentIncomeAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income and other net.",
        "label": "Investment Income And Other Net",
        "terseLabel": "Investment income and other, net"
       }
      }
     },
     "localname": "InvestmentIncomeAndOtherNet",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Monthly Base Rent Per Square Foot",
        "label": "Lessee Operating Lease Monthly Base Rent Per Square Foot",
        "terseLabel": "New campus lease monthly base rent per square foot"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of term of lessee's option for the construction of a fifth building under operating lease.",
        "label": "Lessee Operating Lease Option Term To Construct Fifth Building",
        "terseLabel": "New campus lease lessee option term for construction of fifth building"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionTermToConstructFifthBuilding",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.",
        "label": "Minimum Percentage Of Trading Price To Last Reported Sale Price",
        "terseLabel": "Minimum percentage of common stock price trigger"
       }
      }
     },
     "localname": "MinimumPercentageOfTradingPriceToLastReportedSalePrice",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mitsubishi Tanabe Pharma Corporation",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "MTPC"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2024"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of renewal options under the terms of the lease.",
        "label": "Number Of Renewal Options",
        "terseLabel": "New campus lease number of renewal options"
       }
      }
     },
     "localname": "NumberOfRenewalOptions",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_PatentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Patent term",
        "terseLabel": "Patent term"
       }
      }
     },
     "localname": "PatentTerm",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_PotentialMilestonePaymentReceipts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payment receipts under a collaborative arrangement.",
        "label": "Potential Milestone Payment Receipts",
        "terseLabel": "Potential milestone payment receipts"
       }
      }
     },
     "localname": "PotentialMilestonePaymentReceipts",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payments under a collaborative arrangement.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestonePayments",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PrincipalAmountOnConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount on conversion rate.",
        "label": "Principal Amount On Conversion Rate",
        "terseLabel": "Principal amount on conversion rate"
       }
      }
     },
     "localname": "PrincipalAmountOnConversionRate",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_RentAbatementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent Abatement Period",
        "label": "Rent Abatement Period",
        "terseLabel": "New campus rent abatement period"
       }
      }
     },
     "localname": "RentAbatementPeriod",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_RestrictedCashTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashTextBlock",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_SaleOfStockNumberOfSharesSoldInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares sold by the collaboration partner per stock transaction.",
        "label": "Sale of Stock, Number of Shares Sold in Transaction",
        "terseLabel": "Sale of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesSoldInTransaction",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2.25% Convertible Senior Notes Due in May 2024.",
        "label": "Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]",
        "terseLabel": "2.25% Convertible senior notes due 2024"
       }
      }
     },
     "localname": "SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of reconciliation of cash cash equivalents and restricted cash.",
        "label": "Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_UpfrontPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments made under a collaboration agreement.",
        "label": "Upfront Payments Made",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPaymentsMade",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_VoyagerTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voyager therapeutics.",
        "label": "Voyager Therapeutics [Member]",
        "terseLabel": "Voyager"
       }
      }
     },
     "localname": "VoyagerTherapeuticsMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_XenonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xenon Pharmaceuticals Inc.",
        "label": "Xenon Pharmaceuticals Inc. [Member]",
        "terseLabel": "Xenon"
       }
      }
     },
     "localname": "XenonPharmaceuticalsIncMember",
     "nsuri": "http://www.neurocrine.com/20220930",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r46",
      "r48",
      "r100",
      "r101",
      "r245",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r107",
      "r115",
      "r121",
      "r194",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r349",
      "r352",
      "r354",
      "r355",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r107",
      "r115",
      "r121",
      "r194",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r349",
      "r352",
      "r354",
      "r355",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r107",
      "r115",
      "r121",
      "r194",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r349",
      "r352",
      "r354",
      "r355",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r244",
      "r279",
      "r302",
      "r304",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r458",
      "r502",
      "r504",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r161",
      "r226",
      "r227",
      "r290",
      "r291",
      "r460",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r161",
      "r226",
      "r227",
      "r290",
      "r291",
      "r460",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r244",
      "r279",
      "r292",
      "r302",
      "r304",
      "r308",
      "r309",
      "r310",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r458",
      "r502",
      "r504",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r244",
      "r279",
      "r292",
      "r302",
      "r304",
      "r308",
      "r309",
      "r310",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r458",
      "r502",
      "r504",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r100",
      "r101",
      "r245",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r108",
      "r109",
      "r110",
      "r111",
      "r167",
      "r168",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r330",
      "r331",
      "r332",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r390",
      "r391",
      "r399",
      "r400",
      "r401",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r52",
      "r53",
      "r54",
      "r490",
      "r512",
      "r516"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r51",
      "r54",
      "r60",
      "r61",
      "r62",
      "r104",
      "r105",
      "r106",
      "r342",
      "r421",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "negatedLabel": "Additional paid in capital",
        "negatedTerseLabel": "Additional Paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r311",
      "r312",
      "r313",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r108",
      "r109",
      "r110",
      "r111",
      "r121",
      "r167",
      "r168",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r311",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r330",
      "r331",
      "r332",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r390",
      "r391",
      "r399",
      "r400",
      "r401",
      "r402",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r462",
      "r463",
      "r464",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments",
        "terseLabel": "Equity component of repurchased convertible senior notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r305",
      "r314",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r73",
      "r88",
      "r264",
      "r393"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r68",
      "r88",
      "r264",
      "r395"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r88",
      "r264",
      "r273",
      "r274",
      "r395"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r14",
      "r98",
      "r150",
      "r153",
      "r159",
      "r190",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r340",
      "r343",
      "r373",
      "r422",
      "r424",
      "r469",
      "r488"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r36",
      "r98",
      "r190",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r340",
      "r343",
      "r373",
      "r422",
      "r424"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets on recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r170",
      "r203"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r12",
      "r170",
      "r203"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r301",
      "r303",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r301",
      "r303",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r333",
      "r334",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Aggregate value of all cash transaction"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r103",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Non-cash capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r11",
      "r90"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r83",
      "r90",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r83",
      "r382"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r336",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]",
        "terseLabel": "Collateral"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]",
        "terseLabel": "Collateral"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r424"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 220.0 million shares authorized; 96.1 million and 94.9 million shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r66",
      "r475",
      "r496"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible senior notes",
        "verboseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes",
        "verboseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r293",
      "r300",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r460"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r258",
      "r265",
      "r266",
      "r268",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r97",
      "r102",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r271",
      "r272",
      "r273",
      "r274",
      "r397",
      "r470",
      "r471",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Convertible senior note carrying value of the equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r243",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Convertible senior notes conversion price (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r42",
      "r243",
      "r283",
      "r284",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Convertible senior notes convertible in to shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.",
        "label": "Debt Instrument, Convertible, Stock Price Trigger",
        "terseLabel": "Common stock price trigger (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "verboseLabel": "Threshold common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r241",
      "r271",
      "r272",
      "r394",
      "r397",
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r256",
      "r271",
      "r272",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair Value, Amount"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r41",
      "r261",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Convertible senior note assumed borrowing rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r97",
      "r102",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r271",
      "r272",
      "r273",
      "r274",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Convertible senior notes redemption rate"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Aggregate principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r97",
      "r102",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r267",
      "r271",
      "r272",
      "r273",
      "r274",
      "r283",
      "r285",
      "r286",
      "r287",
      "r393",
      "r394",
      "r397",
      "r398",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Convertible senior notes term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r254",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedTerseLabel": "Unamortized Debt, Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff",
        "terseLabel": "Accrued interest receivables write-off"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r171",
      "r203"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "totalLabel": "Amortized cost, current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r171",
      "r203"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "totalLabel": "Amortized cost, noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r181",
      "r210",
      "r213"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Longer, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r181",
      "r210"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Longer, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r181",
      "r210",
      "r213"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r181",
      "r210"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r177",
      "r206",
      "r213"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r178",
      "r207"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r205",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r176",
      "r209",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r179",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of debt securities available for sale in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Transaction cost related to issuance of convertible senior notes"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r254",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized Debt, Issuance Costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTerseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r88",
      "r222"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r67",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r122",
      "r125",
      "r135",
      "r136",
      "r137",
      "r141",
      "r142",
      "r355",
      "r356",
      "r476",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)",
        "verboseLabel": "Earnings per share, basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r67",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r125",
      "r135",
      "r136",
      "r137",
      "r141",
      "r142",
      "r355",
      "r356",
      "r476",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in USD per share)",
        "verboseLabel": "Earnings per share, diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r60",
      "r61",
      "r62",
      "r104",
      "r105",
      "r106",
      "r109",
      "r118",
      "r120",
      "r144",
      "r194",
      "r282",
      "r288",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r354",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r421",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "terseLabel": "Fair value of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "terseLabel": "Equity securities, stock price"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r16",
      "r370"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r189",
      "r498"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity security investments",
        "terseLabel": "Unrealized gain (loss) on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r184",
      "r487",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities\u2013biotechnology industry"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r358",
      "r359",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Investments Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r363",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r256",
      "r271",
      "r272",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r359",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r358",
      "r359",
      "r361",
      "r362",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r256",
      "r293",
      "r294",
      "r299",
      "r300",
      "r359",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r256",
      "r271",
      "r272",
      "r293",
      "r294",
      "r299",
      "r300",
      "r359",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r256",
      "r271",
      "r272",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r359",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "verboseLabel": "Unrealized gain (loss) included in earnings"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "negatedTerseLabel": "Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r256",
      "r271",
      "r272",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r369",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r186",
      "r187",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r209",
      "r211",
      "r212",
      "r213",
      "r267",
      "r281",
      "r345",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r216",
      "r218",
      "r220",
      "r221",
      "r461",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r216",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r88",
      "r275",
      "r276"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of convertible senior notes",
        "negatedTerseLabel": "Loss on extinguishment of convertible senior notes",
        "terseLabel": "Loss on extinguishment of convertible senior notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r150",
      "r152",
      "r155",
      "r158",
      "r160",
      "r466",
      "r473",
      "r478",
      "r499"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r119",
      "r120",
      "r149",
      "r319",
      "r324",
      "r325",
      "r500"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r85",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r137",
      "r306"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r63",
      "r148",
      "r392",
      "r395",
      "r477"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r81",
      "r84",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivables"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r214"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r34",
      "r424"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r214"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r214"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r467",
      "r482",
      "r521",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Description of Operating Lease"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (3 months remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less accreted interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "New campus lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "New campus lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r98",
      "r154",
      "r190",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r341",
      "r343",
      "r344",
      "r373",
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r98",
      "r190",
      "r373",
      "r424",
      "r472",
      "r492"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r40",
      "r98",
      "r190",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r341",
      "r343",
      "r344",
      "r373",
      "r422",
      "r423",
      "r424"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r55",
      "r57",
      "r62",
      "r65",
      "r89",
      "r98",
      "r108",
      "r113",
      "r114",
      "r115",
      "r116",
      "r119",
      "r120",
      "r133",
      "r150",
      "r152",
      "r155",
      "r158",
      "r160",
      "r190",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r356",
      "r373",
      "r474",
      "r495"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r122",
      "r123",
      "r134",
      "r137",
      "r150",
      "r152",
      "r155",
      "r158",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r124",
      "r129",
      "r130",
      "r131",
      "r132",
      "r134",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r115",
      "r121",
      "r141",
      "r167",
      "r168",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r311",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r330",
      "r331",
      "r332",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r390",
      "r391",
      "r399",
      "r400",
      "r401",
      "r402",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r462",
      "r463",
      "r464",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r150",
      "r152",
      "r155",
      "r158",
      "r160"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r407",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less current operating lease liabilities included in other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r405",
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r411",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r410",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r35",
      "r424"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r49",
      "r50",
      "r52"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on debt securities available-for-sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r49",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on debt securities available-for-sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r424"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r74",
      "r76",
      "r169"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of debt securities available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r82",
      "r185"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "terseLabel": "Purchases"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r424"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuances of common stock under benefit plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r74",
      "r75",
      "r169"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales and maturities of debt securities available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r223",
      "r424",
      "r483",
      "r493"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Repurchase of convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Aggregate repurchase price paid in cash"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r316",
      "r459",
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r11",
      "r90",
      "r95",
      "r468",
      "r489"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r90",
      "r95",
      "r522"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash in connection with operating leases",
        "verboseLabel": "Restricted cash included in other assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r288",
      "r424",
      "r491",
      "r511",
      "r516"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r104",
      "r105",
      "r106",
      "r109",
      "r118",
      "r120",
      "r194",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r354",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r146",
      "r147",
      "r151",
      "r156",
      "r157",
      "r161",
      "r162",
      "r163",
      "r289",
      "r290",
      "r460"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r409",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets acquired through operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r172",
      "r173",
      "r180",
      "r181",
      "r182",
      "r183",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r43",
      "r102",
      "r271",
      "r273",
      "r283",
      "r285",
      "r286",
      "r287",
      "r393",
      "r394",
      "r398",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Notes Net of Discount and Deferred Financing Costs"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)",
        "verboseLabel": "Market price of common stock (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r45",
      "r60",
      "r61",
      "r62",
      "r104",
      "r105",
      "r106",
      "r109",
      "r118",
      "r120",
      "r144",
      "r194",
      "r282",
      "r288",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r354",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r421",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r144",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r282",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under stock plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r288",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r25",
      "r26",
      "r98",
      "r166",
      "r190",
      "r373",
      "r424"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r389",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r389",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r389",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r389",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r425",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r186",
      "r187",
      "r188",
      "r267",
      "r281",
      "r345",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r108",
      "r109",
      "r110",
      "r111",
      "r121",
      "r167",
      "r168",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r311",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r330",
      "r331",
      "r332",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r390",
      "r391",
      "r399",
      "r400",
      "r401",
      "r402",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r462",
      "r463",
      "r464",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r293",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Securities of government-sponsored entities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r124",
      "r137"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r122",
      "r137"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r526": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r527": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r528": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r529": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r530": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r531": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r532": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r533": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r534": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r535": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r536": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r539": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0000914475-22-000058-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-22-000058-xbrl.zip
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M16N)M%*!#MRQ0%SU(Y5[66@N5W((IH,*QB27I" <+$D6E;BU/GI.?9W)JZK
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M-H\<48Z(XSXJ8;UU1"=E7;"$Z<"2/V=S6K-Y#?.IL?E]83X]-N?,$V&"E]:
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M^IVS\GWM_RLA#/,\@<D_K_ &Z'-SZO;*YP]:HC,K[PNMA2F$B+* 9/-T!$W
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M^8='F@DQV;JYO_\JPBB6%MA*;T>QC&YJKODAKEF_K1:H(#PJ:XIDN"X$8;&
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ML"SO6(-WF^!0_G4SZB9@:\ E!'Z4\!X2F)NCT?%-4-:3FBN!QU;;?Q!>12[
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MM<[SD1JO=<AK"TW;$[>J*-,0G/& RH7":SY $LZZ+#-E4GO[;HN2#W<@.^G
M3T9EJ=/!6YH,IJ_\A+Z_-M_H!G?^F4ADV?0T/@NGM""3:X,D701:VBK[OLH=
M<+O_Z*?#N,Y0K/NIPMP/+>47FAQ7INS6:RZN*BN7U'SY<?-GZJ.:PIJ:<@,U
MY?FBN]SDC*@E@4!6W>7%$ M).;"RV,Q&>I6#J\E&YAX.?FX,=*\9:$W_=F.@
MS3#054.IG Q*RR0@UE0)#"*"M]4?E+@C'9@JYM)\\OS:?<X: S4&NE4&6M,3
MW1AH(PRT.)W;\"08!8BH&*#U&2P7''3*S#*A"/4\X5IW54C6&*@QT.TPT)H^
MX\9 FV&@A0E@/$86!8&,N;:?9A)\)@U%&8H^.J6#F&>*LK7[6W7(0#O@#WX\
M/#V;45HG&_>>D>:R.[QOI+EIU]7%4]5H<R7:?+$DUU,Y[;/+Q70T57%CKEB-
M1D,TFLOZ&HL=*6[]*Z5I''2O.6C3SJO&0=_(00MQ?L>5LR$ 3](!BL@@J)!!
MAF0-NB)$F>;NJSZU)FT<U#CH[MU7C8.^C8,6'%BNR$2EK$$G=N' \E%ZB,(%
M(Q(5V<PY2*]=\](XJ''0O7)@-0[Z1@ZZJ@>YG,O1H#T0)P.HO ?+*8/.JEC0
MK'93E96#7)]LL1W(O?IU_@,E\&51_B6=IS5.!^.SV73F1_/;^*8<QZ\$%MHU
M>GB-'7#9+LTU[.A>M^= /0?YI@O9+[GEX3FU')Z]"30YRO.#=7KTB6"^C!*U
MDH*;'+$O%]V=F45*M1.8T9CJ1$ 'O@XM,L%H2R:SG'%>4K#8_:\+0'216WW_
M0-5Y%74#U49!M>"_RUH'6;,]BGB*WAH8N((R*+ILL3*L,S'6,>&XI%]$ ]6F
M0-5Y"6\#U29!M5C4FUE(/F@PAA"0M  OI %FG4/R+@<7YR>5;J"Z-5!U7C_:
M0+514"U,JPD\:($<K*W1;NT2A!P9%'YT(6,B1FY^4BU6E'X!JAUP>ER3M]/1
MW6XY#]R6&7@AA 4Z:$RP$A/\OF@(!A%1NB0@H*MSJ[0LAF".H$165G*JAV]A
M K=DV'1?7'WW#U:W90@V6'4%JX4#5C,9L48O*.1RP!:M-<AH0&!PNM EXT0%
M5J8K4[#!JD>F8(-51[!:8@RJ%%2*(&J&.S*1B][J,["(6&>P%XE5#\NRX<T-
M5MMN##98=06KA;I9-#[P>>,TG\J151L,Q=H54A*W7F?BR<Q/J\6 ^Z(Y^(]9
M[0I?_DW#=_O_7;Y</KR?/?&1RO,SZ?KAYNQK3[>H3_<QT<#'.'Y3/OM#>7X&
MH_&L7'TV'LQ>47VT$XVF5-$]FG<^\N6A&^3AR(_BT)^6U987:G?[Z8./-W_U
M5M_XR<OA",XQ/%_7Q;WN_W>8_&/_VK^[6*?"<B-OQ]-AW>+O)W3J9\-W],,?
MPS1[=0G1S_[JXF/8IS_QH:R\@.7:/[E.%E]97U]$B%^N\/.O=;5S%LBY&#9>
MZA2$P9B]9T(K;BF1I.31_4>(O<L_>C6YO(.WA7 @3,C_#CZ7&_S>G_[A/TSW
M_O&E?(MP+Q9D1%GQU6V^?C._\JCH+T^&6]IDLW23#P^>/SMZ].S)X<'@QR='
MQX^>'!P^.CC^;O#D\-'U3WY?%O_HZ/#QP>'QP>-!^>[XZ)]/'C\\*3\<GY1_
MGAX<GAP/CGXJ/QT]^O_^Y^B?CP^>'?^__X\5W/PP./C7\R<G+VZ*;-$C>?WM
M;.3/TK"PU=]ON'QSS>KG#/Z)7>9]J,I=G/JW4_K^\IL?TG#Z]M1_^'XXFJ]E
M_D<_?/D!ZNV"7C/_O/.W/\'F 3N'SH4K\>*3+]Y^,'_K2B[7^7N2/5!.7_LV
M>\"O?>^O+NL>H%;?=-6_?D\AMK5NR5HY>Z#5MBQVFS:VKM7=Z*H7T84KRA$_
MM\&6FU\K6&H[_*N3\1_7_=D2\_3\6+@=^]1\[:2;GQ,/8SQ[<W8Z5\SG,ZH&
M7T[C.6] ._A;G5.U,/^H5Y+XJU_=Q./OME/@1;QOQJ/!\6P<?^](GA\Q(+9S
M2QZ6M59;KUBDO_AA@B>CP2/_=CCSI[?_P&_]7G[&)X\I#^-P=@N;N :^[S1N
M?K,]_=MP-"A7/2V/Z(TX^-J>TW_E.>W?HW3NG>SD?F_B;;X?F[90I[8U9_3*
M,.W?YI^,KYX9MUW:\=%A=NOU':=^%,OE_&SPOV<C.B\>D^R[00W_7?';797V
M#<;.W@R=VS&0=K60$%*23F5R,7)$%VI>D'0Y*8Y,V^#_\V0>8-5?BP3U-M;S
MX>GP,M;SDM58SM'/+S[\]OK5J\/'SX9')S^]>O'Z7Q]^^_GPS>&;?[$7)_&/
MIX]_._T4ZWDHG[[^_?W12;G^GR_PZ/&SUX=O#M3AZ\/71X^?\Q>O7^!O)T_X
MBS<'[&JLY^GC^.'HI/SNFY_*;[_$PY^?BA<GOXNGXBD>GOQ[>/CZU>G3U_\>
MOCAYEC]F)1RS]T]/GK.CDQ?_89*;$"@"D>& W&0(#A4H2Y8SG7((XIITVF^K
MK;SQ$=7GRN\UD-RW?,:5:\)O>._;R5Z+HW$ZHZYJJ[X:GY:]FQ[\W]EP]J%Q
MUVK<]>=5[DI>"\6#@JR4!/0RU?;. IS0B3GA7 I4Z\)YHZY&73M(79Z9I*Q.
M$EE&E9TSAD>6C$?!C6%A'>K*X\D;/RL?\G[V_>CL#:3Q#"ZNT7AM-5[C5WFM
M")[E*"6X;!.@E0:<CAD,15=4,B')J+U]_IUS;DD];N.VQFU;RFU_6X'<@K4Q
M9\.9]QHS2T&*L@U8-#,;:G>8Z\EM6FZS?-<4M*Z)3%XELG+P>)%-A*2+A8FD
M.113DT#Z[$TYFP)A,2[YLL'2"R[B1F"-P.X5@=FHL_,IH\>,6@@70R)G/:6L
M99"J$=BM$YA:\(Z5$\5SHR#(G &QID0K02!XL3%%].@#V]M7&I<4&#0&:PRV
M?0RVBF<,F78^6*US0B%CD#*QJ%T67F;';#,O>T%J[Q=K?%D4P04!1%( >FTA
M.,:!BAB-S1R)4;4OBU ?K#T9[5;(;0?Z#AS2;#"<Y[%=&QS_JQ#D36<N]8Z0
MYGGXXH>MGX;5I-2DU*34I-2D=#^DM(*B+ 5RY8(Q#"UB8CZXQ%GRLFBTT2JU
M<E><H@N<I[37A/:F#Z^@#Q\^6F+D4U&(DR%PWA8CWW)7(\@<I(U<)Y^1&[FW
MK^V2YE<-H_<%HYUWKFH870.CBS:KYR)9+A@8&0,@J]T(LI8@G7$8M,FVEF_W
M#*0[T!/]^6A"915_4AJ<E@=]4%"6*!0#G^+99#@;UFS:=WYX6HN!(8\G,"TX
M^&XP*M;L. ]F_OTW6;,W'<#2.T;Z-MVN?Z-QFI2:E)J4FI2Z#8GJ0#YFRY7.
M 2UYIQ43B!Q]BLJ'FQA*U\1&YU7!7Q0%GRMGGXZO_QF?UIW]V0]'56,[&AU_
M/,$>3H;3\M;C\N/HY2]E%\:I:'='^<2_;XK=*HK=\6**2+&$47HA@8*U@"%*
M\%KPVMU;V>B#=++&(I;DN:T<7VV0;\3<I/1-Q-R!==R(N=?$O&AQ2Z>UCU*#
M2)@!A2D6=Y0,2(7DLK,FSI/W^L+,7[&U+YM3E7727]-$^\WM_,T=R &89\I
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M\WAIE_[G:/?=J]/W>W\?=?= [@%YY_V[W_/MF2_=U_N2)F.%2BAZCK,=*)N
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M5;801C8ZV8RUT6Q\&4?>T:T!R!1]8/^3X6@R#Q+_7: CMYI?G/\Z]?IQ#I@
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M=]9ZCJ*2"G&60';.R*&#L  >! X>^^RYXIO+$G-#'=<X-/ZU$$1SJT S?NM
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M( < >&D,(XD@ZW5"7.& ''$$1<4(#3*RY$S.WKCBTL+:V'HOD_Z>[ EV C,
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MOF6-N$"3DR!B<BE!S*1:1.((,QP[JIRQM8RE+LA8K8WHV\AJ(A=/"$PKR7!
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M[H5 6@J+, [:P$$$V^9S>EF^J5MT:]&M1;=;HUMKKEM;,#Q; $.?Z\-P+Y'
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M_O+AJ/L']+O]$5C\)>T>O3J#<;/=O7 (8TT[7UZ=[@.*4FZ=05&*E(/:,7+
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M[8!P*<B<8@PP: ,*%-"0.RZ1)CJB:")@H4V24//L.;E3&H<6 5L$7)=)/SD
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MU/T#^MW^>/K^Z"7M'KTZ@W&SW;UP"&--.WNOZ,[6/M'>6&,X<BS;5X)@R.A
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MEQG&S!,:<N4&BCB+%)GH)0(KEK-DM7?45++VM3,J:%Q,2:E5 "L6H-H(6/U
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ML%: !NER:1ZRA+"#"C KP*P \Q<M/9@,1A(A).5>T,R!-.B I;="IV6$?U2
M>2? G OS"$Q9:2A#V'"".*P/<C$XI#6S25$P#(3/85KFX:TV*\"L +,"S)L+
M4IDD(NB5AF &@!E=" 2,/1VUI(3%*MAF=8!T5O.,FC%K%$%@L .0YJU"D' !
M$::%CRQ*B].R:])64%I!:06EBZ%4,LMDTAH;0;@43!M0/VWDD@9FJ+]?T%/E
M[EP>@LY'1 F<'-,<L8@3XM1+9!G)Y4Q"DDP)SK7)[D[&=&6]5PA:(>ACAXT*
MQA-1RF+M.)%$)RVMYER!+F,)<]5N^9.[.^>#T[R,7%M+D:+!(QZU0KF;&[**
M>T:"("0":#(CJQVB"C(KR'SL ",:B O1FD 8E\YK[E(B6C@E$@^Z:O[T#) Y
M%PUHM6&86(.(%P"9Q!-DLL;IH_72 FD;$M<V#"/KM(+,"C(KR'Q4R"02WDK[
MH.$_CITU$M"21$Z",4$+64'FTT/F7$PFD4P'13"*1AO$L=?(:<<0Q4[IY'-F
MJ%Q.3.;*(&81T?D_0PL/A7]#Z\?&Y-4:HPXPA9\0^?CK3+"=-S9X;[PTEF=I
M S]P*['F,&TZR(.MPI%/,$&7'OVK!'U!RB5EUZ/-U!QVNE]R69\^O-^?=M :
M?.OV'##ICSS0[>[)" 8 (_&M=LOF^=^%(?W9[OGCETG\[?A_7\[VOX<31[FL
MGS?;^YT]TOBT!X3Y=ZNQU>[4.Q_.=W8/S^I'?[?VCSZV=SXUCAOG#2#DS[CQ
M^<!YJU0RN5533H'U4B-M(T8@_GD43"80^&NU" AQ E,_[(] \O\O+/:$0#NV
M?]CJ%F0F"TFX5# E^%=H2C.:[C9C+?7:[=XI+'JM(,G:23\.LD^R9FO]*PN>
M>ZW%*_6?<J6G"Q]F[;39\LW::>S'6F=,4C4[K"6@MMJ/3&XUN$=QTY+(:BY3
M66TTR)\'P">M!#S3'0*F7Q(>/ $H;U#[[=_Q1VS7V._K%PQ?<$[QIQSXA/-+
M_H4I;-N307P_^?!': U.VO;L?:M;3$1QT1_C91C#0:Z^-<.[!6^7A_\X;85A
M,PNB=5P*HW%<]OC)X\/KQ:$9/"J/<;ZN-;WV,%XGUQZ[Z;8 CYK+>]WVYF."
M\VJP+VNP^E:W_456P2_S?<S<J0N4:@^P$/O/HSVJA=KC;K,?8ZT.YS4'M0_=
M$,/_NO[_;'R-)\/8<;%?8_C=+2I[OM;I:< O=YF=6U+1:MA;Q0W?MX;P,'^+
MN?BMU:W!<]H@^ :_WZ;:ZQW4QM6F@JPV+NN%;U-N\S5-'%D&>KS2N:F(:BE$
M]:++;9M;.7G^M&W;]3%;#RZ">M[-%@)8'R=PMUZXI\4_3PNKY!:\W<3<URWX
MJW=_)I??[5[Z+F'A7%.+L0TZ!)YHU)AY0YG3B5$=[:2NKOQ5E..%AV3L&\D&
M[O?6L#GG$AE<]8E<=: 4[I7B-J\[./*H+AJ[<&^ZA_<ZVVS_Z,MQX],'OO?]
M8WMG"\XY]_"\C\>-HSTQZT&$^Y)&Y^,17-/:.PJ=QJ?/>&^WV=S[_HTW/GT\
M:ISG^WRFC:-VJK?&83U?\4\8&][9W3M0(:@<\(]B-!IQ(P4R)#GD"*$Q!DVD
M7%XALCOQU,O83ZE \?6#(C74PFL+!K#(D\?.8J^P9=9X3(ABY3[(<X!B!7YW
M ;_S6?#SCAI!HIRD)#*/K%48<8*U3E+A2,3:QO)C&BOD6Q$0J)#O::KR5,CW
MO,A'9I$O4BYA506R.E?R$0F0STF,!"/$!:*Y$/HQ=HTKY%L1$*B0[V;D<RY0
M);"/S(5<%]]:B2VH R+P8,%4*I /5\BWZLC'9I'/XD"U)11%QQ48O"PB#8N+
M5$I$2.T<"[[0^98<8?A(R+>D[EFK#%7_&?5]TP[BX+5TPUHZ6$5NK.=.)T L
MGA2W46DN"<=,.$RB'8<TJ2LA33>AUG_L61&2LMO;]/\=M?KQ2QP,^RT_C.':
MI+O**7<_C#J;=\I)0T60)J#D3&[0DS R,H=!$\6TE<$0QJJBJ*^?KZF@T<N0
M.,..$TT<,<%93;22!&1+R==DPM=D>7Q=\>]=^'?.KX0UK!6.$GD>0,=P0B(G
MF$0D,D:BQ!('M[;!UV7%NZ^6=T$<F\ T3M1*3@@#D]I@08V.4DC'U,(PXTHF
MKPI/SWE,-$N4I1214<PACF5$S@J+;% Z-X<'FQ!7,OGU\W5DP-8D[Q5$R8TW
M#JLDC0L&4Q5H\F.93"J9_*S\.V?W!RLH%YPAKEU"'-1KI#T'F4R2B<PG+35;
M-9G\U)%*12[ ,[#?MVX_PE#.8Z@=VE:W]EN[-QC\7FMU?7L4X$?X*=I^#F(:
MU";KL-1ABG4M;C'2/TYZ@U:FB??]V+;#UH_X1W;K(+9.%B0^.#N(^0YK&[^1
MWZ\F7=P)51<LZJM#548]YCIX8;3E7@<=%$U1)\P]L*;E=_9@+-'O^@E(\M]
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M"D4";E.*_@ORG4HF*6Q6.-PJTT(F>-."&]IV^R(W)K-?&H&$RF-\!^#S,W\
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M0=E-Q)2;MBSLV7(*N@7H=6^,, I3Z?! TLB$# P1671,9!8Y&L!4,C&[@)S
MQ*YM#.*/V$597YQKOI([?\WK06/YE7\L5;*LJ%T%KDX$)2Z\*P@JQ'P;4/T
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M56PR8B"L8I/Q%C0%5#3>V-])F;XJ EI,0/ZTOGE@& /Q$!0*V'O09T1V5NB
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M"/FJ&4%7?'_;\D0$9@Z,8,]E((YQ^$D[)Y.AA.-Q/KG\5?&D:G_[WHRR3<%
MR;YQ$8Q'2FJ"N 2KUW@I$ ]@]$:M*'#-V@8E^ 8@?>;][60UPS21"&_ K3%:
M1<^-M\8F+H6EXR1:/DFB_25-5?O;MR.@.FX<'GC#6=0I9%>VRO&LH)]I&U&.
M<Z56$LN4RZ6GS?I\-/Y3[&]?1O9?NNU*WW3ACIEXINU3DUSER%LN,7[.[A:G
M<<XU32AHGXLO<8DT:&#(F*B-!@U P$+D/C(WT.)B1]Z$;!8+V_6Y9.]'S/C_
MZIN@L[9C20^7PF_PEI/_P5RD,*'!48U T9:(4^R0HXHB'X5P#G"(:3:;S/\(
M-?%NJ;P5\0J][*LK''U%Y.:X>EQ&LL&HT\D.UH5 !S]^C2?#(K^T3(9E^-TB
M0BS^E/>^J')2U!V$MVS;DT%\/_GP1V@-3MKV['VK6XRUN.B/JYIN+KLW4W.P
M*&52'KZLWK&.RPH>XSJTXR>/#Z\7AV;J*(Z/Y90M<NUAO'[]L1MO2]8UE_>Z
M[<W'!.?58*O!5H/-@S6WNNVX/O5,I:9<3&?MNIK5DV*H.)="G7K&]*G]WNEL
M<?D;*EJ719>>INJP_E69H (J_S,QFXI21Z79>FT!_3M,C7F9T_&M>YD DW6<
M94S%*Z"21AS6)O$D%:'D&<E1PK4B3/C*)#P 99ZU=OO%2Q<W?)]W 5K^%M/P
M&Q@G8_-E\/N2F.6JOCA?I_JFE@&K1RA;XTC=6TS.K]_X[4S;I!9)K4AC72YE
MO;W9O#5<5R0XW97H1VQG@;< X%]SFY-+B__1>F&]ZDXE;Z@1B;;">2]QM(%P
M9XGUDK- 3.1*84/(;1N17%_Z\&5[E<?]1]K-_<XVV]O]N]WH?#MM['XYWNM\
MXWOG\.S=;V1_]YO8/SH\V]_ZV)[M/[+S_6-G[R@TZYUO=']WDS0^?6GM[S:/
MZKMUTMC]I]W8;7=VMOX^KG__)]47M#</T;#D:&X"(#7B,7LF(_4HTZLB3"F;
MBE922^AO_E3]\.X)O+-RZ][O\9:!K$*QVZ/8E"MA8@/\)R?"C#IST7=E!<KS
MV.]5@'<WP#N?!3RLM=*,.10P)X@3(9'#N2*SQM%02F@@:0V@3</'/QX;\BJ\
MJ_#NJ5[ZMV<!O/F*4P6X52!V%Q CLR"F N7.N(0TT0QQGA*RTFCD'>:.12.4
M4:"U+8A/G_/!5=A58=?*8]<S0-=,YLR*]2Y^*<C%9I&+.!&LY1BY' '%,1?(
M66U1((2;$"0F(4?'RT7E1ROEJP*P"L#NZS(;%RVJ$.QN"";F#4BIF8R@;.4\
M;*XY1\;A@+#)O>X4-T3&M0W*%E5X?\4(=I=[K/S^S^V8NMC_J='Y[9^YWL:+
MFP<_4V[. \,[MZ*?CNXLT^Q)%=WY&B+EJL%6@WUI@ZVB.ZOHSBJZLXKNK*([
MJ^C.U2.4*KJSBNY\]MFLHCNKZ,XJNK.*[ERVJUK*1"1.@@>.>=#.:1QR1SFF
M*3/,\]M6%'KET9U?CAN=^L\ZW8;_[Q_#-:?U[WLPUOWC^NX'T3@_/MO9/?ZY
MO_7WT:RONO'I,\T^[;VC#^?[G<^XL;7Y<_^HW6QT/O^L[QZSG=UML;/[\;C>
M:2R,[B34A,0=1Q%3BCA)"AEK%;*1F!@E2<:9M0VF%T4*5-&=U8;;R]UPNTNT
MT^/ V"_".RMDNPNRS85Q<BFPCH8B"VN%N$X2.>4$4@I+P;56 N<2G:P*@:H
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M2S/,_C][7[K<N)&E^RH(CV>F/$'2W!=[KB/D6FQUNY8NE=OC_M.1!!(D7"!
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MF=MY25(/4_>VA.02!:X;0-EK/R"E<J,I28Q\&?-GU8OQCUF>.E=SB24 ;IZ
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M/[^B^U]I5#8>JO=G#B]".$R?A^:=X 1);@>[L-O!'GIAU71:"ZZ]!!>A:6I
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MR,07_%&7\--'@.[<S\VIGF:!M,44(-(T=@,*;1!%R<4RC%>2KO@R#B^9[G9
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MN/P&BTF]^"]Z*JWZ!?SN7RLO3S=6\>+7B[-O^(-<+ R^%:-X1RNJ$/&#D$=
MB"EP_26W16),FG '+) DT@EG[UZ=-0JCY,VK,P>SE>2M*0PYKD2=@66>!*ZC
M&]HL(%2=JN-5!-0KJ H+M=G+N<FB:9'>F^K%4W"$*F.!;<4L$<NY<_Y/^(&
MEUYB[ZFO%HTNN)P9VT2W*VB(+OI&RL8]?LC,#^$\!^PF\#0T*Q7$*G3F(/+Q
M\T6$I$   [>44MX)#3+0;@08>6"\1>0BJ#0$_AJW1?9@FD^!'F#_1V&9WQ2@
M8II)\R!;:^&G:AM*@5*_"Y M\)\I_C._AD-Y!4K]BD_9^5N.U1QG^2Q/&2]
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M6\T4#S-Y)I%%7UF6>ZLRJ&<FTUI$/6 !K1WM:ZP-!2^-0[<NI"Z3/32+Q I
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M:RVK<6O)L7(>CZ.K,[;7&.F PV;)"MX+O$?E9.PSHIH,BO#9$[BM-*O5X%K
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M#>,]X6NJY)!&[!SV2: F&1TYP:_R'?ZK]EP,GXL3T,-G"'?;@]9^*VCM\0,
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M<I?$SUF17E0UI<S7]3IFGG W^B5?^)2=&[;+84,TL\1=7TI%G+>8OL^(10Q
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M1DB\ $V(O4#X,4J9N8M?<5=[E5_4';?SHHLWE0PD@YG$T=V^-2%YXH*2!5"
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M+PILT36I+ST6R %;8E7D5I1MQ.)N22_M'PYG9RK>5?FI3B_<)FC1]4C9HJ"
M*61*5L-LRT(14@R_2(@5S^>6F4N1+ZD8&50RQTMGL&1,"LHW45E2P^UK:O9#
MT2GB71Z]RBD)1I?@)DK2O=!7E^(<WBC*STVESY;:FS'QY616AANK5)$6VBQ$
M*8@=0FD'#$0,R&4+IO)I#]&N_/DOHGMO#D]S#-)\7-$\F(,)%,A>E59;/P!W
M!<"#[2[K7)#_\@!8V.E0LMTS>N[%_LAH=+!IO$^0>6;!M.4B+0 2Q7LZGJC3
MSSL/H\$<'9"^8N[]$1+0JM8DV;7H<%ZKS(V_K+0 &G2P;P$4OZ3E]EKO+@0]
MEH6SAO6*\7  =[># %I\SDA<2J7DENJ5Z6?+M*]([V<9$UY(Q2&9-?6&N86D
M+-5W!Y[&6Y,GB;(4R2U> 4/H1N$-]:@^Y[YF\+^BK,#^B-%^'4>7L(;.61#/
MN7#OT]75!*%]7C5U6?K65UT$26@*14>LN7:T3E"^X)%%,<XWL4U(_L%DCY62
M%&60^-F%1RM@N!S=*N3F=>F'&;<.# 5';RDSBM,'//"S2Q1JMLB.?E;54351
MU+[\"_,+>Z^NE;U!.R/G!NN<U4GI_U74%0V'D?> MCB+"%#L;6^96]PC8286
MM6B8"N54X:/##2D=?8QF9=R%=!6--S,ADM7>W%TTPHLB#P>D=$[KA:CKVSP(
MG_CQF.VN'5F7/2B=^UI24-MQ,9IZ/4 M2:PF?KK$:"HI *-ZT=37@E,*PV?%
MF)R-TO<) 'U#"\&B;O)>#)?"BS&!=='Z9AI:A1R-:L_V4MLVF**#](JDEQZA
M:*W:X<L@7%1/VFRC8M3&-W$G2R'1+326W*/GD_,@<UHCYC)!D,ZU.P25 #\<
MX_88AO]TPRF\A_W<$O;S= _[^3CG\MQ0+KNCJDRO6Z/U$;0W! U04LMNZ,H$
M+</,%U?80V&?5,!$GL["-^%((V<U  KZ?,B6ODX\U&]HZ_Q\8*$7WAGXF_,J
MR%4_MJWU/[EA/^_E"/E;/6]G9^Q/ 9Z2EP4SDO!IS,W1;#.$O_HFAX=+RA]\
M'X5ZLY2<"U@E;IM%]K^ECSO_1J2:O?'/1:M!A>-*P&#=:?I/(1SQMX0Q7-(;
M<P9PR9,G#QH(987&/OCEL5X[3B&ZU/'C6U^(F@V=1S2^VJ'[L60D[/ ^SZF]
M,T!9:$X:],YO@);/V_%VJ-+&G7_<PA)(C_GKU$[?U%=0KD%FT'/$!:X]E@^\
M:>J"&H)<K6@1,3=,4%%G:*&7OHRU\P[9GSRO23FX9>] \KAF)V9YP!%'#3WM
MJ*.'CV7WP$OJD$?; ,OCTCE>_!,3%U^,<&[ZB%AV:=LB^W#E->!ET8B@%4>G
M?%ZG3))CHY9H,)&1#2*;*Y( )\I"R>3:'$[<7'3S4&N^5WI2*9MZF<,!,'(+
M.V?-+,>BPAJ$7=RV'.]]Q!W!RJD@Z(:F)F<&<69"^28*OQ<%EPZEVU7.$!+_
M<)$,X$U-7^9!.4Q9=VI21TO1B^OE@7)2PN;TG1)&W()9(5)MFC@Z#F??4><[
MN;F^0^:W/2<"*Q?/@/64^Z#,?IRQKO'443E@]!+3/VGY)2ZK&Q>K7!6-.V;/
M"G>3MT0ON>3 X87VL[[3)F;ZO@9N+UW<QGOL;:XBI/1W'>05#;&-K[2A2\HC
M?S]\=^C'B<80D<]%7V1P[[W6PDLM2KZ5:.N=] "&"A'L@"C/%$HN9)1N<'J4
M)*-2AB2CS' OQ0UMJ4^%1Y."@.'7%H';0ZPAV$-D6D)*S'S'+PXB&5$VE+[R
MY%U+'D_B42,2EP_@:%(NNY;/#R5& 5$4I9%<H$LQ_&CPD S(\;'Q8P\=)K6"
ME7*-]3Z0F3"PR3@_:D& ;G.#?L7-<7.A]2+^1A0@R@#%YR/=10SEO?"V/M+'
M_3'N4Z$8K,J[ >J99*J;C9N:Z[3)VFC%F37<,;%]8'\5+<![,2PWYD_';PW7
MX?6//R2#U]<R8Z9Q ;M?$<\22'X+;KP)Y$EP;<EZ4<!05ZA[$-.\2 _.<]R)
MMJ/<##[=R9'<07C?V*6B9,9X);H=1;X<?4[A7.Y7DHF0G>=>Z18O@>!OZMEE
M<H=/2J (=[X4'43,YZ(4R8ZX88."68J>Y&/N3Y0L1>M%)MV8/3GZ$T.L/TB/
M$!W#A[.7=V.JHF.?I^.=$DZ?/F$ZK=,GI^HICZS_>9W!3AT_??(U\DKIBLBL
M,C4Y#=G]FFL^WK-C<TZ/R'-)[T*?72N-(Q[DHD90, ,RY.A9?>WFEW2>Y>1*
M\/OC9^(Q%+H"2BA5+)&501/$!2'7E;+YL1M=^3[YSK"S:.PJW"%# 1%-JK^3
MI'FZRR;/#Q!!:2:/<Z7^B8/(7&QYZ*K.<SC@6]+RF+ \6J?S'QL8'TJ.PB7G
MRY$(F'R0%\>,0[ZQF9H%,5OEJ=;*(AEXM]JK1:Y:<UQ6G0V'N;5+7PDS)3A!
MBU[^07V0!FKS*!?6=$[U#4N@<240:V'1#4Y@26B&QQD_0%R/&3:V&&5S]Z5E
MYY/RG'3S5YM2_Y[GWF,/M%]=4S\ R,Z9)77C7&]^@':2\1J3 2Z0E1<3SE3U
M*$EH]G?\Q5]O4B>4_%+:.Y0NI/[E('))MU=Z4-GVB$$'JV#VA6_>B"3JW!>N
M,?<@<!U_[\N1)C *%X&Z-]Z=M]N07_#=6D-*ZCZPH%I@UWYI]BMN\!'[]1V'
MVY.64FQVX%.B8W/C%4-QKYZ)#FV'6/AR>(%A$W'00,[1.EX*HZ@^GY+V"9M?
MD!R5^_&IUXKF4\:.>( JR.L-8KO%(B^EA1AFU6V)7,JOXJ'Z1Z?<R#6-3[3J
M [ BM'3[R6VL;SV@-!G,<SPVMXA E232)U+NA3_X:SC^QH7+807; ,TX5V)9
MGL4J_.*619NI#J#[9?X![ *\$AM2Q)0&^GLQ4#<ZSA.C@DQ<@Z8Z1,(07IWK
M4<ABNNK#ZI?\P:5.&>!/!AW&'?38C,[64!5,&5E\5@-;0"K/E-T3V8Q!OHON
MR%=EL\M5Q=!D#C)2V"P\PJ$;+$(57>8ETH;3)6S=7"Z<=N$GV5@X4-9QL/ *
M0314_2IOZ&6W).E"L@_G\\$\;44PU<6;0A _./=7Q0>C*V9*KI@),1(U_X,=
M,U,YH.2+3)/D-WLRTGI!>MEE08JW,@[NL^&H0-DQ$ADBJ[46N$=@"^>Z99SU
MB%[#?8WF2C5OY1A@RP8_>5R6<<;.:B8I>M66%IE%T[A.:34UCS&X)4PGUZC5
M[U,;/VB=B2JQBG Q] ?N)@.+8#:_L&:H$1#';&IU[VNAO]5P/3IZ +70>Y+>
MCOB??1A^'2(<<E;8,DGADK:?;-6B<<X501$7K*9-E"'.\CIO$,3%"B\C6TF!
M%Y=3=S&L3=5/#&TQ:G$9N\D1E;.Y)/DGP:6EH%9\:Z+@1A"F>,NM-X0W6Y+?
ME:$Z@\0E!<G>V7?;UPW4<:+Z!7P&L*(W_UVMFJ8/.;/O3ZTLV*1P6LEXH>OO
M Q]NG*.G7D!_E,9>6; _Z0 RI)EO4YZ2QV(:!O_CFNISQ(EU+UR27T-XOQ5-
M3\[*%:DX%.4#0'K^-.@/$ V: /@AXO8(U@WLU19<M^&Y*#?*>)57[M<7E^X7
M.BR)+YO(K87EH,WMG0G2Q'4/RJ53G83^:QT@N_AX/NBZI$&]RF.DH$=5]!4.
M+\[U<8U?4[063@7I,V<F%CW%@_[]N' Z@N\-('[TX*83PTN*<91'2\2HTRB(
MRKUY12\H(,M+#F_=/N.3V[ZJ#"- 95$V!S4>L4<HLMX>6=;M7-*,+B/@G,66
M^1>;;SX"7.;-8RLP"#9F68";P;M6G!EU'@#;&E4?O9*=^IJ29S/X,KV"Y 9!
ME>-B1D72#C%N['T*H$VQ ,%7\I6X:T$(9,( H=\H6$)+$Y0^*^K/,<K(K=9F
M.8J#3Q81J3F^J?Q!,A98_\J8'3!\D<#>]FD3)*;@W68_"BJ ?M^TGN2_I/BA
MN\[+*X@H=)?M;99#@SJLA&/A]' +X(_?G 3[[A6KPY^/C[\V]G\VM$"3=XSA
MG0";4EZ[E9XIHF$;!3P/AF/C(39FCN#O Q:V?<__)Y@$31OVVIW0>K@3TIZA
M&Y8%KSA<MJQ-^^FYX^FQ*$HR:E%GQ7YWW"WG]AJ*>93L2I=Y9_"%W@,<2]$F
MGC@L"0TZGH]K/V%W3V'"5FI14ZV]8@F*:VD\FE*5,YG _>S<X>PXG[XF_ -/
M#_F.7A1O ;:,JKX*0#Z:LPXBT0@2@_[F?*,@=OKS?LKN<LH$D1%+<6@LZ(4X
M;(U@]R<EXM-BPG0+^7Y&/Y6)1/<><$>3W>8L-[F?CD\U'8/$$@A)F5O47::*
M.-;<QESL.9WN=FX$)N #U5%.(9Q$"E<2$8?]M-PU 63%CL!$7^E^[._2A<OT
M("?F$O1A]2)+0DKSGC)K/PEW:9<F& Q&'>[[&;A+O1=/+U1:IIVN4T7"H9?E
M \_QYY.9@A'IS#][[0[]\8?VLWF700X5ARH4SD(SV7[$/\V(<QVW:+(#.DP@
MK5(WGHM&"GS%:D[U)OK"?E[N\F0)!!R&"7^* []8"L\S(6T,G:+E-V+FL/V$
MW:G W$<3%"7WCY!H3X)[U_X*$U))1AR^!J<8I*RA0+:FOWAHG>[2G)3.5@P'
M%$C"N__'+<YG;V:OBNP\7<_<A= .^$%%RA9H4. .QR9?4Q](98@MMGT]";L$
M/^="8T3_M$QK@QZG[0B:95H2>)G:NX2?@GK56LHC*-*X[%M!Q+&*)![#=Q%6
MSJ_L>B$W!B!"A217Z28Q_+E%$_BHUW5)<GFMP0_A,":,2@XZKH0'!@0C&4.I
MRU(NX^]"J.O#V3MR7SE)$F.+EXPL"N))-,PMSA?;X>5Q5PEKO3$PW]U5VLY)
M?);),6F@!)M%#UX6[O'<.M@DVYH]HD[L30#H>,]C,^@MPEOBEZRWN8<U_V98
M\_$#@#7?*VSHCQ$W$W=>5C2'W,GG>S4I+<SPJUK@^C$]A!)0,KM3LXKA;_?>
MRJO '18O+#.YF:%G0W6M0!Y+K5^"R/9P(IB/U'=F5[V>#X)QI&"#4:@;!>1I
M]*Z7!!P,<$3;;\C>\ 1^J5%;2XRX.H/$(=(WH1$D3*T]=V*$VY.G?_(-+C6Q
MK>M-E2%17[XBC3&&W,VX<6^+_AR_1723IX_]3:2]I17E,;3'S-.2@>>[9.UP
MG*:VSV5J"2JQ8&O;2>=I]9Y\R\4FX<9X;0$DO=9^)![#!VVKDA?P<U-/@,AP
M=%8\=3,@7<ZY-!,)/0PUE6)1]*V1$C-MCC5 GS>]3"*P4<Q$$N%SAE3YGJC)
MMP,,CR@"ZQO&9;<D0+%]\[9F%#^5U+N9D-B*J#![!IT,"I)+SG14?-[(D]"W
M+ A?$)Z:3?RHEWN0 'SQ GG\6/36B$20^,& ^SNL3VZ:[_*8"W=;J(P8JZ6.
MLZ*]M.$QU\<-;2VYANR*%,.>^7LQQ#=9:W;^6)!F/):1\MU.8BXWAA=-NF+Q
M9J7R<DO<(]_:SD6AVG@7P^$X,@W)\, T3(:E;]H^_UBIJL0;6^;&=1YD75X)
M/Q$Z#Y5,EHI1W ? -77#-">:K,3C :'PNC%4ZO)QY5 ',<@F,0%T&U$P>PD@
MO350XZHX#OO(>WW8)GY]FSD*:S5>G+$VRHZE2IP52E8!"Q1)W:M\B)M]]_M%
MKIQUG8M'UO!OO$A'H"#PXM[DH;OQ;)>;J,=1QO\7[B70EY'W#-X"*6'G*7/6
MNZ#D0S<[/N'CC$]0(WK9B5R'/N2*ECIC[>/'T?5YF]4\/9==^MZOH:E)3&93
M*I?^5 P\ZKF2AO.)**(I[KO*+6.T#=S17M'1$YE!5O9TZ\(-'#B068<]V, H
M'HR:4MVE.Y+]UA*YV#BZ#R>6JIRYO0*[[XTCAN_Q(^%)*#*&>(-9N&F#+@+3
MQ:N<+KG!^$D_!N/%0H>$;@1NPVTH\*5AOQ3<"]Y2*$?@B7FT&EOU"7'3>^]4
M_VC9#W0GFFTR9&S<]T5\%LSW.(L>ZP3L@!K3=OIJCS;^--BMN?.OF3VQC;KH
MA03014B/9J_KO2;B70."V*W,C*0;GR)<Q(#U?HN,[O/8:9PZ=O93=<?&;94Z
MS\&Y\%Y1E"C(C 3%C8[!?H;NLE2D^P;>E V[NKP-NN3[+J1/NF?0N*X=>G$,
MRBXR!SSCP'8_,W?NJK7=UIP )1RV) 02DPT8)  H8U1=I!?"V8&J'2A_%HC[
M%GF.RIO![//W VQL/^MWBS]><Q8D[E\R#2\6_K>?B\_0/H&X5<C#][OBD]I"
MR+*%5)5T6 :Q!9;Q"VD;VSS&8IE%RYG"U3HM+JK]!OI4TQ8G?*>SX<]F^]FX
MV]F(-2#'N+J!$M,>._<)=P@D.(##N""$8UD6PB(7]9,3Q'*B5@/'+BK/W/MT
M\<^LG5() BQ_/UDTDK3\Q,!XPLF;OBL 1=8HN *'G.VZ"VU>4:LQL[V'/P[J
M7<)V#)PCM25GG@?):[9<YTSID WR=4J;"P2*X:MF.B<B/)7L>:SN"MXE+7*&
MBF.])AZ)ON(#D-BEM=+B!P2Y1"&+8K??EM1>RH\U(>KBMQ#BPP@ETU)C%LA4
M931+4IF_J+N"_2-" Z3"]FLQ S.%#HKQ,>.! HF^[.R/QZ=?'VKMK'"S#1*%
MBX: ?J!]JJB:5UJ&V_AR*,?9[YB+>PZG/QX_^?KP:7P7]Y"$//!#,C6QI-3V
MZ8?DY/CH\,GL#D?CY)NGAT>ST4"<[<+G)&X0OSDZ?/3KGJO)5RR.223[78HM
MZVX85JWJ+33#]<OU4E4YO4J+4M5164&9L11YH_7NCFS&</L:;'N L4Z<B S^
M7*7O2:Z!:XQ$DDO4>TP,R 6^E LILG.9GC<=O8M_AU" SHJR9T;>>M3IZPOP
M6_=R*]S;R! 8: *UN%2,6**"9),3YFP@D;6'G_YF^.G)'G[Z4<BH<\K'%TQ4
M"#M(-((FNR@HRU!FYUXNA@HBYX63W&W>15D#[!V#PNV.$W#._?>#SG406(/.
M2LY!8Y-L(P0W> <JVNFV0S3D6']>9]G!=^Y(>C_[F9"G[[J&6"G?LA097>+<
MW9J(VF=O&F)04;$X%OY[]^)\](BOTS9+_Z&:>0 5DZH.W=%+$I'UJPU7J6],
M);)'T"RV^8TC0)<V*,^KM-FP0R,2?*%M&=B*!7RGJ$NA3$GV16"Z!+7I! P5
MD2?S9ZV8)Y&9D.@[G9=03!&+"\Y*Y,];#(\GXE2MRHS1I#9][N[&DX;>C#HK
MMC,8B[\W'$DZ99E6>1%VE&T1)D;;7 77JYS.)E)4X6>IJXN:-YW*B)"$;-A3
MX0%3S@KS>[= 7S%D?!54O.@4UR(!W=9,UT=MY8%^A\@.@")-<9$;MAH8^]ML
M&#C8AJ969MKP<->11^W'/?$R(QFZ-A!@*5T1KI$Y>UT@*"E$+ZD*?GJ5<OJ)
M5X;)')K9"DDK!4I1?^3P5;O;; O%#*_[+B@FSG/@\@733S K19F9#>3,UL(S
M+G#WBO:&#]:LE2ZP+>7.'+"SP[]<& W#:764D>SZ@&MY*\GJO8"I?N1Y]]+S
M$:L83EOCY=V\%*F,TP6MH*;@CC&W.J1AB)N3U1"@QT)<Q(?39@&]%+>:ZTV>
ML_6.&)I[HHG^)XU.-"Q=79>M)VR]SN?.=HFRURI/JU:SP'TEUOEP]CQOU_2A
M@=5PBZ< >74\ZN:KK8H9.7OMYN ]^\M0+ZIDT1.__M3LS1DG&MZ/]ZY<VSWP
MW$4VHRZ#('*.N(R<=TY,D[TP1A@I4U8H<@=O78F]+*#6QUM4\QML)# TR< A
MNBIJ+U\;R=! VYV7F+<JB1$_^_6+,HZS_.!"E HC[![$O?.:N<!HH.*W;G-T
M$USE]EVWG8^V>:%TAV(YT/UUACF<:<%"4AR5KM(+U=OARWKBC7*[8GT08HT5
MZZ=4ZL-@#67J8U[TT,*(X[H6E"O$4;"& @]46$G5E"FA;<JY)'Z]P<&0S.8-
MFC)7RGYP4=<91:*?TY2<#$S)M"E]ZY9.2XK'>I:2;7DII'X/\&B0)A$F_??=
M2>QP"]M[YSR/G%70:;,X&[%)]%BD(K&1_)%2I2T3!TI+*U5">XT<,>-SLL6@
M1EAWF95PPD6K[6$<- IF'<",XR;<A!)25(!B<;=+RJ'L$<=W6.&0;+2@2-8A
MHAPNLGTE]DZ!=SEAB?E H&YW)+==Q+P?]CL>]BO6QBN:C"5;<E&-<<X-%9 0
M&JS%3$W0H^X+L'=LGJ2[B:)M<K6&T\)*(\-I@3N'AA_G4KE_:$DM%BAG_@NP
M8K#366[N11"[<Y[^DK-\H!1LK#)9F5<7[EWI+XH8]5)>+;S13HDUYCJ(E!/S
MGH@)6"+LM8E#++Z4\8AMRUV =9.QR$P#P<J0,D!3LVC"Q,)/ROFLVIK.-2<Y
MYX:5+U=4-V4Y)0MT53AEE46&<GAT@4'<-&TELZAKSC_ZX>QL(1IH)!1_/2IZ
M[SP9_;H;*%R1!UA3WYII*T0*2=J[0R@K#7:V!<\VH?/=-0LCH2\5*S*>:8:-
MHI4=WPX=I'I5E1ORG7WF34+C\M2+2#J8W^/>;PS*?2*&I8P6;$-?\>CE\4J1
MC;\"@9F@T,Q'WU?U]<%E?2WSZ/.[V_CJD9R-W'O.MT:1@$2/A8V5KW->8"&N
M2)B3NT&&F[<B$6@5&8>]"/ 'NJ6#GLNH[3&QN1U^&0IVJ>S(J6(:+@32E%JL
M>$5X0+$S&2YXY_T_<=/XTI3.9ZEY6G+.DB8V13CU<.,G\ANE6,9W2+9?!$O4
M7P,;8Z$)E_#4B=UEG#G0S4"]C^@G7TJZ!WE2OD[B<USQ\J$K!>(($>RE95,I
M'Q1TM$6PE>,YR>S'P>&^PON;*[RG#Z#">T_(TM*27*@+&!Y:JZEAQ9%CAD]I
M D6IC&&JYJ!HL7N(C8@XR:YR(9(C.6;G"X"*BYL7J+$AEXA>B0RL>RWZ="6Y
M*[FR=&WYOC^A^/E@MJ1A/64VL4W=S\A:KR"0[8^V< XJD(,RII5F0_589>(5
M*LRMUJBXR.WIL59:^MAP44T?.>/"7]]TO-V#=H(V9QS.7F+ ?$N_R,B&K<^X
M.$Z(2(>_'Q'[?*KIY_\JZ9.0807#421^6 0&U</9J[K):UA5FY1B4 H\Z=']
MHJ=*K^HBX\'0$RG+Z5PP!^ @HQSHD>T=Y9@)BN.*F(O ;M0_ R%L,"%[S4?2
M0J"C$BAQ=3Y1VF0=3"[]%8L9Y8!COT8H^507.SR1ZCJ&S\P#J99SFXO&PQWX
MF3O1%:+D7(R0;F]U>:J/^/S^X>RG>J;1I\[$2K0XAI6-Q(,1;Q[ *N?L*P8R
MNK V&+'S02N:@P-L95KHSO <X#!= >GUG67YE$QH()% CQ)OA:L42>WIA.@D
M1[:H&4^OE EYK4-"/W!P\=+MU-GQX>P'%!/>F(:HY53H.D\7[R\:\F /Q.8N
M\;]GG\H"DU<AJ+2<2#)RR@6WBZ98F]75>G# X>>+O__P'_$^1B02+Z%@XF#,
MR +2"LSR!?1,V<BII@RV(+:&_5UD!.5,@?D7AJ^^\@= R:PAR'XO>ZYTM9WS
MLJ&[*[UOM,20K^E;!=#84*QCA*_VY/-2: ,UC6YKT7]EI5@ZTL)%J'@)U"C-
ME^W (]JL5!R[<7+A30A3?R+OD6S5[$<")GI&%<9](.BJ@WBYBJ=2.7_#Q3AQ
MSELEQ21P3!<?93'?T!<X-^K6%^H9A^ZVUY>[)L1MJ[!;@>N<?'&HJ1(8 K2=
MN1"8A7-C6.2T.0I&O-"H$#:4R?8$E<!2K +-N-VC6.Q4U!P9OQ<_D$2'@??,
MK$3XL+J 3-K"O6<+[5P2A&?-7V+.F?1"-)Q7AR,4C=C,KXHV5%6W1-^<ODJ,
M>G2Y$7>CZJ@H1"RIROQ()6(3Y:,RA?!%DF D@-V+FO-4 NQ>Q/0?6Y;[/B<_
MU@U_0\$;,'&K/&TA1()P#8:!J RYY%RT'#2Y$2@([^W^J46Y20#,QX(W/E_"
M@Y2//5MW7%8/-6[R[>.D&_9>)+T6,'\@4S:RW/"%!*[AKA28^^4Z(^[^5B%;
M2( T6K<,!&KN*I=F!E-.M)4N]&<&:I&1]Q#_:,&R$]ODE^*V7([7@I]Q")2+
M['A>I?:-OLLS ,4&0@37JNKM$VV-;&:+08/9"H'34JXE@"].KSF_GVCE*#HB
M]XG9E</-Z')-70HX4:2RX5,NP9+LO8-XYH;0C0#5H52)>]FB98R]&W(U9=J[
M9$=J,A<^>L]UWT64S?8Y1[H,-S]YB$,4_*G"9K_T3=$2@Z4V3]UJ+!BR0GG0
MC07,C4?9MBQ0@I?MPWC:[,*AU#.=G3&I3^B0E):0P<8RKGXH80,7Z!W:&$E#
M*6I9\Q)'%/3(0GE=6]0=ERH8\@AC;O8*@5  AA',+/J9A$;\_B,#XMEQ;_8*
M]"\G1\='G(UPCA3X]@S8F4;CC,Q2AC/VG%8U - 48ZV8"E?VNAP7YVIL7KC1
MY4E^2\U#BZ*4P_B,VR[YOD@K(I9Q9J;D*YV=G[DXR-V!PE_M+')GL$_GIJV4
M#GCVYDWMW+Y*.T_<;V03$HM@0_F51,VC9#$[TD-0/_6:\_O\'>S;=IT+,6E>
M72(_XY.7&E$MF[1G0&DZ1^#HK 6W-SD;G5<+3WL7LRB;FP"</'A.K=-P!Q[O
MC2[]( ?NDG+ 8B#\-Z6N(XGV.B98E4^!AWXCAIOJ,-@U4M!3Y+.$WV[PX0J'
MFI!XO_'^81Y%C2KQ-T/&ZMYO#R6Y4XE?-P%5+X#(C-9VA_276R*SF@M;-#7*
M3FP,JG R8WH)P>PM&0!Q4%<P9P&D*M21044&FI@PO>BV=!\B8+4NJ#;G^V*K
M:+4O]!R(C07I/YQMZ?XSAXG9(7LBJD^SE/2X4W^%CND>]6>"]J_ZE;,<<][7
MT=$\6_646R(>\2H3!^L5462G139[3B;A+;Y'!PI-)*V#D]/#XS]A01V?'A[]
M2:U.*CI4T>49 $^F4]<F@)J2@<323#1&Q^FQ7RAWN5!<]-==UAE',N[0Y\-8
MEX:+*U04R?ANMUP8R'BF)87AH!:N121',ETP%I=I22)81449*ORC[9PKC7^N
MB &7OHDR 1,4[Q?#'2X&4!UK 2"V"I*/;\.,\Q(QV'E$KERJY6EVWCK0,W#G
MW*@75T764^QQ?5ES KUJR$M$%MQ?EW-8&<=:=7/A(FOFP=F?&'<[]^O4SWWN
M K="IM5Y#>@1P/[UL^1YIN>;*<@Q54O+^AJM+QP@D[^YI"*$OX27*:2%XQ69
MS"HIX H#'9"BL,,Z3\>GI_Z$T3AT3=>B:@D!2:0K8[Z).AY,N/^Q2WN_\.[T
M!.)Q;RA4;3JF8'@>5L=%NF842!]83!'H*KK?GDSP72H"'Q%X)2RZ;YQ3LJY=
M>'E0+P^('<5?DD*DI66SD*1 W$[$?25R>M6R/^CWSFVA+ML4N>7 F6)JR'B!
M-36N9")M%K*+2RYO32W&NN_6$KG[V\YS;V'Y")X:N?UB_516$ME=C8O\DH";
MXQ=7<)7><(.;)%3>,?/U. ?&V3M9Y[OAT7N0TRU!3H\>!LAIOQT__NR@'+!D
M. _.E;3HQ[YCQ:RWRH;]4I0>^4A V8J((P ,76ZT7,QZ+(E"*YF]CXH[T@;O
MB9MSU'@($$6I2>7<)J>''"$X+DK2M61(T*7_U(,HC#4"F.'RSP=H\USEI@65
MDH]LL@RTRCAR*>)WFW\<(&*<"?U;7^4S(A([.3HYGJBIO.O7E&F=G0,IX6SJ
MJF@IFD@MV$OJV1ET>B-\@AM-Y2:C]"? $4@3!\E/\CB[%D:\(2G7N30'T'>P
MY(^>!8^4SFE*A.(/Q\^0L&[R=4X1+,7(YV[NFP=1^93NW(37O99*=@U^TS-'
MQ!OW@M@UL[_0?Y3_+;6+1!H9: JD9HPY$^% "?H8#P.O"%MDW3>4YN;.$]^K
M,,JDAYC!M%K0[$:M$NP9SMUBK6;?Y?.F)VC \6-9:%Q]4W*N=1X:S<_Z"_(?
M]9-@;1F]&& 0E*9H>A1%Q]E.VB(7>;4HE.?LJLBOY;;:HB%.HI=VBD1E033#
M(PAXXJ@&0CY?1/TZ*)C1+N,1]#%-EJ^X1*(8D%]RS?A?I\45 S YI).IHXOG
ML^NZ>1]5/1*___D% :\D.AQJ] V0G'G:.)^X,8Q]>-"MQ9SQU/I'ERH+;$A4
MP:6RDTS9UTK9-ERA4FVB"[RLEJ76KI!;MV4K^J[<Z.7;LV14GIJ*<9$OR5JM
M)V5 ZA0>#F^#6:&DV[VHW2H:K.704T2YL-G&G2#TK(]Y:;H'Y>68TS*I.,X.
MIBNKJ[XC#CYOLH:).XD<9L]U\FG3%%4E+(IT)[)LL5P5P 9:( \!$"4)/R"O
M[$(7"K/6]0*:S35$PT1]B@YL@C^J4%J>Q=GA8:0W#07671]4SGP%^Q>W(V!G
MW 2H169C;PZJ(4-D)Z=#2>/+O2O2R6"^-$%69\H:0RR-''R\""V=#LE(TF,+
MTX*N['M_:/R(I6\106 WRUOC*3!V0U+Z:5:OR4"Z12\0%DQ9VBJ>1%FQ]#IJ
M<BR5H^Q3F R_9M?IA@NPW/HCXK-NQ/LUJA%_XE!X34 %MY[<1&'C@% T9>DY
MS$V?7;@%>BYPDE#!/HZ/$.R$XU.&ZPG;%NUT9Q2'("E4S_VSA;++B*7,V:(F
MY3.$T PO8V7MO]7SEBOR@E9?<7),'$^W5+NB= ]U>DQ&:)&O.TDE$ Z_;F@S
MMCV2K\@R$+[S5>J.0!C)HV!AX1N?'HO*[2Z>2&KQ*@&4"JL_WEZ"0G0;J4O?
MY]6A\R?(V*C,H,&',"XA9:"SG^*0!+8SC/<G'C1^B^,_B5TZH2?EZ7[T)[^?
M"]#CFBG'+G2/A+G2_<?&\VQ%!2<WO3^E+JC?N$=]2\*+2[,.3J93FRK-KNKJ
MD^NRI5XL1K7P^K0KX+)NP:.I:K!$?3;KZ!!EZ T"F=:R=)FE1 ]GNQ:,%P7L
M0ZBZPOE@3"[]G^EM@W$EP$O.N'>WBFGH'H ;:[A4U81X><()1**W+]*A$!(Y
MTL3+WH^R?PUGE=W4O %G#Z,Z B 2?[O<M'3T5.,"&? U"\49GG__\HU;;-JD
M,,3//%;K(U 8XFHR#<N^C$L/TI=IHL#<9=Z(O*1RESG/R-D-)##_RHB8MV#Q
M!5$A8EGWM/[]T.]LSN64B(%1 M!/%%!21R^FYF&WW?N_Y*MOY*MO]#C_Z9*9
M ^%MR"ILP]-(VK^[KF>4?6%)ZT8%3F,K:B* [(H=L+-2VM&O<G_K5W66EPR0
M.'OSJ@W:L*_<LNL.F#[FI7\U_=J[3>NL*;[VZN6;=W ]7U/'*R$7W30]93/&
M28?65$?<9$,N+3BPDNSC9SA_]2[Q<9.8+'+X^9],%P;HH2[I>O> GG5LXJC_
M)"$.7SXM8G\&;6D"CK-M.5NN&GDH\$[=CWY]Q]C%!V GW!I5IBZ/:>5/Y!0;
M1)%;NVA(AW@C$&CGJ\)^;LW3"G<DMY(1 Z&,;"-"'%ZS=B?^ICUTN]5M>7_W
M2R07/+.C/TX$F!T?O9!>;31ZC)PPA>[N!FQR3QHV\/21![X#[L.)X'!\DHC(
M-(8DT7BW&ZK'S_/NFIW$@(*-D2%2[PBJOQPSP[$VQYI:CQA"&W ,&G]Y>J>)
MS).;UY-'B5# TVT\!_CL^%1_3Z_P4].OUD,'GGH7>H[X9%X&68*H#6LT]WX(
M.$_%W9-2)O> 9[VR8FFB)_!E(H^6'M"+:ML?831]TYE[)O8F(KL#^(VG=:W,
M2/ HL)$6ZHA+6&4D-7U==]X7):\VYQ53ND)@AIQI@(IQP'[ W3A/JS1+/4T<
MYL385CO^<5;J.3'1=PJ9EEH*W?G[WBVEV-!^__V[1(TJWMF0,#L;68-BM4V7
M(!*=\WJQ%!4,5#(A"!Y]8 CB\B---L7I[;I&MY X AQC.U>]P*;*"K>+85F:
M$-[S93<24'<"@VA:[W@K@#RW+G,;9*5=G%ZFU^S;\KS2T<R9F98#[^AM)U_1
M;;:2NQ<DRHZ*IJA?7N?N+$ =<W@US80MBP^P.'FL,.WW_[97'5D$YDT.>\*W
M_;!_Y&VY.]^= Y])6/0W=P4D_+",OCG<+KJS+Z#=LH#V^ $4T#Z??S%L^^33
MY>CD.-F> @JF>)0Z3S1_YYRQ58WL\+G2H'"8W-GP]84S\?5JD_BR!/G/+C#H
M"K=K+!0\+5:\K\>^")Q;PES6%?>)XIG](3-ZP-J>$D\3>5EG<.T1<Q[U&KTA
MNTA6PD5M\%S<:WU/=-I #KYAT(7TE78TQJV*;)1Y.#_\R=D$.O>6.$6(VRI%
M*W7.79\!QF[S,W':6KTHY4=EP1D*8CB>$.QS>(YA,XQDB^$N[X!!<30&]A,R
M3'1RN:%R]_&P$V/=B91(Y5/<^!R@R]S=%%3W(!;.#UH7UQ*=Y=B/W 40F?T%
MGQVD?A,]N9%!Q2"/#K5%<>4,JWL]?@'W0.[@]7IT9JSS#XN"NQM UT+8&P9<
M\;MQ98&[EHE !BP$-645<<"EO+0-&$=V@F:6EVDAA]8XHXU</3W/%T7QI1Z+
M6]YGC?Y:@;BJ/WZ-AE^!_WCT] 4.T"8\'>C4T%8LU820BU]3![);C#*[P9=;
MQ9Q484_J\:_^%TY84CP2U&1P61*?X.&\0RE9&LFAFFLB=J,<G&8+5968>W&<
MW]9TDN"WJ3*WAT\-R4E'O!W2:&W2ZUP!#EEQ39X')W,8=NK^H OQ _5,U-_C
MBX&I7BB)+>5Q8"/NMK.?20B<^[@&$$#=]4C&"_F#H>9>IR@EVR!(FFUXRO*(
M.=H&2+[]<+HO5 FN1F&1[;0NN&E) YXXD/&M3%1K\TBBQ(O<:#^=6@F]4QHR
M3%Q!\O'G0/L@BN"T8)%P>CN2EDBB]W8?=V8'=2KCW\,I9IL7FJPQ%GWYWI2]
M[G^:X.=1_RKWK/F2H'%^^85WE']\(I+Z7:40$E6=ADW^B*V;XJ)NB O$EP0]
M^I:&E-M\H]622&MC)*%47U?7:9--]I^*$;[.D4J@,U&9NY@9!@A(+"C6/8CR
M\_%"Y;J"GB9>4#E$Z@<$@LD-6'B@9N/VNIO'M(EOXM/4'&^)I!VW1V\+"+#,
MI6]:L@%:AVNV318_CK(+]'*_>8X#2[@'6!,#E2CWJ9[L<X=-UW)NE5_.!3&>
M;\DRMKG%YYOLAJ0$H2JV2G_Q7!5@P9&*B=R2C"38&RBFHB?45,Y$3Y6U,GYB
MPIE?/(!^UI^'3#F6/9S>PJU=9$W">K=&'#WSX<Q4$BLK+60:+:6?6[HM9;MJ
MRBPF!G(7QGWE3/79P6&";? POI!\F^>=7<,/Q6DU8.#GA<^\> LL,T_D5"_Y
M#J%Q'A?E)3X4%$B)=L7WA7E!MG F,> D)A5W/@]Y=2K;R) A!*0,DX@$/"W;
MH;HL6C$;DJ*.M8X#IP=;#$EH?A1-^[WBVV ;&M*@4N"(-^]24[G<P"_2@D&P
M!F24AJC1_>"6K#NGG3O[A112H][=+[?12[#F4B5IKD"!*38'#<F\X ,UAI&?
M%G,RQ>H@3F(2I;<( L,_):@NCK+09AR(CT6U@F+9 %8,0E(/>X/"!V%]@^ 0
M=8OA5; /6$WH.N>USU  $,?ZL"5A'TX&3I0RDE@_@YP[>A=$[9?>SK=VB)R;
M6X$O!VNY)W>L5!(R>&N]UX/F96TD,N[#6KY1<L"O@?#@'/*%)2%&,TSS8-9C
M.3,0G=VX"NPQIL35H>*=#-OTY3M+MWUR)?3E7V5IE[('L=A(K@!RMQOYN_'H
M(J<8U$!!A,Q[)-Z9<$[9"H@39X#[7.N868S0"T5VJ_^F3I (5L+6719S0OFY
ME\THP 2P=3FU \W(!+I8#(T4;P(6.1(D3Y@IJICW0C*H48G&%_@AA UB=BG]
M1!]G/6'(HL%0!?LSK@E;&J'P!B81/!H,CO*F\R>1<0JK#KM]BZ5471I&?LOZ
MBR=[PMSA%<T0)#XZ6]0'OD3NWK[MO,9;[LDP]-WOOW_U3DVDPB'VE YWK'^N
MYN[,;9.#_RP6[XE4$04M O-P*4-M0#N]"YSU;=7V^HXC! -$F\P9#3V7^6!L
MD>CDA:QIN$1"/AQ(C:GK-?FJK\3 ;S^_13192%O?%Y0NX,9>X6!I<HHZY01P
M/[E]A92O+WQQ29BP(NRVIK;ADS\I#J,J."<"NL;5634J4T<Q@7--"D^@7>72
M'Z?)9%!EU\H1M2(.:LX7ICN"J#$ R 90^^ZZ3[1;..4,QZH!N+F<.N!C4&7\
MW>_P\7/^.-,;$?@*?WNEJ>PW/I7] [N-6#G"N>/OC,? %TWJ6SB#+,J;F1!E
M>])RGMK,8<M"M4;.7DH<I$+""7]:_ICS+K.O%Q(LB8X&BKFRW#V[ H\7%6?)
M7^I+\4Q7*1,!R]_A@2E<$'S%28@1F5EID6,,#*&7)M&I)+#9_GS[W7+'NT40
M$"]]+\$;2LP:,4,2YW#NG?X*VX"P$2_?G)W%J[V=6NZ!W6'K<I;B(%94N[BD
MGB'0L:J3OK$V5DO^:FO#<APLQE@-VEQ!B'ZWKZQ]4?^61?VO'T91?V\8/M8P
MR.;>2N;WTFBL_A1H3.D,83 !\8'14:GMKO(]?X92&L3GX(M(WCX0I*--3BR+
M88*T9S8W5!*6V>9CB,>Y!<9 :]EZIMKO^AKY1+B=>(H\@,\")Q\^AO*DN\1E
MW:/&99, :,H+4:NJ/GD59^5UX%XO?6JDYX;<TH2.NN@E@R#5%\I#)"$)X8MQ
M$E9S65G=">(LX0;E HDPWS?F9V]_O'XB9_2-ASZ_T530NY[2N9409RIK%D '
MK5^<(\I3J01EN< 4 VX#95L$&:5;6L0\(K"7.)8AVM:KM"BQ(F*,1S+JF#R_
M+,JL,4">L;N@.'Y.GS)MX$)ZBGB[ H5 ]5XA)^1B_?FK=W8E1G#74;8,:WPI
M0\ 9,P1C].'0-/&%\QF*2MFBN%4CJV5W82.TD*)84^*I:_BG=9VY#8H?V&VY
M+(@.G#?EE\FX]A=EVV=?:+ 7P.V:XY$+5E3N%)PW>!&) QX;ER2.HF8>-HZ&
M-2:>_L$?J5=];?M"(ZZK'<->7]-#$**:2[^^<PQ:?#F-Q&5>PNB;T0T&K%A!
M4KFC ('VDEMVA./::S'>/2ECZC8[9<#AYB:SLE;@B)(Y3\N6ZR+E9#DI 1R\
MUSP2OCT.C(/T,2VY#1]()=?#39K7XG.Q??@:;E'5Y55H5N8Z*>>\?:JE#7
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MQ@B5^N5#=7T<]7(D E1,K/X"JW47!EF%]E.0#^G^Y,.$=M_H_]LQ =\\ $S
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M).=L>$XQT>(]EJ8NH@A<2-(V#;VMF&0[BEIU#=1,C2<#%%L#^/4#V+8M>U1
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M!ICH$455O+:M57\CF#$%LZT8T$;R \V:G@WR^'P9UA0;BF&@?"9C'8N!B)A
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M\\/3!QW0XPG0Q_XPM&3.GAZ&ZP<R8=8*KBS6 P9(AI$5B(PYL R5R8+7OX_
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M'9J%K$?&*@]%2E0\8HXR-.;,IM@&E<'O\WRZU2SFEU]K[>?@J+ZB9%Z4:).
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M"B!ER%*E(D+>;&?!QL#&5)C?!RD?7+D;1H^G[]<?D9Z*?_SM_P%02P,$%
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MY _>I!Q!@6NVH;W++[9=QF+3=*4P>FD41),EO33&0M N <&4,>M28O.P9R>
MAV?5,6AP3R;NKL(.[-X&L$OQW,+<2RXQ1ML^),\)+G)-6[\*4+@/+#@65?/S
MMATA?N=<8S5V8&TO]_X/]6R@%S,/"56L=0GUA#%HB+98T%*Y[$M@,;:N'[N)
MH"%GKI7+=V[S]A#CNJWDAT7Q\]\K.S'_X\?I>(97WQP-I_AE^F(P?^ _?IS@
MQ_K%?9DP&4][;\>C/$O3-^-EI<JS+_U)CQ6O3!8,"K$>E$8)@6>21S"6.<^S
MSENEN=$#KO& _G7%@4W/;LB";S0H^ 8K[J'&44-Q-C0OU_!<+T7Z9;ZA;@6J
MM](E87]=WP;2TE1LZNYPI>XV.KJM\$8"/ICV2R2/A[@-@GM3<^@]1,8$V!*9
MCDIAT@W?\$-I_4:/C*,H?1>Y=N!)+H']-G>6>L8G;D1QX'4U:X*<F: (%@HT
MT>HDLVD="-\ <#@OL*%21JTDVK OP#S;Z?EH0-\:+9((EH7H2U@^6,^-$H Y
MT *M*! Q"F*T]$6A3LZL%/)NR!S;_(R'K,N6XMOXTO[[3RN2(??RGQVVJGD_
M':5_GHT&A&&RR(^]";%1@YHUCSE,6YJ[UK?2C,9HK73Q119%H;S $!TKAG9S
MTA[C7-[=C&;- YNWH%$JDVU)&M#70UNN(SA/[)4Y1<%XE#RV+F)MWX+FU3"-
M,4SP%US\_6IX6W3OZ&U[.1K_%<:YYV0)WF4&1D8/*D8'40D!V5&T6T-LQULO
M>D>()W'PN@LWUJ0-=::2#OK;K#D+H4TW&Y[!YGG09>K-DQ=0D,6$EA7E6K>B
M.(%#JT[5MGI.L9?,._!5;R^UQ[+346@-+@D-"G/MC:$21)&L#TQY&UKWLMID
MWQXM#?:3>A=5ES>2X11AP<0Y6%'75J(B,!)!)X_&.>.%:5UD?^3<PD-J__ZR
M[J"L<E/.VE5EUW^2#&I#@&6!UYOAM=2U<7]2C_/IG\./;W'<'^7+[*5L# H>
M/'"K**Q7(8./UH/EQL<BG)2V>85V1VMYW'0\"09TD"C_+*71K";^?WQ?C2V)
M:?+'IQIPO*A!RZ0?!_BZ/YGVE#29YQ#!E)K(0>$*!)$5./+^N(_!TR\T)NJ6
MT!XW[[K03P=9]U?IN9,/HV<YSS40!F]#/[\:/@^?^M,PF+MUM>?TO(<J@5^>
M;Y"\)OTI+D]/%J_'.TRCCPL]_E<8S+#GF?=):P[2^T(A!P:(!37(4B+/IA2>
M6K<SZ'I-CYRXI\2(#FH1YI)[-9G,,%_?UQ>QRT6BXLV%]1BFE!5&0)EJU;<R
M$.KI+,7-%-A8:9)7700-N\%\W+SL6F\=5!IL@#Q_#38@UMH6'K,$S80$%8(!
M+T.@N(D7-,%&YMN?WNV*\DD2K976.JAEN'WN@CR6+(2'%#,'Y1TY%/6T3X14
M(L/H@FZ=,'C'65>3PYN<C%:Z9B#S4B]3900? @-?B@X,O1:Q]6WC78<W>R=%
ML9QUCBQ 410]*!_) >2)0XFVH%,Z9]?>MIQ(4M0^Y]%[B/'825&WEK @5MU2
M1L/J>,TS!UQPNI"S!/7&$50Q\W?8@E0E,Y%,M*(S8JP#=")I4SLI>A-G]A9X
M9QVA+C$M+Z.W ;5+#M4N!2KK !TVEZH#Q:WM^]1"Z@>C1(E*<U[(QQ"AEM!X
M"R$D!9(5DVWBK#C[<*FP(<'J6$S81=B=M-8_/Q\MG-UE)@DK,HG:=RR%1.NT
M%--X;Q,8GYD,C+.0.BA1O@GB"#5J^ROG=FWR'I+MX,9ZPUG+$IQ3QAM&%C-D
M14NUG,R>D8)<7Q-RCC9'W;H%SS<!/08*M)-X!V_^LY1FY[-!32':=(>Q!*HT
M*FD4KXU;B+<Z%8H^,X(H40NC$K+4^DI[:W"/@B:=:**3@0A36BOFB]K;):IL
M.-=,$)9<"ZV5DA"\YY!Y$!*]L2:U#B36(WD,9&@@XX;WW#61]?F"G+5[?2F8
MIHOCJC?E61Y]FDNW.D8RH;=:%[#2,E",)W*,D#CJK$?IHE)I*_-Q1S+^-E@>
M<!S9B;@;;@3;X%N^ ]L@;%B;LQVJPQ?JM-?F#E390Q6-JWBV1(I.1LM5 1?0
M0#5U$*-UD#2+F;9.SOE6D><)D^4;]3VGP)5=-'!@CEQ='"]MHC:2_)W"P3.N
M"*OVX%AP]=Y7<22CF/-!;,X*KL.6F72AUUVLT3Y*V1CD-BY$>3/^&(;]_YW?
MI85A?M__..R7?@K#Z546S=O1H)_F_>0N8K97PS(:G\__HU^J4S:8W*<ZI=FS
MFY2L=".)E3H6QPP&)410.:B0G7>%@EG4/!BF1"F]9BCVS=K]Z]KSQJ,A?9D6
MI31OQL_/PO C15_7?Z,_3/U/-:_J\GY)YJ E=R"$EJ#JI6%D)4$]"0PF2!92
MZVO0O4$?*C$P1JV]CQE,3<A7)==&ORX!6I]\+H[K]@=*IYH8>%BFW3=5<!>-
M=7 ^60<;O!I.IN/9HAW^HF'T.\(YCZPRF9Y$/P@?L6>U%<5$"4F)!,H(!E&&
M" J#S Q-R+KUB</VZ)X:O3K26R>7'<//.)Y6PE?0M4/Y;#PF;+TLBQ'H.3@K
M$)3 7/L7&Q A8 HL%Q_;7WIL //4^--&*QT<=_Z"!<?SH;3+AN:O^R'V!_/,
M_3J?@Z 5@Z5F/4E7%TW>M1*!R"UC3D+JY%IW<KT#TE.C3DL-=5 =M.'^IY>S
MX;YX1R$8(T.K9%TR.C"ZU&F0 IEH39P-4)X:85IHI(-BF]5#_VLW0D1QBH.F
MO53+V@1!2D5I4)917!VL F$2LMJSPY;6%NIN5$^-/HWUU,F4B_O)9W%G(1/J
M8I0$&WPMI[86G' ,Z,V0T1CC@FO=H7HOP(=*+3TNZPZGTU-)7+T94LS/O4OD
M-K(D(6#AH!SC$+..X(O+CBE$W7SNX&T4Q[I:/" #OAG<[:R)#H*XFXA^#^=X
M>>M^-ZZ.,EDW83I.,NN^.OLF!?84^"$)P;0T!"B1 584/FJRPCZI %X:AT;E
M%'SK'L.')<(=J:R'XL$N<FZH_WE+M/<X[(_&UXX0?A]-<?+AK]';$0F._G[9
M_XS+$ZA?9K1+_A:^TG<_G(UFDS#,'_ZB[W]].9J-E]=75D=)R^# .0^@3!T;
MY%T!C^B\,=(FO5T;NL; #N]IMU'WZ$1TU?"\>ONK^B(L5\J"-LG6J_I:).@Y
M6.9LK!V:D]PJS'_ .5&'=UPZT<Z14JBV0/@]A>H>VKQ'"M4]5'&D%"J?DD/T
MX**J^4&8P0N7:F6NHI_D8MQ6<=()DV7O%*INN;*+!HZ=0N4T\]YC!$U&$U2>
MBZ(6EFL7+0OD$V[7/>5)I%#MHM=]4JAV44HG=4*7#5I>CL;?L.#+_N,A9R<,
M:)T3J. 91)LS9'K)BN#(5//D_YT /AW/IWO]=7!%]H%^[^I5N"R4NQM31R<Y
MZ_ <YQ2G0S6..M)!!X<[:[$%Z15&VHE9[>ND7!+@/.<@(O+(:M8 ;WU-<3A>
MW'&H<V1:["+Z;HH6UZ>RD<(8,TN0W& R2!:3"6-JF9R!P%T DXI63K',L74#
MUJV '?X09W\=;IM+>&\%'"H)_,;P!(+^NI]J+_UG'\>X?&$:9W[O]\!&$PJ:
MK7DEQ[LVV<."4:N2%!<^)N5\RB$7)8*1NK??H_?-\[M\]F=\-AY79VOQS&&N
MZ64;?OR!OIJ$5'%,KFYN?9'2Z$ ,QEK0X,D;#\(K0,6LUXI\]-#:V+3$OW]J
MR@3IY3RC1_^"GW$P^C2_3)A,</HL_6O6'R^+EC^02_OA;#R:?3S[>3:AIT\F
MST?GL3^<Z_7/<7]*_'E32D_(R!T*!1HMR5/Q C%IA.22%-I$:YM?Y+9>P^'W
M\:,Q^G8&S!'IT$&PNWX]+[[4WGO8B]J8[*.IN&K^H'3@;*:8W!D?(E/%QM:)
M>M\$])UX#135^@KR[8BH/.V'P6_] 4ZFHR&^#5_G,NJE&+EWM=;.ZMH?- KP
MF;SQ;,A;*I9;6>YT(^YXQA.D1$NI-[S9F</ZXQ,);#B]P/);R$A1<C;&RP"6
M"0L*I03OO 5I/1>Z1(Y%;,6"-1_^5-6_KYP;'F4M[K;#@ *M>;>GFW.;WX\&
M^=7PVNI[6FNOD[/ 8\CUVEJ#MQ2-:8J0A(HYQF*WHL/VSWRJ+.E(*QUD@,]A
MO1U3D-0SEG&4J;;5S8(L6" D.JO:8XXK;YU#U[P)[>73GR!3]E1!!TG<BZY"
M5V-"7G[^O4_2^+,_/1O-IN\PY/[@*X7*.#XGASH.\&7HCQ?-[T,I(JA2*^RJ
M[;,^0#!:@8\L9EF8U[JUQWI_M$^8; =2<</Y!O,-==79ZBG&#1E="T+[VIF<
M4?BF@P>I,]="J^*BW,J8K7[R$^3&_A+N8,; .J(^'TVF/<S2>,$]T&880&E%
M*U04N/,0G/*I,!FZZ1)[&\L3Y$I3]70P,F YG?@E2>XY^>EC6G3=VY[/B-OG
M.'[Q)0UFM8E_/3FB_^<Z\0I-$MDX"1H-+N3@- 7Q*:+AUM=>1ZW[3-X#YA,F
M6]=*O<U#W\W)S#M,V/\TG?2DP)ALX: =KYT:C8=0,V]X\<EB,9$ELY7YNO-1
M3Y V'>A@S=G=?A/IWX8*[P.Y6;T0)-<256W36&N %4)T1%SK.(^"XD MMW-E
MKC[SR2K]?E)=H]W]1_2F,\RS>@S00#2+Y*QDO96F))!>)E!,&J#%"$!MD1OO
M"U\]S]L_0&^^BD.5SAZ=D"="A%,IK5UFA%PM:YXG9&P**4D)*"(%&=86")I+
MBC2R)NO-C36M2^76 CE:[]XCDV-]ZM4>2NHB]^J6,,+Z]2^3@+:!VU$6YXY0
MCY/@V4#)J\E9!]#0"1!+8^2F8 %E"L%6'B&$'(!%%9@/B?'<^H#\) AU1V;H
M\?FTBV(Z:>^V?F]>HO/:JI@U!ZZ1/%%A.#@?/!CNO?3,,Y%;9X5^&]'AHX-.
M%7JKK5LS;30NWGT['N59FKX9+^<(+]X336\*XY$LM76TWHQU3C8'H0237##R
M/%LTDU[W["?N]#112>,*W26>NOXEHLFR"FP;4 V+<C<".7P=[OXZNJWP1@)N
M7$:Y&5PLA0EG'&B)LLZ]31"#]R"R=%SRQ'"[8:JGI?5O%-0>2.F[R+4#S^'=
MZ&L83+\N35,4WF-0"6R.U?1% 74Z6TTBLU8KGEEL'0S? '#8ZM=&2EF]*KBW
M1%MWZJCE*CC^%,;3K[6)R9S F&S).KG:Y+'.<HQUFA+]@5*XI',M4FG2F6/-
ML[\;^_U5TGC U3O\-!NGLW"M.F45XD4)^!8@&QK_K8$=H2G'WCH<'4H!C9V#
M[<$&B<'86&?T:4WO1PS@6,R@D\B"*\&C:!%2')DEW^K&<1R2["+WUL4 _XF?
MIC7!],,9CL,GG$W[:?*Z?]Z?8E[:0D3&5$ +WD@&RD8.T00-G!6%J(0->KN:
M@#L?=5@_HB/]C#H3;D-'8X[N0_@GYO#V+(S/0YJ#"X,Z&3(,O]X$:4QV9!LU
M"(VNGJK0NY!K*S5I2[$UN\]MQX!MG_CHB-")J%MO!:_R:#SIKZ"<O)Y>8(LN
M):^2J'E9Y%[+E"F*0G+F@M=".">EY5O1X(X'/3KMMQ1LZ_J?_\;A:+B"[-4P
M770LC-DEG@RD$%4M4_/@%"IP0@:*FHW-JZG]&U3^S<<\.H6W$VKKLI__HC#W
M8ZUVO3)(%P-[ZVFVTP%\)/NCA$!:+"V;(46\3AG-XW:-1#<^XM&IN8TP&Q;G
MS%']_.K9Z[>C\10'X7EX_VR)2.J8DA(2DG<95%01HF>: "9R0%STSFY7Q+7V
MXQ^=:O<78L,RFV6>_70RB_W)6?]#&-+/%MO+\]'XT[)GQ1)C8A9904EKS*%F
M)Q8(02201J1LC-5I2RN]Y0,?G>J[$'3KLI9G,?Y7'Z],"L.B0TZV9BG7%L>>
M @K+:CDYLIB*U=YO9Z=7/OC1*7<?P34L5IFOMAY4SD\8=-:H<DE@:X(@A8.T
M&DM.8.+6&NZ8BVFKB_Z[SETN'OC]2/>>PF]HJB]!7&0N; &CY4GMU:,/?Q9[
M3^&OJF\/R;4^8KT&)XML:5>2D#,2(XLG1DI=BTB8M%X[EG.+D?"=*_ ;QZ1M
M];>+P!KK[3>2U/GL_()(T8<80YW_;4MUVA-X0__4&5EMP6S(5#;0W(V''MC
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MD0_"6M<@;H?L.S6[5&679\?[OT"_DKIJ>^!7PS28Y;K*%V$\I%^9\)XMWL7
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M)C>YIS_/>9.0I\G+@&N/=?5U 5145(#_*#< >06@J@-Q=P4 # T!D@  @ Y
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M:Q9PE9J*$CQJ5@ (0"1\_3Q^JA;&95C?W%P?-?EG5#0G>,,WI2..WM55_3*
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M<9/GRN>"$YH2P_-F-LY%7R>,Y(Q'#"R.3Z>[*;%Y#PW4E,6=H;.PP6-B+F1
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M*$E]'L>UHMPC<]O2O1RJ5$P&=)AXL@,SN+4E!VCQBT_TCA$1ATH&PZQ@X[
M(0</WG2$GT+#H*%B@DVL9M$'4B!VD\"ZM-Q]F SC(?@V)_(X359KK32Y"JVG
MNM_,_D!-&L[F(IZ"63K2MLM^]#DUUJB(SU]/8;E!Y'[>FGOERVG.?!,>F4+
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MS+\S->:9LQE]V%PW(IIH.MGQ-$A'*B'MCDNGA,I3;:;""L\#!*4#'NDT@\F
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M">A78?G01EIU1<5'BXD#6(])3O%G3ZRCQ(B,DLS=';Y]31)'WB**<X%_Y.?
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M"RG%ND+A3 HDXU0O/B35=_91#$F*8[4J20-?"((3W^H,QE:!J=%;HS$@M<J
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M9A/8:+TS\-Q6=XK^+V@I> 6VNH/Z$=U->S]LO^$PC8$+9%WE/+A(EW$3)+B
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MPE0JE@\QE $G7B)%S$*K6S13P5,C\L_+!:R"/M<9"12E;RVP#?PTQ-[P3'X
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M=03>6-58JX* [$4?RSWH+X\4X'<QG^L_N7C4/^&B"F-5/\_*!T#)XA^%&N=
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MQD:[4SME1OM&[>0S[G+U_"TK'WY;+&DA\HH!/BZ>5A4C* NR>5;M4'9#+*H
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MZ[XEFHLJ2O#]]R>Q*$0Q"V.&F4<)3!C63ODRA:G.R(*%#%*<I)2@V*:>^KX
M*YH;K:3Z<N,6+M9ZVA9MWH/1[&3G$G &9L%*M6H,OC^'2(^BS<?-=E:V>:_Y
MD0LW'S?NL'3SB>?Z^B^I"4NM=[8."4U=8!JA("9> -,$J1$=4 33V$>Z=J%
M7#+&D54)D9.2IK:"N68L7U6W.+7"+6\ER^%]&ERS<>X$LH$'?*-CRP-I@'+*
M9Y%PYG]T2L[(3D=GS#WT-#KW@I.+G$_90GPLQ6,Q2T@J?4H3R##5G. 3F#+"
M8<0$\T(92E_R"^YR-H*F1@Z'EQ9:55#I:A@U<1;;7M<[O1 ;_8;'!*Q+;WD.
MD!CFHF<KYC7O>@Z,/7/=<_B\BPQEVV\7*TX@44)@B",?HC3F$!,60QER+R)"
M")\9U3D^(V=JM+"7%.L"5C@%K!DI.(!KZ-N@/DA=F"9L*$8X)>454W^=Y8-S
MC_>G@VT&Q/W<B&^7"[5)7BU7Q=:]3CN>W"Z+3)]%Z3#;NP>R\(,Z?%:MP%>/
MJWD5D: >FZ6!E\0L0E#*5"TVXC"!-!("DH!Q#XF0I0+9Q4\,JJ_1:!LU\$(K
M#+3&P _ K^N#LI:KH];:GJ:&ZW!SLGO=3AR1,KM3R599&-?F[G<L:"R^ M5W
M4.Y]!RW#NS^$7BP\> <YY/+A=!U]1A@<]F/SRO!">US!=2O6*/!YI=V@;F3S
M[V(F4.1YNM**'R=JTF%^ *GD'!*UM47,(S).S6M&]51B:LO<6L'.E.+5=8YY
M2O&+NLC@JG $X,=E_RWY V4$T%9L"!ZL^^=&;GYDXWS1MQLL+BY'Z(Z1;CG?
MG1T X*GIEL5FV#0_<G8I>2&@G3>8?=L>[[KS0NMW[D8O;:OG :O.3/ZQ*%:"
MOUMI]_S:FZ^N&5_]]PTI!-?9'<6BJ$=8X%%)$!508.V,YW$*L:_FJ##R?2%3
MP4)D50VLAPY3FYBT]D1]+U6YBYVD[[7/5/WW)_5. 7[,U.\JVTYG&7365X9G
MN</VP-#'O)6:H-;_"M3_7/\)*\4;5T!PO?55NP)$JD]#SV)29.4J=QBY?@&>
MK@Z+>V@P[CER?X@.CI@O:*IGFMHZC%Z)^EJ2!2<Y+WY[XFJWH/K!\^(FWBCE
M?I1451-Q#)'4B2(9]=4*/D($B01'D15/&DF=&C-NE08;K4&M-M!Z0R^V3%IK
MA+T9[SE'=&"F,P!S@"@F*Y1<9;$UDCEN)EL;& ZRV5J]W(^53N2)G%$N/>+Y
M,?0Q4SSDT11BYG%(D2]\I,,>D]#&-^Z$G*F[R,VK_#7SM;J9K3/-*73-F,8!
M9@-SR^D4L^Z8Y P*CKCCE)11V>*,J?O\<.[QGNN4JG+J3.W.J""I#STI!$1)
M*" )$Q\B%"244802%-D00-WL-,<[J72S7%+4,!FN&:R-'WI1T&VQ_72_8Z"K
M^;QN=-P)>\>0@QEY][<NB@9?TZ+,"2MGJ4>)#*, !MQ+(0H]"0D)*$PC'83#
MO,1+C,[NN\5,;:E_4 RW4;2'"\H14,V&Y^50C7&>;H?2A06#]T$8I%[P1L@K
ME@O>-[2[6O#!T_THH,E9<BORZJQA\[TRWZ,H2-6H]W5(2J!CEFF"813[:81]
M0I/8JD[$*4%3HX%&3_"D#SZUIG^T&_\G$35C !<X#<P!&XB4CO4YY2 T< X)
M1T1P4LRH5'#.V'TR./M\WX"69U&4=6$&13<Z4N:?*UTD:WNULUDE1()[B2XO
MR7 $$18Z'Q%35"%1R'PJU ^L\A&9BYX:9;0TOZHK,E417)7V[;OGOBL*BTXQ
MXYAAH!Z8=1RBW". QA8P9Q$UQH)'#K&Q!>0PYL:ZA==PKFU<JF[R3\O%O<@/
MG&M)P&F "/1HC"!"L81I'' HPX!0YH4Q3Z/&N?;.;LLTF-)&@WK7P_9N!!K=
M.%6J[@6UXJ_J9GNNZ\UW=*_;D__3W&R/?@=3=;,U[*!)N-F>T_5_D)NM(>QN
MW6Q-A?8\[5;">39?Z:Q$6QW??Z^SBWY0 &H7@%6Y+BFYOP%X\W*\@:H(3.#C
MB(DTADF /9WAFD$:I42MVCT?(18'R$-6=_G#Z3JUQ7U;TQ:_61[1#]BWAN?^
MT^BQH2\3CG>6\SI!(Z#IZN9B0$W'O0X9'O*#.Y811/:L_KMU U ;I\J#[&$Y
M5^\7]29J<QZ 8IS$),&0,0_K-"0^Q(%'89K0(/9"GZ214=HT6\%38_&6WM6Q
M05OS/ZP/$2RK_YIV@1D_#P'LP&2[C^GZ*&:(\Q=;=%R5[345.VZ97DLP#LKR
MVK[?(VSL+<GS%T6&UU5JSANY<0G1C+E<B$5YK1;B93FOG)EG$N/$)Y)#B9!:
MGS)/T522(.ACF@H_E8)[YM5X[61/C:D:[5M9377^OL;QZT7[Y]=6 *)#:!H[
M+"*5+#NGF\ &AGQ@#MN@76NN8[\VNH.-\N!:'VT,C[1%*-APB(\4 =;W.W<5
M^M4/P,Z(+\LFQPOTZF?K3GQ7SR8NK/M5>SFI6:HU9ZTKM_";;5$6]<#GY2+?
MJ=%R5U6S#&,ITD#&,(EUHBWN(8@%"6$81Z&7I"CU?&%53MB59E.;=MHEGK;5
MFO2RKJT_^%8I;WE_Z:X[S=;2K])) T]4COJG?]TL5UBZ+HUUL5ZO4_W*%9PG
M"UPY$]"/PC^+\BTI'F[SY7/&!7_S\ENA2V2MRT@KN:S,GBNE9@&-$BXC!OU
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M26>0@BP5'(HT%UE6R AC[D*+SA),C1)-39QYK0& C9.F%&Z$Z#X(=F08%-K
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M&#QC.PYIG*G5;2J_GY2LVJ/^OHOZAQ[4G5G&'4!/#.30\:CLY [(,7,-:&'
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M4]NI'(<TJ:WHWD.:^L;%\LHH*-JA[Y+Z0YIV2KQ02),%B&%#FOH$F$)(DP5
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M7-ZF8)P^\L&0<&E\&HA[Q-WH-O471O2*B1A29I&D$"5QHE(D!RNK -PX[ZI
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M?+>8Y4D,+ GT",4H7UT 1;N_1(BZ!!F+9+ZTOMGV<6K&M4B-U'WO8*&)[#M
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ML#UW^?@IK*9I@L4FK2*"WB2*N<P45VB"OS$V)2LHZFY=K_ @(>,>"+71\3>
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MM67"!(J_1%;@R%/F/@9/'VA_?+0+:>-.J#@E9H?050\0O,K?K-XO'CF=W;C
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MS;AN5/[\T_F**%RMGB_.XG2^>=W-WDB;4K(1",V9@@<A(>B D%CR)3IDN?F
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MWM0PEG8[0'8M1<9E9>5-^(3+RX%O6>I4M 63ZBU\T05R]&.!5 KWGB=+H<0
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M#L#6M%<IQR@MR8Y$Z6MN"Q/XVF?$T9247!$4MC5&Z)^_V7LO0 W9[+V/=CM
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M%/A()5 #4[R BB90=!T+!"=+L$A_H,;M"S^=YF%(O>)7@I'5V.\:V\=7EA*
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MSWBW&V?RR_Y'%W@^9WQ+(__G4OX:>4'W9-Q_UQ=$>LY],JD M_4-1<L $3&
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MBE*+1#]O_8A["GU=^<]G(N+(S=5</>-GDO<_J/^*88W_]1__#U!+ P04
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M\0MST8_0BP=LN?GI7WASK]Y=_!=02P,$%     @ 4(%A5?5.]W="!0  ,B8
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M3)BX/9T5<.I-N_KL,70GT.V/+CRW#VMP'G6[6!!3H92(6L?/:$F483^V#Y!
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M+3(P,C(P.3,P+GAS9%!+ 0(4 Q0    ( %"!856'T+0%!!L  &X$ 0 5
M          "  =DE @!N8FEX+3(P,C(P.3,P7V-A;"YX;6Q02P$"% ,4
M" !0@6%5=MK<V<X^   'KP( %0              @ $000( ;F)I>"TR,#(R
M,#DS,%]D968N>&UL4$L! A0#%     @ 4(%A55AL^:,^1@  TD<  !0
M         ( !$8 " &YB:7@M,C R,C Y,S!?9S$N:G!G4$L! A0#%     @
M4(%A56;_D!F.K0  "OT& !4              ( !@<8" &YB:7@M,C R,C Y
M,S!?;&%B+GAM;%!+ 0(4 Q0    ( %"!855%%25CE&<  ':%!  5
M      "  4)T P!N8FEX+3(P,C(P.3,P7W!R92YX;6Q02P$"% ,4    " !0
M@6%5_-XEC!P(  #&)P  %@              @ $)W , <3,M,C R,GAE>&AI
M8FET,S$Q+FAT;5!+ 0(4 Q0    ( %"!855&*(1]'@@  -4G   6
M      "  5GD P!Q,RTR,#(R>&5X:&EB:70S,3(N:'1M4$L! A0#%     @
M4(%A5?5.]W="!0  ,B8  !4              ( !J^P# '$S+3(P,C)X97AH
@:6)I=#,R+FAT;5!+!08     "@ * )<"   @\@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
